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Abstract 
The focus of this thesis is on the application of decision models to the economIC 
evaluation of health care technologies. The primary objective addresses the correct 
choice of modelling technique, as the attributes of the chosen technique could haye a 
significant impact on the process, as well as the results, of an evaluation. Separate 
decision models, a Markov process and a discrete event simulation (DES) model are 
applied to a case study evaluation comparing alternative adjuvant therapies for early 
breast cancer. The case study models are built and analysed as stochastic models: 
whereby probability distributions are specified to represent the uncertainty about the 
true values of the model input parameters. Three secondary objectives are also 
specified. Firstly, the empirical application of the alternative decision models requires 
the specification of a 'modelling process' that is not well defined in the health economics 
literature. Secondly, a comparison of alternative methods for specifying probability 
distributions to describe the uncertainty in the model's input parameters is undertaken. 
The final secondary objective covers the application of methods for valuing the 
collection of additional information to inform the resource allocation decision. 
The empirical application of the two relevant modelling techniques clarifies the 
potential advantages derived from the increased flexibility provided by DES over 
Markov models. The thesis concludes that the use of DES should be strongly 
considered if either of the following issues appear relevant: model parameters are a 
function of the time spent in particular states, or the data describing the timing of events 
are not in the form of transition probabilities. The full description of the modelling 
process provides a resource for health economists wanting to use decision models. No 
definitive process is established, however, as there exist competing methods for various 
stages of the modelling process. The main conclusion from the comparison of methods 
for specifying probability distributions around the input parameters is that the 
theoretically specified distributions are most likely to provide a common baseline for 
comparisons between evaluations. The central question that remains to be addressed is 
which method is the most theoretically correct? The application of a Vol analysis 
provides useful insights into the methods employed and leads to the identification of 
particular methodological issues requiring future research in this area. 
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Introduction 
Chapter 1 Introduction 
1.1 Introduction 
The methodological focus of this thesis is the use of decision modelling techniques in 
the economic evaluation of health care technologies. The first two sections of this 
Chapter provide the background for the thesis, setting out the purpose of decision 
models in health technology assessment (HTA), and a brief history of the use of 
decision modelling in the economic evaluation of health care interventions. The final 
two sections describe the specific objectives addressed in this thesis, and the structure of 
the thesis. 
1.2 The purpose of decision models 
Decision models are most commonly employed to infonn an immediate resource 
allocation decision, using only the data available at the time of the evaluation. 
However, decision models may also be used to advise on the collection of further data 
to make a more infonned resource allocation decision. In the context of health care, 
decision models facilitate the comparison of alternative interventions through the 
following attributes: 
• Aids to reasoning - the central role of any modelling technique is to develop a 
representation of the treatment area of interest at an appropriate level of detail to 
support the reasoning of the practitioner. The model acts as an aid. offering 
practitioners insight into the complex relationships between variables associat~d 
with patient pathways. 
Introduction 
• Structures for ordering and synthesising information - decision models can act as 
frameworks in which to organise evidence from a wide range of relevant sources, 
such as the incorporation of expert opinion alongside the results of primary and 
secondary data analyses. 
• Explicit formulations of assumptions - an important dimension of decision 
modelling techniques is that the assumptions and definitions made in defining the 
structure of the model are explicit. All issues captured in the model are open to 
scrutiny by experts, both from clinical and economic perspectives. so any 
difficulties in the model are more likely to be raised and addressed. Through this 
refinement process, those assessing the model can increase the degree of confidence 
that they have in the model and the results that it produces. 
• Test for the implications of uncertainty - there is uncertainty associated with all 
economic analyses of health technologies. The development and use of decision 
models provides an opportunity to explore the sensitivity of the results to variations 
in the assumptions that underpin the model. Such sensitivity analysis helps 
highlight areas in which further research is likely to be most useful. 
1.3 The use of decision modelling in economic evaluation 
Decision modelling, alternatively labelled 'decision analysis', originated from 
operations research (OR) and game theory in the 1950's and was taken up by the 
medical research community in the early 1970's. By 1987, a progress report on the use 
of decision analysis in clinical decision making hailed "several hundred articles" that 
had used decision analysis in medicine [Kassirer et aI, 1987]. Kassirer et al [1987] cited 
improved computer accessibility that aided the design and analysis of decision models, 
as well as the development of clinically relevant measures of utility, as the main factors 
in increasing the use of such models. Since 1987 these factors have moved further 
forward so that a simple keyword search on Medline for 'decision analysis' highlighted 
1341 relevant articles up to the year 2000. 
One of the earliest applications of decision analysis to the economic analysis of health 
care interventions evaluated the costs and economic benefits of screening for spina 
bifida cystica [Hagard et aI, 1976]. A rudimentary flow diagram, as a precursor to the 
now established decision tree, illustrated the patient pathways, but the key 
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characteristics of a decision analysis were clearly eyident. The number of published 
economic decision analyses steadily increased throughout the 1980' s. The majority of 
these early examples were undertaken in the US, which was probably due to the greater 
recognition of economic evaluation per se in the US. 
In the UK, the need for a guided rationale in allocating available resources, which 
provides explicit reasons for the choices made, was a key development in the National 
Health Service (NHS) in the 1990's [Buxton, 1993]. The increased awareness of the 
economic aspects of health care led to a rapid increase in the number of published 
economic evaluations throughout the last decade. U sing the Office of Health 
Economics' economic evaluation database [OHE, 2000] an elementary analysis of the 
proportion of economic evaluations using decision analysis in 1990 and 1999 was 
undertaken. In 1990 forty-four applied studies are recorded on the database, of which 
only 1 was labelled a modelling study (2.3%»), in 1999 the number of recorded studies 
was 767 including 88 specified as modelling studies (11.50/0). Such statistics are 
indicative of the growth in economic evaluation, but especially of the disproportionate 
increase in the use of modelling techniques to the application of economic evaluation. 
Debates on the merits of basing clinical and policy decisions on the results of modelling 
studies have accompanied the expansion in the use of decision models. Opinion on the 
use of such models is divided. Views have been expressed that range from the sceptical 
to the cautious to the welcoming. Sheldon [1996] exemplified the former view stating 
that the results of model-based evaluation could be manipulated more easily and with 
more subtlety than other forms of evaluation. Drummond [1992] stated that the lack of 
well-defined methods made modelling studies easier to manipulate, and confidence was 
not enhanced by the 'black box' feel about the analysis of such models. 
The cautious approach to the uptake of modelling studies was demonstrated by a paper 
that represented a synthesis of the ideas put forward by a group of senior health services 
researchers [Buxton et aI, 1997]. The authors described the main instance in which 
decision models were employed in economic evaluation as situations where clinical 
trials had not been conducted or had not included economic data capture. They stated 
that economic analyses should be based on unbiased estimates of effect and that 
randomised controlled trials (RCTs) were likely to be the best source of such data. 
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Similar concerns to those raised by Sheldon were discussed and the use of pragmatic 
trials as an alternative to modelling was proposed. In conclusion, howeyer, Buxton et al 
recognised that modelling is an unavoidable fact of life, but recommended that the use 
of modelling should be restricted to two scenarios. Firstlv. to the earlY staaes of 
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development to identify the value of, and to infonn, further research. Secondly. as a last 
resort when RCTs have not been possible or the available trials have not proyided 
sufficient information. 
Halpern et al [1998] complete the spectrum of opinion with their call for the use of 
decision models to be expanded. These authors stressed the fact that clinical trials are 
often not suitable for collecting relevant data as patient groups and the implemented 
treatment patterns may differ significantly between trials and the real-world. Decision 
models were also deemed to provide more timely infonnation to aid decisions, rather 
than having to wait for the completion of clinical trials. Moreover, they claimed that the 
results from a prospective study might well be irrelevant by the time they are produced. 
Halpern et al suggested that the use of decision models is grounded in the economic 
theory of decision-making under uncertainty by providing an explicit outlet for the 
representation of the inherent uncertainty in all clinical resource allocation decisions. 
They accepted that there are problems associated with modelling studies, but argue that 
many of the cited problems could be countered through 'rigorous peer review and 
methodological development'. 
1.4 Aims and objectives of the thesis 
Methodological development in the application of decision models to the economic 
evaluation of health care technologies is necessary to overcome the expressed concerns 
about the use of such models to infonn policy decisions. The range of potential 
problems stem from such issues as the inappropriate use of clinical data, possible biases 
in the use of observational data and expert opinion, the range of discretion available to 
the analysts, the potential for financial conflict between sponsors and researchers, and 
concerns about the transparency or validity of models [Buxton et al, 1997; Luce, 1995: 
Kassirer and Angell, 1994]. There have been attempts to define guidelines for 
modelling studies in recent years [Kassirer et al, 1987; Sonnenberg et aI, 1994; Halpern 
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et aI, 1998; Sculpher et aI, 2000], though such papers only scratched the surface of the 
issues involved in the modelling process. 
An important issue in the use of decision models to evaluate health care interventions is 
the correct choice of modelling technique, as the attributes of the chosen technique 
could have a significant impact on the process, as well as the results, of an eyaluation. 
Modelling to assess the economic impact of health technologies is currently dominated 
by two techniques - the decision tree and the Markov model. Computer science experts 
have suggested that discrete event simulation (DES) offers important advantages over 
the other forms of modelling. DES is relatively untested in the field of HT A, though it 
has been used extens!~vely in the OR field, including applications to the planning of 
health care services [Bolger and Davies, 1992; Lehaney and PauL 1994]. 
The issue of choosing the correct modelling technique has been referred to in the health 
economics literature [Sonnenberg et aI, 1994; Chaussalet et aL 1999], but the 
consequences of the choice have not been fully explored. This thesis aims to investigate 
the effect of the choice of decision modelling technique on the process and output of 
modelling projects, concentrating on a comparison of Markov models and DES to 
model extended time horizons. It was hypothesised that alternative modelling 
techniques could be compared on the basis of two broad criteria, flexibility and analytic 
input: 
• Flexibility describes the representation of interrelationships between parameters, as 
well as the use of different forms of input data. This criterion reflects how closely a 
particular modelling technique allows the reality of patient pathways to be 
modelled. 
• Analytic input relates to the complexity of the technique in terms of the level of 
expertise and the amount of time required. 
The companson of the modelling techniques is also presented in the context of a 
stochastic evaluation. A number of papers have described the use of probabilistic 
sensitivity analysis in economic evaluation [Felli and Hazen, 1998; Lord and Asante. 
1999; Pasta et aI, 1999]. Alternatively labelled as stochastic cost-effectiveness analyses 
[Briggs. 1999], the value of the input parameters within such models are described as 
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probability distributions. Distributions of each of the model's outputs are informed by 
randomly sampled sets of input parameter values from the specified probability 
distributions, which enables the statistical analysis of cost-effectiveness. Three 
secondary objectives for this thesis relate to the stochastic analysis of decision models. 
Firstly, the full process for developing an economic HTA model. from the point of 
specifying the project to the final experimentation with the model, is presented. 
Methods are incorporated from various disciplines, including health economics, clinical 
research, OR and the social sciences. 
Methods for assembling the necessary probability distributions to populate stochastic 
decision models have been presented [Eddy et aI, 1990a; Eddy et aI, 1990b; Pasta et aI, 
1999], and the theoretical basis for the alternative methods have been reported [Lipton 
et aI, 1995], but they have not been compared empirically. Another secondary objective 
of this thesis is to describe alternative input data analysis methods, and to apply them 
empirically to gain a better understanding of the differences between them, and of their 
respective merits. 
Stochastic decision models also facilitate the statistical analysis of the value of 
conducting further research. Bayesian value of infonnation (Vol) analyses aim to 
estimate the optimal sample size for a prospective trial to inform parameter values 
within a decision model. In the context of economic HT A models, parametric methods 
for the analysis of the Vol are complex and require strong assumptions [Claxton, 1999]. 
Non-parametric methods are available, which are in the early stages of development. 
The final secondary objective of this thesis is to apply these non-parametric methods 
empirically in order to highlight particular areas for future methodological research. 
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1.5 Structure of thesis 
The thesis consists of nine further chapters, as set out below. 
Chapter 2 introduces the alternative modelling techniques that were considered for 
comparison in this thesis, providing a commentary on the state of kno\\-ledge at the 
outset of the thesis. A general introduction to the three main techniques - decision 
trees, Markov models and DES models - is followed by a review of the decision 
modelling literature providing examples of the use of the different modelling 
techniques, which informs a preliminary assessment of the strengths and weaknesses of 
the alternatives. Chapter 2 also contains an assessment of possible criteria for the 
comparison of alternative modelling techniques. Five statements are defined in relation 
to modelling characteristics that could affect the choice of technique employed in an 
economic evaluation. These five statements form the basis for the comparison of the 
modelling techniques presented in this thesis. 
Chapter 3 describes the modelling process from the point of considering a modelling 
project to the analysis of the model's outputs. Five stages of the modelling process are 
defined and discussed in chronological order: 
1. Specifying the theoretical model; 
2. Undertaking of a literature review to obtain data to populate the model; 
3. Analysis of the identified data to populate the model; 
4. Implementation of the model; 
5. Experimentation with the model. 
Guidance is drawn from the mainstream clinical and health economics literature, as well 
as from the OR and social sciences literature. Most areas of the modelling process are 
open to differential interpretation and analyst discretion, and where applicable. 
alternative options are presented. 
Chapters 4 to 9 relate to the application of the methods described in Chapter 3 to a case 
study evaluation, which compared alternative adjuvant therapies for early breast cancer. 
Chapter 4 reports the first stages of the case study evaluation, including a reyiew of 
previous economic analyses of early breast cancer. The treatment area is described as 
part of the process for developing the preliminary model structure. which provides the 
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framework for the literature review. The description of the literature review focuses on 
the adopted inclusion and exclusion criteria, and the sources searched. The final section 
addresses the issue of sub-group analyses with the aggregate patient population. 
Chapter 5 presents the reappraisal of the preliminary model structure and the process of 
harmonising the identified data. The final section describes the analysis of the data 
gathered from the literature review and the specification of probability distributions to 
describe the uncertainty around the true values of each input parameter. Three 
alternative approaches to specifying input distributions are described: 
• Specification of theoretical distributions for each type of input parameter, usmg 
formulae derived by method of moments to estimate distribution parameters; 
• Creation of weighted datasets, which are inputted to a software package that fits 
analytical distributions; 
• Creation of weighted datasets used directly as input distributions. 
Chapter 6 describes the construction of a Markov process and a DES model to evaluate 
alternative adjuvant therapies for early breast cancer. Decision trees are excluded at this 
stage, because they are not considered a realistic option to model extended time 
horizons. The differential aspects of implementing a Markov process and a DES model 
are presented in relation to the description of the health states within the model, but also 
to controlling the model inputs and outputs. Two issues relating to the analysis of the 
models are also addressed: an assessment of an adequate sample size to minimise the 
impact of first-order uncertainty on the results of the DES model, and a comparison of 
alternative methods for describing probabilistic 'length of time' input parameters. 
Chapter 7 outlines the verification and validation processes employed to check that the 
models are internally consistent, and to check that the models' outputs are realistic, 
respectively. Three categories of verification are applied, which cover different aspects 
of the model's operations. The main form of validation involves the identification of a 
range of relevant sources of data, which are compared to the outputs from the case study 
evaluation. The corresponding outputs from the case study models are compared to the 
identified data and reasons for any differences between the compared outputs are sought 
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in the context of methodological and data differences between the case study evaluation 
and the identified studies. 
Chapter 8 presents the results of the experimentation with the two decision models. 
The results of the analysis to inform an immediate allocation decision using only the 
identified data from both models and for all three data input analysis methods are 
presented. These results are presented as incremental cost-effectiveness ratios. but also 
as net benefits employing cost-effectiveness acceptability curves. The results of the Vol 
analysis are presented for both decision models. 
Chapter 9 discusses the comparison of the DES model and the Markov process in the 
context of the case study evaluation, relating to the five model characteristics statements 
defined at the end of Chapter 2. The comparison of the alternative methods for 
specifying probability distributions is also discussed, as well as the methodological 
implications concerning the use of the alternative modelling techniques and methods for 
pooling and formatting the input data in a Vol analysis. 
Chapter 10 addresses each of the objectives specified at the beginning of the thesis. 
The methodological insight gained from the development of a framework for the 
modelling process and the implicatiQns of the empirical evidence derived from the case 
study evaluation are presented, and areas for future research are recommended. 
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Chapter 2 Alternative modelling techniques 
2.1 Introduction 
The aim of this thesis is to compare the main decision modelling techniques that have 
been employed in the economic evaluation of health care technologies to date. This 
chapter provides a commentary on the state of knowledge regarding alternative 
modelling techniques prior to this thesis, concluding with the specification of criteria 
that are used as the basis for the comparison of the alternative decision models 
undertaken within this thesis. 
Modelling, as a decision analytic tool, is a prominent resource in the health economists' 
toolbox [Buxton et aI, 1997]. The critical evaluation of most aspects of the modelling 
process is under developed, but this problem appears to be particularly acute with 
respect to the appropriate choice of decision modelling technique. A recent paper 
reviewed modelling economic evaluations published in 1997 [Barton et al. 
forthcoming]. Of the 119 papers reviewed it was reported that 76 (64%) employed 
decision trees, 43 (360/0) used Markov processes and only 2 (2%) reported results of 
discrete event simulation (DES) models (two studies reported results from both a 
decision tree and a Markov chain). 
The characteristics of decision trees and Markov processes are very different and the 
choice between the two techniques in alternative treatment settings is relatively 
straightforward. With the introduction of DES to the field of economic evaluation in 
health care the issue of choosing the appropriate technique could become an important 
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decision in the initial stages of modelling projects. The choice of the correct modelling 
technique has been referred to in the health economics literature [Sonnenberg et al, 
1994; Chaussalet et aI, 1999], but the consequences of the choice have not been fully 
explored. 
This chapter provides an introduction to the three forms of decision modelling referred 
to above - decision trees, Markov processes and DES models. A review of the clinical 
literature relating to modelling methodology was undertaken, as well as referring to 
work outside the discipline such as operations research and social science texts. The 
purpose of the literature review was to inform the characteristics of the alternative 
modelling techniques, but also to identify research covering the whole modelling 
process, which is described in chapter 3. Full details of the review are presented in 
Appendix 1. A large number of applied modelling economic evaluations have been 
published and a systematic review collating and reviewing all such published studies 
was not deemed to be a fruitful exercise. Instead, handpicked studies are used to 
illustrate particular aspects of the alternative techniques, as well as to highlight any 
limitations identified with respect to the characteristics of different treatment areas. 
2.2 Decision trees 
Decision trees are the simplest of the commonly ~sed decision modelling techniques. 
As a tool for modelling relatively uncomplicated scenarios, decision trees provide a 
means of structuring a problem, and an effective method for combining data from 
varIOUS sources. Costs and effects are typically incorporated into a decision tree in 
different ways. The outcome measures of interest are generally attached to the 
endpoints of a tree, and the proportions of patients completing the tree at the respective 
endpoints are summed to give a measure of effect. Costs, however, may be attached to 
events within the tree, as well as to endpoints. To calculate total costs for each 
intervention, the costs associated with each unique pathway in the relevant section of 
the tree are summed. At each chance node, probabilities, conditional on the previous 
event, detennine the proportion of patients progressing along each unique pathway in 
the tree. 
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Decision trees are most appropriate for modelling programmes in which the relevant 
events occur over a short time period, or evaluations that use an intermediate outcome 
measure. Decision trees are especially convenient for capturina a range of uni-o ..... 
dimensional outcomes. The following paragraphs provide examples of the use of 
decision trees in evaluations that covered short time horizons, either due to the nature of 
the interventions being evaluated or to the scope of the evaluation. Examples are also 
given of evaluations that extrapolated outcomes from the end of the decision tree to 
cover extended time horizons. 
Evaluations of screening programmes provide good examples of the strengths of the 
simple decision tree [Lieu et aI, 1994; Gessner et aI, 1996]. Fletcher et al [1995J used a 
decision tree to synthesise data for a cost-effectiveness analysis of different antenatal 
screening policies for Down's syndrome. The decision tree covered the time period 
from the first point of contact with the screening programme (after confirmation of 
pregnancy) to the birth of the child (or termination of pregnancy). Figure 2.1 illustrates 
the use of the decision tree to describe the possible pathways following the offer of a 
serum test. Chance nodes related to the uptake of screening, high or low risk result, 
acceptance of amniocentesis, procedure related miscarriage, positive or negative test 
result, and a live birth or natural miscarriage. The decision tree simplified the 
expreSSIOn of the relationships between these chance events in determining the 
outcomes. The frequencies of the following outcomes were recorded at the terminal 
nodes of the tree for each of the screening options: the number of live births with and 
without Down's syndrome, miscarriages with Down's syndrome, cases of Down's 
syndrome detected antenatally, amniocentesis performed, and the number of women 
offered screening. Costs were presented per Down's birth prevented, though the other 
important outcomes were also presented making the decision-maker aware of the 
negative outcomes. 
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Figure 2.1 Section of decision tree describing pathways associated with 
antenatal screening for Down's syndrome 
Procedme-related misc~ 
Positive - Down's detected 
AmrUocentesis 
ega.tive - Continue pregnancy 
Offer serum test 
as from contim.e pregnancy 
Low risk 
as from continue pregnancy 
Down's birth 
Miscany' 
Continue pregnancy th.er birth 
Down's birth 
Live birth 
th.er birth 
Adapted from Figure 1 [Fletcher et aI, 1995] 
A good example of an evaluation of alternative therapeutic interventions uSIng a 
decision tree is an evaluation of commonly used forms of prophylaxis for 
thromboembolism in patients undergoing hip replacement surgery in South Africa 
[Abdool-Carrim et aI, 1997]. The outcome measure was the number of cases of deep 
vein thrombosis avoided. A decision tree was suited to such an evaluation because 
there was a well-defined period beyond which the outcome of interest would not occur. 
The treatment area, rather than the analyst, defined the time horizon for the model. 
Alternatively, decision trees have been employed to model costs alone over short time 
horizons, assuming that outcomes are equivalent between the treatment options. For 
example, Jansen et at [1996] compared the cost of different non-steroidal anti-
inflammatory drugs (NSAID's) relating to gastrointestinal (GI) complications. On the 
basis of expert opinion. the tree covered a 30-day treatment period for patients with 
osteoarthritis, which was judged to be sufficient to assess the incidence of NSAID-
induced GI injury. The decision tree incorporated seven categories of mutually 
exclusive events ranging from no GI complications to hospitalisation. 
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A less commendable example of the use of a decision tree is a comparison of 
risperiodone versus haloperidol for the treatment of chronic schizophrenia [DaYies et al. 
1998]. This study covered a relatively long time horizon of two years, comparing the 
difference in costs with the number of patients responding at the end of the two years. 
A problem with this example was the arbitrary choice of time horizon at which the 
respective outcome measures were defined. Some authors have attempted to 
incorporate longer-term outcomes in decision trees by extrapolating from the short-term 
outcome at the end of the tree. 
Midgette et al [1994] used a decision tree to compare intravenous streptokinase \\'ith 
conservative treatment for (suspected) acute myocardial infarction (MI). Patients 
entered the tree between 4 and 24 hours after the onset of symptoms, and left the tree 
within 35 days having either survived or died (fatal MI or other cause). Costs were 
associated with treatment-related adverse events - systemic bleeding, which may be 
fatal, and acute cerebrovascular accident, which may be fatal, disabling or non-
disabling. The study incorporated survival by simply assuming a life expectancy of five 
years per survivor, and dividing the incremental costs by five to calculate a "cost per 
year of life saved". 
The five-year life expectancy was obviously a very crude assumption designed to give a 
rough indication of the incremental cost per life year. Other studies have extrapolated 
from the short-term outcomes of a decision tree in greater detail. Kalish et al [1995] 
employed a decision tree to compare alternative thrombolytic therapies for acute MI. . 
The tree described possible short-term events in some detail, including stroke (disabling 
and non-disabling), CABO, reinfarction, haemorrage, anaphylactic reaction and severe 
hypotension. Following any combination of these events the terminal nodes described 
five long-term health states - dead, stroke, reinfarction, stroke and reinfarction, and 
neither stroke nor reinfarction. From these endpoints constant costs and utility values 
were assigned to the surviving patients for an average life expectancy. This 
extrapolation reduced the explicit nature of the study because a long period of the 
treatment's effect. which had a large impact on the results of the study. was not 
analysed transparently. The authors had access to relevant data covering the longer-
term outcomes of the patient group. but the decision tree did not facilitate the full 
incorporation of such data. 
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2.3 Markov models 
Within Markov models, events are modelled as transitions from one health state to 
another. The time horizon covered by the model is split into cycles of equal length. At 
the end of each cycle a patient may move to a consequent health state, or remain in the 
same state (unless the current state is a tunnel state). This process of moving between 
states continues until a patient enters an absorbing state, such as the state • dead' . 
Markov models are commonly described as being either a Markov chain or a ?\Ilarkov 
process, which differ in their representation of transition probabilities between health 
states. In a Markov chain the occurrence of events is determined by probabilities that 
are conditional only upon the current health state. In a Markov process, transition 
probabilities are also conditional on the current health state, but they may also vary 
according to the overall time spent in the model. Markov processes are particularly 
effective in clinical situations which involve continuous risk over an extended time 
horizon [Sonnenberg and Beck, 1993]. 
Utility values can be attached to each health state modelled, reflecting the severity of 
the state; similarly, costs are attached to individual health states to reflect the cost of 
remaining in a particular health state for the length of one cycle. A Markov model's 
outputs are estimated by multiplying the respective costs and utility values by the time 
spent in each health state, and then summing across all possible states. 
There are three alternative methods available to evaluate Markov models. The matrix 
algebra solution is the purest (from a mathematician's perspective), but is rarely used 
due to the easy availability of computer power. A second approach analyses Markov 
models stochastically, whereby large numbers of individual patients are followed 
through the model. Monte Carlo simulation is used to randomly generate values from 
distributions that reflect the relevant transition probabilities. (This application of \10nte 
Carlo simulation is referred to as first-order simulation. It should not be confused with 
second-order simulation, which samples the actual values of the transition probabilities 
from probability distributions (see section 3.4.3)). For example, if patients can move 
from state A to either state B or C and the respective probabilities are 0.75 and 0.15. 
each patient in state A will sample a value representing either state B or C from a 
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commensurately defined binary distribution. However, the most common approach in 
the economic evaluation of health care technologies is the cohort method, which is a 
deterministic analytic approach that follows a cohort of patients through the model. At 
the end of each cycle the proportion of patients remaining in a state is multiplied by the 
relevant transition probabilities to determine how many patients move to each 
consequent state. It should be noted that the choice of evaluative method does not affect 
the characteristics of the modelling technique. 
Figure 2.2 presents a simplified version of a Markov process used to evaluate the cost-
effectiveness of various adjuvant therapies applied to a range of breast cancer patients 
[Hillner and Smith, 1991; Hillner and Smith, 1992a; Hillner and Smith, 1992b]. The 
arrows between the health states indicate the possible pathways, until patients reach the 
absorbing state 'dead'. The authors stated that their reasons for taking a Markov 
approach were 'the relatively long time-frame and the time-dependent nature of the 
events considered' [Hillner and Smith, 1991]. 
Figure 2.2 An illustrative example of a Markov model comparIng adjuvant 
therapies for early breast cancer 
Cycle 
2 
3 
Adapted from Figure 1 [Hillner and Smith, 1992a] 
The remainder of this section on Markov models describes some of their limitations 
relating to the lack of memory and the need to specify constant cycle lengths, as well as 
means of overcoming these problems. The final illustration describes the combination 
of decision trees and Markoy models. 
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Firstly, an often-cited drawback of Markov models is their lack of memory. which 
means that the probability of moving from a particular state is not influenced by the 
route taken to arrive in the state. This assumption of the irrelevance of the history of 
patients is known as the Markovian assumption [Klein et aI, 1993]. The follo\Ving 
examples illustrate the differing impacts of this assumption. Danese et al [1996] 
modelled a screening policy for mild thyroid failure against a no screening scenario. 
The model consisted of a wide range of health states encompassing initial clinical states. 
clinical states of mild thyroid failure and related states (uncomplicated angina, MI, 
intermittent claudication and cerebrovascular accident). The model focussed on the 
immediate health states following screening - the clinical states of mild thyroid failure -
with little detail given to the related cardiovascular health states. The analysis of the 
related overt hypothyroidism and cardiovascular health states could have been 
expanded, but it is likely that this would have required stronger assumptions to 
compensate for the lack of memory within the model. It is not clear whether the model 
structure was unduly influenced by the presence of the Markovian assumption. 
Jonsson et al [1993, 1995] looked at treatment intervention in patients with established 
osteoporosis in order to reduce the risk of fractures. The Markovian assumption 
hindered the incorporation of differential probabilities for patients who had, and had 
not, experienced a fracture. The model was based on yearly calculations of risk. 
Patients could move from a healthy state to either death or a fracture state. Following a 
hip fracture, they were assumed to remain in one of three hip fracture states, reflecting 
varying quality of life, until death. The risk of a second hip fracture, re-operation, etc., 
was included in the associated cost and quality of life values of the hip fracture state. 
Following a year spent in any of the alternative fracture states all patients returned to the 
healthy state with no continuing impact on their risk of mortality, and were subject to 
the fracture risks again. This study appears to employ stronger assumptions about the 
risks of fractures that could be overcome if the patients' treatment histories could be 
recorded. 
Technically, the Markovian assumption may be overcome by splitting health states so as 
to describe the path taken to reach the present state, for example, state C could become 
"state C after state A' and "state C after state Bit. An alternative approach IS 
demonstrated by Sharples et al [forthcoming], \\'ho used linked Markov chains to 
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analyse the cost of the main clinical events following lung tansplantation. F ollo\\lng 
transplantation patients could be in one of five health states - well, rejection. 
cytomegalovirus, infection (non-CMV) or dead. The first Markov chain coyered the 
first six months post-transplant. The second model covered the subsequent six months 
and included the possibility of developing BOS, a condition that alters the probability of 
experiencing the other health states within the model. At the point at which patients 
developed BOS they were transferred to a subsequent model with the same structure but 
alternative probabilities of experiencing the events described above. 
The memory less nature of the Markov model also impacts on the ability of the model to 
analyse subsections of an aggregate patient group who might haye differential 
characteristics that influence their pathway probabilities. 
Johannesson et al [1991] used a Markov model to investigate the cost-effectiveness of 
cardiovascular disease prevention using 8-year logistic risk equations for Coronary 
Heart Disease (CHD) and stroke. The values of age, sex, diastolic blood pressure, 
serum cholesterol, smoking, glucose intolerance and left ventricular hypertrophy, for 
each patient, were determined at the start of the model. Patients were subject to three 
forms of risk - CHD, stroke, and death from other causes. CHD was divided into five 
separate states - immediate death, recognised MI, unrecognised MI, angina pectoris and 
coronary insufficiency. From each of these health states, as well as from stroke, the 
only possibility was to remain in that state or to die. The values of the risk factors were 
varied according to the use of different interventions, but not to alternative patient 
characteristics. If the policy question referred to the aggregate patient group, separate 
analyses of the constituent groups would need to be combined to calculate the relevant 
cost-effectiveness results. 
Another limitation of the standard Markov model is that a single time period for a cycle 
must be chosen after which patients are allowed to move to the next health state [Klein 
et aI, 1993]. The length of a cycle is chosen to represent a clinically meaningful time 
period and to reflect the available data [Beck and Pauker. 1983]. For example. in 
choosing one month as an appropriate cycle length to evaluate the cost of glaucoma 
treatment Kobelt and Jonsson [1999] stated that longer cycles would not reflect clinical 
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management accurately, whilst shorter cycles would misrepresent clinical observation in 
glaucoma. 
If the events modelled are subject to different meaningful periods a Markov model can 
be inflexible. Anton and Revicki [1995] evaluated the cost-effectiveness of 
antidepressants for major depression. The time horizon for the model was the lifetime 
of patient's, who were assumed to be 30-year old women. A Markov cycle of one year 
was chosen to reflect the probability of patients recovering from depression or recurring 
from remission over the course of their lifetime. Within the course of a year spent 
receiving treatment for an episode of depression the effects of five separate states \\ith 
varying cost and utility values were calculated outside of the model. 
It is possible to link separate Markov processes using differing lengths of cycles, each 
describing a particular section of a patient's possible prognosis, as described above 
[Sharples et aI, forthcoming], though such an approach is dependent on suitable patient 
pathways, and does increase the complexity of the modelling task. 
Markov models are often used effectively in conjunction with decision trees. In 
evaluations that comprise numerous events within the early part of the model, Markov 
models are then attached to the terminal nodes of the decision tree to describe less 
complex patient pathways in the following years. This approach utilises the simpler 
mechanisms of the decision tree to describe events that occur only at the beginning of 
an extended time horizon. 
Eckman et al [1995] combined a decision tree and a Markov chain to examine the cost-
effectiveness of approaches to the diagnosis and treatment of patients with type 2 (non-
insulin-dependent) diabetes mellitus who have foot infections and suspected 
osteomyelitis. The pathway of patients up to a constant health state, including diagnosis 
and initial treatment of the condition, was modelled within a decision tree format. The 
initial tree differentiated between medical and surgical treatment options, following a 
variety of testing strategies that related to either a high sensitivity or a high specificity 
of the diagnostic procedure. The tree also incorporated the possibility of recurrent 
infection or initial treatment failure. Thereafter, the surviving patients entered a ~vlarkov 
chain where patients could die of diabetes, of a co-morbid disease, or according to the 
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age-specific mortality rate of the general population. The Markov chain was yery basic. 
The lack of descriptive states in the Markov chain appears to reveal more about the 
authors' concentration on the initial treatment section of the model, and their assumption 
of subsequent constant costs and utility, than the shortcomings of Marko\' chains. 
2.4 Discrete event simulation (DES) 
Both DES models and Markov processes are forms of simulation, though DES allows 
more complicated representations of the system being modelled [Hillier and Lieberman, 
1995]. Within DES, patients move through the model experiencing events at any 
discrete time period after the previous event. DES models may only be analysed 
stochastically using first-order Monte Carlo simulation as described in the previous 
section. This is because DES is event-orientated, whereby the model asks what and 
when is the next event for every patient at each event, rather than a Markov model, 
which asks what events are occurring at regular intervals. The analysis of second-order 
uncertainty is similar for both modelling techniques, consisting of testing alternative 
combinations of input parameters by undertaking multiple runs of the models. 
The following section describes and provides examples of the main advantages of DES 
over Markov models, namely increased flexibility over data requirements and an ability 
to overcome the restrictions of the Markovian assumption. Two potential disadvantages 
are also described, concerning the dangers of overspecifying models and the need for 
increased analytic input. 
The greater flexibility of DES with respect to the required data was demonstrated by 
Hart et al [1997] who used DES to estimate the direct lifetime costs of an insulin-
dependent diabetes mellitus (IDDM) patient. Only those chronic conditions assumed to 
have the greatest economic impact were modelled - nephropathy, retinopathy and 
cardiovascular complications. Unaffected patients entered the system and were 
assigned a probability of developing IDDM, as well as a corresponding time of 
diagnosis. Individual patients' experience of chronic health states associated with 
IDDM were sampled from probability distributions representing incidence rates and 
times of onset. An overall time to cardiovascular complications for a proportion of all 
IDDM patients was calculated. If the simulated time to death after diagnosis was 
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greater than the average time to cardiovascular complications an adjustment to costs and 
life expectancy was made. For retinopathy complications the proportion of patients 
requiring photocoagulation increased with duration of the disease, for which costs were 
incorporated into the model using an algorithm describing the increasing: incidence oyer 
time. 
Urban et al [1997] used a stochastic simulation model to simulate the natural 
progression of ovarian cancer. A screening programme was then superimposed, and the 
change in life years gained and costs evaluated. A public use database was used to 
estimate the proportion of women diagnosed in 5-yearly groups and in each stage of 
diagnosis (local, regional or distant). Assuming a uniform distribution within the 5-
yearly groups, an exact age (month) at diagnosis for each patient was sampled, as well 
as a stage from the calculated distribution of stages at diagnosis. The length of each 
subsequent stage was determined in relation to the length of the local stage. Women 
were then randomly assigned a percentile in the relevant age- and stage-specific 
empirical survival distribution. Age at death was calculated by adding survi\'al time to 
age at diagnosis. An average cost for each disease stage was assigned to the time spent 
in each stage. Various combinations of transvaginal sonography and/or the tumour 
antigen CA 125 were inserted into the model. The stage, timing within a stage, and the 
sensitivity of each of the screening tests were all defined in relation to specific 
distributions. When screening resulted in earlier detection, a new age at death was 
assigned by indexing the new relevant age- and stage-specific survival distributions, and 
adding survival to age at diagnosis following detection by screening. The input data' 
used to populate the model were inputted in their original formats, such as the specific 
length of time to the occurrence of another event, rather than transforming data as 
would be required using a Markov model. This increases the realism of the model. 
DES overcomes the limitations of the Markovian assumption by assigning attributes to 
patients that describe relevant characteristics or their treatment history, which may 
influence their pathway through the model [Davies and Davies, 1987]. For example, 
patients may be assigned an age or stage of cancer, prior to entering the model, they 
may also acquire attributes as certain events within the model are experienced. In 
addition, patients may have attributes that influence the costs and/or utility values 
associated with a particular state. In the absence of patient attributes. costs and utility 
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effects are incorporated in a similar manner to Markov models, whereby costs and 
utility values are attached to each health state within the model and the time spent in 
each state is multiplied by their respective values. 
The MISCAN (MIcro simulation SCreening ANalysis) model, developed by Habbema 
et al [1984, 1987] to simulate models of mass screening for disease, demonstrates the 
use of patient attributes whereby the experience of previous health states, and their 
duration, influenced the duration in subsequent health states. The simulation described 
here was based on models of the natural history of cervical cancer. and the change in the 
natural history due to screening. Disease history was represented by a sequence of 
disease states and the ages at which a person entered these states. The model was split 
into seven categories of health states - not at risk of cervical cancer due to previous 
hysterectomy, screen-eligible states (normal, pre-invasive or pre-clinical invasive), 
clinical states (clinically or screen-detected cancer) and end states (death from cancer 
and death from other causes). Transitions between states were based on probabilities. 
and each transition had a corresponding probability distribution describing when the 
transition will occur. The attribute "age" could also influence transition probabilities. 
An additional feature of the model was that the time spent in a state could depend on the 
dwelling time in the previous state, which would be useful, for example, if there was a 
relationship between the growth rates of different stages of the disease. 
Warner et al [1996] used a "stochastic, discrete event, object-oriented simulation" to 
investigate the health and economic implications of a smoking-cessation programme in 
the workplace. Model complexity was reduced due to the assignment of attributes to 
workers, both before and during their time in the system, which influenced their 
transition probabilities. The events within the model related to the actions of quitting 
smoking, leaving the firm, retiring and dying. The model was run twice, with and 
without the smoking-cessation programme in place. On activating the programme. 
smokers had a higher probability of quitting smoking, which sequentially influenced 
other variables of interest (mortality, medical costs, etc.). Each worker in the model 
was assigned an age, sex, time at firm and smoking characteristics that influenced their 
progression through the model. At the end of every year age was increased by one year. 
as well as other variables, such as years of smoking or smoking cessation. which in turn 
influenced progression through the model. If a worker neither died. retired. nor left the 
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firm, he/she continued cycling through the model. Former workers who either left the 
firm or retired were subject to only two probabilistic events - background (non-
programme-related) smoking cessation and dying. 
A possible drawback of DES is that an analyst may attempt to make a decision model 
overly complex due to the increased flexibility of DES [Balmer and PauL 1986]. 
Ideally, a model would describe reality as closely as possible. However. there are two 
constraints on data collection, and hence, on the complexity of a decision model: limited 
research resources and the need to inform policy within a limited timeframe. Though 
the most important elements of a model cannot be objectively tested until the final 
analysis of the model, it is possible to identify parameters on the periphery of the model 
that could be safely excluded. An example of underplaying the capabilities of DES 
because the identified data did not warrant a more complex representation of events is 
provided by the model used to estimate the costs associated with IDDM [Hart et aI, 
1997]. As described above, this model included the impact of cardiovascular and 
retinopathy complications as affecting a proportion of all patients if death did not occur 
before the average time to the occurrence of such complications. Such a portrayal of 
events was all that the available data supported, though the events could have been 
modelled in much more detail given the capabilities of DES, but more complexity may 
have distorted the available data. 
Finally, DES models are generally more complicated to build as they are based on the 
use of programming code. Three of the four examples quoted above used complex 
programming languages (Gauss, FORTRAN and Objective-C). Though the advent of 
'visual interactive modelling systems' assists the development of DES models, without 
the need for 'proper' computer programming [Pidd, 1998], the additional features of 
DES do increase the complexity of the modelling task. 
2.5 Criteria/or comparison 
Two broad criteria on which decision modelling techniques can be compared are the 
quality of the decision model and the corresponding analytic input. The following two 
sections describe the issues relating to these two criteria, which form the basis for the 
empirical comparison of the alternative modelling techniques undertaken in this thesis . 
., .. 
-,j 
Alternative modelling techniques 
2.5.1 Model quality 
It has been argued that the true test of the quality of a decision model is in tenns of its 
value to the decision-maker(s) as the ultimate aim of the model is to help the user reach 
a better infonned and rational decision [McCabe and Dixon, 2000]. In principle the 
quality of a model could be tested by randomising decision-makers to use and not to use 
a model, with quality being proven if the outcomes associated with the model-based 
decisions are better than those associated with the control group [Sculpher et aI, 2000]. 
Unfortunately, in practice it is probably not feasible to test models in this manner and 
softer, more subjective measures of quality are necessary. Recent guidelines on 
estimating cost-effectiveness in health and medicine referred to decision models being 
as good as their ability to represent reality 'at the level needed to draw useful 
conclusions', noting that this depends upon model structure and the assumptions 
regarding relationships between model parameters [Mandelblatt et aI, 1996]. 
Indeed, most of work that has attempted to describe positive aspects of decision model 
design has been reduced to general statements that can only be interpreted subjectively. 
The following quotes provide examples: 
'models should be kept as simple as possible to aid understanding by decision makers.' 
[Buxton et aI, 1997] 
'it is important that the possible pathways described by the model are feasible and 
sensible.' [McCabe and Dixon, 2000] 
'the analyst should choose the type of model ... selecting the simplest fonnat which 
adequately reflects the disease.' [Sculpher et aI, 2000] 
The main conclusion drawn from these examples is that good modelling practice can 
only be developed in general terms because the application of the derived principles 
'requires knowledge of the clinical domain and involves subjective judgement' 
[Sonnenberg et aI, 1994]. The derivation of criteria for the comparison of alternative 
modelling techniques is also based on this principle of generalisability. The approach 
sought to link the desirable characteristics of a model with the differential 
characteristics of the modelling techniques and detennine the importance of each 
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characteristic in the representation of patient pathways. Sculpher et al [2000] grouped 
the dimensions of quality into three categories - the structure of the model. data, and 
consistency - which described the areas in which the choice of modelling technique 
could affect the quality of a modelling project. Sonnenberg et al [1994] classified 
alternative models by their design and use of time as a model function. The discussion 
around model quality, therefore, covers three broad areas; representation of time. 
structural considerations and data flexibility. 
The main characteristics of the decision tree are that any event within the tree may 
happen only once and that the timing of the events within the model can only be 
incorporated in the tenninal nodes. As the other two modelling techniques handle long 
time horizons more adequately the first statement over the choice of modelling 
technique relates to the required time horizon. 
1. If anything other than short-term outcomes are to be modelled decision trees are an 
inappropriate choice of modelling technique. 
This does not mean that decision trees are necessarily the right choice to model short 
time horizons, but the following discussion concentrates on the representation of 
extended time horizons within decision models. At present the main techniques 
available to incorporate such time horizons are Markov models and DES. 
The structure of the model refers to the actual health states included in the model, as 
well as the relationships between them. The inclusion of relevant health states would 
appear to be similar in Markov models and DES, but differences do emerge in the 
ability of the two techniques to represent certain relationships between health states. 
The crux of the difference is the Markovian assumption that infonns the relationship 
between any two health states only on the basis of the current health state and the 
overall time spent in the model. This assumption is not necessarily a hindrance as the 
natural history of many chronic diseases can be approximated by state of health and 
time since diagnosis [Beck et al, 1994]. Problems are apparent in other disease areas. 
such as cancer, where the transition probabilities between stages depend on the length of 
time spent in each state [Beck and Scardino, 1994]. Similarly, the probability of 
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patients with a history of depression experiencing further episodes of depression is 
dependent on the length of time they spend as asymptomatic [Nuijten et aI, 1995]. 
Alternatively, there are evaluative areas in which the route taken to reach a particular 
state will influence the pathways out of the state. For example, in an evaluation of a 
hospital at home scheme versus conventional inpatient care for elderly patients, the 
probability of experiencing a readmission following discharge differentiated between 
patients admitted to the scheme through the accident and emergency department and 
from inpatient wards [Campbell et aI, 2000]. Such instances do not necessarily preclude 
the use of Markov models as subsequent states can be described with reference to the 
experience of previous states. 
The following quality statements set out the basis for the structure of the model to 
correspond as far as possible to the reality of the disease. 
2. If model parameters are a function of the time spent in particular states DES will 
more accurately reflect the true relationships between health states. 
3. If the specification of similar health states that differ only with respect to the 
experience of previous states compromises the clarity of the model, the use of DES 
should be considered. 
The main issue around the use of data within decision models relates to the accurate 
depiction of the timing of events. The probability of an event occurring within a 
Markov model must always be defined as a function of cycles of fixed duration. This 
format can cause problems if an event is likely to occur within a specified time period 
and the state from which the event occurs is not an initial state. Another data-related 
issue concerns the specification of the length of a cycle in a Markov model. This 
characteristic means that when two events of widely differing duration are included in a 
model the representation of the timing of one of the events is likely to be unrealistic. 
F or example, a model describing the lifetime treatment costs of patients with sickle cell 
disorders would necessarily include a range of acute and chronic conditions [Kamon et 
al, 2001]' Acute conditions typically occur sooner and more frequently than chronic 
conditions. If a cycle length of I-month is chosen to reflect the length of acute events 
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then the time spent in the chronic states must also be represented as monthly 
probabilities. In a DES model the timing of events is completely flexible. Such data 
can be represented as the probability of an event occurring at specified times or the time 
to an event can be stated directly. 
The fourth quality statement covers the flexibility of the modelling technique with 
respect to the realistic representation of the data. 
4. If the data describing the timing of events are not in the form of transition 
probabilities then DES will provide a truer representation of reality. 
2.5.2 Analytic input 
The level of analytic input associated with the alternative decision modelling techniques 
encompasses two aspects. Firstly, the issue of available expertise may be relevant. 
Though increasingly user-friendly software for the development of DES models is 
available, there remains a steeper learning curve associated with the use of DES as 
opposed to the relative simplicity of developing and analysing Markov models. 
Secondly, Markov models and DES may differ significantly in the time required to 
build, and experiment with, the model. Obviously, the time spent building the model 
will be a function of the expertise of the analyst, but the greater flexibility of DES is 
only achieved through added complexity, which increases the likelihood of modelling 
error. The cohort method of analysing Markov models is adequate for the majority of 
economic evaluations in health care (this issue is developed further in Chapter 3). 
Experimentation with a DES model can only be undertaken using first-order Monte 
Carlo simulation, which requires much longer experimentation times than cohort 
analyses. It should be borne in mind that the time to build and analyse a decision model 
covers the testing, verification, validation, baseline analysis and sensitivity analyses 
undertaken. The following statement, regarding analytic input, relates to the availability 
of such input. 
5. The advantages of DES need to be weighed against the additional resource 
requirements. Realistic assessments of the necessary inputs should inform the 
choice of modelling technique. 
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Conclusions 
The preceding sections described the varying characteristics of three alternative 
modelling techniques that have been used to model the cost-effectiveness of health care 
technologies and possible criteria for the comparison of these alternatives. Preliminary 
inferences can be drawn from the discussion with respect to the general characteristics 
of treatment areas that are best suited to the alternative modelling techniques. 
Simple scenarios occurring over a short time horizon may best be modelled using a 
decision tree. Markov models allow longer time periods to be analysed, in \vhich the 
risks of events are continuous, and the timing of an event is uncertain [Sonnenberg et aL 
1994]. Such models do not impose unduly restrictive assumptions unless the treatment 
area of interest conflicts with the Markovian assumption of pathway independence. In 
such cases, DES may be viewed as a superior technique. The biggest advantage of DES 
appears to be that it allows the analyst to model more complex and dynamic systems 
than other types of modelling, as well as permitting experimentation that might not be 
feasible otherwise. The greater flexibility inherent in the use of discrete event 
simulation may also enable the model to capture more detail about the uncertainty in the 
system being modelled [Bolger and Davies, 1992]. 
The choice of modelling technique should be based on an in-depth assessment of the 
particular disease area. The process of matching the characteristics of the alternative 
modelling techniques to the disease area, as described above, should provide an 
indication of the specific differences in the quality of prospective models. Such 
differences should then be traded against the more objectively defined variation in the 
required analytic inputs. 
Five statements linking issues of model quality and analytic input to the main modelling 
techniques employed in the economic evaluation of health care have been defined in 
this chapter. The statements, presented below, will form the basis for the comparison of 
the alternative modelling techniques that will be developed in the remainder of this 
thesis: following the empirical application of the competing techniques the associated 
modelling process and cost-effectiveness results will be assessed on the basis of these 
five statements. The application of this approach to the retrospective identification of a 
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'good' model in the case study presented in this thesis will test this process for the 
prospective determination of the appropriate modelling technique for indiyidual disease 
areas. 
1. If anything other than short-term outcomes are to be modelled decision trees are an 
inappropriate choice of modelling technique. 
2. If model parameters are a function of the time spent in particular states DES will 
more accurately reflect the true relationships between health states. 
3. If the specification of similar health states that differ only with respect to the 
experience of previous states compromises the clarity of the model, the use of DES 
should be considered. 
4. If the data describing the timing of events are not in the form of transition 
probabilities then DES will provide a truer representation of reality. 
5. The advantages of DES need to be weighed against the additional resource 
requirements. Realistic assessments of the necessary inputs should inform the 
choice of modelling technique. 
The modelling process 
Chapter 3 The modelling process 
3.1 Introduction 
This Chapter aims to provide the framework for the empirical application of alternative 
modelling techniques that will be described in the following Chapters. The full process 
for developing and analysing an economic health technology assessment (HT A) 
decision model is described from the point of setting up a project to the final 
experimentation with a computer-based model. The formulated process will be adopted 
explicitly in the case study evaluations, which will enable the process itself to be 
evaluated in the final Chapters of this thesis. At this stage the choice of modelling 
technique is left open because the underlying process of a modelling project is similar 
regardless of the type of model employed. 
To inform the modelling process a wide-ranging literature search was undertaken, 
incorporating texts from the disciplines of medicine, social science and operations 
research. The details of the search are provided in Appendix 1. 
A well known source of guidance for clinical decision analyses is the seminal 
publication by Weinstein and Fineberg [1980], though earlier papers had applied the 
techniques of decision analysis to clinical research. In particular, Kassirer published an 
introduction to decision analysis in a clinical context in 1976. The main limitation of 
both these sources was that they concentrated on the principles of decision trees. only 
providing a brief summary of other aspects of the process such as the assignment of 
probabilities. Indeed, the majority of the identified texts covering the use of decision 
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models within the evaluation of health care technologies focussed on the principles of 
the use of specific modelling techniques rather than other aspects of the modelling 
process [McNeil and Pauker, 1984; Detsky et aI, 1997; Beck and Pauker, 1983: Briggs 
and Sculpher, 1998]. 
The most useful publications relating to the process of modelling projects in health care 
were those that did not focus solely on the principles of the modelling techniques, but 
rather on a framework for modelling studies. Three sources were identified that aimed 
to improve the general process of undertaking medical decision analytic models [Eddy, 
1985; Sonnenberg et aI, 1994; Sculpher et aI, 2000], whilst another paper aimed to 
increase standardisation with regard to modelling practices [Halpern et aI, 1998]. Each 
study produced good practice recommendations. In addition, general texts from the 
operations research and social science literature were sought to inform various aspects 
of the modelling process. 
The remainder of this Chapter is split into five sections covering the modelling process 
in chronological order: 
1. Specifying the theoretical model; 
2. Undertaking of a literature review to obtain data to populate the model; 
3. Analysis of the identified data to populate the model; 
4. Implementation of the model; 
5. Experimentation with the model. 
3.2 Specifying the theoretical model 
Sonnenberg et al [1994] constructed a framework of progression from the decision 
problem to the resulting model. Using current knowledge, their first step required the 
development of a theoretical model that represents the initial understanding of the 
possible pathways experienced by patients. The problem should be structured in an 
attempt to understand the issues that need to be addressed within the model [Pidd, 
1998], by specifying a set of assumptions that take the form of logical or mathematical 
relationships comprising possible patient pathways [McHaney, 1991]. The 
development of the theoretical model may be clarified using simple diagrams to 
represent the relationships, such as influence diagrams [Marshall and Oliver, 1995], or 
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activity cycle diagrams [paul and Balmer, 1993]. Gottfried lists several early questions 
to guide the construction of the conceptual model [Gottfried, 1984]: 
• 
• 
What are the relevant problem parameters? What are the state variables, the decision 
variables and the system parameters? 
What are the pertinent cause and effect relationships? How can they be expressed in 
mathematical terms? 
• What data are required? Are the data readily available? If not, how much effort is 
required to obtain meaningful data? 
The main parameters of interest to the health economist are the state variables, which 
are chosen to represent patient pathways. In the vast majority of economic evaluations, 
the only decision variable relates to the objective of the evaluation. Two types of 
system parameters are apparent in economic HT A models. One system parameter is the 
patient group of interest. The definition of the relevant patient group for an evaluation 
is obviously an important topic and is discussed below under 'study inclusion criteria'. 
The second system parameter describes the scope of model, which determines the range 
of events included in the model. For example, limited scope models concentrate only 
on those events that have cost implications for the health service, which can be 
broadened to include events that impact on the costs incurred by the patient and society 
in general. 
Interrelationships within an economic HT A model are possible in the sense that the 
occurrence of an event along a patient pathway can influence the likelihood of the 
patient experiencing another particular event(s). Such knowledge is useful as an 
indicator of the data that will be required to populate the model and may be 
incorporated into the strategy adopted for the identification of data. It may also affect 
the choice of decision modelling technique. Goodwin and Wright [1998] highlight the 
problem of biased assessment of correlation as a source of modelling error. People 
often see non-existent associations between events because they can easily imagine the 
events occurring together. It is, therefore, particularly important that any assumed 
relationships between variables within the model are confirmed by available data. 
The modelling process 
Most modelling textbooks encourage the development of models with the least amount 
of detail that maintains the veracity of the model [McHaney, 1991]. A cyclical process 
may be enacted whereby increasing detail is added until the structure of model satisfies 
all parties involved in the evaluation. 
3.3 The literature review 
Most economic HT A decision models collect and integrate data from the existing 
literature. Ideally, such data would be identified using similar methods to those used in 
systematic reviews, being comprehensive, rigorous and explicit. The aim of a literature 
review has been interpreted as the avoidance of missing useful studies placed in sources 
'outside one's habitual purview', not identifying every paper that is somehow related to 
the area of interest [Sutton et aI, 1998]. 
There is a substantial methodological literature on systematic reviews, covering each of 
the main stages: study questions, study inclusion criteria, search strategies, study 
validity (quality), data extraction, and data analysis. The proposed methods for dealing 
with each of these issues should be described explicitly in the review protocol, which 
should be specified before the main study commences. The following sub-sections 
describe the development of the study questions, study inclusion criteria, search 
strategies, and data extraction, whilst methods for pooling the data (including a 
discussion around data quality) are covered in the next main section (Analysing the 
literature review data). However, prior to the development of the review protocol some 
background work is required to inform its structure [NHS Centre for Reviews and 
Dissemination, 1996]. This initial task consists of a brief literature search for two 
purposes. Firstly, it is necessary to estimate the volume of literature in the field so that 
an estimate of the size of the review can be made. Secondly, it is useful to have an idea 
of the most frequently employed study designs in the area of interest in order to inform 
the study designs included in the review. 
3.3.1 Study questions 
A series of study questions should be raised for separate elements of patients' pathways 
within the preliminary model, which can be treated as separate reviews. For example, a 
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typical economic HT A decision model might require separate questions to describe 
treatment side effects, response to treatment, and progression from response, as \vell as 
for the collection of resource use, cost, and utility-based data. 
Real associations between parameters can be missed because there was no prior 
expectation of such a relationship [Goodwin and Wright, 1998]. It may be advisable to 
facilitate the collection of qualitative data within the review process so that potential 
relationships may be uncovered even if they were not hypothesised a priori. 
3.3.2 Study inclusion criteria 
Sutton et al [1998] identified four areas in which study inclusion criteria should be 
specified: 
• Relevant patient groups 
• Health intervention/technology of interest 
• Outcome measures used 
• Types of study design 
Sonnenberg et al [1994] promoted the use of generic models that are applicable to a 
representative population or a broad category of patients, which would appear sensible 
to maximise the potential outputs of a model. It is important to recognise that the 
relevant patient group for reviews informing parameters within the model will probably 
be a subset of the aggregate patient group. For example, the original patient group may 
be split between responders and non-responders further down the patient pathways. 
The explicit limiting of a literature search by defining inclusion criteria relating to the 
sources of data is not recommended in guidelines for systematic reviews or meta-
analyses [Sutton et al, 1998; NHS Centre for Reviews and Dissemination, 1996]. 
However, the specification of multiple study questions relating to different events 
within a decision model means that the research burden can escalate very quickly, 
especially in treatment areas for which data are plentiful. In such cases, the need to 
populate the model with the 'best available data' [Buxton et aI, 1997], must be balanced 
against the time and resources available to complete the study; 'best' may be redefined 
as 'sufficiently robust to engender confidence in the model inputs'. Additional 
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inclusion criteria may be specified that relate to the intensity of the search. such as 
restricting the search by setting a cut-off year, or excluding sources on the basis of 
methodology, for example, the review could be restricted to trial-based data. 
Alternatively, non-English language studies could be excluded. Research into the 
hypothesised Tower of Babel bias has been undertaken [Gregoire et al. 1995], but no 
evidence of the expected bias against negative studies was identified. An obvious 
inclusion criteria is to seek only published work, though such a criterion could be 
subject to publication biases, whereby negative results are less likely to be published. 
However, focusing solely on published research is legitimate in two circumstances. 
Firstly, if the quantity of published research is large it is unlikely that the direction of 
the aggregated results will be wrong, although the magnitude may be overestimated. 
The magnitude of any differences between intervention should then be interpreted 
cautiously. Secondly, the parameter of interest to the study question may not be the 
primary focus of the research identified. The bias towards significant results in 
publications is unlikely to apply to secondary results [Cooper, 1998]. 
These extra criteria can be relaxed with respect to some threshold of data quantity or 
quality for the individual study questions. F or example, if few data, or data from poor 
quality studies are available during the initial review, then the inclusion criteria can be 
progressively widened until sufficient quality data are identified. The collection of 
additional data may also form part of an iterative procedure, whereby the model can be 
improved by obtaining additional data on key parameters that are identified by a 
sensitivity analysis of a populated model. 
3.3.3 The literature search 
The literature search defines the sources that are inspected for relevant data based on the 
specified inclusion criteria for each study question. It is quite feasible that different 
ranges of sources will be employed for study questions aimed at populating alternative 
sections of the decision model. The following paragraphs describe various data sources, 
though comparisons are difficult because there has been little empirical research on their 
respective merits [Cooper, 1998]. The easy access available to electronic databases, 
such as Medline, via the Internet, makes them an obvious starting point, though the 
EMBASE and SCISEARCH databases are recommended for inclusion in any 
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systematic reVIew [NHS Centre for Reviews and Dissemination, 1996]. Other 
databases include the database of abstracts of reviews of effectiveness and the NHS 
economic evaluation database, both provided by the Centre for Reviews and 
Dissemination, and HEED, the economic evaluation database provided by the Office of 
Health Economics. Variable success has been reported for searches of electronic 
databases, which may be due to narrow searches or inadequate indexing on the part of 
database compilers or the relevant authors [Sutton et al, 1998]. 
Other sources include research registers, such as the NHS Research Register and the 
Cochrane library. Registers can contain information on research studies, based in the 
past, present and/or future. The precision of such databases is improving continuously 
and hopefully they will soon become the most reliable source of data, both published 
and forthcoming [NHS Centre for Reviews and Dissemination, 1996]. Additional 
studies are often unearthed through handsearching journals and scanning the reference 
lists of retrieved studies. Similarly, scanning the contents of relevant conference 
proceedings can provide details of the current state of knowledge and what research has 
recently been completed, usually before it has been published [Rosenthal, 1994]. Data 
may also be identified through informal channels that include the personal solicitation 
of research, by contacting individual researchers about any relevant research in which 
they have been involved. 
If no usable data for a particular model parameter is identifiable it will be necessary to 
seek the opinions of experts in the field of interest. Two formal techniques have been 
identified that elicit the opinions of experts. The Delphi method involves sending an 
initial questionnaire to the chosen experts, the results of which inform the development 
of a second questionnaire. The second questionnaire is sent, along with the results of 
the first questionnaire, to the same experts. The attachment of the results from the first 
rounding of questioning empowers each expert with the same information for 
completing the second questionnaire [Hillier and Lieberman, 1995]. 
The expert group technique involves bringing together a group of experts who interact 
with each other to produce a consensus. The experts can be asked to specify a 
probability distribution. However, the Delphi method is generally preferred because it 
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does not attempt to forge a group consensus, the conclusions reached by an expert group 
may reflect the personalities in the group [Sculpher et aI, 2000]. 
Whichever sources are employed in a literature search an important criterion is that the 
results obtained should be reproducible. Thus, full details of the search methodologies 
should be provided enabling the interested reader to obtain similar results. 
3.3.4 Data extraction 
The process for extracting data from the identified studies should use a specified data 
extraction form. In the context of a series of literature reviews to populate an economic 
HT A decision model the development of an evidential database to collect and manage 
the relevant data is a useful tool. The development of such a database is described in 
Appendix 2. 
Recommended methods for the extraction of data state that it should be undertaken by at 
least two people [NHS Centre for Reviews and Dissemination, 1996], though the 
combination of limited resources and quantity of data may militate against such ideals. 
3.4 Analysing the literature review data 
The process of analysing the literature review data encompasses three broad activities, 
which are described in this section. Firstly, in the light of the identified data, both 
quantitative and qualitative, a reappraisal of the theoretical model should be undertaken. 
Secondly, the identified data should be appraised to ensure that the relevant variable 
definitions are the same. If not, it may be possible to harmonise the definitions by 
making adjustments to the reported data. Finally, the identified data for each input 
parameter should be pooled and arranged into a form that can be used to populate the 
model. 
3.4.1 Reappraising the model structure 
The theoretical model is developed primarily to inform the literature review. There are 
two reasons that the structure of the initial model may be altered. Firstly, additional 
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qualitative data may be identified that tends towards an alternative set of pathways to 
describe the progression of patients through the model. Alterations driven by an 
increased understanding of the treatment area are uncontroversial as they can only add 
to the validity of the model. 
The alternative source of change to a model's structure is the existence of insufficient or 
inadequate quantitative data to populate the model in its initial form. The extent to 
which the model structure should be based on the available data is a moot point. 
Sonnenberg et al [1994] define the practical model as 'the most detailed model that can 
be constructed given the limitations of available data', reflecting that such changes are 
'necessary and useful compromises' pgJS54. Sculpher et al [2000] warn that structuring 
models on the basis of the quality of data available could cause the loss of important 
clinical events. In their view the use of expert opinion to inform parameter values is 
always preferable to changing the original structure of the model because the sensitivity 
of the results to changes in the parameter values can be assessed. 
A general rule might state that extensions to the initial model informed by the identified 
data, which increase the detail of the model, should be accepted at this stage of the 
modelling process. Conversely, in cases where few data to populate certain sections of 
the model are identified, subtle modifications to the structure of the model may be 
enacted that rearrange the relationships relating to the 'difficult' parameters to reconcile 
the format of any available data. If such modifications fail to accommodate the 
available data then expert opinion may be sought to fill the void. It should be borne in 
mind that the process of obtaining the opinions of experts may result in such widely 
conflicting estimates that their inclusion detracts from the overall predictions of the 
model. 
The extent to which the model structure will need altering will be influenced by the 
scope of knowledge used to inform the initial structure and the complexity of the 
treatment area. The reassessment of the model structure at this stage of the modelling 
process should be regarded as a pre-emptive effort to improve the validity of the model, 
which will be affected by both the model structure and the input data. 
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3.4.2 Harmonising the identified data 
Combining the data involves the specification of the patient groups and interventions of 
interest, but also the tight definition of events included in the model. If large amounts 
of data are available it may be possible to use only the data that correspond to an exact 
definition of a particular event. If relevant data are not plentiful the analyst may be 
reluctant to discard data on the basis of subtle differences in the defmition of certain 
events and sometimes steps can be taken to improve the comparability of data from 
alternative sources. The process of harmonising the data makes explicit assumptions 
about the differences in the data presented by different studies and attempts to revise the 
results of outlying studies to a baseline definition of an event. Taking a hypothetical 
example, the common definition of an objective response to treatment may include a 
stabilisation of disease, but one identified study restricted the definition of objective 
response to an improvement in the disease condition. If the number of stable responses 
within this study is reported they can combined with the positive responses. If 
stabilisation is not reported, then to avoid losing the data from this study an estimate of 
the number of stable responses could be made by fitting the proportion of stable cases 
reported by the remaining studies to the odd study on the basis of study characteristics. 
The decision to harmonise data should be made carefully. For example, the analyst 
should be clear that the harmonised studies reflect the same underlying endpoint, 
otherwise the data may describe unwarranted variability in the observed value of an 
input parameter. If there appears to be underlying variation between the studies it may 
be necessary to control for heterogeneity using the methods presented in section 3.4.3.1. 
The process of harmonising the data cannot be subject to hard and fast rules as the 
adjustments made to the data will depend on the event described and the format of the 
available data. Some general principles can be identified, such as the estimation of 
missing values, but harmonisation is mainly determined by the individual circumstances 
of the modelling project. More details of the process of harmonisation are described in 
Chapter 5, where such methods are applied to the case study. 
3.4.3 Pooling and formatting the data 
The final stage of the input data analysis requires quantitative techniques to arrange the 
data into a suitable format for populating the decision model that allows for the 
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representation of uncertainty in the values of the input parameters. Unless the observed 
estimates for each parameter are identical it will be necessary to analyse the effect of the 
uncertainty in the values of the input parameters on the decision model's outputs. 
Methods for pooling and formatting data to populate deterministic and stochastic 
models are described in separate sections, following a brief discussion of altematiYe 
types of uncertainty. 
Exogenous sources of uncertainty relate to the structure of the model. The US Panel on 
cost-effectiveness advised that such uncertainty should be tested using alternative 
specifications of the model employing alternative assumptions with respect to the 
functional form of the relationships described in the model [Manning et al, 1996]. 
Briggs [2000] argues that assessing the multitude of assumptions that create a decision 
model is beyond the scope of a single analytic team and that structural forms of 
uncertainty should be assessed by different researchers. However, given limited 
research funds it may not be feasible to employ multiple research teams to 
simultaneously investigate the same research topic and some form of 'internal' 
sensitivity analysis of the model's structure may add to the comprehensiveness of an 
evaluation. Examination of this source of uncertainty is beyond the scope of this thesis, 
suffice to say that such sensitivity analysis would add significantly to the research 
burden of any modelling evaluation. 
Endogenous uncertainty must be handled within the experimentation of each defined 
model. There are two orders of such uncertainty - first and second. For any given set of 
input parameter values, first-order uncertainty describes the variation in the results of a 
decision model at the level of the individual patient. Each patient is subject to the same 
probabilities of experiencing an event from a particular state at any given time, so the 
variation observed between patients is due entirely to the 'inherent uncertainty of the 
probabilistic structure of the model', which can be interpreted in a similar manner to the 
variation observed in a clinical trial [Briggs, 2000]. First-order uncertainty can only be 
measured using decision models that follow individual patients through the model and 
record the individual estimates of costs and effects. 
Running larger numbers of patients through the model will provide a more accurate 
representation of the mean outcomes for the population of patients, but the estimates of 
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variation (the standard deviations) will be a function of the number of patients run 
through the model. Some analysts have used the number of patients expected in a 
particular location in a given time period to estimate the standard deviations in order to 
represent uncertainty more realistically, reflecting the context of the analysis [Sharples 
et aI, 1996; Szeto and Devlin, 1996]. However, the description of fust-order uncertainty 
is irrelevant to the representation of uncertainty for resource allocation using cost-
effectiveness data [Briggs, 2000]. Such decisions are based on the mean differences in 
costs and effects for the populations of patients receiving alternative treatments. It is, 
therefore, the uncertainty around the mean costs and effects for a particular intervention 
that is of interest to the decision-maker. This is termed second-order uncertainty. 
Second-order uncertainty is represented by the estimation of the mean value of the 
model outputs for alternative values of the input parameters. 
3.4.3.1 Input values for deterministic models 
Historically, deterministic analysis has been mostly employed in the economIC 
evaluation of health care interventions, whereby non-random inputs lead to non-random 
outputs. The stochastic nature of the problem is not captured in the output of the model. 
Weinstein and Fineberg [1980] state that it is 'only the averaged-out, or expected, 
probability that matters at any given chance node. This means that the "spread" around 
a probability does not matter' (pg174). However, it is now commonly accepted that 
sensitivity analysis should be undertaken to measure how important individual input 
parameters are to the model's outcome. Common forms of deterministic sensitivity 
analysis include one-way, multivariate, threshold and extreme analyses [Briggs et aI, 
1994]. Other than threshold analysis, each of the methods involves specifying feasible 
ranges for the values of the input parameters that are being tested. The relevant point 
estimate for each input parameter should be specified as the weighted mean value 
derived from all the identified studies, whilst the values to be employed in sensitivity 
analyses of deterministic models should be informed by the spread of the weighted 
parameter values. 
The methods available for weighting data depend on the format of the identified data. If 
good primary data that incorporates measures of the within sample variance are 
available then methods for weighting data based on meta-anal:1ic methods may be 
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employed. The combination of survival curves from the literature adapts the meta-
analytic methods slightly and is presented in Appendix 4. Alternatively, for parameter 
values derived from sources that do not report sample variance more subjective means 
for combining the data need to be pursued. The following two sections describe 
methods that can be employed to weight data in these two scenarios. Firstly, howeyer, a 
unique scenario is addressed, which concerns parameter values for which there are no 
direct empirical estimates, but which may have been estimated previously using 
decision modelling techniques. Various options, differing with respect to the required 
analytic input, are available. If a number of separate studies (of adequate 
validity/quality) are available, employing alternative modelling techniques and 
structures, then each study's parameter estimate could be incorporated using equal 
weights. However, the analyst should check the similarity of the data inputted into each 
model with respect to the timing and comprehensiveness of the data collection process. 
If some data appear to be out of date it may be necessary to re-model some or all of the 
observed data using more up-to-date data obtained from the other studies, or from a 
fresh review. The same approach could feasibly apply to the synthesis of all modelling 
studies, including full cost-effectiveness studies. 
Weighting parameters with known sample variance 
The techniques used in meta-analysis to weight data from separate studies follow a 
general approach that can be adapted to most data types [Sutton et aI, 1998]. The 
formulae for weighting data using the fixed effects and random effects models are . 
presented in Appendix 3, as well as a test for the extent of heterogeneity in the available 
data. Methods for weighting data according to their assumed precision can be linked to 
the level of heterogeneity between the studies. If the selected studies are thought to 
display only limited heterogeneity then the fixed effects model provides an adequate 
representation of variation, representing sampling error alone. If unwarranted 
heterogeneity remains in the dataset, more complex methods to weight the data might be 
considered, such as those used in random effects models. The basic aim in using 
random effects models is to account for the increased variation between studies 'when 
assuming the studies are estimating different (underlying) effect sizes' [Sutton et ai, 
1998]pg69. 
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U sing the random effects weighting procedure will always produce a greater variance in 
the parameter estimates, but its use is not universally accepted. Raudenbush et al 
[1994] suggested that the fixed effects model is the sensible choice if onlv a few studies 
~ 
exist as between study variation will be very poorly estimated by the random effects 
model. Others claim that the random effects model replaces the 'implausible 
assumptions of fixed effects analysis [with] untenable assumptions of its own'. such as 
between study heterogeneity can be represented by a single variance, and that the 
between trial distribution is normal [Thompson and Pocock, 1991]. Peto [1987] 
claimed that such models move the objective (of the weighting process) to answering an 
unimportant question concerning randomly chosen treatments and patient populations. 
However, Spector and Thompson [1991] specified perhaps the most pragmatic 
approach, treating the random effects method as a type of sensitivity analysis looking at 
how the results change as the distribution of weights between the incorporated studies 
are altered. 
Attempts may also be made to adjust the weight of a study's input according to the 
perceived quality of the study. Quality may be defined with respect to the study design 
and to the conduct of the study. For example, experimental studies are generally ranked 
higher than observational designs, but a poorly conducted ReT may be less reliable than 
a sturdy observational study [Sutton et aI, 1998]. However, much disagreement exists 
over the use of quality weights and the only practical recommendation on this issue is 
that a subjective assessment of the quality of the identified studies should be made. A 
quality threshold of inclusion may then be employed rather than a system of differential 
weighting. 
Weighting parameters with unknown sample variance 
If within-study variance is unknown then the choice of weighting technique will depend 
on the sources available for the individual estimates. If data are available from primary 
studies that report the associated sample size informing the estimated parameter values 
then the respective sample sizes can be used to weight the individual estimates. 
Other parameter values may be derived from secondary sources that do not report any 
information that can be used to objectively weight the individual estimates. Most 
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commonly resource use and cost data are derived from such sources, such as Trust 
returns or charges data. Two options are available to weight such data: 
• each estimate can be assumed to be of equal validity; 
• a sUbjective judgement of validity can be made. 
Subjective judgements are analogous to the quality weights discussed in the previous 
section, but their use may be justified in this context because no statistical basis is 
available for the application of weights. The relevance to particular evaluations of 
alternative parameter estimates may differ according to their source. F or example. 
estimates derived from the country in which the model is to be used to inform policy 
will probably be of more relevance to the evaluation and receive a larger weight. 
A two-stage process for weighting data obtained from secondary sources is proposed 
here. The first step is to rank the available estimates in increasing order of subjective 
validity. The second step involves weighting the data on the basis of the ranks. The 
simplest approach would be to weight the data linearly with respect to the ranks. For 
example, from a series of 10 estimates the top ranked estimate would receive a weight 
of 10, whilst the least confident estimate receives a weight of 1. Alternatively, the 
assigned weights could be specified with respect to a baseline value that is taken to be 
most (least) relevant point estimate. For example, if estimate x is given a weight of 1 
and estimate y is thought to be half as relevant as x then it receives a weight of 0.5. 
Using data derived from expert opinion, the mean value specified by either process 
(Delphi panels or expert groups) will represent parameter point estimates. To represent 
uncertainty the individual estimates produced by the Delphi method automatically 
provide a range of values, whil~t the expert group can be asked to specify a feasible 
range. 
3.4.3.2 Input values for stochastic models 
A number of papers have described the use of probabilistic sensitivity analysis in 
economic evaluation [Felli and Hazen, 1998; Lord and Asante, 1999; Pasta et ai, 1999]. 
Alternatively labelled as stochastic cost-effectiveness analyses [Briggs. 1999]. the 
values of the input parameters within such models are described as probability 
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distributions. The objective of a stochastic analysis is to obtain a distribution for each 
of the model's outputs that is informed by randomly sampled sets of input parameter 
values from the specified probability distributions. Stochastic cost-effectiveness 
analyses incorporate the Bayesian paradigm where the parameter is seen as a "ariable. 
with its own probability distribution, since the true value of the parameter is unknown. 
In the Bayesian context the input parameter distributions are posterior distributions 
informed by the available data [parmigiani et al, 1996], which represent second-order 
uncertainty as defined above. As long as there is uncertainty about the particular value 
of a parameter, the parameter is treated as a variable and probabilities are used to 
express the uncertainties [Iverson, 1984]. 
Stochastic analyses may be viewed as the ultimate application of multivariate 
deterministic sensitivity analyses, where the aim is to test the impact of every 
combination of parameter values for every parameter within the model. If the definition 
of uncertainty for each of the input parameters is valid, then stochastic analyses present 
the most comprehensive and appropriate form of sensitivity analysis. 
F our methods for defining probability distributions to represent the sampling 
distributions of the mean values of the input parameters are described in the following 
sections. There is no consensus on the appropriateness of the four methods. The first 
three methods (theoretically defined distributions, empirical distributions, and fitted 
distributions using statistical fitting software) were applied to the case study. The 
applied methods are described in Chapter 5, the alternative results in Chapter 8, whilst 
the implications derived from the use of the alternative methods are discussed in 
Chapter 9. The fourth method (bootstrapped primary data) applies to parameters 
informed by patient-level data and is not relevant to the employed case study. 
Theoretical distributions based on parameter type 
The first option applies purely theoretical considerations to the choice of probability 
distribution for different categories of input parameters. The characteristics of the 
different types of parameters included in a decision model are examined and a 
probability distribution with properties that match those of the input parameter is 
assigned. The same type of probability distribution is applied to groups of input 
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parameters. The full process for choosing appropriate probability distributions and 
fitting the distribution parameters is described in Appendix 5, though an abbreviated 
narrative is provided below. 
The choice of probability distributions to describe alternative parameter types is an 
individual choice, as is the categorisation of the input parameters. The following 
exposition was formed through discussion with colleagues and with reference to 
Bayesian statistics texts [Iverson, 1984; Berry and Stangl, 1996; Gelman et aL 1995]. 
F our categories of parameters were identified - proportions, survival times (length of 
time to the next event), costs and utility values, for which appropriate probability 
distributions were chosen: 
1. Proportions describe the probability that a patient will experience an event, which is 
bounded by 0 and 1. The beta distribution, which is bounded by 0 and 1, provides 
the most realistic representation of proportions. as it can lie in a wide variety of 
shapes when the two distribution parameters (alpha and beta) are varied [Iverson, 
1984]; 
2. Survival times describe the length of survival (or time to next event), they are 
bounded by O. The gamma distribution is bounded by zero and approximates the 
normal distribution at large samples. It is also extremely flexible, using a shape 
parameter to describe the available data accurately [Rice, 1995]; 
3. Cost parameters have been described by the . lognormal distribution [Pasta et al, 
1999; Fenwick et ai, 2000], though the gamma distribution may provide a more 
flexible description of the sampling distribution of costs [Parmigiani et al, 1996]; 
4. Utility values portray similar properties to a proportion though 0 and 1 do not 
strictly bind them. The beta distribution is still advocated as a scale parameter can 
be fitted to the beta distribution to incorporate a larger range than 0 to 1. 
The method of moments specifies formulae for estimating parameters for alternative 
probability distributions by finding expressions for them in their lowest order moments, 
then substituting sample moments into the expression [Rice, 1995]. The available data 
can be combined directly with these formulae to estimate relevant parameters for the 
chosen probability distributions. 
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Empirical distributions 
The easiest approach to specifying a probability distribution is to use the collected data 
'as is', this is known as a trace simulation [McHaney, 1991]. However, the individual 
parameter estimates should be incorporated on the basis of their relative weights as 
estimated using the methods described above. A weighted dataset comprising 
replications of each parameter estimate according to their respective weights can be 
created that may be inputted directly in to the decision model. The inverse of the 
variances may be large, so a consistent method for creating weighted datasets is to limit 
its size to 100 observations. The following steps will create such a dataset: 
1 . Calculate the weight for each of the identified parameter estimates Wi, where i = 1 
... n; 
2. Divide each Wi by the sum of the Wi and multiply by 100 (value = Xi); 
3. Create Xi copies of each parameter estimate. 
U sing the available data directly means that the model is based on exactly what has 
been observed in the past, which may increase the credibility of the model's 
conclusions. However, the fact that no values other than those observed could be 
sampled may misrepresent the full set of possible values. This is particularly likely if a 
limited dataset is available [Kelton et aI, 1998]. Empirical distributions have been used 
in previous stochastic models when the available data were extensive [Parmigiani et aI, 
1996]. 
Fitted distributions 
Rather than using the observed data directly, probability distributions can be specified 
as a projection of the sampling distribution of the parameters. Lipton et aZ [1995] 
describe the manual process for specifying distributions and estimating the respective 
parameters. However, there are an increasing number of computer-based packages that 
will analyse the available data and choose the best fitting distributions, as well as the 
appropriate distribution parameters [Crystal Ball, 2000; Stat: :Fit, 1996]. The aim of this 
procedure is to select a probability distribution with random samples that is 
indistinguishable from the collected data [McHaney, 1991]. The choice of distribution 
can be tested on the basis of goodness-of-fit tests, such as the chi-square and 
Kolmogorov-Smimov tests, though these tests are known to have very low power so the 
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probability of rejecting a fit is small, even when the distribution postulated is wrong 
[Bratley et aI, 1987]. 
It may be appropriate to consider the properties of computer-based distributions, as the 
software does not have knowledge of the intended use of the specified distribution. 
These problems can be minimised by careful consideration of the characteristics of 
different probability distributions. Most statistical fitting packages allow the user to 
select a range of theoretically sound distributions, so improper distributions can be 
excluded at the start of the process. Alternatively, restrictions imposed within the 
decision model can be used to block the use of infeasible parameter values within the 
model. Fitted distributions allow a more rounded description of the data, though it is 
possible to sample values that are not feasible or to lose important characteristics of the 
data such as sequential patterns [Kelton et aI, 1998]. 
Bootstrapped distributions 
The definition of bootstrapped distributions involves taking a large number of repeated 
samples of size n, with replacement, from a dataset with n observations. The set of 
mean values provides an empirical approximation to the sampling distribution of the 
'true population' value [Lord and Asante, 1999]. Pasta et al [1999] recommended using 
the bootstrap sampling distribution directly. This approach was deemed to have a 
number of advantages including the fact that the estimated value would never lie outside 
the range of values identified in the available studies. It was also noted that the 
divergence of the bootstrap sample reflects the divergence in the original sample. 
Alternatively, the bootstrap dataset could be used as the basis for the choice of a fitted 
distribution. If the bootstrap sample is normally distributed then confidence intervals 
calculated parametrically can be applied to a normal distribution [Lord and Asante. 
1999], otherwise a fitted distribution can be specified using the bootstrap sample as 
discussed in the previous section. 
Unfortunately, when the number of different observations from the literature is small 
the bootstrap means do not differ greatly from the mean of the weighted dataset. 
Bootstrapped distributions are only applicable in cases where a large number of 
observations are available [Lipton et al, 1995]. Lipton et al give no indication of what 
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constitutes a small sample, which would appear to be an empirical question that relates 
to the variation within individual datasets. The main circumstance in which 
bootstrapping should be used to inform input probability distributions is when patient-
level data from a primary study is available. Variation between patients represents fust-
order uncertainty, but model parameters should represent uncertainty about the \'alue of 
the population mean (second-order uncertainty). Bootstrapped distributions based on 
patient-level data represent second-order uncertainty. 
3.5 Implementing the model 
The implementation of a decision model refers to the act of preparing an analysable 
form of the model through the transfer of the theoretical model to a computer-based 
software package. This stage of the process does not question the states included in the 
model or the relationships assumed between them, rather it is concerned with the 
optimal strategy for describing the structure of the model. Consideration of the 
appropriate modelling technique should only be addressed at this stage of the modelling 
process. The current state of knowledge regarding the choice of modelling technique 
was discussed in Chapter 2. The decision should be based on a number of factors, 
relating to both the characteristics of the treatment area and to the research resources 
available. If the final choice of modelling technique does not accommodate all of the 
prior assumptions made with respect to the description of patient pathways, then 
modifications to the model structure can be implemented. 
The topics covered in following sections include the process of building a computer-
based model, the verification of the model to check the internal operation (section 
3.5.2), and the validation of the model where it's realism is tested (section 3.5.3). The 
methods described are applied to the case study in Chapters 6 (building the model) and 
7 (verifying and validating). 
3.5.1 Building the model 
Sonnenberg et al [1994] and Detsky et al [1997] provided a series of good practice 
guidelines towards the construction of a decision model. F or example, it was 
recommended that embedded decisions within the model should be avoided. Though 
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decisions made within the model can be automated, separate analyses of the model \\-ill 
be required for each estimate of the decision-makers criterion for adopting the more 
effective technology. For stochastic models especially, the required time for 
experimentation may be infeasibly extended. Linkage between probabilities \\ithin 
models was also suggested as good practice. For example, where the probability of an 
event influences separate events within the model that probability should be 
incorporated into the formula for the probabilities associated with each of the respectiYe 
events. The common probability can then be varied simultaneously, during stochastic 
or deterministic sensitivity analyses, for each of the associated probabilities. 
Three additional issues must be considered in models covering extended time horizons. 
Firstly, allowance must be made for the outputs of the model to be adjusted with respect 
to differential timing. The discounting of costs is an uncontroversial issue, though the 
theory underpinning the discounting of health benefits is less secure it is advised that 
such model outputs also require discounting [Lipscomb et aI, 1996]. The discount rate 
will not necessarily be the same for costs and effects so separate discount rate 
parameters should be specified [Briggs and Sculpher, 1998]. 
Secondly, using a time-oriented model, i.e. a Markov model, a cycle length will need to 
be specified. The length of the cycle should be chosen to represent a clinically 
meaningful time interval [Sonnenberg and Beck, 1993]. If the available data describes 
the probabilities of events over longer time periods than that chosen for the cycle length 
they will need converting to probabilities that describe the chance of an event in a 
shorter period. This conversion requires that the original probabilities be transformed to 
rates of incidence, which inform the instantaneous probability of an event rather than 
the probability of an event occurring over a specified period. The rate is then used to 
calculate the probability of an event over the shorter period of time [Sonnenberg and 
Wong, 1993]. If it is assumed that transition rates remain constant over the longer 
period, the formula 3.1 can be used to convert the probabilities directly [Miller and 
Homan, 1994]. 
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where PCtoti+l) is the probability of an event between time period i and i+ 1, and i 
represents the number of shorter time intervals within the originally specified time 
period. The assumption of constant rates of occurrence is often acceptable~ but if there 
are good reasons to assume that rates are not constant then the longer period should be 
split into shorter periods that best reflect the expected variability in rates. F or example~ 
converting annual mortality data to monthly probabilities it may be expected that 
patients are more likely to die in the latter half of any particular year. If so, the 
proportion of patients dying in the full year can be split unevenly between the first and 
second six months, applying the above formula to each period. 
Markov models are run so that movement between states within the model occurs 
between cycles so according to the model all patients leaving state x in year 1 leave at 
the end of year 1. This will naturally overestimate the time spent in state x so a half-
cycle correction should be applied to each transition on the basis that, on average, each 
patient leaves state x after 6 months [Sonnenberg and Beck, 1993]. Also, median or 
mean survival estimates must be converted to probabilities based on the choice of cycle 
length. This involves calculating the rate of events over the whole period and then 
converting the rate to the correct probability, an example, assuming a monthly cycle 
length and an average survival of 30 months, is provided within formula 3.2. 
Rate = }j'0=O.03* ~Probability=l-e-o.03" =0.0328 (3.2) 
DES models are more flexible in their handling of time, but such models still require the 
specification of a minimum time period of advancement, which should also be chosen 
on the basis of a clinically meaningful time interval. The chosen period defines the 
shortest time that patients can remain in any given state within the model. A half-cycle 
correction is only required in a DES model if the length of time spent in a state is not 
sampled from a continuous distribution. 
Operations research textbooks provide advice on the computer implementation stage for 
DES models [Pidd, 1989]. To manage the additional complexity of DES, models 
should be built in stages, or modules. Each module should represent a definable section 
that can be run separately from the remainder of the model. This approach allows the 
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location of any bugs in the programming to be narrowed down and identified more 
efficiently. If there are difficulties in the translation of the modelling assumptions into 
the computer-based software they should be represented openly, not buried. In all 
models, it is recommended that a log should be kept during the process of building a 
model to record the assumptions made within the model, as well as potential sources of 
bias (and their likely direction) [Halpern et aI, 1998]. 
3.5.2 Verification 
The processes of verification, followed by validation, are the final steps prior to the 
actual use of a model to generate useful results. Verification involves checking that the 
model is working in an internally consistent manner, i.e. that the model is free of 
programming bugs. Three sequential phases of verification are presented below 
covering the verification of logic, sensitivity testing and stress testing [Bratley et aI, 
1987]. 
Verification of logic involves running models with values for which there is a logical 
expected result that could easily be estimated without the model. The results produced 
are then compared to those expected. In a stochastic model, for example, all patients 
can be set to move from a state in a single specified time period, and within that state 
the cost and utility weights can be set at a constant value. The process of verifying 
model logic can be split into two categories covering the clinical parameters, and cost 
and utility parameters. The latter parameters are grouped together because they both 
involve the assignment of weights to the time spent in different health states. Finally, 
the logic relating to discounting both the costs and the effects must also be verified. 
The second type of verification is labelled sensitivity testing, which involves varying 
one parameter, whilst keeping all others fixed in order to check that the behaviour of the 
model is sensible. The definition of sensible model behaviour is subjective and must be 
redefined for each parameter within the model. It may be difficult to judge the absolute 
magnitude of the effect of different parameters within the model, so sensitivity testing 
may limit the definition of sensible behaviour to a prediction of the relative magnitudes 
of the individual parameter effects. For example, the observed and expected relative 
effect of individual parameters on the variance of the model's outputs can be compared. 
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Such predictions may simply encompass an ordinal ranking of the expected outputs, or 
an attempt to incorporate cardinality between alternative parameters. 
A secondary objective of this fonn of verification is a deeper understanding of the 
model and it's workings. If the results of the sensitivity testing are unexpected then the 
working of the model should be explored. The inspection may lead to the discovery of 
a programming error or to an admission that the original prediction was based on a false 
premIse. The debasing of a false assumption can only improve the analyst's 
understanding of how the parameters within the model behave, which may inform the 
process of experimentation. 
Stress testing is the final form of verification. Such testing searches for extreme errors, 
such as the acceptance by the model of infeasible parameter values, such as probability 
parameters set to values over 1. The process of stress testing involves setting 
parameters within the model to strange values and checking that the models 'implodes'. 
The likely sign of any implosion is not dramatic, an error message usually suffices. 
3.5.3 Validation 
Validation is 'the process by which the modeller and the client satisfy themselves that 
the model ... is suitable for use within its defin~d experimental framework' [Pidd, 
1998]pg33. 
In the OR field, it is often the case that the input data for a model are derived from the 
'real' system that is also used to validate the model. The usual objective of an OR 
project is to represent the system of interest, and then undertake a series of 'what if?' 
experiments in order to understand their impact on the future behaviour of the system. 
Though problems remain around the collection of data from the real system [Kelton et 
ai, 1998], the process is less complicated than for economic decision models used in 
HT A. Economic HT A decision models commonly wish to represent a system in order 
to make decisions on the present behaviour of the system. 'What if analyses may be 
undertaken to represent the uncertainty in the main output, but they are not the primary 
output. OR studies generally concentrate on structural validity, whereas in economic 
53 
Ch 
The modelling process 
HT A modelling projects, the data used to populate the model are also subject to the 
process of validation ( content validity) [Halpern et al, 1998]. 
In HT A possible sources of comparative observations that have been suggested include 
previously developed models [Halpern et aI, 1998], and intermediate outputs that are 
more readily available [Sculpher et aI, 2000]. Close comparisons with alternatiYe 
models improve confidence in the validity of both models because it is less likely that 
two (or more) modelling teams will produce inaccurate results than just one group. 
Conversely, where differences are apparent comparisons of the separate models may 
highlight disparate assumptions that require resolution [paul and Balmer, 1993]. 
One subjective approach to validation is the use of 'Turing's test'. The output from the 
model and from the 'real' world is shown to experts who then try to distinguish between 
them. If they are able to differentiate between the two sources then the explanation 
behind the correct definition of the outputs may inform the revision of the model [Paul 
and Balmer, 1993]. Such an exercise is intuitively appealing and could be conducted 
using the views of clinicians, though such a process could be time-consuming and not 
guaranteed to produce a concordant result. 
There are obvious problems with all of the above validation methods, for example, an 
accurate prediction of 5-year survival does not necessarily validate the required output 
of the model, which may be the gain in QAL Y s over a patient's lifetime. However, the 
process of validating decision models of alternative health care interventions will 
always be an imprecise exercise. Indeed, the hypothetico-deductive approach states that 
a model can not be proved valid in any true sense, a valid model being defined as 
unrefuted for certain scientific purposes [popper, 1965]. If the model is refuted during 
the process of validation then the current approximations to reality contained within the 
model need to be changed. Sometimes additional parameters, which were previously 
believed to be unimportant, will need to be included. Relationships between variables 
may have been ignored, either several possibly separate parameters could have been 
aggregated and treated as one, or independence between variables may have been 
assumed. Otherwise, functional relationships within the model may have been 
simplified, nonlinear functions may have been assumed to be linear. Finally, it may 
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have been assumed that the values of parameters within the model were stationary over 
time, whereas they are actually dynamic [Bratley et aI, 1987]. 
Sculpher et al [2000] and McCabe and Dixon [2000] considered the issue of validating 
economic HT A decision models in detail and both sets of authors came to similar 
conclusions that the creation of objective tests of validity are unlikely. Instead, both 
papers proposed that a framework for model development is required that would enable 
an explicit method of assessing the quality of decision models. However. it should also 
be expected that the possible avenues of validation are undertaken and that the outputs 
of the model are judged fairly against the available data. 
3.6 Experimentation 
This final phase of the modelling process involves the evaluation of the model, and the 
analysis of the model's outputs. Experimentation with deterministic decision models is 
relatively straightforward, though a more subjective interpretation of the outputs is 
required. Most effort in the following sections, therefore, is given to describing 
experimentation with stochastic decision models. 
The process of evaluating the model comprises the basic actions for collecting the 
model's outputs for a particular set of inputs. The first section below describes the 
methods for collecting the relevant output data from the two main types of stochastic 
models - Markov models and DES models. The following sections describe methods 
for analysing the model and the output data that relate to the objective of the evaluation. 
Two main objectives are possible. 
1. to inform an immediate resource allocation decision, where the only economic data 
available are those included in the decision model. 
2. to advise on the collection of further data with which a more informed resource 
allocation decision can be made. 
3.6. 1 Evaluating stochastic decision models 
The usual objective of a stochastic evaluation is the estimation of the relevant outputs 
describing a population mean and representing population uncertainty. otherwise 
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referred to as second-order uncertainty (see section 3.4.3). The following steps describe 
the associated process for evaluating both a cohort-based Markov model and a DES 
model: 
1. Randomly sample a set of parameter values from the input probability distributions; 
2. Undertake a 'run' of the model and collect the mean value for each of the model's 
outputs; 
• 
• 
a 'run' of a cohort-based Markov model produces an exact solution for each 
model output for the sampled set of input parameter values; 
a 'run' of a DES model involves sending a large number of individual patients 
through the model (see section 3.6.1.1), where each patient is subject to the same 
set of sampled parameter values. The variation between patients is the first-
order uncertainty associated with the sampled set of parameter values, which 
will vary according to the number of patients specified. Only the mean values of 
each of the model's outputs are required from a run. 
3. Redo steps 1 and 2 until sufficient runs have been completed to inform a 'trial', 
which is defined as a set of 'runs' (see section 3.6.1.2); 
4. Analyse the data within the 'trial' to describe the second-order uncertainty around 
the model outputs. 
3.6.1.1 Estimating the required patients within a model 'run' 
A great advantage of the cohort-based Markov model is that first-order uncertainty is 
controlled because an exact solution is produced for each set of parameter values. The· 
stochastic evaluation of second-order uncertainty using a DES model should only be 
undertaken when the analyst is certain that the first-order estimates are sufficiently 
precise, because the aim is to remove first-order uncertainty from the model's outputs. 
To reduce the impact of first-order uncertainty within a DES model the corresponding 
model outputs should be based on the mean values of a large number of patients for 
each set of parameter values [Stinnett and Paltiel, 1997]. However, the running time for 
the second-order analysis of a DES model is influenced by the number of patients 
included in each run, so the required number of patients should be the minimum number 
that provide an adequate level of precision in the first-order estimates. 
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Decision models, such as DES models, that represent uncertainty around individual 
patient's outputs are termed first-order Monte Carlo models [Halpern et aL 2000]. To 
get a better idea of the necessary number of patients previously published studies that 
employed such models were sought. Unfortunately, the identified first-order Monte 
Carlo economic HT A decision models did not analyse second-order uncertainty 
stochastically by sampling sets of input parameter values, but rather estimated the mean 
values of the model's output for a specified set of parameter values [Habbema et aI, 
1987; Hart et aI, 1997; Paltiel et aI, 1998; Urban et aI, 1997; Warner et al, 1996]. 
Sample sizes of up to 100,000 were employed in these evaluations, but such large 
numbers were not constrained by computing time because the models were evaluated 
only a few times (alternative sets of parameter values were only specified as part of 
deterministic sensitivity analyses). 
Unlike the economic HTA literature, a number of applications of first-order Monte 
Carlo models employing probability distributions to represent second-order uncertainty 
were identified in the general clinical literature. Bagust et al [1999] simulated bed use 
in accommodating emergency admissions. Each run of the model comprised a 1000-
day period with a mean daily admission rate of almost 25, so each run included 25,000 
patients. Davies and Roderick [1998] used DES to aid the planning of resources for 
renal services. Their main analysis ran a population group one-tenth the size of the UK 
population over a period of 50 years. Michel et al [1996] modelled the planned health 
care facilities for neonatal extracorporeal membrane oxygenation. Their methodology 
is slightly unclear, but it appears that they ran the model for the period of 1 year 
incorporating all births in each year, replicated 1000 times. Cronin et al [1998], 
modelling cancer screening, simply chose 10,000 patients as an adequate number. 
Most of the -identified studies based run size on some measure of actual activity in the 
country of origin. Intuitively, this appears unnecessary. The purpose of sending a large 
number of patients within each run is to establish an accurate mean value for the outputs 
associated with each sampled set of input parameter values. On closer inspection, 
however, it is apparent that the representation of actual activity appears to be chosen on 
the basis of the number of patients it generates. The superficial representation of actual 
activity is disingenuous because it hides the real reasons for choosing the appropriate 
number of patients to be run through the model, which should be to reduce first-order 
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uncertainty to an acceptable level (however defined). However, the artificial 
representation of reality may be a means of selling the results of the simulation to the 
intended audience. 
The necessary number of patients to reduce first-order uncertainty to an acceptable level 
is related to the complexity of the decision model. The more complex the model the 
more possible pathways there are for the patients to experience and the greater the 
extent of first-order uncertainty, which means a greater number of patients will be 
required to achieve an adequate level of precision. An adequate number of patients may 
be informed by undertaking a number of preliminary runs for a range of different 
sample sizes that are all subject to the same input parameter values. For example, 1000, 
5000 and 10000 patients could be run through the model 50 times. If there were no 
first-order uncertainty the same mean values for the model's outputs would be expected 
for each run, in the presence of first-order uncertainty the mean values will vary. 
Plotting the mean values of the model's output according to the number of patients 
included in the individual runs provides an indication of the level of precision offered 
by the different sample sizes, which can be used to inform the final choice of run size. 
An empirical investigation of the required number of patients within a run is presented 
in section 6.5. 
3.6.1.2 Estimating the required model 'runs' within 'trial' 
As described above a 'trial' comprises a series of 'runs', each of which represents the 
mean values of the model's outputs for a randomly selected set of input parameter 
values. The adequate representation of population uncertainty (second-order 
uncertainty) should only be addressed after the analyst is certain that first-order 
uncertainty has been controlled. 
Papers advising on the use of stochastic analyses in the economic HT A literature have 
not discussed the requisite number of runs [Parmigiani et al, 1997; Felli and Hazen, 
1998]. Applied studies using probabilistic sensitivity analyses have tended not to 
discuss the issue, but common practice appears to have settled on the use of 1,000 runs 
to represent second-order uncertainty [Kuntz et ai, 1999; Sisk et al, 1997; Kattan et al, 
1995], though others have employed 10,000 runs [Fenwick et al, 2000]. More complex 
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decision models will have wider dispersions of outputs, which will require larger 
numbers of observations (runs) to accurately represent uncertainty. On that basis, the 
distributions of the model's outputs should be visually inspected during the evaluatiye 
process and additional runs should be undertaken until the definitions of the 
distributions are judged adequate to describe population uncertainty. 
3.6.2 Analysis to inform immediate allocation decision 
If resource allocation is to be based on the results of an economic evaluation it is 
important that the economic data is presented in a format that aids the decision making 
process. The methods available for presenting the results of economic evaluations have 
developed greatly during the last few years. The following section describes the 
progression of methods for representing uncertainty in economic evaluations, moving 
from deterministic sensitivity analyses to the estimation of confidence intervals around 
incremental cost-effectiveness ratios (leERs) to the use of the net benefit statistic and 
cost-effectiveness acceptability (CEAc) curves. 
Until recently, the results of most cost-effectiveness analyses, as opposed to cost-benefit 
analyses, were simply presented as the incremental cost per additional unit of 
effectiveness, using formula 3.3. 
(,uCl - ,uco ) 
(,uEl - fl EO) (3.3) 
Where flCi and ,u Ei are the mean values of the costs and effects of intervention i, i = 0 
and 1. In the absence of uncertainty such a ratio would be adequate - the decision-
maker could judge whether the additional health benefits outweighed the additional 
costs and the decision would be made. Unfortunately, uncertainty is a major factor in 
the evaluation of any clinical intervention, and especially in economic evaluation. 
Briggs et al [1994] identified four separate sources of uncertainty, though Briggs and 
Gray [1999] later categorised uncertainty as relating either to the underlying 
methodological framework or to the data used in the evaluation. The former issue is not 
relevant to this discussion (the definition of a framework has been the topic of this 
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Chapter), but the handling and expression of uncertainty surrounding the data is central 
to the presentation of the output from a economic HT A decision model. 
Previous evaluations that attempted to describe uncertainty around the point estimates 
oflCERs concentrated on specifying ranges within which the true ratio was likely to be 
found. Most studies were deterministic and the commonest approaches to sensitivity 
analysis specified alternative values (from the base case) for input parameters, either 
individually or jointly, and then recalculated the model outputs. Such methods - one-
way, multi-way and extreme scenario analyses - result in a high and low estimate of the 
ICER that is presented as the plausible range. A variant on this theme is threshold 
analysis, which requires a value to be placed on an additional unit of effect. The value 
of an input parameter is varied until the allocation decision switches from one 
alternative to another, ie. a threshold is reached [Briggs et aI, 1994]. 
The earliest identified method for the stochastic analysis of sensitivity was labelled 
probabilistic sensitivity analysis [Doubilet et aI, 1985]. Probability distributions were 
specified around each parameter within the model and following multiple simulations of 
the model the mean and standard deviation of the expected utility of each strategy were 
recorded (costs were not included in this model). A later review of sensitivity analysis 
in economic evaluation found that very few had 'dealt adequately with the problem of 
uncertainty' [Briggs and Sculpher, 1995]pg363. Probabilistic sensitivity analysis was 
only identified in 1 of the 75 studies that had undertaken any form of sensitivity 
analysis, though even in this study the authors of the review stated that the 
representation of uncertainty around the leER was unclear. 
A number of approaches have been developed to represent interval estimates of the 
ICER using stochastic data, the alternative methods can be grouped into three categories 
_ Taylor-series intervals, FieBer's method confidence limits, and bootstrap confidence 
intervals [Heitjan et ai, 1999]. Several studies have compared the various approaches, 
and, though the Fieller theorem and bootstrap methods are preferred to the Taylor-
series, general shortcomings in the estimation of interval estimates around the ICER 
have been noted [Heitjan et al, 1999; Briggs et ai, 1999; Polsky et aL 1997]. The 
underlying and unresolved problem is that ratio statistics, in which the denominator can 
take verY small values, cause problems for the estimation of confidence intervals 
., 
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[Briggs, 1999]. Using bootstrapped samples the representation of negative values of 
differences in effects, combined with positive differences in costs reduces both upper 
and lower confidence intervals because such results are represented as a negative leER 
and misplaced at the left of the ICER distribution [Heitjan et al, 1999]. 
Due to the problems surrounding interval estimation around the leER alternative 
approaches have been sought, which led to the definition of the net benefits statistic in 
1998 [Stinnett and Mullahy, 1998 ; Tambour et aI, 1998]. The calculation of net benefits 
requires the assumed knowledge of the decision-makers maximum willingness to pay 
for an additional unit of effect, A. The incremental net benefits (!NBs) of a one 
intervention, t], over another, to, can be calculated using formula 3.4. 
where J.lCi and J.l Ei are the mean costs and effects of intervention i, i = 0 and 1. The 
formula also illustrates that the INBs are the difference between the mean net benefits of 
the interventions, so the decision rule is to allocate resources to the intervention with the 
highest mean net benefits. Parametric and nonparametric methods for the estimation of 
confidence intervals for net benefits have been described. The use of the net-benefits 
statistic to format the output is much more convenient than the ICER statistic [Briggs, 
1999], mainly because the net benefits statistic is linear in costs and effects [Stinnett and 
Mullahy, 1998]. The calculation of confidence intervals around a single value of A is 
of limited applicability because the value of A is likely to vary for different decision-
makers. One approach to the presentation of uncertainty around the net benefits statistic 
that overcomes the need to specify a single value representing A is the specification of 
a CEAc curve. 
The initial implementation of the CEAc curve was based on the estimation of 
confidence intervals for ICERs, the CEAc curve presented the probability that an ICER 
was under A for non-negative values of A [van Hout et al, 1994], though the concept 
has since been linked to the presentation of net benefits [Stinnett and Mullahy, 1998; 
Briggs, 1999]. To define a CEAc curve for net benefits using the output of a stochastic 
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decision model, assuming multiple interventions, the following steps should be taken 
[F enwick et aI, 2000]: 
1. Undertake a large number of model runs and calculate the mean net benefits 
associated with each intervention for a wide range of non-negative values of A ; 
2. For each value of A calculate the probability that each intervention has the highest 
mean net benefits; 
3. Plot the probabilities as a function of the value of A. to obtain a family of CEAc 
curves. 
CEAc curves represent the probability that the INBs for one intervention over another 
are positive as a function of the value of A.. A hypothetical CEAc curve is presented in 
Figure 3.1, a horizontal line has been added to the figure to highlight the point at which 
intervention f} becomes the intervention more likely to be cost-effective. From the 
curve, the probability of intervention f} being the cost-effective option reaches the 0.5 
threshold at a value of A. of just under £2,000. The intuitive interpretation of this 
hypothetical CEAc curve, regarding the allocation of resources to intervention t1, would 
state 'allocate resources to intervention tl if the value an additional unit of effect is at 
least £2,000'. Unfortunately, such a decision rule maximises the probability of 
choosing the optimal intervention, but it does not necessarily maximise the expected 
benefits of the available resources. If the distributions of net benefits are skewed then 
the intervention with the highest probability of net benefits will not necessarily offer the 
highest expected net benefits [Fenwick et aI, 2000]. 
A slight adaptation to the conventional CEAc curve is to plot, on the pr(0.5) line, the 
value of A. at which the sum of the INBs becomes positive for intervention fl. The 
presentation of the absolute level of the INBs alongside the probability of positive INBs 
draws attention to any discrepancy between the objectives of choosing the strategy with 
the highest probability of positive INBs and maximising the expected benefits. In 
Figure 3.1, X marks the value of A at which the sum of the INBs becomes positive for 
intervention tl - £3,000. The objective of economic evaluation is to maximise health 
benefit, given the available resources; so the decision to allocate resources should be 
made on the basis of expected net benefits [Fenwick et al, 2000]. In the hypothetical 
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example, therefore, the decision rule becomes 'allocate resources to intervention t} if 
the value an additional unit of effect is at least £3,000'. 
An alternative method for representing uncertainty around nets benefits involves the 
estimation of confidence intervals for the INBs between two interventions, t] and to. 
The minimum value of A at which the INBs are statistically significant from zero can 
then be found [Tambour et aI, 1998]. Similarly, Stinnett and Mullahy suggest plotting 
point estimates and confidence intervals for the net benefits over a continuous range 
of A [Stinnett and Mullahy, 1998]. 
Undertaking the analysis described above provides a good representation of the 
uncertainty surrounding the relative cost-effectiveness of the alternative interventions 
for the chosen model structure, the set of probability distributions describing the 
uncertainty in the values of the input parameters, and the discount rates for the costs 
and effects. Additional analyses may be necessary if any of these factors are also 
subj ect to uncertainty. 
3.6.3 Analysis to inform further data collection 
It is well documented that there is an excess of technically feasible and potentially 
beneficial health care interventions over the economically possible [Buxton, 1993]. 
The surplus of desirable health care has inevitably led to an increase in the demand 
for evidence to inform the enforced process of choosing between interventions. 
Funds for the evaluation of health care technologies are also limited and programmes 
of research should be developed on the basis of cost-effectiveness [Harper et al, 
1998]. To date, it appears that explicit criteria for the allocation of research funds 
have been applied only qualitatively in the UK [Medical Research Council, 1994; 
NHS Executive, 1997], though a review of the literature on the preliminary economic 
evaluation of health care technologies identified five separate quantitative approaches 
to the prioritisation of research funds [Harper et al, 1998]. The primary issue in all 
the approaches concerned the estimation of the effect of future research on health 
policy or treatment practice, and hence, the potential health benefits within the 
relevant population. Most approaches recommended that previous research should 
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inform predictions of the results of future research though the analytic level of 
inclusion varied. 
Eddy [1989] and Townsend and Buxton [1997] proposed the detailed description of 
possible policy scenarios, incorporating the associated costs and health benefits 
, 
resulting from a prospective trial, but provided the least detail on the estimation of the 
likelihood of the different scenarios occurring. Drummond et al [1992] demonstrated 
their approach by undertaking a retrospective analysis whereby the results of the 
'prospective' trial were known, though they stated that the increased benefits derived 
from the new intervention should be accessed from the data employed in sample size 
calculations. Given the power to detect a stated improvement in outcomes, it was 
suggested that the effect on clinical practice should be derived from the views of 
practitioners applying the alternative therapies. Detsky [1989] proposed a more 
formal application of the available data, which, for a given sample size, linked the 
power of the prospective trial to the prior probability distribution of the different 
effect sizes. 
The fifth study adopted a decision analytic approach to the prioritisation of research 
that accounted for the existing uncertainty in the values of all parameters affecting the 
cost-effectiveness of the alternative interventions [Claxton and Posnett, 1996], which 
has since been labelled Bayesian value of information (Vol) analysis [Fenwick et aI, 
2000]. Harper et al [1998] questioned the practicality of this last approach, which 
was based on parametric methods. More recent expositions of Bayesian Vol analyses 
have developed equivalent non-parametric techniques [Fenwick et aI, 2000; Felli and 
Hazen, 1998; Felli and Hazen, 1999], which ease the analytic burden. However, the 
application of the full Vol methodology is rare, the only identified publication 
described a hypothetical parametrically derived Vol analysis [Claxton, 1999]. Work 
is ongoing on the conduct of the non-parametric analysis of the Vol, and the process 
of analysis described here is a product of the author's work through collaboration with 
experts in the field (Fenwick, Briggs and Claxton). 
The following sections describe the methodology for a full Bayesian Vol analysis, 
which comprises three main stages. Firstly, the expected value of perfect information 
(EVPI) is generated for the evaluation as a whole, or for individual parameters. 
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Knowledge of the EVPI for individual parameters within the model pro\'ides a 
measure for assessing the value of eliminating the uncertainty associated with each 
parameter. Secondly, integrating the process of estimating the EVPI with 
assumptions about how additional sample information will affect the probability 
distributions for the input parameters provides an estimate of the expected value of 
sample information (EVSI). Finally, combining the EVSI with the expected cost of 
collecting additional sample information allows the estimation of the expected net 
benefits of sampling (ENBS) [Claxton and Posnett, 1996; Claxton, 1999]. The 
process for estimating the EVPI and the EVSI, which leads to the estimation of the 
ENBS is described below, whilst the full methodology is applied to the case study and 
the results reported in Chapter 8. 
3.6.3.1 Estimating the expected value of perfect information (EVPI) 
The EVPI IS defined as the difference in the expected payoff of decisions USIng 
perfect information and the payoff using the currently available information, which is 
a function of the value of an additional unit of effect. To estimate the EVPI a large 
number of iterations of the decision model are required (as discussed in section 
3.6.1.2). Each iteration provides a separate observation of the mean net benefits of 
treatment 1 (tl) and treatment 0 (to), informed by randomly sampled sets of input 
parameter values. If there is uncertainty about which treatment option really is cost-
effective (at the chosen value of It) some observations will demonstrate that tl has 
larger mean net benefits, whilst others report larger mean net benefits for to. 
Resources should be allocated to the therapy option that has the highest expected net 
benefits over all observations at the relevant value of It. Using the available 
information a single resource allocation decision is made across all observations of 
net benefits. Assuming perfect information individual allocation decisions can be 
made for each observation of relative cost-effectiveness within the distributions of net 
benefits (derived from the decision model). 
The individual observations of incremental net benefits are categorised as being 
positive for either tl or to. If (1 is the more likely cost-effective intervention, in the 
proportion of observations for which (1 is found to be cost-effective the resource 
allocation decision informed by the available data and by perfect information are the 
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same. In the proportion of observations in which to is the cost-effective option, 
without perfect information an aggregate resource decision would allocate all 
resources to tl, but assuming perfect information there is no uncertainty and to would 
be funded. The expected cost of uncertainty (the EVPI) is the sum of the positive 
incremental net benefits in the proportion of observations in which to displays positive 
incremental net benefits (see formula 3.5). 
n 
E VP I episode = 
LNBto - NBII ( J -1~--n--- ; (3.5) 
Where EVPleP/~mde is the expected EVPI per patient treated [Fenwick et aI, 2000], n is 
the number of observations in which to displays positive incremental net benefits. NBti 
are the mean net benefits of intervention i (i = 0 and 1), and N is the total number of 
observations. The EVP I population is estimated by multiplying the EVP I epi.mde by the 
relevant patient popUlation over the time for which the additional research is assumed 
to influence the allocation decision, discounted at an appropriate rate (see formula 
3.6). 
EVPI population = EVPlepisode. L~=l [1 p /(1 + r)P] (3.6) 
Where p is a period, P is the number of periods for which the research is assumed to 
inform decision-making, I is the incidence in a period and r is the discount rate. 
The estimation of the full EVPI for the decision model provides a maximum estimate 
of the value of removing all uncertainty within the model. Similar techniques can 
also be applied to estimate the cost of uncertainty in the value of individual input 
parameters within the model, or sets of input parameters. These estimates can be used 
to focus further research on the input parameters with the most impact on the overall 
uncertainty in the model [Fenwick et al, 2000]. To estimate the EVPI for a set of 
parameters, the full EVPI is estimated and then the EVPI is re-analysed, but holding 
the input values of the parameters of interest constant at their mean values. The 
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difference between the full EVPI and the re-estimated EVPI is the partial EVPI for the 
parameters of interest. 
3.6.3.2 Estimating the expected value of sample infonnation (EVSI) 
The basic concept driving the estimation of the EVSI is that the original probability 
distributions for the input parameters can be updated, reducing the variation described 
by the prior distribution to reflect improved precision due to the collection of more 
data. The key assumptions in updating the probability distributions in particular, and 
the Vol analysis in general, relate to the choice of data used to update the prior 
distributions. This aspect of Vol analysis - the hypothetical representation of 
additional data - is a key element in ongoing research. The methods adopted in this 
paper assume that the additional data will yield the same mean values as derived from 
the original data, because the mean represents the best estimate of the true value of the 
individual parameters. Bayesian methods of statistical inference were employed to 
estimate updated distribution parameters, whereby the properties of conjugate families 
of prior distributions incorporated an increased sample size on posterior distributions 
[Berry and Stangl, 1996; Berger, 1980]. The estimation of the updated probability 
distributions is straightforward for all categories of input parameters, details of the 
methods for updating the input distributions are provided in Appendix 5. 
The EVSI must be estimated a number of times to reflect the impact of successive 
increments in the sample size of prospective studies. If the assumption is made that a 
single trial would be undertaken that will collect data on all the parameters included in 
the decision model, it is important to note that this does not mean that the increased 
sample infonning the updated distributions will be the same for all parameters. Fewer 
data will be available for parameters within the model. For example, a study with a 
sample of 100 patients will not provide 100 observations regarding, say, the cost of 
relapse if only half the patients experience a relapse within the trial. Likewise, if the 
100 patients are randomised between two treatments, only 50 observations of the cost 
of providing the two treatments will be available. The proportion of patients likely to 
provide data on the different parameters within the model should be estimated using 
the mean results from the baseline analysis of the original decision model. 
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Next, the optimal sample allocation between the treatment arms should be addressed. 
Claxton proposed that the optimal sample allocation between the treatment arms in a 
proposed trial should maximise the ENBS on the basis of the loss function, which 
describes the value of information associated with sample allocations between the 
treatment options, as well as differences in the cost of sampling between the t\VO 
interventions. This would appear to require a very large amount of time to 'estimate 
ENBS ... for every feasible allocation of each sample considered' [Claxton, 1999]. A 
simpler, and quicker, method of allocating a proposed sample between the treatment 
options being evaluated is derived from Neyman's allocation to strata, which accounts 
for both differential variances and costs of sampling between different strata 
[Cochrane, 1977]. A ratio of the sample allocation between two treatment options is 
estimated by supplanting treatment options for alternative strata. Formula 3.7 
estimates the allocation ratio of the sample between treatments to and t1 : 
(3.7) 
Where ni is the sample allocated to treatment option i, i = 0 and 1, c; is the marginal 
cost of investigating a sampling unit of treatment option i, and (Y; is the standard 
deviation of the net benefits of treatment option i. Because the hypothetical data 
assumed to update the prior probability distributions are drawn from the patient 
population, the relevant measure of variation is described by first-order uncertainty, 
ie. variation between patients, rather than between populations. The standard 
deviation for each of the treatment options is estimated by running a first-order 
simulation using the mean estimates of each of the input probability distributions and 
calculating the standard deviation among the data observed for each patient within the 
run. This method estimates a constant ratio that can be applied to all prospective 
samples that are evaluated within the decision model. The optimal allocation of the 
prospective samples would account for the loss function within the decision model. 
which may produce alternative ratios for different sample sizes. The adaptation of 
Neyman's allocation provides a proxy for the optimal allocation, which reduces the 
required period of experimentation considerably. 
69 
Chapter 
The modelling process 
Applying the updated input distributions the EVPI is re-estimated and the difference 
between the original EVPI and the revised EVPI is the EVSI for the each prospective 
sample. The EVSI can be estimated for the model as a whole or for sets of input 
parameters within the model. Estimating the EVSI for alternative sets of input 
parameters allows a comparison of the incremental net benefits associated with 
alternative primary studies set up to collect data on different sets of input parameters. 
3.6.3.3 Estimating the expected net benefits of sampling (ENBS) 
The ENBS is simply the EVSI minus the cost of obtaining the additional sampling 
infonnation. The cost of sampling includes the cost of setting up the study, and 
monitoring, analysing and reporting the data collected. The cost also includes any 
additional treatment cost compared to current practice, which could feasibly be 
negative if current practice is the more costly option. Formula 3.8 is used to estimate 
the ENBS population for an additional sample of size n. 
nn ENBS population = EVSI population - C Fixed - nCVariahle - -(Cn - CTO ) (3.8) 
n 
Where C Fixed are the fixed costs of a trial, C Variahfe is the marginal cost per patient 
included in a trial, and CTl - CTO is the difference in costs between the interventions 
where T 1 is the intervention that would not be provided in the absence of a trial. 
The ENBS should be estimated for a range of sample sizes, which allows the ENBS to 
be plotted as a function of increased sample size. If any ENBS is positive then it will 
be efficient to gather more information and the optimal total sample size is where the 
ENBS reaches a maximum. 
3. 7 Conclusions 
This aim of this Chapter was to describe the full process of an economic evaluation 
comparing health care interventions that amalgamates data from disparate sources 
within a decision model. The modelling process was covered in chronological order 
moving through five main stages: specifying the theoretical model. undertaking a 
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literature review to obtain input data from the model, analysis of the identified data to 
populate the model, implementing the model, and experimentation with the model. 
Previous work undertaken in the field of health economics was sought, though much 
of the process drew on issues common to the general area of clinical research. 
Insights into individual stages of the modelling process were also obtained from other 
disciplines including the social sciences and operations research. In addition, new 
approaches to handling some of the issues raised in the description of the modelling 
process were proposed. 
As well as providing a general resource infonning the full methodology for the 
application of decision models to economic HT A evaluations, this Chapter also 
provides a framework for the remainder of this thesis, wherein the methods described 
above are applied to a case study evaluation from Chapter 4 onwards. The issues to 
which this Chapter has contributed, and the location in this thesis of their application, 
are described in chronological order below. 
The initial stage of the modelling process involves the specification of a theoretical 
model. This Chapter established the importance that such a model is developed prior 
to the literature review as it provides an explicit framework to guide the review. 
Advice from operations research texts was adapted to fonnalise the process of 
specifying a theoretical model, whereby the problem is structured in an attempt to 
understand the issues that need to be addressed within the model. The specification of 
a theoretical model representing possible pathways for patients with early breast 
cancer is described in first sections of Chapter 4. 
The methods employed in the literature reVIew were mainly derived from the 
systematic review literature. This Chapter stated that the process of identifying data 
to popUlate an economic HT A decision model comprises a series of individual 
literature reviews each informing a particular input parameter, or group of parameters. 
If the evaluative area is blessed with plentiful data, it may be necessary to limit the 
length of the literature review, mainly by the specification of search related criteria 
that limit the search with respect to the type, year, and language of available studies. 
The objective of the literature review was defined as 'the collection of data 
sufficiently robust to engender confidence in the model inputs', which respects the 
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need for an unbiased selection of data whilst recognising that is may not be possible 
to incorporate every piece of evidence into the model. The methods employed for a 
literature review to inform an economic HT A decision model of alternative therapies 
for early breast cancer are set out in the latter sections of Chapter 4. 
The next stage of the modelling process involves the analysis of the data derived from 
the literature review, which was the greyest in terms of established methods. In the 
first phase of analysing the literature review data a reappraisal of the structure of the 
theoretical model was proposed. The reappraisal could incorporate adjustments to the 
model structure derived from an improved understanding of the important events, or 
subtle alterations to the relationships between existing parameters could be made that 
better facilitate the format of the identified data. The reappraisal of the early breast 
cancer model is described in Chapter 5. The next phase of the input data analysis 
introduced the explicit adjustment of data according to observed differences in their 
definitions of events to improve their homogeneity, which was labelled 
harmonisation. No reference to such methods was identified in the existing literature, 
though it is unlikely that such modifications have not been made implicitly. Whilst it 
is not feasible to expect a full account of the steps taken to harmonise data in papers 
presenting the results of economic HT A decision models, details should be made 
available from other sources to persuade the interested reader of the quality of the 
model. Various sections of the case study model required elements of harmonisation, 
the methods for which are described in Chapter 5. 
The final issue in the analysis of the gathered data covers the methodology employed 
to organise the data into a suitable format to populate the decision model. Four 
alternatives were identified. Two methods required the creation of weighted datasets, 
which are either inputted directly or used to fit probability distributions using 
statistical fitting software. A full description of the available methods for weighting 
the identified data was provided, including the introduction of methods for the 
subjective weighting of data, when no objective measures of precision are available. 
The third approach specified particular distribution types to different groups of input 
parameters and used method of moment's formulae to estimate the distribution 
parameters using the identified data. The comparison of these three methods is a 
secondary objective of this thesis. The application of these methods is described in 
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Chapter 5, whilst the derived results are presented in Chapter 8 and discussed in 
Chapter 9. The fourth approach - bootstrapping distributions from the assembled data 
- is not applied to the case study because it is most appropriately used to specify 
distributions for parameters that are informed by patient-level data. 
The implementation stage of the modelling process includes the act of choosing the 
appropriate modelling technique, because the modelling technique should be chosen 
with full knowledge of the available data. To guide the building of the decision 
model a collection of good practice guidelines drawn from the health economic , 
clinical and operations research literature were presented. The applied process of 
building both a Markov process and a DES model is described in Chapter 6. 
As more complex decision models are employed in economIC evaluation so the 
process of verification will become more important. This Chapter adapted the process 
of verification from operations research texts, which provided a thorough and 
structured process for checking that a model is internally consistent. The process of 
validating decision models also drew from the operations research field, but 
underlying differences in the modelling objectives and data availability between the 
OR field and economic HT A decision models limited the relevance of such work. 
The validation of economic HT A decision models is extremely difficult, though 
intermediate forms of validation are available, the main conclusion appears to be that 
the analyst should aim to convince her audience that the model was developed and 
analysed using an explicit framework of good practice. Nevertheless, Chapter 7 
presents the attempts made to objectively validate the early breast cancer model using 
various sources of external data. Chapter 7 also presents full details of the application 
of the three-stage verification process. 
In the final stage - experimentation - this Chapter addressed issues relating to the 
stochastic analysis of economic HT A decision models, describing the conduct of such 
analyses in terms of 'runs' and 'trials'. Relating to first- and second-order uncertainty. 
respectively, the questions of 'how many patients to include in a run?', and 'how many 
runs to include in a trial?' were discussed with reference to applied studies undertaken 
in all areas of clinical research. No specific solutions to these questions were 
identified, though some practical suggestions were put forward that are tested within 
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the case study and presented at the end of Chapter 6. A review of the chronological 
development of methods used to present cost-effectiveness data was presented, which 
informed the presentation of the case study results in Chapter 8. Finally, this Chapter 
adapted methods for the non-parametric analysis of the value of information, a 
process that estimates the monetary value of future research aimed at reducing the 
uncertainty of the resource allocation decision. The results of a full Vol analysis of 
the early breast cancer evaluation are presented in Chapter 8 and discussed in Chapter 
9. 
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Case study: Specifying the theoretical model and gathering 
4.1 Introduction 
The methods for the modelling process described in Chapter 3 are applied to a case study 
evaluation in Chapters 4 to 8. The application aims to test the appropriateness of the 
methods, as well as to compare alternative methods where options within the modelling 
process exist. This Chapter preserits the preliminary stages of the modelling process. 
These include the definition of the clinical area to be evaluated, which leads to the 
development of an initial model structure. The use of the theoretical model to guide the 
main literature review is then presented. The final section illustrates the selection of 
stratified patient groups for separate analysis within a model. This latter aspect is not 
necessary if the study question relates to a narrowly defined, homogeneous patient group, 
but when the patient group is heterogeneous such selection of sub-groups of the popUlation 
may improve the analysis and enhance the interpretation of the results. 
4.2 Defining relevant evaluation characteristics 
Cancer is a major disease area that accounts for about one in every five deaths in England 
and Wales [Office of National Statistics, 2000]. Breast cancer is the commonest female 
cancer in the United Kingdom with around 33,000 newly diagnosed cases and 15,000 
deaths from the disease each year [Cancer Research Campaign, 1998]. Diagnosis of cancer 
75 
Cha ter4 
the theoretical model and aatherina data 
In the breast and/or axilla is defined as early breast cancer, which may be further 
disaggregated to stage 0, I, or II breast cancer [Fowble, 1991]. A proportion of patients 
with early breast cancer will be 'cured' by local treatment. However, there is a risk of 
micrometastatic disease, which causes systemic relapse. The aim of adjuvant therapy is to 
destroy this subclinical disease. The main objective of adjuvant therapy for breast cancer is 
to prolong survival while maintaining a high quality of life [Glick, 1991]. As a treatment 
area, breast cancer fulfils several criteria that make it a suitable area for modelling: there 
are clear definitions of the disease and its natural history, definable benefits and risks with 
different modes of therapy, competing alternative approaches and controversy [Gelber et al, 
1991]. In addition, new types and combinations of adjuvant therapies continue to be 
devised meaning that conclusive clinical trial data for all possible adjuvant therapy 
schedules and for all patient groups are unlikely ever to be available. Two types of 
adjuvant therapy are used for breast cancer, either alone or in combination: 
1. Chemotherapy, which are usually administered as a combination of anticancer drugs, 
such as CMF (cyclophosphamide, methotrexate, and fluorouracil), 
2. Hormonal therapy, which deprives cancer cells of oestrogen and may influence the 
growth of cancer cells. The two main hormonal treatments are tamoxifen and ovarian 
ablation (for premenopausal patients) [National Cancer Institute, 1996]. 
The evaluation presented in this thesis was initiated alongside the UKCCR ABC Trial. The 
ABC trial is a national collaborative randomised clinical trial, the principal aim of which is 
to determine the value of adding chemotherapy to tamoxifen for postmenopausal patients, 
and chemotherapy and/or ovarian ablation to tamoxifen for pre/perimenopausal women 
with early breast cancer [UKCCR, 199~]. Prior to the trial, chemotherapy and ovarian 
ablation had both been clearly shown to prolong both relapse-free and overall survival in 
pre/peri menopausal women, with the benefit lasting for at least 10 years. Tamoxifen had 
also produced a significant improvement in disease free survival in pre/perimenopausal 
women [Tormey et al, 1992]. However, it was uncertain whether the benefits of these 
treatments were additive [EBCTCG, 1992]. In postmenopausal women, trials had 
demonstrated a reduction in recurrence, and suggested an improvement in survival from 
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tamoxifen plus chemotherapy, compared to tamoxifen alone. However, it was not clear 
whether any additional survival benefit was large enough to outweigh the side effects of 
chemotherapy. 
The ABC trial is currently in progress and the data from the trial will not be available for a 
number of years. The case study evaluation for this thesis was undertaken usina secondary 
o . 
data with the primary aim of estimating the relative cost-effectiveness of the alternative 
adjuvant therapies to inform decision-makers prior to the availability of the trial results. 
The following section provides a brief summary of the previous economic studies 
comparing adjuvant therapies for early breast cancer, which were identified during the main 
literature review (see section 4.4.3 for details). 
4.2.1 Review of economic studies of adjuvant therapies for early breast cancer 
Only one identified economic study collected prospective cost data [Legorreta et aI, 1996]. 
Based in the US, this 4-year longitudinal study followed 16 patients with stage 0-, 99 
women with stage I, and 73 patients with stage II breast cancer in a health maintenance 
organisation. The results were split by stage at presentation. All cost data were obtained 
from medical records and claims data, though only inpatient and specialist outpatient costs 
were captured. The estimated 4-year mean costs for stages 0, I, and II were $18,900, 
$23,200, and $28,800, respectively (1993 US$). A UK-based study estimated 4-year 
treatment costs of 102 patients diagnosed with stage I breast cancer, and 13 patients with 
stage II breast cancer [Wolstenholme and Whynes, 1998]. Resource use was obtained from 
a detailed examination of the case notes and unit costs were attached using resource use 
algorithms. The mean costs were estimated as £3,576 and £3,996 for stages I and II. 
respectively (1991 UK sterling). A Canadian group modelled the treatment costs of breast 
cancer therapy for the lifetime of patients using clinical data from various databases and 
cancer registries, as well as surveys of Canadian clinicians [Will et al, 1998]. Detailed 
costing methods were employed including a 10-province comparison of the cost of the most 
commonly used breast cancer tests and surgical procedures. The treatment costs only 
included direct health costs and were split by stage at presentation. Average lifetime costs 
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for stage I and II breast cancer were estimated as $23,098 and $25,671. respectiYely (1995 
Cdn$) 
A number of full economic evaluations were identified, though none were undertaken in the 
UK. The principal economic investigators in the area of adjuvant therapies for early breast 
cancer appear to be a group of American clinicians - Hinner, Smith and Desch. These 
authors have published a range of economic evaluations covering most combinations of 
adjuvant therapies and most patient groups [Hinner and Smith, 1991; HiBner and Smith, 
1992a; Hinner and Smith, 1992b; Hillner et aI, 1993; Desch et al, 1993; Smith and Hillner. 
1993]. All the evaluations were based on the same methodology, which employed a 
Markov process that was populated using clinical data derived from published clinical 
trials. Only direct costs were included and these were obtained from charges and from 
Medicare data, utility values were derived from surveys of oncology staff. The estimated 
cost per quality adjusted lifeyear (QAL Y) gained ranged from $5,700 comparing tamoxifen 
versus no treatment in a 45-year old premenopausal woman with node-positive. ER-
positive breast cancer to $280,000 comparing tamoxifen versus no treatment 'in a 45-year 
old premenopausal woman with node-negative, ER-negative breast cancer (1998 US$) 
[Earle et aI, 2000]. 
An Australian evaluation compared tamoxifen alone with no therapy using clinical data 
from the early breast cancer trialists' meta-analysis [EBCTCG, 1992], though they did not 
appear to differentiate between node negative and node positive patients [Glasziou and 
Haas, 1994]. The methodology was very basic using a spreadsheet and defining patients as 
either 'well' or in 'recurrence', though the calculations undertaken were not dear. The 
only costs included were the costs of tamoxifen and a general cost of recurrence taken from 
the literature. The model stopped at 10 years and utility values were assumed. The 
estimated cost per QALY gained was $1365 (1990/1 Aus$). Messori et al [1996] 
compared 12 cycles of CMF with no adjuvant therapy in patients with node positive breast 
cancer based on an Italian clinical trial with more than 20 years follow-up. The outcome 
measure was life years gained and a lot of effort was spent extrapolating the area under the 
curve to estimate long term survival. Unfortunately, less effort was put into estimating 
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costs as only the cost of adjuvant chemotherapy was included in the eYaluation. The 
estimated cost per lifeyear gained was $447 (1995 US$). The final identified evaluation, 
which was only available as a conference abstract [Selke et aL 1998], employed a stochastic 
Markov process to evaluate a range of adjuvant therapies, though the definition of patient 
groups was not reported. The estimated cost per additional lifeyear saved from using 
chemotherapy and hormonal therapy over hormonal therapy alone was presented as $4.071 
(US$). 
The above review suggests that the evidence base for allocating resources to alternative 
adjuvant therapies in the UK is thin with only one UK-based study providing limited 
information that could be used to inform such decision-making. The development of a UK-
based decision model describing the costs and health effects associated with alternative 
adjuvant therapies for different patient groups would provide useful information for 
decision-makers. 
4.3 Specifying the theoretical model 
The preliminary structure of the model represents the main events experienced by patients 
diagnosed with early breast cancer. The objective of the preliminary model structure was 
to provide guidance for the main literature review in the form of a series of study questions. 
Each study question invoked a separate literature review relating to different aspects of the 
decision model. 
The events included within a decision model should describe significant occurrences in 
relation to the outcomes of the model. Here, the outcomes are costs and QAL Ys so the 
structure of model was based on events that have a significant influence on either the 
resources allocated to breast cancer patients, their survival, or their quality of life. 
Information on the relevant events to be included in the decision model was sought from 
health professionals involved with the ABC trial as well as a preparatory review of the 
breast cancer literature. In addition, the Internet was searched for basic information on the 
impact and progression of breast cancer, sites such as www.oncolink.org provided a wide 
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range of infonnation, aimed at both health professionals and patients. The use of three 
sources reduced the danger of incorporating biases from anyone source into the theoretical 
structure of the model, which was infonned by general agreement between the alternative 
sources. The preliminary structure of the model is discussed in the following sections. 
which split the possible events into two main categories - treatment side effects and 
relapses or death. The two sections describe how the relevant events to be included in the 
model were chosen, following which the full structure is presented. 
4.3.1 Side effects of adjuvant therapies 
Following the administration of the adjuvant therapies the most immediate event that 
patients are likely to experience is some form of treatment side effect, especially following 
the administration of chemotherapy. The trial clinicians advised that the therapy side 
effects would be more easily classified in relation to their associated resource use, and that 
the severity of the side effects would be correlated with the resources used to treat them. A 
large number of different direct toxic effects were identified and each type of effect may be 
subject to a range of severities, it was also reported that a small proportion of patients die as 
a result of chemotherapy toxicity. The preliminary model described four classes of direct 
toxic effects: 
1. mild complications that required additional clinician time and anti-emetics, 
2. moderate complications needing additional clinician time and anti-emetics, as well as 
referral to a specialist, for example, a dietician, 
3. non-fatal major events necessitating inpatient care, and 
4. fatal events. 
4.3.2 Relapses and death 
The only other events included in the model were relapses and death. Following the 
removal of the primary cancer, a relapse is the appearance of a new lesion(s) in patients, as 
confirmed by any relevant diagnostic procedure [Thorpe et aL 1993]. There were various 
possibilities for modelling the pathway of breast cancer patients from the point of relapse. 
Hurley et al [1992] investigated the cost of breast cancer relapses and identified five 
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categories of sites. Two other studies also used a similar categorisation of relapses to 
describe the differences in prognosis relating to the site of metastases [Richards MA et aI, 
1993; Goldhirsch et aI, 1988]: visceral, central nervous system (eNS), bone. local, and 
regional. 
Presenting the information from the few studies identified to the trial clinicians, it was 
suggested that the three metastatic sites of relapse - visceral, eNS and bone - could be 
reduced to two - bone and non-bone - as relapses in visceral or eNS sites typically have 
the worst prognosis. Such relapses are not curable and the only event following a 
metastatic relapse is death. It was also suggested that local and regional relapses be treated 
as a single site within the model, but that the combined locoregional event could be either 
operable or inoperable. The distinction between operable and inoperable locoregional 
relapse was confirmed in the preparatory review. In the preliminary model a patient with 
an inoperable locoregional relapse entered an 'uncontrolled' state, in which the main 
objective of treatment is palliation. Following an operable relapse a patient entered a 
'remission' state from which she could experience a further relapse or die without evidence 
of disease. 
4.3.3 Model structure 
An activity cycle diagram (ACD) was used to portray the preliminary model structure [Paul 
and Balmer, 1993]. The model structure is presented in Figure 4.1. The structure only 
includes events that are assumed to influence the progression of the disease, treatment side 
effects were described within the state 'disease-free'. 
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Figure 4.1 
LocoreglOnal 
relapse 
Preliminary model structure 
metastases 
Arrows indicate possible pathways between events. 
4.4 The literature review 
metastases 
The aim of the review was to gather data to populate a decision model that described the 
pathways of patients with early breast cancer. Defining the structure of the model prepared 
the ground for targeting the literature review, five distinct data categories were defined: 
• adjuvant therapies; 
• treatment side effects; 
• timing of relapse or death with no evidence of cancer; 
• types of relapse; 
• progression from relapse. 
Adjuvant therapies comprised only the estimation of resource use and the unit costs 
associated with the various therapies, the four other categories included clinical parameters. 
resource use, unit costs, and utility values. The review protocol outlines the plan of the 
literature review, covering the study questions to be answered and the methods used to 
identify relevant data [NHS Centre for Reviews and Dissemination. 1996]. The following 
sections describe the formulated study questions, the search inclusion criteria and the 
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sources included in the literature search. The final sub-section presents the results of the 
literature review. 
4.4.1 Study questions 
The literature review for a modelling project comprises a series of mainly independent 
reviews that aim to identify data for the separate elements of the model. In the case study, 
separate questions were defined for each of the five data categories: 
• What are the resource, and cost, requirements for the provision of the alternative 
adjuvant therapies? 
• What proportion of patients, receiving the respective adjuvant therapies. experience the 
defined categories of side effects? 
• What are the resource, cost and utility implications of the defined categories of side 
effects? 
• What disease-free interval (DFI) profiles are associated with alternative adjuvant 
therapies? 
• What are the resource, cost and utility implications of remaining disease-free? 
• What proportions of patients experience locoregional relapse or metastases following 
DFI? 
• What proportions of patients die without relapsing following DFI? 
• How do patients progress from the point of relapse, either locoregional or metastatic? 
• What are the resource, cost and utility implications of the defmed categories of relapse? 
4.4.2 Search-related inclusion criteria 
The study questions did not contain any description of patient characteristics because it was 
intended to collect data on all patients with breast cancer. However, detailed data on the 
characteristics of patients included in each relevant study were collected, which facilitated 
the definition of more homogeneous sub-groups within the aggregate patient population 
(see section 4.5). 
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With respect to other inclusion criteria, the preliminary search used to inform the structure 
of the preliminary model had revealed a wealth of clinical research on most aspects of 
breast cancer. It was also noted that the majority of comparative studies were randomised 
clinical trials (RCTs). Due to resource constraints on the amount of time that could be 
spent appraising possible data sources, the initial literature review was limited to papers 
published from 1992 onwards. Another justification for limiting the review was that most 
clinical trials do not simply report once, rather they report at regular intervals as the length 
of follow-up increases and more definite judgements about the results of the trial can be 
made. Also, chemotherapeutic agents have evolved over time, so that some of the drugs 
administered in trials that reported in the 1980's (meaning their protocols may have been 
specified in the 1970's) may not be considered relevant today. The reduced relevance of 
chemotherapy regimens used in past trials may relate to the actual drugs applied, the doses, 
or the frequency of administration. 
The identified RCTs provided a large amount of data covering the clinical parameters, so 
there was no reason to collect data from other primary studies of lower methodological 
quality. Therefore, searches relating to the clinical parameters were restricted to RCTs and 
reviews. Reviews were included for two reasons. Firstly, reviews present an overview of 
the general results within a clinical area so providing a source of primary studies. 
Secondly, reviews typically discuss the meaning of observed results in more detail than 
papers presenting primary results. It was hoped that such qualitative data would improve 
the understanding of the mechanisms of the disease, which could be useful during the 
analysis of the data or any revision of the model. Non-English written studies were 
excluded from the review on the basis that sufficient data to inform the required parameters 
could be accessed in the English language literature so the costs of translating foreign 
language articles could not be justified in terms of the additional data collected. Also, bias 
against negative studies by the main English language journals is less likely in a prominent 
research area such as breast cancer. 
It was recognised that limiting the literature review to mainly RCTs published from 1992 
onwards might identify insufficient data for some parameters. If necessary further searches 
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for non-RCT based studies would be made, and the search parameters could be v.idened to 
include the pre-1992 literature. 
4.4.3 The literature search 
The aim of the literature search was to identify a comprehensive selection of RCTs and 
reviews to address the study questions stated above. The search comprised both 
computerised and manual searches. A number of electronic databases were searched , 
including Medline, the Science Citation Index, the NHS database of abstracts of reviews of 
effectiveness, the Cochrane library, the NHS economic evaluation database and the Office 
of Health Economics economic evaluation database. Indexed terms were used wherever 
possible to search the different databases, though the use of the different databases was 
tailored according to the different types of parameters. For example, it was unlikely that 
new clinical data would be included in the economic evaluation databases so broad 
searches for any economic studies relating to breast cancer were undertaken. The broader 
medical databases contained studies reporting resource use, costs, utilities, as well as 
clinical parameter estimates, so more well-defined searches were used that informed 
specific elements of the model. Mariual searches of the reference lists reported in studies 
identified from the databases and of selected journals were also undertaken. Full details of 
the literature search are provided in Appendix 1. The sources included in the literature 
search have been justified previously in the collection of data for decision analysis models 
[Murphy et al, 1994]. 
The titles of all the studies identified using the specified search terms were read and the 
abstracts downloaded if they appeared to have any connection to the parameters required 
for the decision model. Relevance was defined both quantitatively and qualitatively. 
Papers were accepted if they appeared to provide quantitative data that could be combined 
with data from other papers to inform parameter values within the model. Alternatively, 
qualitative data were sought to increase understanding of the treatment area, which might 
provide insights into the progress of disease and other input parameters. 
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Following the literature search, the data extraction process involved the collection of all the 
necessary data from the identified studies. It was important that the method of extraction 
created a database that could be searched, allowing papers holding data on similar 
parameters to be identified. The papers within the database were labelled with respect to 
the type of data reported. Furthermore, it was anticipated that the analysis of the collected 
data would require extensive use of spreadsheets so the easy transfer of required data into a 
spreadsheet package was essential. The creation of an evidential database, using an 
established reference database software package [Procite 5, 1999], is described in Appendix 
2. 
4.4.4 Literature search results 
The initial Medline search resulted in the collection of 636 abstracts that were assessed for 
inclusion in the review. From the 636 abstracts, 230 full papers were defined as potentially 
relevant to the analysis. These papers were collected and read in full. Including studies 
from all sources, by the time of the final analysis a total of 343 full papers or documents 
had been reviewed. The basic results of the data extraction process are presented alongside 
the parameter categories in Figure 4.2 - the number of papers presenting data on the 
respective parameters. These results were gathered in March 2000, meaning that papers 
published after this date were not incorporated into the analysis. The most populous 
category contained clinical data on 'progression from relapse', which reflects the large 
number of clinical trials that have compared alternative therapies for patients with 
metastatic breast cancer. The next most frequently observed parameters covered data 
relating to treatment toxicities, DFI and overall survival, as clinical trials of adjuvant 
therapies tended to present data on all three issues. 
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Figure 4.2 Pro forma used to extract data from the literature review 
Autltor (01): 
Title (04): 
Journal (09): 
Date ofp1lhlication (12): 
Aims (13): 
Location of study (14): 
Time period (15): 
Study design (17): 
Study population (18): 
Vari3h1e definition (19): 
OmissioJlS in context (22): 
Com.menis (23): 
Assessors (24): 
idToxicities (25): 58 
idMeJUJpausal symptoms (26): 15 
idDisease free inienral (27): 63 
idRates of relapse (28): 24 
idTypes ofrecun-ence (29): 73 
idProgression from recun-ence (31): 99 
idOverall survival (33): 70 
co Chemotherapy (34): 21 
co 0variaJt ablation (35): 2 
co Toxicities (36): 9 
coMeJUJpausal symptoms (37): 6 
coTreatm.ent ofrecun-ence (38): 57 
quToxicities (39): 10 
quMeJUJpausal symptoms (40): 3 
quDisease free in1enral (41 ): 6 
quRecun-ence (42): 37 
quGeneral (43): 11 
co Overall Cost (44): 2 
Parameter Keywords (45): 
In the cost and resource use categories information on the 'treatment of recurrence' was 
most commonly identified. The data extracted for this set of parameters mostly described 
the range of resources associated with the different areas of treatment for metastases, i.e. 
therapies, surveillance and hospital visits. Fewer papers reported such data relating to 
chemotherapy as an adjuvant therapy for breast cancer, though more actual cost data were 
identified. Most quality of life data was again captured for the recurrence parameters, 
though this data mainly described toxicity associated with the chemotherapy regImens 
administered to patients with metastases. 
4.5 Definition ojpatient sub-groups 
An objective of the ABC decision model was to analyse sub-groups of the aggregate 
population of patients with early breast cancer, which allows the investigator to ask whether 
the response difference between two treatments depends on the type of patient [Pocock, 
87 
Chapter 4 Case study: specifying the theoretical model and gathering data 
1983]. In addition, the choice of comparators within an evaluation should reflect the most 
relevant treatment options to the policy question [Drummond et aI, 1997], which do Yaf\-
according to the age and prognosis of breast cancer patients [Silva and Zurrida, 1999: 
Glick, 1991]. The following two sections describe the methods used to define relevant sub-
groups and the resulting definition of sub-groups. 
4.5.1 Methods 
Subgroups can be defined with respect to either prognostic indicators or predictor markers, 
or both. Biological prognostic indicators are used to inform a patient's survival and 
disease-free survival, whilst predictor markers forecast tumour sensitivity or resistance to 
various therapies. The most important prognostic indicator for breast cancer is the nodal 
status of a patient, which is either positive or negative. In addition, widely investigated 
breast cancer biological markers include estrogen and progesterone receptors, p53, Bcl-2, c-
erbB-2, cyclin expression, proliferative activity, DNA ploidy and the urokinase 
plasminogen activation system [Ravaioli et aI, 1998]. Estrogen receptors have been found 
to be weak prognostic indicators, but good predictors of response to endocrine therapy. 
There are consistent data suggesting that proliferation indices are good indicators of 
prognosis, and that they are directly related to response to chemotherapy and closely related 
to response to hormonotherapy. Otherwise, there is.no evidence, or conflicting data for all 
of the other biological markers [Ravaioli et aI, 1998]. In relation to menopausal status, 
postmenopausal women have been found to derive less overall benefit from chemotherapy, 
which may be related to the biology of breast cancer in older patients [Fox, 1991]. 
Another factor in the definition of patient sub-groups was the need to identify sufficient 
data to inform the parameter values within the model for each of the relevant adjuvant 
therapies for the specified sub-groups. All studies reporting relevant data were carefully 
read to identify any prognostic information reported on the patient groups included in the 
study. 
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4.5.2 Results 
The full details of the infonnation collected on patient characteristics are presented in 
Appendix 6. Eligibility criteria for the identified studies varied widely, ranging from open 
studies that might only specify that patients must be node positive [Schumacher et aL 1994; 
Fisher et aI, 1997], to strictly defined patient groups that controlled for nodaL receptor and 
menopausal status [Pritchard et aI, 1997; Cummings et aI, 1993]. Some of the open studies, 
however, presented relevant data for sub-groups of the study population [Chacon et aI, 
1997; Wood et aI, 1994]. 
Data on the following indicators were recorded - nodal status, age, menopausal status, 
number of positive nodes and estrogen and progesterone receptor (ER) status. 
Unfortunately, very few studies reported proliferative activity, so this indicator could not be 
used to differentiate patient groups. Due to the aggregated level of reporting only relatively 
broad patient groups could be defined. Nodal status (primarily node positive) was the 
most commonly defined prognostic indicator, though menopausal status was often 
distinguished. Fortunately, a number of studies combined these two indicators meaning 
that sufficient data were available to estimate parameters for two main patient groups -
node positive and postmenopausal, and node positive and premenopausal. 
Fewer studies evaluated alternative adjuvant therapies for node negative patients. 
Therefore, less strict inclusion criteria were drawn up, whereby study results were included 
in sub-groups on the basis of the proportion of patients with the relevant characteristics. 
F or example, patient groups were defined on the basis that over 800/0 of the patients were 
node negative. Some studies reported infonnation on age but not menopausal status, and 
vice versa [Gelber et aI, 1993; Fisher et al, 1996]. These characteristics are highly 
correlated, so to make the best use of the available data patient age and menopausal status 
were used in combination to define patient groups. 
In total, 29 separate patient categorisations were identified. Tables 4.1 and 4.2 present the 
number of studies satisfying the chosen patient characteristics for each defined sub-group. 
The final column - 'minimum number of studies' - describes the least number of studies 
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included in any of the three treatment categories for DFI and events ending DFI. The 
minimum number of studies is highest for groups including older node positiye patients. 
Younger node positive patients were adequately represented in trials of chemotherapy 
and/or tamoxifen+chemotherapy, but few such patients received tamoxifen alone. Even 
less choice was available for the analysis of node negative patients. A minimum of two 
trial treatment arms reported DFI for the patient categorisation '80% node negative, and 
median age over 50 years or 50% postmenopausal'. The final configuration of analyses is 
presented in Table 4.3. 
4.6 Conclusions 
This Chapter has applied methods informing the first stages of the modelling process to an 
economic HT A evaluation comparing alternative adjuvant therapies for early breast cancer. 
The stages covered included the specification of a theoretical model structure, the literature 
review to identify data to further inform the model structure and to populate the model, and 
the process of identifying relevant patient sub-groups. 
To create an initial model structure information was sought from three distinct sources; 
consultations with oncology clinicians, a preparatory review of the literature, and the 
Internet. The use of these three sources was deemed necessary to ensure that a balanced 
view of the relevant events was obtained. The theoretical model highlighted five distinct 
categories within the model, which were used to inform the subsequent literature review. 
Separate literature reviews were undertaken for a range of study questions that were 
derived from the five parameter categories: adjuvant therapies; treatment side effects; 
timing of relapse or death; types of relapse; and progression from relapse. Strict inclusion 
criteria were defined due to the anticipated volume of data, though it was recognised that 
the review might be expanded if insufficient data were identified. The subsequent data 
analysis revealed areas where the review needed to be expanded, this is reported in Chapter 
5. The explicit formulation of search-related inclusion criteria is important to avoid 
accusations of bias in the data collection process. 
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The definition of relevant patient sub-groups was necessary because data were collected on 
the whole population of patients with early breast cancer, which incorporates a \vide range 
of prognoses. Possible foundations for the grouping of patients were discussed, and 
reasons provided for the final sub-classifications. The precision in the definition of sub-
groups should be balanced against the availability of data, as demonstrated by the sub-
group definitions for node-positive and node-negative patients. 
The reVIew of the modelling process presented in Chapter 3 could not provide a 
prescriptive methodology for all such evaluations as elements of the process are influenced 
by the characteristics of the treatment area being evaluated. This Chapter has illustrated the 
application of the first stages of the methodology and how choices specific to the treatment 
area can be made. 
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I able 4. J ~ umber 01 stuales satlstylng nineteen alternative categorisations lor noae positive patients, oy aOJuvant ~ 
therapies 
Patient categories Disease free interval Clinical events ending OFI Minimum 
Tamoxifen Chemotherapy T +C Tamoxifen Chemotherapy T +C number of 
studies 
100% node positive 7 64 11 6 38 10 6 
80% node positive 7 66 11 7 41 10 7 
100% node positive, and 100% postmenopausal 6 16 5 5 3 I 
100% node positive, and 100% premenopausal 0 30 4 0 10 4 0 
100% node positive, and median age over 50 years or 50% 7 32 6 6 17 5 5 
postmenopausal 
100% node positive, and median age over 55 years or 55% 7 25 6 6 10 5 5 
postmenopausal 
80% node positive, 60% postmenopausal 6 17 5 6 6 3 3 
100% node positive, and median age under 50 years or 50% 0 40 5 0 25 5 0 
premenopausal 
80% node positive, and median age under 50 years or 50% 0 40 5 0 25 5 0 
premenopausal 
80% node positive, and median age over 50 years or 50% 7 32 6 7 20 5 5 
postmenopausal 
100% node positive, 70% postmenopausal, and 50% 1-3+nodes 4 10 3 4 3 
100% node positive, 50% 1-3 positive nodes, and median age 0 30 5 0 20 5 0 
under 50 years or 50% premenopausal 
100% node positive, 50% 1-3 positive nodes, and median age 5 14 4 5 5 5 4 
over 55 
100% node positive, 60% ER positive, and 60% postmenopausal 3 9 3 3 3 1 
80% node positive, 60% ER positive, and median age under 50 0 19 5 0 12 4 0 
years or 50% premenopausal 
80% node positive, 90% ER positive, and 70% postmenopausal 3 2 3 2 
80% node positive, 60% ER positive, and 50% 1-3 positive nodes 3 22 8 3 I I 8 3 
80% node positive, 60% ER positive, 50% 1-3 positive nodes, 0 14 5 0 10 4 0 
and median age under 50 years or 50% premenopausal 
80% node positive, 60% ER positive, 50% \-3 positive nodes, 3 9 3 3 2 4 2 
and median age over 50 years or 50% postmenopausal 
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Table 4.2 Number of studies satisfying nine alternative categorisations for node negative patients, by adjuvant therapies ~ 
Patient categories Disease free interval Clinical events ending DFI Minimum 
Tamoxifen Chemotherapy T +C Tamoxifen Chemotherapy T +C number of 
studies 
100% node negative 7 5 2 5 3 2 2 
80% node negative 7 5 2 5 3 3 2 
100% node negative, and 100% postmenopausal 2 0 0 2 0 0 0 
100% node negative, and 100% premenopausal I 0 0 I 0 0 0 
100% node negative, and median age under 50 years or 50% 2 3 0 3 0 0 
premenopausal 
80% node negative, and median age over 50 years or 50% 5 2 2 4 0 3 0 
postmenopausal 
80% node negative, and median age under 50 years or 50% 2 3 0 3 0 0 
premenopausal 
80% node negative, and 70% postmenopausal 3 0 0 3 0 0 0 
80% node negative, and 60% tumour grade 1 2 0 2 2 0 2 0 
80% node negative, and 45% age under 50 1 2 2 0 2 2 0 
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Table 4.3 Patient categorisations used for the analysis of the four generally 
defined patient groups 
General patient group 
Younger (premenopausal) 
node positive 
Older (postmenopausal) 
node positive 
Younger (premenopausal) 
node negative 
Older (postmenopausal) 
node negative 
Patient categorisation 
100% node positive, and 100% 
premenopausal 
'100% node positive, and 100% 
postmenopausal' and '100% node 
positive, median age over 55 years' 
100% node negative, and median age 
under 50 years or 50% 
premenopausal (80% node negative, 
and 45% age under 50, for 
tamoxifen+chemotherapy) 
'80% node negative, and median age 
over 50 years or 50% 
postmenopausal' 
Adjuvant therapies analysed 
Chemotherapy and 
tamoxifen+chemotherapy 
Tamoxifen, chemotherapy, 
and 
tamoxifen+chemotherapy 
Tamoxifen, chemotherapy, 
and 
tamoxifen+chemotherapy 
Tamoxifen, chemotherapy, 
and 
tamoxifen+chemotherapy 
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Chapter 5 Case study: analysing the literature review data 
5.1 Introduction 
At this stage in the modelling process, data to populate the decision model have been 
extracted from the literature, which must now be assembled into probability distributions to 
represent the uncertainty about the true values of the model's input parameters. The first 
task addressed, however, is the reappraisal of the preliminary model structure, which may 
be altered due to an improved understanding of the treatment area, or to better facilitate the 
format of the identified data. The following sections present the hannonisation of the 
identified data, and the quantitative analysis of the data to specify representative probability 
distributions. 
The hannonisation of the data makes explicit assumptions about data presented by different 
studies with respect to the definition of relevant events, and attempts to revise the results of 
outlying studies to a common definition. As discussed in Chapter 3, there are various 
approaches to the definition of input distributions. The applied options involved the 
creation of weighted datasets (that were inputted directly into the model, or used to fit 
probability distributions using statistical fitting software) and the specification of 
theoretical distribution types for different categories of parameters. The bootstrapping 
option was not applied to the case study evaluation because it is more suited to decision 
modelling studies based on patient-level data. 
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The application of the modelling process to the full range of sub-groups defined within the 
aggregate early breast cancer popUlation is not feasible due to space restrictions. From this 
point onwards, therefore, the presentation of the case study evaluation is limited to a 
comparison of chemotherapy and tamoxifen versus tamoxifen alone in node-positive, 
postmenopausal women with early breast cancer. In addition, this Chapter concentrates on 
the methodological aspects of analysing the literature review data, presenting the 
reappraisal of the theoretical model, the harmonisation, and the definition of the probability 
distributions in three separate sections. To avoid overburdening the reader. details of the 
data and the presentation of the resulting distributions have not been included in this 
Chapter. Full details are provided in Appendix 7. 
5.2 Reappraisal of the theoretical model 
The process of reappraising the preliminary model structure is presented in two sections, 
describing the representation of treatment side effects and the depiction of events associated 
with the experience of relapsing and dying. The amended model structure is presented in 
Figure 5.1. 
5.2.1 Reappraisal oj the treatment side effects categories 
The range of side effects associated with chemotherapy is huge, and the categorisation of 
the toxicities into a limited number of groups was a particularly difficult task. The 
theoretical model had specified four categories based on increasing orders of severity, with 
the most severe category representing fatalities. At the point of reappraisal, it became clear 
that the inclusion of a separate fatality category would cause problems for the estimation of 
the length of disease free interval (DFI) because the fatalities due to treatment side effects 
were included in the aggregate DFI survival curves. The number of toxicity categories was 
reduced to three. In addition, the basis for the category definitions was altered to reflect the 
presentation of toxicity data in the published literature. The theoretical model had specified 
alternative categories on the basis of differential resource use, whilst the literature tended to 
define side effects as major toxic events (primarily cerebrovascular events) and graded 
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toxicities, differentiating between grades 1 or 2, and grades 3 or 4. The identified data also 
specified that patients could experience multiple categories of side effects simultaneously. 
5.2.2 Reappraisal o/the relapse categories 
The most radical change to the model structure concerned the representation of 
locoregional relapses. The theoretical model had defined a locoregional relapse as operable 
or inoperable. Unfortunately, few data were identified describing the respective pathways 
of these two patient groups. An alternative structure was informed by the format of the 
data presented in the literature. Most studies reporting on the prognosis of patients 
experiencing a locoregional relapse presented survival curves illustrating the proportion of 
patients remaining in remission from the point of diagnosis with locoregional relapse. The 
revised model structure assumed, therefore, that all locoregional relapses were controlled, 
and all patients entered the health state 'remission', even if the period of control was 
instantaneous. The events following a locoregional relapse could then be described in the 
same way as the events following DFI, though no allowance was made for the experience 
of a second locoregional relapse. From the point of dissemination, the progression scenario 
switched to the relevant site of distant relapse. For the proportion of patients who do not 
progress to metastases, it was reported that survival did not differ from that of the general 
population [Willner et aI, 1997]. 
It has been shown that progress from distant relapse is related to the site of metastases 
[Clark et aI, 1987]. The most common distinction made in the literature separated visceral, 
bone and soft tissue sites. The model was again restructured to represent three sites of 
metastases, rather than the original distinction between bone and non-bone sites. It was 
also noted from the literature review that patients could experience metastases at two or 
more sites simultaneously, though additional states describing double sites of relapse were 
not included as few data described progression from multiple sites of relapse. In addition to 
survival data, events such as remission, stability and progression of the disease were 
investigated as well as the use of second- and third-line therapies, though few data other 
than survival data were identified. Due to the lack of data and the relatively short survival 
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time from metastases, the original representation of patients progressing only to death from 
diagnosis with metastases was maintained. 
Figure 5.1 Reappraised structure of the ABC model 
metastases 
5.3 Harmonising the data 
The process of harmonising the data was only required for some of the clinical parameters 
included in the model. The following sections illustrate some of the available methods that 
can be used to increase the comparability of identified data describing treatment side 
effects, DFI and events ending DFI, and progression from the point of relapse. 
5.3.1 Treatment side effects 
The decision model only describes the effect of toxicity in the DFI state because side 
effects associated with the treatment of a relapse were incorporated within a general 
description of those states. The analysis of treatment side effects did not distinguish 
between different patient groups, rather data were sought on the toxicity caused by 
alternative combinations of chemotherapeutic agents, with tamoxifen, as well as by 
tamoxifen alone. The amalgamation of all patient groups for the analysis of toxicity 
increased the available data substantially. 
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The analysis of the treatment side effects involved three main issues. Firstly, the aggregate 
proportions of patients experiencing each class of toxicity were required. Secondly, for the 
purpose of costing information was needed on the types of conditions, and the frequency of 
their occurrence, within each of the toxicity categories. Finally, compliance with the 
adjuvant therapies is connected to the experience of toxicity. The areas in which action was 
required to hannonise these data are described below. 
In the estimation of aggregate incidence of the graded toxicity categories the majority of 
studies used the WHO classification index, although a couple of studies referred to less 
well-known indices, for example, the South West Oncology Group grading [Budd et al, 
1995; Rivkin et aI, 1996], or the ECOG index [Tormey et al, 1992]. No major differences 
between the grading systems were identified and they were analysed simultaneously with 
no adjustments. Aggregate data were reported for grade 3 or 4 toxicity, in particular, 
enabling an accurate estimate of the proportion of patients experiencing these grades of 
toxicity. Unfortunately, the grade 1 or 2 toxicity category mostly reported the proportions 
of patients experiencing the constituent conditions within the aggregate category. Although 
tending towards an underestimate, the proportions of patients experiencing the most 
common condition within the relevant category were taken as minimum estimates of the 
aggregate proportion. 
Due to the number of conditions that were reported in the published literature the analysis 
of the type and frequency of events was difficult. In studies where specific conditions were 
not reported, that condition was assumed not to have occurred, i.e. to have a zero 
proportion. To prevent distortion due to limited reporting of toxicity conditions, studies 
reporting less than four toxicity conditions were excluded from the composition analysis. 
Ten studies were identified that provided quantitative data on patient compliance with 
chemotherapy. However, four broad methods for presenting such data were established. 
Four studies presented the proportion of patients completing the specified cycles of 
chemotherapy [Scottish cancer trials breast group, 1993; Velez-Garcia et aI, 1992; Zambetti 
et aI, 1992; International breast cancer study group, 1996], and two studies each used the 
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following methods: the proportion completing cumulative cycles [Schumacher et al, 1994: 
Coombes et aI, 1996], the proportion of individual components of the chemotherapy 
regimen completed [Misset et aI, 1996; Marini et aI, 1996], and the cumulative percentages 
of protocol dose completed [Fisher et aI, 1996; Marini et aI, 1996]. The clearest data 
covered the proportion of patients completing cumulative cycles of chemotherapy and this 
data was included in the analysis. 
5.3.2 Disease free interval (DFI) and clinical events ending disease free interval 
DFI describes the period following primary treatment of early breast cancer until the 
experience of a relapse or death with no evidence of disease (DNED). The length of DFI 
and the events ending DFI are possibly the most important in terms of the relative 
effectiveness of alternative therapies, but they are assessed jointly because of their natural 
connection. Indeed, the majority of studies used to inform DFI also provided data on the 
clinical events, and the issues around the harmonisation of both categories are similar. 
Two discrepancies were found in the inclusion criteria for DFI. Firstly, most studies 
included DNED as ending DFI, though a few studies analysed such deaths as censored 
events [Eckman et al, 1998; Ve1ez-Garcia et aI, 1992; Gundersen et aI, 1995]. If DNED 
data were not reported for a particular study the proportion of cases of DNED from a study 
with similar patient characteristics and adjuvant therapies was used as a proxy, which was 
added to the annual proportions of patients ending DFI. 
Disparity was also noted in the reporting of second primary tumours. All studies providing 
data on the length of DFI were reviewed to ascertain whether second primaries had been 
included. Forty-seven studies provided useful data on the annual proportions ending DFI, 
of which 25 definitely did not include second primary tumours as an endpoint for DFL and 
12 definitely did include second primaries. Of the remaining 10 studies, six appeared likely 
to exclude second primaries, two appeared likely to include such events, and two gave no 
indication. The early breast cancer trialists excluded second primaries from the analysis of 
DFI. Taking this approach as a lead, second primaries were excluded from the annual 
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proportions of patients ending DFI in all the inclusive studies. Thus, second primaries, as a 
proportion of events ending DFI, were subtracted from the annual proportions ending DFI 
in studies that included such events. 
Ipsilateral breast tumour relapses were also excluded because they can only occur after 
breast conserving surgery, and their prognosis is considerably better than other local 
relapses following mastectomy [Harrold et aI, 1998]. Thus, in studies where breast 
conservation was an eligible option, the proportion of relapses that were in the ipsilateral 
breast was subtracted from the annual proportions of patients ending DFI. In studies not 
reporting the proportion of such relapses, the proportion reported in similar studies, with 
respect to treatment and the proportion of patients receiving breast conserving surgery, was 
substituted. Some studies included patients receiving breast conserving surgery, but did not 
state the proportion. In such studies it was assumed that five per cent of relapses were in 
the ipsilateral breast - an intermediate figure derived from all studies reporting ipsilateral 
relapses. 
As the model did not describe the experience of multiple sites of metastases, harmonisation 
was also required for studies that reported the proportion of patients with different sites of 
metastases, but which included patients experiencing multiple sites of relapse. Visceral 
metastases was documented as being the most severe form of metastases, so the reported 
proportions of visceral metastases were not amended. However, the proportion of bone and 
soft tissue relapses were re-estimated using formulae 5.1 and 5.2, respectively: 
pr(bone) = [bone /(bone + softtissue )]x [1- visceral] (5.1) 
pr(softtissue) = [softtissue /(bone + softtissue )]x [1- visceral] (5.2) 
5.3.3 Progress from relapse 
Patient pathways following the diagnosis of a relapse were analysed separately for 
locoregional relapses and metastases. Within the locoregional category, the only 
divergence between the identified studies related to the assumption made in the models that 
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patients could not experience a second locoregional relapse. Such events are rare, but it 
was still necessary to ensure that the data reported by the identified studies described the 
time to the experience of metastases or death. The only data required from the point of 
diagnosis with metastases were survival times and no areas of harmonisation were 
identified for these data. 
5.4 Pooling and formatting the data 
Quantitative analysis was required to pool and format the identified data for all the 
parameters included in the model. The following sections describe the issues arising in the 
analysis undertaken for the different types of clinical parameters, resource use and cost 
parameters, and utility values. 
5.4.1 Treatment side effects 
Probability distributions were described for the proportion of patients experiencing each of 
the three categories of toxicity. Distributions were not assembled for the data on the type 
and frequency of events because such detail would increase the complexity of the model 
programming, but also because specifying distributions around the cost estimates could 
represent such uncertainty. The methods applied to create the alternative forms of 
probability distributions are described below. 
The first two methods - empirical distributions and fitted distributions - are based on the 
creation of weighted datasets. As all the identified data on toxicity were collected from 
clinical trials meta-analytic methods for weighting the data could be employed. The 
analysis was based on the fixed effects model as strict definitions of toxicity had been 
specified, so only limited heterogeneity between the identified studies was assumed. The 
data from each identified study was weighted using formula 5.3. 
(5.3) 
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Where Pi is the proportion experiencing a particular category of toxicity and ni is the 
sample included in the study (see Appendix 3). After weighting the individual 
observations, a weighted dataset of 100 observations was created by dividing each weight 
by the sum of the weights and multiplying by 100 (value = Xi). The dataset comprised Xi 
copies of each parameter observation i (see section 3.4.3.2). The reSUlting datasets were 
inputted directly into the models as one form of representing the uncertainty in the values 
of the toxicity parameters, and they were also used to fit probability distributions. The 
fitted distributions were defined by inputting the datasets into statistical fitting software 
[Stat::Fit, 1996]. The software calculated goodness-of-fit statistics for each defined 
probability distribution so the best-fitting distribution could be selected. 
The theoretically defined probability distribution assigned for proportion parameters is the 
beta distribution. Estimating the beta distribution parameters (a and P) did not require the 
creation of a weighted dataset as a and p are related to the number of events experienced (x) 
and the total number of patients (n) [Iverson, 1984]: a = X and f3 = n - x (see Appendix 5). 
5.4.2 Disease free interval and clinical events ending disease free interval 
The DFI data were collected from survival curves presented as the results of clinical trials. 
Though a couple of authors were contacted for assistance in deciphering the data presented 
in unclear figures, or figures presented on a log scale, the majority of data were read 
directly off the printed page. The data initially assembled were the annual proportions of 
patients in the original cohort (in year 0) leaving DFI, which required transforming to the 
proportion of patients remaining event free at the beginning of a particular year 
experiencing an event during that year. Formula 5.4 was used to transform the data (see 
Appendix 4). Separate datasets describing the proportions of patients leaving the state DFI 
were created for each year following primary treatment. The weighted datasets and the 
theoretical distributions were specified using the same methods as for the treatment side 
effects data described in the previous section. 
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prevent / .. h] P[ event / originalcohort]. remaznzngco ort . = I 
I P[remaining /originalcohortl (5.4) 
Some of the data describing the types of events ending DFI were collected from 
retrospective observational studies [Goldhirsch et aI, 1994; Kamby et ai, 1987]. No attempt 
was made to weight the evidence according to the type of study and such data were 
analysed on the same level as the clinical trial data. Both sources provided the respectiYe 
sample sizes so the weighted datasets and the beta distributions were estimated as described 
above. 
5.4.3 Progression from relapse 
The quantitative analyses of the data describing progression from the two main forms of 
relapse - locoregional and metastases - are presented in this section. The majority of the 
identified data describing the time in remission following a locoregional relapse were in the 
form of survival curves. The DES model recorded the time at which individual patients 
entered the locoregional state and the separate probabilities of leaving the state in 
subsequent time periods could be applied individually to each patient. Thus, the data were 
analysed in a similar manner to the data for the length of DFI, as described above. The 
Markovian assumption precluded the use of differential annual probabilities of remaining in 
the remission state. Time in remission was described as a constant probability of 
experiencing a further relapse. 
The definition of the input distributions describing the length of remission in a DES model 
was identical to the definition of the input distributions for the length of DFI. Weighted 
datasets were created for each year following the treatment of a 10coregionaI relapse, which 
were used directly within the model, as well fitted to probability distributions using 
statistical fitting software. Alternatively, using theoretically defined beta distributions the 
numbers of patients experiencing, and not experiencing, a relapse in each year informed the 
relevant distribution parameters. Only a single input distribution was required to describe 
the remission data in the Markov model. In the initial quantitative analysis the reported 
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median times In remISSIOn were weighted according to the sample included in the 
respective studies and a weighted dataset created. This data was inputted directly into the 
model, as well as to fit probability distributions. The dataset was also used to estimate a 
mean and a standard deviation for a theoretically defined gamma distribution of the median 
time spent in remission. During the process of validation, however, it became apparent that 
the patient-level distribution of time in remission was heavily skewed and median estimates 
were underestimating the mean length of remission (see section 7.3). Using the presented 
survival curves representing time in remission, the mean remission periods were estimated 
on the basis of a common cut-off length of remission for those patients remaining III 
remission at the end of each studies follow-up (see section 9.2 for a full discussion). 
Very few studies presented survival from metastases in the form of survival curves. As the 
survival period is relatively short most studies simply reported the median survival (usually 
in months). The use of median times, rather than annual proportions or rates, simplified the 
analysis. Three options for the analysis of the data on the progression from each of the 
three separate sites of metastases were possible, which would use differing amounts of the 
available data: 
• create weighted datasets using studies presenting separate data for individual metastases 
categories; 
• create weighted datasets using studies in which a single metastatic site is dominant in 
over 50% of patients; 
• regress survival on three explanatory variables, defined as the proportions of patients 
with soft tissue, bone, and visceral metastases in each identified study (observation). 
The available data were mostly taken from clinical trials of alternative therapies for 
metastatic cancer, of which there was a reasonable amount. 113 separate treatment arms 
were identified, 68 of which presented an aggregate survival estimate and details of the 
component proportions of the different metastatic sites. The remaining treatment arms 
reported survival estimates for individual sites - 11 soft tissue, 15 bone and 19 visceral. 
All three quantitative options were explored. Only poorly fitting regression models could 
be specified and as a reasonable amount of data describing survival from the separate 
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metastatic sites were identified, their use was preferred to the data including combinations 
of all sites of metastases. A number of studies also presented data on metastatic survival 
differentiating with respect to nodal status [Koenders et aI, 1992; Venturini et aI, 1996]ER 
status receptor [Koenders et aI, 1992; Vogel et aI, 1992; Alonso et aI, 1995; Venturini et at 
1996], PgR receptor status [Koenders et aI, 1992], menopausal status [Venturini et aI, 
1996], and the administration of prior adjuvant therapies [de Takats et aI, 1993: Venturini et 
aI, 1996]. These data were used to estimate a survival multiplier for alternative patients 
groups. 
Each estimate of survival was weighted by the corresponding sample size and three 
weighted datasets were created. The datasets were used directly, to fit distributions using 
statistical fitting software, and to define the mean and standard deviation for the 
theoretically specified gamma distributions. 
Though the model structure did not record events following the development of metastases 
explicitly, the time to progression (TTP) for the alternative sites and therapies were 
recorded in order to estimate monthly costs for the metastases states (see section 5.4.4.4). 
Fewer trials presented data on the TTP; such data were available for only 2 of the 19 
treatment arms presenting specific data on survival from visceral metastases. The 
regression models were again poorly specified and so weighted datasets were created using 
data from studies in which a single metastatic site was dominant in over 50% of patients. 
The input distributions were defined in a similar manner to the survival data. 
5.4.4 Cost parameters 
The following sections describe the sources for the estimates of the cost parameters, as well 
as the methods for specifying input distributions around the baseline point estimates. The 
collection of data to inform the cost parameters would ideally identify UK-based estimates 
of the resources used to treat patients experiencing each of the events described in the 
model and then attach current unit costs to the recorded resource use. Unfortunately, such 
ideal data is rarely available and a pragmatic approach is required. For the case study 
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evaluation, alternative approaches were adopted for the different parameter categories 
depending on the data available. Priority was given to data describing disaggregated 
resource use rather than aggregate cost estimates because current unit costs could be 
attached to the former. If only aggregate cost estimates were available they were uprated to 
year 2000 prices using the health services pay and prices index. UK -based studies were 
preferred to foreign studies, though when there was no alternative the estimates proyided by 
foreign studies were converted to UK prices using the health services purchasing power 
parity index for the year in which the data were recorded (and then uprated to year 2000 
prices using the health services pay and prices index). The data are presented in four 
categories covering adjuvant therapies, surveillance, treatment side effects, and relapses. 
Details of the costing are provided in Appendix 7. 
5.4.4.1 Costs of adjuvant therapies 
The cost of chemotherapy is an integral parameter in the model and a wide search for 
alternative estimates of the cost of a cycle was undertaken. Six cost estimates were 
calculated by combining costs for the three resource elements of a cycle of chemotherapy -
drugs, health professional's time, and outpatient visits. The latter two elements were varied 
according to alternative estimates in the literature [Lober et ai, 1988; Lokich et aI, 1996], 
and on the basis of discussion with clinicians involved in the ABC trial. Published 
estimates of the aggregate cost of the two most commonly administered chemotherapy 
regimens, CMF and CAF [Silva and Zurrida, 1999], as well as the aggregate cost of a cycle 
of chemotherapy from the NHS reference costs were obtained [The new NHS - 1998 
Reference Costs, 1998]. An estimate of the aggregate cost of chemotherapy was also 
obtained from an individual NHS Trust hospital to represent the lowest end of the scale. 
The associated costs are presented in Table 5.1. 
The data sources for the cost of a cycle of chemotherapy provided no objective measure of 
variability that could be used to weight the separate estimates. Subjective weights were 
defined with respect to the perceived relevance of each estimate to the intended audience 
for the evaluation. To specify a probability distribution of chemotherapy costs the ten 
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individual estimates were ranked according to their relevance. as judged by their source. 
The costs were then inversely weighted according to their rank, so that the highest-ranking 
cost had a weight ten times that of the lowest ranked cost. This process is presented in 
Table 5.1. 
Table 5.1 Separate cost estimates for a cycle of chemotherapy, and associated 
rankings and weights 
Method Source 
Separate CMF, baseline (see Appendix 7) 
CAF, baseline (see Appendix 7) 
CMF, baseline (I clinic visit) 
CMF, health professionals time costs l 
CMF, health professionals time costs2 
CAF, health professionals time costs2 
Aggregate NHS reference cost (HRG v.3) 
E Anglia Trust cost 
CMF3 
CAF3 
Rank 
1 
2 
3 
6 
7 
8 
4 
5 
9 
10 
Weight 
10 
9 
8 
5 
4 
3 
7 
6 
2 
1 
Cost 
284.94 
226.65 
198.59 
141.86 
700.46 
467.60 
269 
67 
596 
648 
All costs uprated to year 2000 prices, foreign costs exchanged using health services purchasing power parity index 
1 [Lober et ai, 1988], 2 [Lokich et ai, 1996], 3 [Silva and Zurrida, 1999] 
Each cost estimate was replicated according to its weight and the resulting collection of 
estimates was then assembled as a dataset. The weighted dataset was used directly in the 
models, but also to fit probability distributions. Because cost distributions cannot include 
values less than zero, only four distributions were tested as feasible distribution types for all 
the cost distributions: lognormal, gamma, weibull and beta distributions. A gamma 
distribution had been specified as the theoretical distribution for cost parameters and the 
mean and standard deviation from the weighted dataset were used to solve for the 
distribution parameters (see Appendix 5). 
5.4.4.2 Costs of surveillance 
Surveillance is an ongoing component of the health care that breast cancer patients receive, 
but it is not constant. Separate estimates of the cost of monitoring patients were established 
for the first year following primary surgery, subsequent years in the state DFI, and from the 
point of diagnosis with metastases. 
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Estimates of the cost of surveillance following pnmary surgery were derived from a 
representative selection of published follow-up procedures in clinical trials. During DFI. 
the intensity of surveillance following primary surgery is known to be higher than in 
subsequent years. The period of increased surveillance seems to range between 9 months 
and 3 years [Arriagada et aI, 1992; Bonadonna et aI, 1995]. As the surveillance procedures 
reported by clinical trials are generally more intensive than normal practice, the intensity of 
surveillance was assumed to decrease after the first year. In order to estimate a range of 
costs three alternative surveillance procedures, each incorporating two levels of the 
intensity of follow-up, reported by separate clinical trials were itemised and costed. The 
main cost driver appeared to be the number of breast clinic visits so five alternative unit 
costs for outpatientlbreast clinic visits were also included. In total, 15 estimates of the cost 
of surveillance for both the first year and subsequent years were established. 
No data reporting surveillance of patients following locoregional relaspe were identified so 
patients in remission were assumed to have similar levels of health service contacts to 
patients in their first year of DFI. To inform follow-up after metastases a UK-based 
observational study comparing two options for the surveillance of patients with metastatic 
breast cancer was identified. The options comprised UICC assessment and Serum marker 
assessment, each method was costed twice, reflecting an intensive and a less intensive form 
of surveillance [Robertson et aI, 1995]. Given the' relevance of the identified study no 
further exploration of this cost parameter was undertaken. 
To create a weighted dataset for the costs of surveillance during DFI the ranking method of 
weighting the estimates described in the previous section for the costs of chemotherapy was 
employed. The lowest level of intensity was chosen as the highest ranked pattern of 
follow-up, though no rank difference was employed between the respective costs. This 
weighting structure was chosen because surveillance reported in clinical trials is likely be 
higher than in normal practice, also Liberati has investigated the impact on survival of 
different intensities of follow-up schedules and detected no difference [Liberati, 1995]. 
The four estimates for the cost of surveillance for patients with metastases were assigned 
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equal weights as there were no grounds for increased confidence III one estimate oyer 
another. 
The three methods for assigning input distributions were derived from the \yeighted 
datasets using the data directly, inputting into statistical fitting software and estimating the 
mean and standard deviation to calculate the parameters for a gamma distribution. 
5.4.4.3 Costs of toxicity 
To inform the associated cost values, it was necessary to describe the events experienced in 
each of the toxicity categories. A list of possible events experienced within each category 
of toxicity was established, and the proportion of patients experiencing each event was 
estimated from the literature (see section 5.3.1). The baseline cost of treatment for the three 
main categories - major, grade 3 or 4, and grade 1 or 2 - comprised a weighted cost of the 
different conditions experienced. 
The events described in the major toxicity category were all well defined conditions that 
have been the subject of economic evaluations in their own right, such as thromboembolic 
and cerebrovascular events. The costs associated with treatment for such conditions were 
derived from published economic evaluations [Lloyd et al, 1997; Holloway et aI, 1996]. 
Within the grade 1 or 2, and 3 or 4, categories of toxicity, up to twelve separate conditions 
were identified. To reduce the complexity, only conditions experienced by more than ten 
per cent of patients were costed. Very little information was available from the literature 
review on the cost of treating these less serious forms of toxicity so the treatment of each 
condition, at the relevant level of toxicity was discussed with a team of health professionals 
(clinicians and nurses) involved with the ABC trial. Costs were then attached to the 
resources specified by the team to calculate a baseline cost for each condition. 
Due to the lack of data describing the costs of toxicity minimum and maximum costs w"ere 
estimated as 50% and 150% of the baseline costs for each category of toxicity. Given a 
baseline estimate and a minimum and a maximum value, the statistical fitting software 
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estimated a triangular distribution for each level of toxicity. The triangular distributions 
also represented the empirical estimates of the costs of toxicity as only one real cost 
estimate was available for each form of toxicity. To inform the theoretically defined 
gamma distribution, the baseline estimate was defined as the mean and the standard 
deviation estimated to be one quarter of the range. 
5.4.4.4 Costs of relapse 
Few quantitative data were identified to cost the time spent in relapse states. It was evident 
that the quantitative data alone were insufficient, so the cost estimates were derived from a 
combination of quantitative and qualitative data. Differential costs were estimated for each 
of the four sites of relapse included in the structure of the model - locoregional, soft tissue, 
bone, and visceral. 
The treatment for locoregional relapse was included as a one-off cost because patients were 
assumed to move from the state 'locoregional relapse' to 'remission' after one month, 
though parts of the treatment, such as the administration of chemotherapy and radiotherapy, 
may continue for a number of months. Using the available qualitative data the treatment of 
locoregional relapse was costed as a single event requiring surgery to remove the returning 
tumour, followed by radiotherapy and chemotherapy. The cost of surgery was obtained 
from the National Schedule of Reference Costs [The new NHS - 1998 Reference Costs, 
1998]. In addition to the mean value, the minimum and maximum costs of 'Intermediate 
Breast Surgery' from all NHS Trusts were used to define a range of values for the costs of 
surgery. Little variation was found around the cost of a fraction of radiotherapy [Read, 
1994], but the number of fractions undertaken appeared to be more uncertain. Different 
estimates of the number of fractions were taken from the literature to inform a range 
[Aberzik et al, 1986; Toonkel et aI, 1983]. The cost of chemotherapy following 
locoregional relapse was described using the same estimates and distributions derived for 
the cost of adjuvant chemotherapy. 
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U sing the defined ranges and the mean values for the cost of surgery and the number of 
fractions of radiotherapy, triangular distributions were specified by the statistical fitting 
software. The three elements of locoregional treatment were each assigned distributions 
that were incorporated in the models and the aggregate cost of treating locoregional relapse 
was estimated within the model. 
For the model analysed using theoretical distributions a distribution of aggregate costs was 
established. To establish a dataset of costs a Monte Carlo simulation was undertaken. The 
distribution describing the number of fractions of radiotherapy was linked to the cost of 
radiotherapy, which was linked to the distributions describing the costs of surgery and 
chemotherapy. F or each simulation a value from each distribution was sampled and an 
aggregate cost of the treatment of loco regional relapse estimated. From a total of 1,000 
simulations a mean and standard deviation were estimated to inform the parameters of the 
theoretically defined gamma distribution. 
The cost of treating patients with metastases varies considerably over time. Several studies 
have remarked on the moving profile of resource use over the period of relapse [Hurley et 
aI, 1992; Will et aI, 1998; Baker et aI, 1991; Koopmanschap et aI, 1992], with the final 
three to six months of life being the duration of expensive terminal care, whilst the initial 
three months are also relatively resource intensive. However, the model did not 
differentiate between the different stages of metastases because more data were available 
that informed aggregate costs of treatment for metastases. Protocols were again developed 
from the literature to estimate separate monthly costs for the treatment of the metastases 
with respect to systemic therapies, local treatment, and inpatient episodes. 
The appropriate systemic therapeutic strategy for individual patients is influenced by a 
number of characteristics, including the extent of disease, DFI, ER status and age 
[Hortobagyi, 1998]. Treatment for both soft tissue and bone metastases was differentiated 
with respect to good and bad prognoses using the only available prognostic indicator - the 
length ofDFI (good DFI>2years, bad DFI<=2 years). There was a general consensus in the 
literature on the ordering of different types of therapy for metastases, with respect to the use 
112 
Chapter 5 Case study: analysing the literature review data 
of honnonal therapy and chemotherapy. The two schemas' presented in Figure 5.2 
illustrate a similar choice of therapies for alternative patient characteristics [Coleman and 
Rubens, 1987; Leonard et aI, 1994]. 
Figure 5.2a Schema for the treatment of metastases[Coleman and Rubens, 1987] 
non-aggressive disease agressive visceral disease 
/ ~ E~ E~ 
~ 
endocrine therapy 
~ 
premenopausal 1 postmenopausal 
~. bl' ovarIan a atlOn ~ tamoxifen 
~ ~ 
secondary endocrine therapy 
-------1 •• cytotoxic chemotherapy 
Figure 5.2b Schema for the treatment of metastases[Leonard et ai, 1994] 
Good prognosis 
relapse in bone or lymph nodes 
long OFI 
ER+ 
~ Hormonal Treatment (lIT) ----. no response 
~ 
response then relapse 
,ecot line lIT ____ -I •• no response 
~ 
response then relapse 
~ 
third line HT _____ ....... no response 
Poor prognosis 
relapse in visceral sites 
short OFI 
ER-
---t.~ chemlerapy (CT) ----1.~ no response 
~ 
response then relapse 
second tne CT treatment of symptoms 
or experimental CT 
The second element of resource use in treating metastases included all local treatment. The 
treatment for the local conditions associated with the alternative metastatic sites were 
mostly drug therapies and the costs were taken from the British National Fonnulary, the 
cost of radiotherapy had been estimated previously. The types of treatment administered to 
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patients experiencing the different forms of metastases, and their frequency, were informed 
by various studies identified during the literature review. The final resource category 
included all contacts with hospital services, from outpatient visits for monitoring to 
inpatient admissions, which were informed by one quantitative study that differentiated 
between the types of relapse with respect to hospital contacts [Hurley et al, 1992]. Data 
from English Trust returns including 55 Trusts were used to estimate the mean cost per 
patient day in medical oncology specialities and per outpatient visit. 
The estimation of the monthly costs associated with each of the three metastatic sites 
comprised the aggregation of the various components - systemic therapies, local 
treatments, hospital contacts and surveillance. The monthly cost of systemic therapies was 
calculated on the basis of mean TTP and survival. Using the presented schema's for the 
progression of systemic therapy patients received their appropriate therapy until disease 
progression, at which point they would receive the next appropriate form of therapy. The 
addition of therapies continued until death, or until patients received two full courses of 
chemotherapy. The total cost was divided by the months of survival to estimate a monthly 
cost. Table 5.2 provides an example of the calculation of the cost of systemic therapies. 
Table 5.2 An example of the calculation of the costs of systemic therapies for 
patients experiencing bone metastases, with a DFI of 22 months 
Month Therapy Cost per month Total cost 
0-7.4 Anastrozole 83.16 615.38 
Response to anastrozole: 
7.5 - 14.9 Megace 29.30 216.82 
15 -22 Chemotherapy* 285.00 1710.00 
Cost per month 115.55 
Non-response to anastrozole 
7.5 - 15.7 Chemotherapy * 285.00 1710.00 
15.8 - 22 Chemotherapy* 285.00 1710.00 
Cost per month 183.43 
* chemotherapy is assumed to be administered for six cycles in each case. 
To represent the uncertainty in the cost of treating metastases probability distributions 
representing the aggregate monthly costs for each metastatic site were established. Firstly, 
probability distributions were defined for each significant factor affecting the aggregate 
cost. Bootstrapping the observed estimates created distributions around the relevant 
categories ofTTP and survival. The cost of chemotherapy was assumed to be similar to the 
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cost of adjuvant chemotherapy. In the local treatment of soft tissue and visceral metastases 
no probability distributions were assigned as the drugs administered have a negligible cost. 
Probability distributions were originally assigned to the number of fractions of radiotherapy 
received as treatment for bone metastases, but following the validation process the 
frequency of radiotherapy was revised downwards to a level that did not warrant inclusion 
as a probability distribution. There was a wide variation in the estimates of the cost of 
hospital visits over the country, which informed mean, minimum and maximum estimates 
for the three types of contact - inpatient, day case and outpatient. Using these data gamma 
distributions describing the cost of each element of treatment for metastases were defined. 
The distribution describing the cost of surveillance discussed in the previous section on 
surveillance was employed. 
Using the defined costs and associated probability distributions a similar process to 
estimating probability distributions for the aggregate costs of treating locoregional relapse 
was employed. The individual treatment components were linked so the respective 
components of each form of metastases were aggregated and Monte Carlo simulations were 
run sampling a value from each of the specified probability distributions. 1000 
observations of the monthly costs for each cost element were generated. The resulting 
dataset was used directly within the model, as well as inputted into statistical fitting 
software to estimate aggregate distributions for each site of metastases. Finally, the mean 
and standard deviation from the datasets were used to solve for the parameters of the 
theoretically defined gamma distributions. 
5.4.5 Utility values 
Quality of life in breast cancer patients has been investigated, but the majority of identified 
studies used condition- or symptom specific measures. The conversion of non-generic 
measures to utilities was not attempted, though the identified data could be used to inform 
descriptions of health states if the primary collection of health state utilities were to be 
considered. Few utility data associated with health states that a breast cancer patient may 
experience were identified. A number of previous modelling studies had assigned utility 
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values using either focus groups of oncology professionals [Hillner et aI, 1992; Hillner and 
Smith, 1991; Smith and Hillner, 1993; Desch et aI, 1993], or direct measurement 
techniques from oncology nurses [Hutton et aI, 1996]. In addition, three studies were 
identified that reported utility values from primary studies aimed at defining quality of life 
in patients experiencing health states similar to those described in the ABC models [de 
Haes et aI, 1991; Daly et aI, 1993; Ashby et aI, 1994]. 
Empirical utility weights for the separate toxicity categories were not identified in the 
literature review, only an aggregate weight for all patients receiving chemotherapy [de 
Haes et aI, 1991]. U sing these data the individual toxicity states were assigned utility 
values so that the weighted aggregate utility value (using the proportions experiencing the 
different toxicity categories) would equal the value quoted in the literature (0.72). The 
process is demonstrated in Table 5.3. 
Table 5.3 
states 
Example of interpolation to estimate separate utility values for toxicity 
Proportion of Utility Proportionate 
patients value utility value 
experiencing 
event 
Aggregate utility weight 0.72 
Grade 1/2 toxicity 0.57 0.78 0.44 
Grade 3/4 toxicity 0.38 0.65 0.25 
Major toxicity 0.05 0.51 0.03 
Sum 0.72 
No utility values were found that described the period of remission following locoregional 
relapse, so the value for the period 2 months to one year following mastectomy was used as 
a proxy [Ashby et aI, 1994]. Likewise, no direct weights were identified for patients 
experiencing visceral, bone or soft tissue metastases. Thus, the utility value reported for 
patients with metastases receiving chemotherapy was used as the proxy value for visceral 
disease. The utility value for bone or soft tissue metastases was calculated as a weighted 
proportion of the values for patients receiving hormonal therapy and chemotherapy for 
metastases, reflecting the proportion of time spent receiving the alternative therapies [de 
Haes et aI, 1991]. 
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From the available data, point estimates were specified for each of the health states 
included in the ABC models. F or some health states there were sufficient data to estimate a 
mean and a range for the associated utility value, ie. three separate values. However. for 
other health states only one point estimate could be identified. In the latter cases relaxed 
(wide) estimates of the possible ranges of utility values for the respective health states were 
made after consultation with economic and clinical colleagues. 
Inputting three values into statistical fitting software estimated a similar probability 
distribution for each utility value - the triangular distribution. Too few data were available 
to justify inputting the empirical data directly so the triangular distributions were used to 
represent the empirical data. U sing the specified ranges, the parameters for the beta 
distribution were estimated assuming that the standard deviation of the required distribution 
was a quarter of the range. With the mean and variance the beta parameters were estimated 
by simultaneously solving the equations presented in Appendix 5. 
5.5 Conclusions 
This Chapter has described the process of reappraising the theoretical model structure given 
the identified data, as well as the analysis of the data into a suitable format to populate a 
decision model. The process of harmonising data for selected input parameters was 
introduced as a means of improving the homogeneity of the available information. 
The reappraisal of the preliminary model structure was primarily based on the format of the 
identified data. The alterations made to the model structure were subtle changes that did 
not remove (add) any important events from (to) the model. The most significant 
difference combined operable and inoperable locoregional relapses within a single 
remission state because the identified data described pathways from locoregional relapse in 
that manner. Such an alteration simply moved the model from an explicit consideration of 
operable and inoperable relapses to an implicit account of these events. The reappraisal 
described in this Chapter demonstrated that a careful reconsideration of the preliminary 
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model structure can make better use of the identified data without compromising the 
theoretical basis of the model. 
Much of the process of harmonisation involved the identification of differences in the 
definition of similar events presented by different studies. To facilitate the combination of 
such data, explicit adjustments were made to the values reported by one or more of the 
relevant studies so that the comparability of underlying parameter definitions were 
improved. The application of harmonising the data reported in this Chapter showed that the 
process cannot be governed by hard and fast rules as the adjustments made to the data will 
depend on the event described and the format of the available data. However. the 
harmonisation of the case study data illustrated a range of issues potentially relevant to 
other disease areas. For example, during the harmonisation of the DFI data, the studies that 
treated death as a censored event reported the number of deaths observed, which were then 
used to adjust the original disease-free survival data. If the relevant data to harmonise a 
parameter were not presented by a study, data from studies with the most similar patient 
and treatment characteristics were used to adjust the initial estimate. 
The explicit presentation of the harmonisation of the data is necessary to enable the reader 
to judge the appropriateness of the parameter definitions and the alterations made to the 
data. The data adjustments are possible solutions to the noted divergence in the definition 
of events. 
This Chapter also demonstrated alternative methods for the specification of probability 
distributions to represent the uncertainty around the values of the input parameters. When 
creating the weighted datasets, the preferred approach to weighting the data used the 
variance associated with each identified value. If the variance was unknown then the 
sample size informing each value was employed as the weight. Some cost parameters were 
informed by various primary estimates with no objective measure of variance, whereby 
subjective methods of weighting the data according to their perceived relevance to the 
objective of the study was introduced. Least satisfactorily, some cost and utility parameters 
were informed by only one identified value in the literature. In such cases wide ranges of 
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values were specified to reflect the uncertainty. The specification of theoretically derived 
probability distributions for alternative groups of parameters and the use of defined 
formulae to estimate the distribution parameters provided a simpler method of specifying 
probability distributions. However, this latter method did not provide an alternative to the 
subjective weighting of the cost and utility parameters as the distribution parameters for 
these variables were necessarily based on the subjectively defined weighted datasets, or the 
specified ranges. 
The comparison of the alternative methods for defining probability distributions around the 
input parameters is a secondary objective of this thesis. The results of the comparison are 
presented in Chapter 8, the implications of which are discussed in Chapter 9. 
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Chapter 6 Case study: implementing the model 
6.1 Introduction 
The two previous Chapters described the identification and analysis of data to populate 
a decision model, which incorporated the specification of a preferred model structure. 
The next step in the modelling process is the development of an analysable model. This 
Chapter describes the implementation of two separate decision models, a Markov 
process and a discrete event simulation (DES) model, to represent the pathways of 
patients diagnosed with early breast cancer. The aim of this Chapter is to describe the 
analytic input required to develop the different modelling techniques. as well as to 
explicitly define the differing representations of the data used to evaluate alternative 
therapies for the early breast cancer. 
The first two sections justify the implementation of two alternative decision models, and 
the application of stochastic analyses. The implementation of each model is then 
described, starting with the Markov model. F or each modelling technique the 
implementation process is presented in two parts. Firstly, the process of establishing the 
relationships between the health states included in the structure of the model is 
presented (Modelling the health states). The second section describes the population of 
the models using the previously presented probability distributions, and the collection of 
the models' outputs for further analysis (Controlling inputs and outputs). A short 
section highlighting the differences in the modelling assumptions between the two 
techniques is then presented. 
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During the process of implementing the models two methodological issues were raised 
that affected the analysis of the models. These are explored in the final sections of this 
Chapter. The first issue related to the use of the DES model, where the question of an 
adequate sample size to minimise the impact of first-order uncertainty is addressed (see 
section 3.6.1.1). The second issue involved an assessment of alternative methods for 
describing probabilistic 'length of time' input parameters. 
6.1.1 The choice of modelling technique 
To build a decision model an appropriate modelling technique must be chosen. The 
economic evaluation employed as the case study for this thesis - a cost-utility analysis 
of alternative adjuvant therapies for early breast cancer - incorporates a relatively long 
time horizon. As discussed in Chapter 2 the decision tree technique can be adapted to 
cover patient pathways with long time horizons, but such models soon become 
cumbersome. The effective choice of modelling technique for the case study, therefore, 
was between a Markov model and a DES model. Only a partially informed choice 
could be made between the two alternatives as their relative merits have only been 
explored superficially [Chaussalet et al, 1999; Kamon and Brown, 1998]. From these 
earlier considerations of Markov modelling and DES it was clear that neither alternative 
dominated the other in every aspect of the modelling process. For example, it appears 
that DES allows greater flexibility in the representation of patient pathways, but a 
Markov model is generally easier and quicker to build. No empirical comparison of the 
two techniques was identified. To inform the appropriate choice of modelling technique 
both a Markov process and a DES model were developed to evaluate the economic 
impact of the relevant alternative adjuvant therapies. 
A Markov process, rather than a Markov chain, was chosen because time dependent 
transition probabilities (dependent on the time spent in the model) were considered to be 
important in the modelling of early breast cancer (see section 2.3 for full definition of 
Markov processes and Markov chains). The Markov process was built as a cohort-
based model, whereby a cohort of patients is sent through the model, rather than 
foHowing single patients through the model (first-order Monte Carlo simulation). A 
cohort-based Markov process is simpler to build and provides a starker contrast with a 
DES modeL which can only be analysed using first-order Monte Carlo simulation. 
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Moreover, first-order Monte Carlo simulation-based Markov processes (as opposed to a 
cohort-based Markov process) only provide additional information about first-order 
uncertainty, which is irrelevant to the required outputs of the model (see section 3.4.3). 
The cohort-based Markov process is also the most common fonn in the economic 
evaluation literature. 
6.1.2 Stochastic or deterministic? 
Both modelling techniques can be analysed deterministically, whereby single estimates 
of cost-effectiveness are generated for individually specified sets of input parameter 
values, or stochastically, whereby the output consists of distributions of the relevant 
costs and effects based on sets of input parameter values randomly sampled from 
specified probability distributions. F or the economic evaluation of health care 
technologies it has been proposed that stochastic analyses provide a more realistic 
method of describing uncertainty in the overall results of decision models [Fenwick et 
aI, 2000]. Stochastic models were chosen because such models facilitate the statistical 
analysis of model outputs for resource allocation decisions in the present, as well as 
enabling the statistical evaluation of the value of obtaining further primary information 
about the input parameters. Both of these objectives are explored in thesis. 
6.2 Building the decision models 
Wherever possible, the general points of good practice described in Chapter 3 were 
incorporated into both models. For example, no decision nodes other than at the root of 
the model were included and all common parameters were linked. 
The specification of a minimum time period of advancement was required for the DES 
model, as well as a cycle length for the Markov process. Though a case could be made 
for differential timing on the basis of model running time, it was decided that the patient 
pathways could be most accurately represented in both models using a time period of 
one month. The choice of one month as the models' cycle length meant that the annual 
probabilities collected in the literature review, describing the length of DFI and 
remission, needed converting to monthly probabilities. Transition rates were assumed 
to remain constant over the year, because no data were identified that contradicted this 
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assumption. Formula 6.1 was used to convert the annual probabilities to monthly 
probabilities [Miller and Homan, 1994]: 
P = I - [1 - P ]){2 monlhly annual (6.1) 
Where P is the probability of an event. A similar time horizon for both models was 
also adopted with patients living to a maximum of 100 years. Separate descriptions of 
the process of building the two models are presented in the following sections. In each 
section the description of the actual modelling of the health states is followed by the 
necessary structures for controlling the model inputs and outputs. 
6.3 The Markov process 
The Markov process was built in Excel using the Crystal Ball 2000 add-in, which is a 
risk analysis programme that is "easy to learn and easy to use" [Crystal Ball, 2000]. A 
deterministic Markov process can be built using the spreadsheet package alone, but 
Crystal Ball uses second-order Monte Carlo simulation to analyse the model 
stochastically. Sets of parameter values are randomly sampled from the input 
distributions, each of which is analysed using the cohort-based method. The process of 
building the model is described in chronological order. 
6.3.1 Modelling the health states 
Firstly, the model structure was transferred to the spreadsheet, which is presented in 
Figure 6.1, which shows the possible transitions that could be made within the model 
moving from period 't' to 't+ l' at different phases of the model. All patients began the 
model in the health state 'disease free interval' (DFI). During the first six months 
patients in the DFI state could experience toxic effects caused by the adjuvant therapies, 
a relapse in one of the four specified sites of relapse - locoregional, soft tissue, bone or 
visceral, or they could die from a cause other than breast cancer. Patients could also 
experience a relapse or die from other causes from the toxicity states. In the absence of 
relapsing or dying patients in the toxicity states returned to the original DFI state at the 
end of the first six months. 
Jrlpre6.1 
Mandl 
I( <'111D11d16) 
1+1 
1(~6) 
1+1 
RepreHlltadon of the poaible patient pathways within tbe ABC Markov process 
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Patients could experience one of three fonns of toxicity, though the different fonns of 
toxicity could not be experienced simultaneously. There were two reasons for this 
assumption. Firstly, four extra health states would be required to represent the 
occurrence of the joint toxicities. Secondly, further assumptions would be required to 
describe the probabilities of experiencing the different combinations of toxicity 
because no data describing the proportion of patients experiencing joint toxicities 
were identified. Other than the probability of experiencing toxicity, patients in the 
DFl state were subject to monthly probabilities of moving to a relapse state or straight 
to the dead state (with no evidence of disease). After the first six months, the 
proportion of patients remaining in the DFl state in month t was estimated using 
formula 6.2. 
pr(DFI)/ = pr(DFI)/_1 - pr(endDFI)/ (6.2) 
The probability of moving to a particular site of relapse incorporated the probability 
of leaving DFl and the probability of experiencing the different fonns of relapse. For 
example, the proportion of patients experiencing a locoregional relapse (LR) in any 
given month was described using fonnula 6.3 
pr(LR} = pr(endDFI)/ x pr(LRI endDFI)/ (6.3) 
Patients experiencing locoregional relapses were assumed to remain in that state for a 
maximum of one month, after which they entered a period of remission, experienced a 
more severe metastatic relapse, or died from other causes. From remission, patients 
could experience metastases or die from other causes, from the metastases states 
patients could only die. F onnula 6.4 described the proportion of patients entering, 
and remaining in, a metastatic state of relapse (MR), because patients could enter 
from DFl, locoregional relapse (LR) and from remission following a locoregional 
relapse (RM), as well as the patients remaining in a state from one cycle to the next. 
pr(MR)/ = pr(MR)/_1 - pr(endMR)/ + [pr(DFI)/_1 x pr(endDFI), x pr(MRI endDFI),] 
+ [pr(LR)'_1 x pr(endLR)/ x pr(MR I endLR)t]+ [pr(RM)t_1 x pr(endRM), x pr(MR I endRM)t] 
(6.4) 
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From the metastatic states the monthly probability of dying was converted from the 
median length of survival using the formula presented in section 3.5.1. 
6.3.2 Controlling inputs and outputs 
The actual Markov process ran on one spreadsheet, wherein each health state was 
assigned a column and each successive cycle (month) was represented by a row. 
From this allocation of columns and rows the basic operation of the Markov process 
involved describing the proportion of patients placed in each health state in each time 
cycle of the model. Using the formulae described in the previous section to represent 
the movement of patients between states the building of the model was relatively 
straightforward. 
Separate spreadsheets were established to hold the relevant data on clinical 
parameters, costs and utility values. Within each of the parameter spreadsheets the 
relevant probability distributions were established using the Crystal Ball add-in 
[Crystal Ball, 2000]. Stochastic analyses consist of multiple deterministic analyses 
using alternative sets of parameter values that are randomly sampled from the defined 
probability distributions for each input parameter. Each deterministic analysis is 
defined as a 'run'. A single deterministic analysis (run) of a Markov process involves 
the following steps: 
1. The relevant monthly cost and utility values are multiplied by the proportion of 
patients in each state in each cycle (month); 
2. The respective costs and utility values are summed for each cycle; 
3. Separate discount factors are applied to the cost and utility values assembled for 
each month; 
4. Aggregate values for the model outputs are calculated by summing the costs, life 
years and utilities for all cycles. 
The stochastic analysis consisted of 10,000 separate runs. Crystal Ball ran the 
necessary number of second-order Monte Carlo simulations 'solving' the model for 
each run. The required output data from all the runs - total costs, life years and 
QAL Y s - was collected in the form of frequency charts, which was easily extracted 
for further analysis. A full model was built and submitted for verification and 
126 
Chapter 6 Case study: implementing the model 
validation in less than 2 weeks. U sing a 700MHZ PC with a pentium II processor 
10,000 trials were completed in around 1 hour. 
6.4 The discrete event simulation (DES) model 
The first task in building a DES model was to identify an appropriate software 
package that could handle the characteristics of an economic HT A decision modeL 
and which did not require a high-level of programming skills. Five software packages 
were identified for building simulation models - Simul8, Witness, Microsaint. ithink, 
and Powersim. On the basis of cost and perceived user-friendliness the Simul8 
software was chosen [SimuI8, 2000]. The process of learning to use the software was 
undertaken on a separate project that employed a simpler model comparing a hospital 
at home scheme with inpatient care for elderly patients [Campbell et aI, 2000]. The 
process was gradual and continued into the time spent building the ABC DES model. 
The building of the model is described below. 
6.4.1 Modelling the health states 
The structure of the DES model is presented in Figure 6.2. which is the visual 
interface of the simulation software. Relationships between states, activities within 
states, and the collection of data associated with each state were handled by 
programming code. Code was implemented as patients entered a state, when they 
were within a state, or as they left a state. This will become clearer as the process of 
building the DES model unfolds. 
As discussed in Chapter 3 the model was built up in modules [pidd, 1989]. The first 
module described the period of time spent in the state DFI. DFI was not the first state 
because it was easier to assign the time spent in DFI prior to the patient entering the 
state. Within the first state 'trial entry' every patient passed through a loop command 
that sampled from a binary probability distribution for consecutive months until a 
'relapse' was experienced. At that point the month was noted and transferred to the 
DFI state to inform the length of DFI. The binary distributions reflected the 
probability of experiencing a relapse in each month that the patient remained disease 
free. For example, if the monthly probability of experiencing a relapse was 0.01. 
127 
Chapter 6 Case study: implementing the model 
patients sample from a binary distribution with a 1 % chance of experiencing a relapse 
in that month. 
The most noticeable difference between the DES and Markov process was that fewer 
health states were described in the DES model. In the DES model, toxicity was 
modelled as an attribute of the health state DFI, rather than as individual states. 
Incorporating toxicity as part of DFI meant that the model could describe patients 
experiencing different types of toxicity simultaneously. During DFI patients sampled 
from a series of binary distributions to determine which, if any, fonns of toxicity were 
experienced, and the respective durations of toxicity. The collection of the cost and 
utility data associated with the DFI state was especially complicated because the 
impact of toxicity had to be incorporated. It was possible for a patient to experience 
more than one type of toxicity at the same time; the associated costs of each event 
experienced were attached to the patient. In addition, the length of major toxicity was 
sampled from pre-specified distributions (the graded toxicities were assumed to last as 
long as the number of cycles of chemotherapy). The utility value attached to 
individual months spent in DFI was a function of the length of the different types of 
toxicity. For example, for a patient experiencing two types of toxicity, the utility 
value associated with the less severe form of toxicity would only be required if the 
less severe toxicity lasted longer than the more severe form. 
Prior to leaving DFI the destination of the patient was decided. The five probabilities 
covering the likelihood of experiencing each of the possible events - locoregional, 
soft tissue, bone, or visceral relapse, or death - were combined and adjusted 
proportionately so that their sum equalled one. Each patient then sampled from the 
combined distribution to detennine which health state they moved to from DFI. 
The second module represented the passage of events from the point of locoregional 
relapse to either a metastatic relapse or death. Again, patients remained in the 
locoregional relapse state for exactly one month before moving onto the remission 
state. During the locoregional relapse state the relevant cost and utility value was 
attached to patients. Analogous to the role of the trial entry state. the length of 
remission was also determined using a similar process of looping through months 
until an event was experienced. At the end of patients' time within the remission 
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state, a value was randomly sampled from a combined distribution representing the 
subsequent states that patients could enter. 
The final module described the experience of patients within the three metastatic 
relapse states. As the only possible exit state from these states was death they were 
relatively easy to model. The patients simply entered the relevant state, remained in it 
for the allotted period, and then moved into the dead state. 
6. 4. 2 Controlling inputs and outputs 
In the DES model, a single run followed a large number of individual patients through 
the model. At the start of each run a set of parameters from each distribution was 
randomly sampled from the specified probability distributions and applied to each 
patient. At the end of a run only the mean values for each of the model outputs were 
required. Unlike the Markov process, first-order uncertainty was an issue in the 
analysis of DES models because no definitive estimates of the outputs for each run 
were obtained. Applying the same input parameter values to different sets of patients 
(ie. using different random number seeds) produced varying mean values for the 
model outputs. The only way to reduce this variation was to increase the number of 
patients included in each run. 
Within the model the cost- and utility-based experiences within each state had to be 
described at the end of the state and aggregated as patients left each state. This aspect 
of the programming code was the most complicated due to the need to discount the 
outputs, which involved sectioning the time spent in each state into the corresponding 
years that the patient had spent in the model. Annual discount rates were applied 
because the monthly description of the cost and utility effects within the DFI state, 
which were dependent on the length of time spent in the state and the types of 
treatment side effects experienced, was deemed to be to complex. 
Running totals of the costs and QAL Y s were attached to each patient as she passed 
through the health states. On entering the dead state the fmal totals for each patient 
were stored in an internal spreadsheet. For each run, the mean values for the model 
outputs were calculated and stored in a separate internal spreadsheet. When data from 
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a sufficient number of runs had been collected the data was exported to a spreadsheet 
for further analysis. 
2,500 runs of 10,000 patients, running the model consecutively, took around 72 hours. 
Around two months were required to build a model to the point at which it could be 
subjected to the verification and validation process. Due to the learning curve the 
time required to build future models should be appreciably reduced. 
6.5 Comparison of modelling assumptions 
The respective assumptions incorporated in each model are presented in Table 6.1. 
Table 6.1 
DES model 
Respective assumptions employed in the Markov process and the 
Area 
General 
Disease free 
interval 
Toxicity 
Locoregional 
relapse 
Remission 
Metastases 
Markov process 
Cycle length of 1 month. 
Maximum age of patients 100 
years old. 
Annual probability of leaving DFI 
informed by survival curve. 
Annual probabilities converted to 
monthly probabilities assuming 
constant transition rates. 
Patients can experience one of 
three categories of toxicity. 
Grade 112, 3/4 and major toxicity 
end after 6 months. 
Patients remain in locoregional 
relapse for exactly 1 month. 
A mean time spent in remission 
employed. 
Patients subject to a constant 
monthly probability of leaving the 
remission state. 
A median time spent in metastatic 
states employed. 
Patients subject to a constant 
monthly probability of dying. 
DES model 
Minimum time period of 1 month. 
Maximum age of patients 100 years 
old. 
Annual probability of leaving DFI 
informed by survival curve. 
Annual probabilities converted to 
monthly probabilities assuming 
constant transition rates. 
Patients can experience any 
combination of three categories of 
toxicity. 
Grade 112,3/4 toxicity end after 6 
months, length of major toxicity 
sampled from probability distribution. 
Patients remain in locoregional relapse 
for exactly 1 month. 
Annual probability of leaving 
remission informed by survival curve. 
Annual probabilities converted to 
monthly probabilities assuming 
constant transition rates. 
A median time spent in metastatic 
states employed. 
Patients remain in metastatic states for 
set amount of time. 
6.6 Assessing an adequate sample size to minimise the impact of first-order 
uncertainty on the results of the DES model 
This section addresses a methodological issue that was first raised in section 3.6.1.1, 
which affects the analysis of the DES model. The DES model was analysed using 
first- and second-order Monte Carlo simulation. Sets of input parameter values were 
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randomly sampled from the specified probability distributions (second-order), which 
were analysed by sending a 'large' number of individual patients through the model 
(first-order). For each set of parameter values the only results of interest were the 
mean values for the model outputs, the variation around these means measured first-
order uncertainty, which should not influence resource allocation decisions [Briggs, 
2000]. The mean output values estimated for each set of parameter values were 
collated and analysed to inform the second-order uncertainty associated with the 
model, which describes the variation within the population of eligible patients. 
The question addressed in this section is what is an adequately 'large' number of 
patients to be run through the first-order Monte Carlo simulations to be sure that the 
mean values obtained for the required outputs are as close as possible to the true mean 
value for each parameter set? To test the adequacy of alternative sample sizes the 
input parameter values were held constant at their mean values. Repeated replications 
of the model were undertaken using different random number seeds for each 
replication of the same sample size. The use of alternative random numbers meant 
that patients within alternative replications sampled different values from probability 
distributions within the model, but the mean values of the model outputs should have 
remained the same. Sample sizes of 100, 1,000 and 10,000 were tested. For each 
sample size the DES model was run fifty times, each run starting from a different 
random number seed. 
The results of the analyses are presented in a cost-effectiveness plane in Figure 6.3. 
The plots show a very wide dispersion of estimates derived from runs of 100 patients, 
whilst the level of variation remained large when 1,000 patients were run through the 
model for each set of parameter values. A much tighter concentration of estimates is 
observed for the runs informed by 10,000 patients with the difference in costs varying 
between around £1,000 and £1,250 and the effects difference falling between 0.5 and 
1 QALY. Though larger samples would reduce the observed random error further, 
runs of 10,000 patients provided the best trade-off between accuracy and the running 
time of the DES model. 
1"", .)-
Figure 6.3 Cost-effectiveness plane illustrating the accuracy of alternative run sizes for the analysis of the DES ABC model 
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6.7 Methods of describing probabilistic 'length of time' input parameters 
The second methodological issue addressed in this Chapter relates to the correct 
method of describing and sampling time dependent data in decision models. The 
parameters affected by this issue were the length of time patients remained in the state 
'OF!' in both the Markov process and the DES model, and the time spent in remission 
following locoregional relapse in the DES model alone (this parameter was not 
modelled as being time dependent in the Markov process). The data informing these 
parameters were presented as the probability of leaving the respective states in 
successive years, in the fonn of survival curves. 
Ideally, a probability distribution of individual survival curves (from separate sources) 
would be specified for each relevant parameter, which would be sampled as part of 
the second-order Monte Carlo simulation. Each survival curve could be weighted 
using the methods described in Chapter 3 and for each replication of the model a 
single survival curve could be sampled from a weighted dataset of survival curves. 
The advantage of this approach would be that the probabilities of experiencing events 
in successive years are consistent because they are derived from the same source. 
Unfortunately, it is rarely possible to assemble survival curves in the manner 
described above because different studies report differing lengths of follow-up and 
survival curves are rarely the same lengths. 
I t is normal practice to combine data from survival curves using one of the methods 
described in Appendix 4. The preferred method is the 'meta-analysis of failure time 
data' (MFO) [Earle and Wells, 2000], which involves pooling the number of patients 
at risk and the number of events in each time interval. Using formula 6.1 (pg120), 
both models interpolated the annual data describing the probability of leaving OFI to 
monthly probabilities. However, the DES model was set up to sample a separate 
probability of leaving the state every month, whereas the Markov process sampled 
one monthly value and applied it to all 12 months within a single year. Subsequently, 
in the DES model the annual probability of leaving DFI in any given run of the model 
was much closer to the mean of the distribution describing the probability of leaving 
DFI in any year. This was because the annual mean in the DES model is the mean of 
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12 separate samples from the distribution, rather than a single sample as was the case 
in the Markov process. To investigate the effect of the alternative sampling strategies 
the programming code in the DES model was altered so that a single probability was 
sampled and applied to all 12 months in any given year. The model was then re-
analysed and the outputs compared to original set of results. Figure 6.4 plots the 
results using the alternative sampling methods on a cost-effectiveness plane. 
Visual inspection suggests that the choice of sampling the probabilities on a monthly 
or an annual basis had a substantial impact on the variation observed in the estimates 
of cost-effectiveness. Both models could have been constructed to sample annually or 
monthly, but the intuitive approach encouraged by the alternative modelling 
techniques led to this important divergence in the representation of the input 
parameter 'length of DFI'. 
In order to represent the level of variation in the available data most accurately, the 
appropriate method of sampling should follow the intervals in the original data. The 
data used in the ABC models were presented as annual probabilities, which were 
transformed to monthly probabilities because a month was considered to be the 
appropriate interval within the models, which was based on clinical relevance. To be 
consistent with the available data, therefore, the models should sample a monthly 
probability and apply it to the 12 months within each year. 
6.8 Conclusions 
The focus of this Chapter has been the development of computer-based decision 
models. The construction of two alternative decision models were described - a 
Markov process and a DES model. Within the DES model, patients move through the 
model, experiencing events at any discrete time period after the previous event. The 
analysis of the model is triggered by the occurrence of an event, at which point the 
model asks what and when is the next event for this patient? This differs from a 
Markov process, which asks, what events are occurring within regular periods. 
The procedure for building a Markov process using Excel spreadsheets, employing 
the Crystal Ball add-in [Crystal BalL 2000], was described. The development of the 
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Markov process was generally straightforward. Formulae that described the 
proportion of patients moving between states were linked to cells representing the 
clinical parameter values, whilst the cost and utility value parameters were linked to 
the proportion of patients in each state in each time period. 
The process of building the DES model required more complicated methods than the 
Markov process, though the use of specialised software provided assistance. The 
DES model was built on the basis of programming code that described what events 
occurred when. This also facilitated the collection of the required output data as 
patients left each state within the model. There was a steep learning curve associated 
with the building of the DES model. During the course of building the model many 
blind alleyways were encountered, and numerous improvements in the efficiency of 
the programming code were made over time. The time to develop future DES models 
will be significantly reduced, though the required time is unlikely ever to be reduced 
to the time to build a comparable Markov process. In addition, the analysis time for a 
DES model was substantially longer than the time taken to run a Markov process. 
Moreover, the analysis time not only included the final 'correct' experimentation with 
the models, but also the whole process of verification and validation, which is often 
more time consuming than the final process of experimentation. 
Finally, two important issues that were raised during the building of the decision 
models were addressed. Within the experimentation of the DES model, the issue of 
an adequate number of patients to include in each (first-order) run of the model was 
investigated. After testing alternative sizes it was concluded that a sample of 10,000 
patients was sufficient to provide stable estimates of the mean output values estimated 
for each set of input parameters. The second issue concerned the appropriate method 
for sampling time dependent events with decision models. Substantial differences 
were demonstrated between the alternative sampling strategies and it was concluded 
that to represent the level of variation in the available data most accurately, the 
appropriate method of sampling should follow the intervals in the original data. For 
example, if data are included in the model as monthly probabilities that have been 
interpolated from annual probabilities, as presented in the literature, a single monthly 
probability should sampled and applied to the 12 months within each year. 
13' 
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Chapter 7 Case study: verification and validation 
7.1 Introduction 
The previous three Chapters have applied the modelling process described in Chapter 3 
up to the point at which the decision model has been implemented as two types of 
computer model, both as a Markov process and as a DES model. The final steps before 
experimentation can proceed, involve the verification of the models to ensure that they 
are internally consistent, and validation to check that the models' outputs are realistic. 
Respective methodologies for verification and validation were described in Chapter 3, 
the objective of this Chapter is the application and assessment of the proposed methods 
with respect to the models built to evaluate adjuvant therapies for early breast cancer. 
7.2 Verification 
Verification is the process of ensuring that the computer model accurately represents the 
conceptual model and the available data. The verification process consisted of three 
phases - verification of logic, sensitivity testing, and stress testing - as described in 
section 3.5.2. The following sections report the application of these methods to the case 
study evaluation. 
7.2.1 Verification a/logic 
The verification of the models' logic ensures that the model is analysing the inputted 
data correctly. The tests involve entering simple combinations of input data for which 
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the expected output can be manually calculated, allowing the output of the model to be 
compared with the anticipated output. The model logic was verified in three categories. 
Firstly, the models' representations of the clinical parameters were assessed, followed 
by tests on the incorporation of the costs and utility values. Finally, the action of the 
model in discounting both the costs and the effects was verified. The following sections 
present the parameter values chosen to test model logic within these categories, and the 
resulting comparisons of the expected and actual outputs of the models. 
7.2.1.1 Clinical parameters 
The clinical parameters represent the probabilities of events occurring within the model, 
and their timing. The events described, in sequential order, were the: 
• Incidence of toxicity (including effect on the completion of chemotherapy). 
• Timing of relapse or death from the period of disease free interval (DFI), 
• Type of event experienced following DFI, 
• Timing of relapse or death from remission following locoregional relapse, 
• Type of event following remission, 
• Timing of death from metastatic relapse. 
Selections of the parameter values inputted to the models and the expected and observed 
outputs from the models are shown in Table 7.1. The verification process for the 
clinical parameters produced model outputs that were broadly consistent with the 
expected results. Moving sequentially through the model, Test la describes the timing 
of events following the initial period of DFI. The inputted probabilities were chosen so 
that 25 per cent of the original patient cohort would relapse in each of four years - 1, 3, 
5 and 7. A constant rate of occurrence was assumed. The results for both models show 
that the mean survival estimates were close to the expected output, though the results of 
both models slightly underestimated expected survival. Th~ underestimated survival is 
due to the conversion of annual probabilities to monthly probabilities assuming a 
constant rate of events over the year in which an event occurs. The expected model 
outputs were estimated on the basis that events in a particular year occurred, on average, 
halfway through the year. However, assuming a constant rate of occurrence more 
patients experience events in the earlier months of any particular year. This issue is 
developed further in verification Test 1 b below. 
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Table 7.1 Comparison of verification outputs for the DES and Markov model 
Tests Parameter categories Parameter Expected Observed output* 
values Output* DES ~1P 
la Timing of event from DFI 
Pr(event following DFI in year 1) 0.25 
Pr(event following DFI in year 3) 0.33 
Pr(event following DFI in year 5) 0.50 
Pre event following DFI in year 7) 1.00 
Pr( dned following DFI) 1.00 
Output* cAO.63 40.53 40.32 
Ib Pr(event following DFI in year 3) 0.5 
Pre event following DFI in year 5) 
Pr(dned following DFI) 
Output* c.39.25 38.90 37.92 
2 Type of event from DFI 
Pr(soft tissue metastases following DFI) 0.50 
Pr(dned following DFI) 0.50 
Pr(event following DFI in year 4) 1.00 
Survival from soft tissue metastases Empirical distribution, mean 3 1 
Output* c.52 52.17 50.83 
3 Type of event from remission 
Pr(bone metastases following remission) 0.50 
Pr(dned following remission) 0.50 
Pr(event following DFI in year 2) 1.00 
Pr(locoregional relapse following DFI) 1.00 
Pre event following remission in year 8) 1.00 
Survival from bone metastases Normal distribution, mean 16.8 
Output* c.105A 105.38 104.89 
* survival in months. 
Test 1 b investigated further the effect of assuming a constant rate of events by stating 
that 50% of events following DFI occur in year 3, and the remainder in year 5. If all 
events occurred halfway through the year the expected survival would be 39.25 months, 
but both models underestimated survival by a larger amount compared with Test la. 
This discrepancy between the expected and observed output is not as important as it 
might appear. The illustrative examples assumed that all patients experienced an event 
in the same year, which maximised the impact of the constant rate assumption. In fact 
the maximum annual probability of an event using the real data is approximately 10 per 
cent. Figure 7.1 demonstrates the reduced impact of the constant rate assumption when 
an annual probability of 10 per cent is converted to monthly probabilities compared to 
the situation when 99.9 per cent of patients experience an event within a single year. 
The large diamonds represent the month in which the median patient experiences an 
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event and shows that with an annual probability of 10% the median patient leaves DFI 
in month six. 
Tests 2 and 3 specified the type of events patients' experienced following the DFI 
state and remission, respectively. The results revealed that the DES model was 
slightly more accurate than the Markov process. This was due to the DES model's 
more precise description of time on remission and survival from metastases (see 
section 9.2 for a full discussion) 
7.2.1.2 Cost and utility parameters 
The parameters describing the cost and utility effects of the various health states 
within the model could only be verified in connection with specified clinical 
parameter values. Within the decision models the cost and utility parameters were 
attached to the clinical parameters, so following the verification completed in the 
previous section the action of attaching costs and utility values to health states was 
relatively straightforward. However, the full benefit of such detailed verification 
became apparent during the testing of the utility values within the DES model. 
Informal testing of the model had been undertaken during the building process and 
prior to verification the model appeared to be producing consistent QAL Y outputs. 
However, during the verification process some subtle errors in the programming code 
were identified that led to the miscalculation of the associated QAL Y s in some of the 
later health states within the model (the remission and metastases states). Fortunately, 
the errors were rectified and both models passed this stage of the verification process. 
7.2.1.3 Discount factors 
The actions of the model with respect to discounting the estimated costs and effects 
are independent of the actions associated with moving patients through the model and 
attaching costs and utility values to the time spent in the model. To ensure that the 
discount factors were being applied properly within the models two sets of parameter 
values were used to compare expected and observed output. During the initial process 
of testing the discounting process the observed output from the DES model was 
consistently higher than the expected output. Within the DES model the process of 
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discounting costs and QAL Ys at the end of each state comprised the most 
complicated set of programming code (see section 6.3.2). Following examination of 
the programming code driving the discounting, an error in the programming code was 
discovered that discounted costs and QAL Y s at lower than appropriate discount rates. 
Once rectified the resulting estimates were extremely close to the expected outputs 
and the DES model was deemed to have passed the discounting stage of the 
verification process. The final input values, and expected and observed outputs are 
presented in Table 7.2. 
Table 7.2 Parameter values used to verify the action of the discount factors 
for costs and effects * 
Test Value Input values ' Expected Observed output outpu~ ~M~M~k-o-v-p-ro-c~es-s--=D=E=S-m-o-d~e~I--
pre event following DFI in year 5) 1 
cost (surveillance) £50 
utility(DFI) 0.8 
2 pr(event following DFI in yeM 5) 1 
pr(visceral metastases) 1 
survival from visceral metastases 1 yeM 
cost(visceral metastases) £500 
utility(visceral metastases) 0.5 
2092, 2092, 2111, 
2.79 2.79 2.81 
4098, 
0.34 
3894, 
0.32 
4059, 
0.34 
* A discount factor of 10% was applied to both costs and effects to aid the calculation of the expected effects. 
t All other cost and utility pMameters are assumed to be equal to zero 
t Outputs Me presented as total costs and quality adjusted life years. 
A more fundamental discovery was observed over the discounting in the Markov 
process. Test 1 in Table 7.2 shows that the observed output from the Markov process 
matched the expected output, but the observed outputs in Test 2 underestimated the 
expected values. The difference in Test 2 is due to the Markov processes' description 
of the length of time spent in states for which survival curves (in the case study 
model: time in remission) and set survival times (in the case study model: survival 
from metastases) are converted to constant probabilities. Taking the scenario 
described in Test 2, the input data states that patients survive 12 months from the 
point of being diagnosed with visceral metastases. However, the Markov process 
cannot remember when each patient enters the health state 'visceral metastases' and so 
applies a constant probability of dying to each patient remaining in the state. The 
problem with the conversion of survival curves and set survival times to constant 
probabilities is that the associated discounting will be erroneous. In Test 2, the 
correct procedure applies a discount rate of 0.792 (1/1.104 ) to the cost of treating 
visceral metastases over the whole of the fifth year, which is the period over which all 
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patients experience metastases. However, in the Markov process a monthly 
probability of leaving the state was applied to all patients, so that some patients left 
the state after one month, whilst 14.7% and 5.4% of the original cohort were still in 
the state at the end of 24 and 36 months, respectively. In the absence of discounting 
the mean results would represent the data correctly, but the application of higher 
discount rates to those patients surviving beyond the set survival time results in 
underestimates of the true outputs for both costs and QAL Y s. This issue is raised in 
more detail in Chapter 9, where its' impact on the overall results of the case study is 
discussed. 
7. 2. 2 Sensitivity testing 
The second type of verification involves varying one parameter, whilst keeping all 
others fixed in order to ensure that the behaviour of the model is sensible [Bratley et 
aI, 1987]. Sensitivity testing involved running the models stochastically using the 
probability distributions specified for each parameter and noting the variance around 
the model outputs. The model was re-analysed with point estimates describing the 
values of chosen parameters, rather than probability distributions. The resulting 
variation in the model output was then compared to the baseline run of the model. 
Explicit predictions of the absolute magnitude of the ~ffect of different parameters 
within the model were difficult, though it was mainly possible to predict the relative 
magnitudes of the individual parameter effects. Each included parameter was ranked 
in order of their expected relative effect on the variance of the baseline net benefits. 
The results were then compared to these a priori predictions. Table 7.3 illustrates the 
sensitivity testing of various parameters. It was anticipated that holding DFI 
probabilities constant would reduce variance by more than holding event types 
constant, and both would reduce variance more than holding a cost or utility value 
parameter constant. The comparison of the cost of bone metastases and the utility 
values associated with DFI was less certain and these parameters were used to check 
the similarity of the two modelling techniques, ie. whether both models reported the 
same ranking between these two parameters. 
144 
Chapter 7 Case study: verification and validation 
The results of the sensitivity testing are also presented in Table 7.3. The reduction in 
the variation around the net benefits was greatest assuming absolute certainty about 
the values of the 'length of DFI' parameters. Assuming certainty about the 
proportions of patients experiencing the alternative health states following DFI 
reduced overall variation by a larger amount than holding either the cost of bone 
metastases or the utility values associated with DFI static. No prediction was made 
about the ranking of the latter two parameters, but both models reported that the 
utility values associated with DFI had a larger impact on overall variation of the net 
benefits. The a priori assumptions about the ranking of the first two parameters were 
confirmed, and the Markov process and the DES model produced a similar order of 
ranking for the unknown rankings. 
An additional result that required explanation was that the absolute values of the 
standard deviations between the Markov process and the DES model were very 
different. The reason for this difference was that only 5,000 patients were included in 
each run for the DES model in order to reduce the required running time for the 
sensitivity testing, which meant that first-order uncertainty was not adequately 
controlled (see section 6.5). However, the elimination of first-order uncertainty was 
not a necessary condition for the process of sensitivity testing, and the resulting data 
provided sufficient evidence for the sensitivity of the DES model to be verified. 
Table 7.3 Examples of sensitivity testing 
Parameters held constant 
Probability of event following DFI in all years 
in patients receiving tamoxifen+ chemotherapy 
Type of event following DFI for patients 
receiving tamoxifen+chemotherapy 
Cost of bone metastases 
Utility values for DFI 
7. 2. 3 Stress testing 
A priori 
ranking 
2 
3/4? 
3/4? 
Standard deviation of the net benefits 
(A = £ 1 0,000) 
DES MP 
3718 2020 
4333 
5420 
5028 
2660 
2800 
2759 
The scope for stress testing, which tests that the model does not run if infeasible 
values are inputted, was limited. F or example, possible areas for such testing 
included the assignment of negative values for probabilities. However, the models 
were built to transform negative values to a value of zero because input distributions 
145 
Chapter 7 Case study: verification and validation 
describing probabilities could include negative values, e.g. normal distributions. The 
only area in which stress testing was possible covered the inputting of negative cost 
values. Originally, no mechanisms had been incorporated to highlight such errors, but 
it was recognised at this stage that such a device could prevent potentially serious 
errors and that such mechanisms were relatively simple to create. Within the DES 
model a single line of code was placed after the code that sampled each cost and 
utility value at the beginning of each trial. The code stopped the model if a negative 
value was sampled from any of the input distributions. In the Markov process, using 
the facilities in the Crystal Ball add-in, forecast windows were set up that highlighted 
the occurrence of a negative value at the end of each trial. Both mechanisms captured 
deliberate negative values accurately. 
7.3 Validation 
The objective of validation is to legitimise the output of a decision model by 
demonstrating that the model provides a credible representation of reality. As 
described in Chapter 3 the precision of the validation process for most economic HT A 
models is not likely to be high as the process of validation is hampered by a lack of 
credible 'real' world data. However, a number of economic analyses involving 
adjuvant therapies for early breast cancer were identified. These studies provided 
some indication of the case study models' comparability with previous research, 
which is one method for validation that has been suggested (see section 3.5.3). 
Details of the identified studies were presented in section 4.2.1. 
From the review of previous economic analyses (see section 4.2.1), only four studies 
were felt to provide relevant sources of comparison. Indeed, data describing survival, 
rather than economic outputs, were employed from one of the economic studies 
because the cost data was so weak [Messori et ai, 1996]. The remaining studies were 
excluded for various reasons. One of the cost analyses was omitted from the 
validation process due to the large number of uncertainties around the estimated costs 
[Legorreta et al, 1996], whilst the Australian economic evaluation was excluded 
because the patient group was ill-defined [Glasziou and Haas, 1994]. The study only 
available as a conference abstract did not define their patient group and was also 
excluded from the validation process [Selke et ai, 1998]. In addition to the data 
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derived from economic studies, survival estimates from the models were also 
validated against estimates from clinical papers. In the case study models, survival 
was determined by combinations of the length of DFI, the length of remission and 
survival from the three metastatic sites. Straight survival data were not inputted into 
the model, so any available survival data could be compared to the life years predicted 
by the model to validate this aspect of the model. 
The most reliable data of this fonn was accessed from a series of meta-analyses 
prepared by the early breast cancer trialists group [EBCTCG, 1992; EBCTCG, 1998a: 
EBCTCG, 1998b]. The internal reliability of the meta-analytic data was high but 
several problems remained. Firstly, survival data were only presented for the first 10 
years from the point of diagnosis so only the first 10 years of the ABC models could 
be validated. Secondly, survival curves were not presented for combination therapies, 
such as tamoxifen and chemotherapy and the survival data presented included all 
patients receiving the therapy of interest compared to all patients not receiving the 
therapy. F or example, comparisons were stated as 'tamoxifen versus no tamoxifen', 
whereby trials reporting tamoxifen and chemotherapy versus chemotherapy were 
included alongside trials comparing tamoxifen versus no to adjuvant therapy. More 
usefully, the meta-analyses presented reduction ratios for annual rates of mortality for 
a wide range of treatment comparisons, including tamoxifen and chemotherapy versus 
no treatment, and tamoxifen versus no treatment. Survival for these two patient 
groups was estimated by applying the appropriate reduction ratios to survival 
estimates for patients receiving no adjuvant therapy, which was informed using data 
from two identified studies that reported survival up to 12 years from diagnosis 
[Castiglione-Gertsch et aI, 1994; Cummings et aI, 1993]. The mean survival times are 
presented in Table 7.4, the method of calculation was as follows: 
1. Multiply the proportion of patients dying in each year by the year of death (-0.5): 
2. Multiply the proportion of patients remaining alive at the end of the period by 12; 
3. Swn the annual totals to estimate the mean number of years alive. 
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Table 7.4 Estimation of mean 12-year sunrival for alternative adjuvant 
therapy options 
Year No adjuvant therapy Tamoxifen alone (annual Tamoxifen-7-chemotherapy 
mortality reduction 20% vs. no (annual mortality reduction 30% 
treatment) vs. no treatment) 
Prop. Prop. Annual Prop. Prop. Annual Prop. Prop. 
Surviving dying survival surviving dying survival Surviving dying 
estimate estimate 
1 0.96 0.04 0.02 0.97 0.03 0.02 0.97 0.03 
2 0.89 0.07 0.10 0.91 0.06 0.08 0.92 0.05 
3 0.79 0.10 0.26 0.83 0.09 0.21 0.84 0.08 
4 0.67 0.11 0.40 0.73 0.10 0.33 0.74 0.09 
5 0.62 0.06 0.27 0.68 0.05 0.23 0.69 0.06 
6 0.57 0.05 0.26 0.64 0.04 0.23 0.64 0.04 
7 0.49 0.08 0.51 0.57 0.07 0.47 0.58 0.07 
8 0.44 0.05 0.35 0.52 0.04 0.32 0.53 0.05 
9 0.39 0.05 0.46 0.47 0.05 0.44 0.48 0.05 
10 0.34 0.05 0.45 0.43 0.05 0.44 0.43 0.05 
11 0.29 0.05 0.51 0.38 0.05 0.50 0.38 0.05 
12 0.29 0.01 0.07 0.37 0.01 0.08 0.37 0.01 
0.29 3.42 0.37 4.45 0.37 
Mean survival 7.08 7.81 
Table 7.5 Validation data and comparison results 
Test Output 
Stage II, 4-year costs* 
2 Stage II, lifetime costs* 
3 QAL Ys in patients receiving 
tamoxifen 
QAL Y s in patients receiving 
tamoxifen+chemotherapy 
Incremental cost per life year 
4 Survival in patients receiving no 
adjuvant therapy 
Survival in patients receiving 
chemotherapy 
Validation 
estimate 
2417 
9974 
6.47 
6.59 
28537 
13.17 
16.74 
MP estimates DES estimates 
Original Revised Original Revised 
4610 4181 4576 4161 
10154 9058 9895 8942 
8.26 8.26 8.4 8.4 
8.44 8.44 8.57 8.57 
5013 5254 5748 6012 
14.90 14.90 15.15 15.15 Survival in patients receiving 
tamoxifen 
Survival in patients receiving 15.70 15.70 15.91 15.91 
tamoxifen+chemotherapy 
5 Survival in patients receiving 7.81 8.58 8.58 8.43 8.43 
tamoxifent 
Survival in patients receiving 7.88 8.71 8.71 8.57 8.57 
Annual 
survival 
estimate 
0.01 
0.08 
0.21 
0.33 
0.26 
0.23 
0.45 
0.34 
0.43 
0.45 
0.50 
0.13 
4.46 
7.88 
tamoxifen+chemotherapy t 
Test sources: I [Wolstenholme and Whynes, 1998], 2 [Will et al, 1998], 3 [Hillner and Smith, 1992], 4 [Messori et 
al. 1996], 5 [Castiglione-Gertsch et ai, 1994; Cummings et ai, 1993]. . . . 
The estimates presented in the foreign studies were converted to UK sterhng usmg the health purchasmg power 
parity, all costs were up rated to year 2000 values using the health services index . 
• revised to subtract costs associated with diagnosis and primary surgery. 
t mean survival at 12 years from diagnosis. 
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The validation data and results are presented in Table 7.5, discount rates and length of 
follow-up were altered within the ABC models to match those employed in the 
identified studies. The similar estimates produced by the Markov process and the 
DES model implied that the remaining variation was an artefact of sampling variation. 
The original estimates refer to the estimates derived from the models without any 
modifications, whilst the revised estimates resulted from the changes made as a result 
of the validation process, as described below. 
Comparing the models' original outputs with each other it was apparent that the 
Markov process estimated lower outputs than the DES model which was caused by , . 
differences in the estimated time spent in remission following a locoregional relapse. 
The identified data describing this parameter were in the fonn of disease free survival 
(DFS) curves, in which a proportion of patients remained alive at the end of the 
follow-up periods. It was not possible, therefore, to estimate mean DFS precisely. 
The DES model facilitated a more accurate representation as the survival curve data 
could be applied to each patient over the initial 11 years in the state, after which time 
age-specific mortality rates in the general population were applied to those patients 
remaining disease-free. Such methods could not be applied to patients within the 
Markov process because the model could not note when individual patients entered 
the state and a constant probability rate had to be applied to all patients within the 
state. Time dependency within a Markov process may only be applied from the 
starting point in the model and remission following a locoregional relapse was not a 
starting state. Initially, the median DFS was employed as a proxy for mean DFS but 
the distribution of DFS was highly skewed and the median greatly underestimated the 
mean. On the basis of the validation process mean DFS were estimated on the basis 
of a common cut-off length of remission for those patients remaining disease-free at 
the end of each studies follow-up. 
In the comparisons of the models' outputs with published sources Test 1 showed that 
the ABC models estimated far higher costs than the retrospective UK-based study 
[Wolstenholme and Whynes, 1998]. No obvious data-related differences were 
apparent, no data on the resource use or unit costs associated with different events 
were presented, or the proportion of patients undergoing any of the included events, 
though it was noted that the cost estimates were based on only 13 patients. The 
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immediate conclusion of exaggerated cost estimates was tempered by Test 2, in which 
a Canadian study predicted lifetime treatment costs that were roughly similar to those 
produced by both case study models [Will et aI, 1998]. However. the Canadian study 
~ ~ 
included costs associated with the administration of radiotherapy following primary 
surgery in the Canadian study. Without such costs the Canadian study would have 
produced substantially lower cost estimates. 
The conclusion drawn from this section of the validation process was that some of the 
costs assumed in the case study models were too high. It appeared that the costs 
associated with both interventions might be overestimated, so the input data 
describing the cost of relapses were critically reviewed. The initial assumptions 
regarding the treatment of relapse are described in section 5.4.4.4. These costs had 
been estimated using mainly published guidelines on the course of treatment for such 
patients. Empirical data were only used to inform the frequency of hospital contact 
[Hurley SF et aI, 1992]. A major component of the assumed cost of treating 
metastatic relapses covered the cost of chemotherapy, which had been assumed to 
continue from the point of diagnosis to death. It was felt that this area was the most 
likely to be exaggerated. To improve the understanding of the administration of 
chemotherapy in practice, data from eight sets of deceased patient notes on treatment 
following diagnosis with recurrent breast cancer were inspected. The review of the 
notes indicated that the assumptions made with respect to the treatment of 
locoregional relapse were broadly correct, but that the assumed use of chemotherapy 
in patients with metastatic relapse was certainly over-estimated. The estimation of the 
monthly costs associated with metastatic disease was revised in line with reduced use 
of chemotherapy. The details, and the resulting cost estimates were described in 
Chapter 5. The revised validation estimates are presented alongside the original 
estimates in Table 7.4. The revised analysis did not aim to match the validation 
estimates due to the inconsistencies in these data discussed above, but rather to make 
the ABC estimates appear more realistic. 
In Test 3, the ABC models estimated higher estimates of life years and QAL Ys 
gained than estimated by HiBner and Smith [1992]. This difference was possibly due 
to the assumptions made with respect to the continued occurrence of relapses in both 
patient groups. The current study used survival curves derived from the literature 
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review in both models that tailed off to a relapse rate of 0 from year 15 onwards, 
whereas the US group assumed a constant probability of recurrence for the duration of 
the model (4% in the baseline). In addition, the incremental cost per lifeyear gained 
was significantly lower in the ABC models than in the Markov process used by 
HiBner and Smith. The QAL Y differences between the treatment groups were 
similar, which indicated that the difference in costs between the treatment groups was 
larger in the US-based study. Looking at the inputted costs it was clear that the costs 
associated with the tamoxifen+chemotherapy treatment group were higher in the 
published study. For example, the average cost per cycle of chemotherapy was 
estimated at £500 (£285 in the case study evaluation), whilst the average cost of major 
toxicity was inputted as almost £5000 (c.£2000 in the case study evaluation). No 
toxicity was assumed for the tamoxifen alone arm in the US study. Allowing for the 
differences between the two studies it was difficult to refute the validity of the ABC 
models on the basis of these economic comparisons. 
Test 4 compared the ABC models' outputs with the full survival estimated by Messori 
et al [1996], in which the ABC model appears to slightly underestimate the published 
survival times. However, the comparisons undertaken in Test 5 showed the ABC 
models overestimating 12-year survival [Castiglione-Gertsch et al, 1994; Cummings 
et aI, 1993]. The mid-placing of the ABC estimates is an encouraging validation 
result. 
An additional issue raised in the validation process concerned the need to assess 
model outputs for periods less than the full running time of the model, i.e. for 4 and 
12 years in order to provide an appropriate basis for comparison with the identified 
data used to validate the model. After specifying the possible avenues of validation, it 
soon became apparent that significant modifications to the programming code within 
the DES model were necessary to facilitate the collection of output data for periods 
less than the full lifetime of patients. This process is described in more detail in the 
comparison of Markov process and DES models (Chapter 9). 
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7.4 Conclusions 
This Chapter described the final stages in the implementation of the decision models 
prior to actual experimentation. Verification and validation are necessary elements of 
the modelling process as they give the model user confidence in the results emanating 
from the experimentation phase. 
The process of verification applied to the case study evaluation was adapted from 
methods described in the general operations research literature [Bratley et al, 1987]. 
Three categories of verification covered different aspects of the model's operations. 
Firstly, the verification of logic was dependent on the specification of simple input 
data for which the expected output could be determined manually, which ensured that 
the internal mechanisms of the models were working correctly. The explicit 
presentation of three classes of logic testing - clinical parameters, costs and utility 
values, and discounting - provided ample evidence of the analyst's attention to detail. 
The verification of logic highlighted several issues of interest relating to the 
implications of formatting data to populate the models and to differences in the 
mechanisms between Markov processes and DES models. Firstly, the implications of 
assuming a constant rate of occurrence when converting data describing annual 
probabilities of experiencing an event to monthly probabilities were identified. To 
test the logic of the models large annual probabilities were inputted and the models' 
outputs were consistently lower than the expected results, which had been estimated 
assuming that the mean event within a year would occur at six months. On closer 
inspection it transpired that this effect was not significant for the annual probabilities 
inputted to the ABC models. However, such effects may be important in other 
treatment areas. Secondly, during the logic testing of discounting within the two 
models the Markov process produced lower than expected estimates for scenarios that 
included time within a metastatic site. This result was due to the necessary 
conversion of set survival times to constant probabilities that spread the occurrence of 
events over a longer period. 
The second form of verification tested the sensitivity of the models by comparing 
expected and observed effects on the variation in the models' outputs caused by the 
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uncertainty in the values of different input parameters. The sensitivity tests provided 
an alternative method of verification that complimented the verification of logic. A 
particular advantage of sensitivity testing was the improved understanding about the 
functioning of the models that it provided. In the context of building two separate 
decision models to evaluate the same interventions, it also confirmed that the two 
decision models were producing consistent outputs. The final form of verification, 
stress testing, provided assurance that the models would recognise nonsensical input 
data, alerting the analyst to data entry errors. 
The technique adopted in this thesis to validate the case study models identified a 
wide range of sources of data that could be compared to any of the outputs from the 
models. The corresponding outputs from the models were compared to the identified 
data and reasons for any differences between the compared outputs were sought in the 
context of methodological and data differences between the case study evaluation and 
the identified studies. The process proved to be beneficial as it highlighted an area of 
the model that appeared to be inconsistent with the published data. Further data were 
collected on the costs associated with breast cancer relapses and revisions were made 
to some of the cost input data, which improved the comparability of the estimated 
data with the published sources. 
The process of validating separate models that were built to evaluate the same 
interventions also produced benefits, as demonstrated by the identification of the 
inaccurate use of median estimates of disease-free survival (DFS) as proxies for mean 
DFS in the Markov process. Better estimates of mean DFS were applied to the 
model, which improved the comparability of the different models. The 
methodological issues raised in this Chapter are potentially important and are 
discussed in more detail in Chapter 9, in the context of the experimentation with the 
case study models. The full and explicit process for verifying and validating the case 
study models identified a range of errors in the construction of the models and 
inaccuracies in the representation of the identified data, it also provided great insight 
into the functioning of the models. 
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Chapter 8 Case study: results of experimentation 
8.1 Introduction 
The results of the experimentation undertaken with the two decision models are 
presented in this Chapter. There are two main sections. Firstly, cost-effectiveness 
results are presented in order to inform the allocation of resources between the two 
therapy options on the basis of the available information. F or each decision model, 
three sets of results were derived relating to the alternative methods for assembling 
input distributions for stochastic analyses (see section 3.4.3.2). To recap, the three 
methods specified theoretical distributions for alternative categories of input parameters 
(using the empirical data to inform the distribution parameters), used weighted 
empirical data directly, and specified fitted distributions based on the weighted 
empirical data. The results from the two models are presented in separate sections, 
within each section the results derived from the three methods for specifying probability 
distributions are presented. 
The second method for experimentation analyses the value of information (Vol), where 
the objective was the estimation of the value of securing more accurate data on the 
values of the input parameters. The presentation of the results includes a commentary 
on the stages of experimentation, and the respective results from the two models are 
presented together. 
The policy implications of the differential results are discussed in the final section of 
this Chapter. whilst the explanation for the differences is presented in the following 
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Chapter. Discount rates of 6% for resources and 1.5% for QAL Y s were applied to all 
the analyses undertaken, in accordance with Treasury guidelines [H}.,1 Treasury, 1997]. 
Life years were not discounted as they were not incorporated into a cost-effectiveness 
ratio. 
8.2 Results from alternative methods for assembling input distributions 
In Chapter 3, three alternative methods for specifying input distributions were 
described. Two methods involved assembling weighted datasets to describe the 
available data, the datasets were either inputted into the model directly or inputted into 
statistical fitting software that fitted the data to the best fitting distributions, which were 
then entered into the model. The third method employed distributions that were 
theoretically derived according to the characteristics of the alternative categories of 
parameters within the model. The available data were used to estimate the appropriate 
parameters for the chosen distributions. The results produced by the two models using 
the three methods for assembling the input parameter distributions are presented in the 
following sections. 
8.2.1 Results from the case study Markov process 
The analysis for each method for specifying input distributions involved a total of 
10,000 runs, each sampling an alternative set of parameter values from the relevant 
input distributions. Table 8.1 presents the mean estimates of costs, QAL Ys and life 
years for each approach to assigning input distributions. Employing the mean of the 
three data methods as the baseline point estimate for each output parameter, the Markov 
process estimated that the lifetime treatment costs between the two therapies differed by 
£2,130 and the difference in QAL Ys was 0.53. The mean life expectancy for a patient 
receiving tamoxifen and chemotherapy was 15.70 years, and for tamoxifen alone it was 
14.90 years. The mean incremental cost-effectiveness ratio (lCER) was calculated 
using the 'ratio of the means', rather than the 'mean ratios' [Stinnett and Paltiel, 1997]. 
Based on these estimates the ICER was £3,988. 
155 
Case study: results of experimentation 
Table 8.1 Mean costs, QAL Y s and life years associated with the two adjuvant 
therapies estimated using three alternative methods of specifying input 
distributions 
Costs QALYs Life years 
Tamoxifen and chemotherapy 
Theoretical £8,718 12.01 15.74 
Fitted £8,893 11.56 15.63 
Empirical £8,862 11.62 15.72 
Mean* £8,824 11.73 15.70 
Tamoxifen alone 
Theoretical £6,709 11.41 14.86 
Fitted £6,721 11.07 14.90 
Empirical £6,653 11.11 14.94 
Mean* £6,694 11.20 14.90 
* Mean values estimated by dividing sum of theoretical, fitted and empirical estimates by three. 
The extreme closeness of the models' outputs using the fitted distributions and the 
empirical data directly was as expected and provided further proof of the correct 
workings of the models, though the results varied little between all three input data 
analysis methods. The mean QAL Y s associated with tamoxifen and chemotherapy 
displayed the largest percentage range between the three (taking the mean as the base) 
of just under 4%, the corresponding range for tamoxifen alone was just over 3%. None 
of the life year estimates varied by more than 1 %, whilst the estimates for costs varied 
by 1 % and 2% for tamoxifen alone and tamoxifen and chemotherapy, respectively. 
Table 8.2 presents the mean estimates of the leERs for tamoxifen and chemotherapy 
versus tamoxifen alone, as well as details of the percentiles derived from the different 
methods of specifying probability distributions. The largest leER was derived from the 
fitted distributions data, which estimates an leER of £4,473, whilst the data based on 
theoretical distributions estimated the lowest leER of £3,334 - a range of almost 30% 
around the mean I CER. 
Table 8.2 Incremental cost-effectiveness ratios estimated using three 
alternative methods of specifying input distributions 
Method Mean ICER 2.5th percentile 97.5th percentile 95th percentile 
Theoretical £3,334 £452 Tamoxifen dominates Tamoxifen dominates 
Fitted £4,473 £248 Tamoxifen dominates Tamoxifen dominates 
Empirical £4,295 £314 Tamoxifen dominates Tamoxifen dominates 
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Figure 8.1a Observations of the cost and QALY differences plotted on the cost-effectiveness plane derived 
from the case study Markov process using theoretically specified input distributions 
• 
• 
• 
til • 
• • • 
• 
• 
• 
• 
• 
• • 
• 
• 
•• 
~--~-~-~~~~l ~--
-2 -1 
• • ••• • 
• • , . 
. ,.. . 
. , . 
• •• 
• ·1 ., •• ~ ••• ~. .,. . ~ ....... .. 
• 
• 
--2-
Effect difference (QAL Ys) 
• • 
• • 
• 
• 
• 
• • 
• 
•• • 
• • •••• 
• ••• ~ - . ...... 
• 
. ,- ~~-. 
• ., .. 
• •• 
'", ... 
.. . 
.. 
•• 
...... I It • , 
. '. . 
• • 2 
• 
• 
T ~~-
3 
"I11III 
4 
1.'\7 
,.-... 
(I) 
(:, 
0 • 0 
~ 
---Q) • 
u 
c:: 
~ 
~ .-. 
. - • • "0 
-
(I) 
0 
u • 
• • 
-3 
• 
• 
-
Figure 8.tb Observations of the cost and QALY differences plotted on the cost-effectiveness plane derived 
from the case study Markov process using distributions fitted to the weighted empirical data 
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Observations of the cost and QAL Y differences plotted on the cost-effectiveness plane derived 
from the case study Markov process using weighted empirical data directly 
• 
• 
I 
• .• i , • 
• •• • 
• • 
I· 
-• 
• 
• • 
.. • 
.. " 
• • •• • 
• •• , • ··f 
.. \ .-; 
. ., ' 
. . ,.... .. -
•• --;-;-- i -.J ·a.--.lt-
• • 
• • 
• • 
• • • 
• • • 
• 
T 
• 
-3 -2 -1 
-~ 
Effect difference (QAL Ys) 
• 
· t · 
•• 
• 
• 
• 
• , . 
• 
• 
.., 
. ... 
• • 
• 
• 
• •• 
• 
• 
• 
••• 
• 
• 
• 
.~-..:... .. . . 
. ,.. .. . ~~~ _a---" \ .-t • • 
.., , -.: .. 
• 
• • fl·· .. .. . . ... ""' .. .. ,.~ .... 
. .. -.,~. . . , . 
I ... • :' ••• 
., .. .: . 
• • 
• 
• • 
• 
.3 4 
----~ 
159 
~ 
"".. 
.~ 
-u ~ 
CI) 
I 
ti 
o 
u 
~ 
tU 
t 
~ 
5 
1.0 
0.9 
0.8 
0.7 
0.6 
-5 0.5 ] 
t: 
~ 0.4 .~ 
o 
~ 
:E 0.3 
~ 
.g 0.2 
0: 
0.1 
0.0 
Figure 8.2 
T ---
o 2 3 
Cost-effectiveness acceptability curves derived from the case study Markov process, using the 
alternative methods for specifying input distributions 
Theoretical 
FittedlEmpirical 
sec text for explanation of symbols 
~-I-- ---T- -~--r---- ---r-- --T ~ - r--- --- r r ---r- ----
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
Value of an additional QALY (£OOO's) 
1 ()O 
~ 
.. 
Case study: results of experimentation 
The observations of costs and QAL Y s for each data method have been plotted 
separately on cost-effectiveness planes in Figures 8.1a, 8.lb and 8.lc. These plots show 
that the majority of observations were located in the north east quadrant which 
indicates increased costs and effects associated with tamoxifen and chemotherapy. A 
sizeable minority of the plots derived from specifying fitted distributions and using the 
empirical data directly indicated increased costs and lower effects whilst very few 
, .-
observations revealed lower costs associated with tamoxifen and chemotherapy. The 
'credible interval' percentiles, presented in Table 8.2, show that all the 2.5 th percentiles 
were under £500. At the upper end, the 95 th percentiles showed tamoxifen alone 
dominating tamoxifen and chemotherapy according to all three data methods. The 
threshold percentiles at which tamoxifen alone no longer dominated were 9.2% for the 
theoretical distributions, and 34% for both the fitted distributions and empirical data. 
From the vertical axIS, the first, second, and third crosses presented in Figure 8.2 
represent the values of a QAL Y at which the sum of the incremental net benefits 
became positive for the theoretical, empirical, and fitted distribution data sources, 
respectively (see section 3.6.2, pg60). From Figure 8.2 it can be seen that the sum of 
the net benefits became positive at values of an additional QAL Y that were close to the 
point at which the probability of tamoxifen and chemotherapy being the cost-effective 
therapy reached 0.5. However, the slight skewness apparent in each of the distributions 
was in opposite directions for the data derived from weighted datasets compared to the 
theoretical distributions. FO.r the theoretical distributions-based data the probability of 
being cost-effective reached 0.5 (median) at a lower value of an additional QAL Y than' 
the sum of the net benefits reached zero (mean), which meant that the distribution was 
left-skewed. Basing the resource allocation decision on the probability of tamoxifen 
and chemotherapy being cost-effective may lead to the inappropriate allocation of 
resources to chemotherapy. Conversely, using the other methods of specifying input 
distributions, which produced right-skewed distributions of net benefits, resource 
allocations based on the probability of tam ox if en and chemotherapy being cost-effective 
may wrongly withhold resources from chemotherapy. 
The remaining portion of the CEAc curve shows that the probability of positive net 
benefits associated with the empirical data directly and the fitted distributions did not 
rise above 0.67. The corresponding probability for the theoretical probability 
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distributions was around 0.9. These results follow from the proportion of observations 
in which tamoxifen alone was dominant. 
8.2.2 Resultsfrom the case study DES model 
The results produced by the DES model using the three methods of specifying 
probability distributions are presented in this section. The following section compares 
the results from the Markov process and the DES model. 
2,500 runs for each method of specifying input distributions informed the analysis of the 
DES model. For each run 10,000 patients receiving tamoxifen and chemotherapy, and 
tamoxifen alone were sent through the model. Table 8.3 presents the mean results for 
each approach to assigning input distributions. Using the mean of the three data 
methods to represent the baseline point estimate of cost-effectiveness the lifetime 
treatment costs differed between the two therapies by £2,176 and the difference in 
QALYs was 0.51. Based on these estimates the 'ratio of means' leER was £4,226. The 
mean life expectancy for a patient receiving tamoxifen and chemotherapy was 15.91 
years, whilst a patient receiving tamoxifen alone could expect to live for 15.15 years. 
The aggregate costs, life years and QAL Y s, estimated by the three data methods, for the 
alternative therapies varied by less than 5% from the mean. 
Table 8.3 Mean costs, QAL Y s and life years from the DES model associated 
with the two adjuvant therapies estimated using three alternative methods of 
specifying input distributions 
Costs QALYs Life years 
Tamoxifen and chemotherapy 
Theoretical £9,146 12.14 16.01 
Fitted £9,439 11.63 15.82 
Empirical £9,473 11.71 15.91 
Mean* £9,353 11.83 15.91 
Tamoxifen alone 
Theoretical £7,115 11.56 15.16 
Fitted £7,182 11.17 15.13 
Empirical £7,233 11.22 15.18 
Mean* £7,177 11.31 15.15 
• Mean values estimated by dividing sum of theoretical, fitted and empirical estimates by three. 
The mean leERs estimated using the different data input analysis methods are presented 
in Table 8.4. The largest leER was derived using the fitted distributions data (£4,869), 
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whilst the data based on theoretical distributions estimated the lowest leER (£3,483) - a 
range of almost 33% around the mean I CER. 
Table 8.4 Incremental cost-effectiveness ratios from the DES model estimated 
using three alternative methods of specifying input distributions 
Method Mean ICER 2.5th percentile 97.5th percentile 95th percentile 
Theoretical £3,483 £584 Tarnoxifen dominates Tamoxifen dominates 
Fitted £4,869 £288 Tarnoxifen dominates Tamoxifen dominates 
Empirical £4,498 £325 Tarnoxifen dominates Tamoxifen dominates 
The differences in the observations of costs and QAL Y s for each data method are 
plotted on cost-effectiveness planes in Figures 8.3a, 8.3b, and 8.3c. The majority of 
observations were located in the north east quadrant for each data method, though a 
significant minority of observations derived from the fitted distributions and the 
empirical data direct were located in the north west quadrant, which indicated tamoxifen 
alone dominating tamoxifen and chemotherapy. Only a few observations portrayed 
tamoxifen and chemotherapy as the lower cost option. The 'credible interval' percentiles 
presented in Table 8.4, show that all the 2.5th percentiles were under £600. At the upper 
end, the 95th percentiles showed tamoxifen alone dominating tamoxifen and 
chemotherapy according to all three data methods. The threshold percentiles, at which 
tamoxifen alone no longer dominated were 10.8%, 33.6% and 34.6% for the theoretical 
distributions, fitted distributions and empirical data, respectively. 
The CEAc curves derived from the DES model are presented in Figure 8.4. The 
probability of tamoxifen and chemotherapy being cost-effectiveness passed the 0.5 
probability threshold at a value of a QAL Y of around £3,400, using the theoretically 
specified distributions, and between £4,500 and £5,000 using the alternative data 
methods. The distributions of the net benefits appeared to be slightly skewed for two of 
the data methods - left skewed for the theoretical distributions, and right skewed for the 
fitted distributions. The distribution of net benefits derived from the direct use of the 
empirical data displayed an extremely close fit to a normal distribution. The remaining 
portion of the CEAc curve shows that the probability of positive net benefits associated 
with all the data methods levelled out at around 0.88 based on the theoretical 
distributions, and 0.65 for the results derived from the fitted distributions and the direct 
use of the empirical data. 
163 
r-.. 
Vl 
o 
o 
o 
~ 
'--' 
o 
u 
C 
~ 
~ 
.-
"0 
.... 
Vl 
o 
U 
Figure 3a 
r ----1 
-3 -2 
Cost and QAL Y differences plotted on the cost-effectiveness plane derived from the case study DES 
model using theoretically specified input distributions 
• 
• 
• 
• 
• 
•••• 
• 
• 
• • 
,-
-1 
• 
• 
• • 
• 
• 
• 
• 
• 
• 
.. 
-Q-
• 
• 
• 
• 
• 
----- -
• • 
.: • 
••••• J ••• • •• 
• 
• 
• 
Effect difference (QAL Ys) 
• 
• 
• 
----r r 
2 3 
~ 
4 
164 
-----
en 
b 
o 
o 
<.H 
'-" 
CI.) 
u 
c: 
~ 
~ 
:.a 
+-' 
en 
o 
U 
• 
• 
• 
• 
-3 
Figure 3b Observations of the cost and QAL Y differences plotted on the cost-effectiveness plane derived from 
the DES model using distributions fitted to the weighted empirical data 
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Observations of the cost and QAL Y differences plotted on the cost-effectiveness plane derived from 
the DES model using weighted empirical data directly 
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8.3 Comparison of Markov process and DES results to inform immediate resource 
allocation 
The model outputs derived from the two modelling techniques, using all three methods 
of specifying probability distributions, are brought together in Table 8.5. 
Table 8.5 Comparison of the model outputs from the case study Markov 
process and DES model 
Costs QALYs Life years ICERs* 
DES model Markov DES model Markov DES model Markov DES model Markov 
process process process process 
Tamoxifen and chemotherapy 
Theoretical £9,146 £8,718 12.14 12.01 16.01 15.74 £3,483 £3.334 
Fitted £9,439 £8,893 11.63 11.56 15.82 15.63 £4,869 £4,473 
Empirical £9,473 £8,862 11.71 11.62 15.91 15.72 £4,498 £4,295 
Mean £9,353 £8,824 11.83 11.73 15.91 15.70 £4,226 £3,988 
Tamoxifen alone 
Theoretical £7,115 £6,709 11.56 11.41 15.16 14.86 
Fitted £7,182 £6,721 11.17 11.07 15.13 14.90 
Empirical £7,233 £6,653 11.22 11.11 15.18 14.94 
Mean £7,177 £6,694 11.31 11.20 15.15 14.90 
* The mean ICER is calculated as the ratio of the difference in mean costs and the difference in mean QAL Y s, rather 
than the mean ratio of the ICERs. 
The mean cost, QAL Y, and life year estimates varied between the two modelling 
techniques, but in the same direction - all three outputs were higher in the DES model. 
The differences in the cost estimates were between £406 and £611. The QAL Y 
estimates varied by between 0.07 and 0.15 QAL Ys, though for this output tamoxifen 
alone was subject to the greater differences. These results led to small divergences in 
the leERs reported by the two models, though the maximum difference was under. 
£400. The credible intervals derived from the two models, presented in the sections 
above, were also similar. None of the 2.5 th percentiles exceeded £600 and the 95th 
percentiles all reported tamoxifen alone dominating tamoxifen and chemotherapy. The 
reasons for these differences are explored in section 9.2. 
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8.4 Value of information analysis 
The results presented in the previous sections infonned the decision regarding the 
provision of the alternative therapies given the available data. An additional objective 
of an economic HT A decision model may involve the valuation of securing more data 
on the values of the input parameters. The following sections present the results of both 
the Markov process and the DES model with respect to valuing the collection of further 
information to inform the resource allocation decision. Differences in the respective 
results are highlighted, though their implications are discussed in the conclusions 
section of this Chapter, and the causes of variation are explained in the following 
Chapter. 
The Vol is partly determined by the value to the decision-maker of an additional unit of 
effect - in this evaluation the value of a QAL Y. If the relevant value is unknown the 
Vol should be re-estimated for a range of non-negative values. For the purpose of the 
case study evaluation a Vol analysis was undertaken for a single baseline value of a 
QAL Y, which enabled an understanding of the approach, as well as facilitating a 
comparison of the two modelling techniques. The value of an additional QAL Y was 
assumed to be £5,000 - a value chosen to demonstrate different facets of the technique. 
rather than an attempt to accurately reflect decision-makers beliefs. Chapter 3 contains 
a full description of techniques adopted to analyse the value of infonnation (VoJ). 
Summaries of the three phases in the estimation of the Vol - estimating the expected 
value of perfect information (EVPI), the expected value of sample infonnation (EVSI) 
and the expected net benefit of sampling (ENBS) - are provided alongside the results 
presented in the following sections. 
8.4. 1 Estimating the expected value of perfect information (EVP 1) 
From the baseline analysis presented in the previous sections, at a value of an additional 
QAL Y of £5,000 tamoxifen and chemotherapy had the highest probability of positive 
incremental net benefits, but there was a probability that tamoxifen alone was the cost-
effective therapy option. The costs of uncertainty (the EVPI) are the expected benefits 
of providing tamoxifen alone in the proportion of observations in which tamoxifen 
alone displayed positive incremental net benefits. 
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The EVPI per patient, also known as the EVPlep;sode' describes the costs of uncertainty 
in applying the resource decision to a single patient. The process for calculating the 
EVPlePisode is portrayed in Table 8.6. For example, the results derived from the Markov 
process for the theoretically defined probability distributions showed that there was a 
0.346 probability that tamoxifen alone was the cost effective therapy option at a value 
of an additional QAL Y of £5,000. The mean net benefits per patient receiving 
tamoxifen alone minus the mean net benefits associated with tamoxifen and 
chemotherapy was £619.59 for the observations in which tamoxifen alone displayed 
higher net benefits. Without perfect information, tamoxifen and chemotherapy would 
be provided to all patients, but with perfect information the decision-maker could 
identify the observations in which tamoxifen alone was the cost-effective option. The 
EVPlePisode was estimated as the net benefits lost in the proportion of cases in which 
tamoxifen alone was observed to be the cost-effective therapy option (£619.59) 
multiplied by the proportion of cases in which tamoxifen alone was the cost-effective 
therapy option (0.346), which was £214.19. 
Table 8.6 Calculating the EVPlep;sode for both ABC models* 
Markov process 
A. Tamoxifen alone mean net benefits 
B. Tamoxifen and chemotherapy mean net benefits 
C. Incremental net benefits (A-B) 
D. Probability tamoxifen alone cost effective 
EVPlepisode (CxD) 
DES model 
A. Tamoxifen alone mean net benefits 
B. Tamoxifen and chemotherapy mean net benefits 
C. Incremental net benefits (A-B) 
D. Probability tamoxifen alone cost effective 
EVP I episode (CxD) 
Observations reporting positive incremental net 
benefits for Tamoxifen alone 
Theoretical Fitted 
distributions distributions 
£17,722.76 £24,774.89 
£17,103.35 £22,484.60 
£619.59 £2,290.29 
0.346 0.486 
£214.19 £1,113.77 
Theoretical 
distributions 
£18,542.87 
£17,877.73 
£665.13 
0.3594 
£239.08 
Fitted 
distributions 
£25,350.01 
£23,019.75 
£2,330.25 
0.4998 
£1,164.74 
Empirical data 
direct 
£24,876.76 
£22,607.40 
£2,269.36 
0.487 
£1,106.09 
Empirical data 
direct 
£24,957.33 
£22,589.88 
£2,367.45 
0.4891 
£ 1,157.92 
• The value of an additional QAL Y is assumed to be £5,000. 
The estimates of the EVPlepisode emanating from the DES model are very similar to the 
results from the Markov process, not only in the relationship between the different 
methods of specifying probability distributions, but also in terms of the magnitude of 
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the results. However, the EVPlep;sode estimated using the input data analysis methods 
based on the creation of weighted datasets was considerably larger than the EVP I 
episode 
estimated using the theoretical distributions. At a value of an additional QAL Y of 
£5,000, the probability oftamoxifen and chemotherapy being the cost-effective therapy 
option is around 0.51 using the weighted datasets, which maximises the costs of 
uncertainty. 
The prospective decision informed by the collection of additional data will not be 
limited to a single patient, but the whole population of eligible patients [Claxton, 1999]. 
The EVP I po pula/ion is the EVPI for the relevant patient population, which can be 
estimated by multiplying the EVPlep;sode by the eligible patient population over the 
period for which the allocation decision is expected to remain, discounted at an 
appropriate rate (see section 3.6.3.1). There are around 33,000 new cases of breast 
cancer diagnosed annually in the UK [Cancer Research Campaign, 1998]. Roughly 
20% of the new cases involve postmenopausal women with node positive (stage II) 
breast cancer, so the annual incidence for the patient group evaluated in this evaluation 
was estimated as 33,000 x 0.2 = 6,600. The specification of the number of years over 
which the research will inform the decision-making process was primarily subjective. 
In this treatment area, five years appeared to be a reasonable estimate of the time 
between the availability of new therapy options and was employed as the baseline value. 
Sensitivity analyses were undertaken to test the impact of the assumed length of 
usefulness of the results of the prospective research. 
The relationships between the value of a QAL Y and the EVP I popula/ion are presented in 
Figure 8.5 for the alternative methods of specifying probability distributions for both 
ABC models. The first result to note is that the two models produced very similar 
curves for the respective methods for specifying probability distributions. Looking at 
the alternative input data analysis methods the curves derived from the theoretical 
distributions show that the EVPI increased steeply from a value of a QAL Y of £0 to 
£4 000 which was around the value at which tamoxifen alone had the highest , , 
probability of being cost-effective. At the point at which tamoxifen and chemotherapy 
became the more likely cost-effective option the EVPI fell successively until the value 
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of a QALY was £19,000, at which point the EVPI resumed an upward path. This 
relationship demonstrates that the EVPI is not necessarily higher with larger values of 
an additional QAL Y because the probability of choosing the 'wrong' therapy option is 
likely to decline at higher values, which may be a stronger factor on the EVPI than the 
value of an additional QAL Y. At extreme values of an additional QAL Y, where the 
probability of tamoxifen and chemotherapy being cost-effective levels out, the EVPI 
rose continuously. 
The EVP I popu/alion estimated using the fitted distributions and the empirical data directly 
were substantially larger than the EVPI popuialion estimated using the theoretically 
specified probability distributions. The increased magnitudes were due to differences in 
the level of certainty that tamoxifen and chemotherapy was the cost-effective therapy 
option. Using the theoretical distributions it was more likely that tamoxifen and 
chemotherapy was cost-effective. Using the fitted distributions and the empirical data 
direct the probability of tamoxifen and chemotherapy being cost-effective never rose 
above 0.7. This meant there was always a sizeable probability that tamoxifen alone was 
the cost-effective option, whereas the probability of tamoxifen and chemotherapy being 
cost-effective using the theoretical distributions reached 0.8 by a value of a QAL Y of 
£7,000. 
Similar methods for the analysis of the EVPI for specific input parameters, or groups of 
parameters, can be applied, whereby the model is analysed with only the parameters of 
interest being described stochastically. The estimated EVPI is then attributed to the 
stochastic parameters. The segregated analysis of particular parameters can be extended 
to the full Vol methodology, but only an aggregate Vol analysis is presented in this 
Chapter because it provides a sufficient basis for understanding the methodology, as 
well as for the comparison of the two modelling techniques. 
Figure 8.5 
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8.4.2 Estimating the expected value of sample information (EVSJ) 
The EVSI is the difference in the EVPI estimated using the baseline input data and the 
EVPI estimated using alternative input distributions that reflect the assumed impact of 
additional data. The additional information reduces the variation described in the input 
distributions, which in turn reduces the EVPI because the variation in the distribution of 
the net benefits is also decreased. 
Updating the input probability distributions to reflect an assumed decrease in the 
uncertainty around the values of the input parameters is a key element in the estimation 
of the EVSI. Any form of distribution may be updated using the Bayesian statistical 
software - WinBUGS - but the operation of updating data using this method is not fully 
developed, though work is ongoing (personal communication: Liz Fenwick). The 
development of methods for updating input probability distributions would shift the 
focus of this thesis away from the central aim, which is the comparison of alternative 
modelling techniques. Therefore, the estimation of the EVSI presented in this thesis 
was undertaken using only the theoretically defined input distributions. Simple 
formulae for updating these probability distributions were available that used 
established knowledge about the relationships between conjugate families of probability 
distributions [Barnett, 1999]. As discussed in Chapter 3, a reasonable assumption about 
the mean value of the additional data for any parameter is that they are most likely to 
have the same mean values as the data used to populate the baseline model. Details of 
the process for updating the probability distributions are provided in Appendix 5. 
To establish the relationship between the size of a prospective study and the reduction in 
the costs of uncertainty the EVPI was re-estimated for successively increasing 
prospective samples until the optimal size was determined, i.e. the net benefits of 
sampling started to decline. Each patient entered a prospective trial as a node positive, 
postmenopausal patient with early breast cancer. Within each therapy group the 
proportions of patients who would provide data on each of the health states within the 
model was estimated using the baseline point estimates describing the probabilities of 
experiencing events. 
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The allocation of a prospective sample of patients between the two therapies may not be 
equal. Ideally, the optimal sample allocation between therapy options in a prospectiYe 
trial would be established by estimating the ENBS 'for every feasible allocation of each 
sample considered' [Claxton, 1999]pg355. However, to reduce the analytic burden in 
this evaluation a constant ratio of patients allocated to the alternative therapy options 
was estimated using Neyman's allocation to strata formula, which accounts for 
differential standard deviations and costs within separate strata (or in this case _ 
treatment arms). In this formula the standard deviations of the net benefits describe the 
variation between patients, which required the estimation of the first-order uncertainty 
associated with the point estimates for each input parameter. The estimation of first-
order uncertainty was possible using the DES model, but the Markov process was 
cohort based, which precluded the analysis of first-order uncertainty so the deviations 
from the net benefits associated with the two therapy options were assumed to be equal. 
The marginal sampling costs were obtained from the ABC trial and included the 
average cost of recruiting each patient into the trial, which was based on a grade F nurse 
spending an hour explaining the trial to each patient and a successful recruitment rate of 
1 in 3 patients (£ 150). Additional treatment costs were attached to patients receiving 
tamoxifen and chemotherapy, which were estimated as the baseline difference between 
the two therapies (£1,225). The above data were applied to Neyman's allocation to 
strata formula (see section 3.6.3.2) to estimate a constant ratio of sample allocation 
between tamoxifen alone and tamoxifen and chemotherapy for the Markov process: 
n ·n = 1I.J15O . 1/~1,375 =0.752:0.248 
1· 2 (1/ Mo) + (l I .jl,375) . (l I AA) + (l I ~1,375) 
and for the DES model: 
n ·n = 47656/.J15O : 48586/~1,375 =0.748:0.252 
1· 2 (476561.J150) + (485861.jI,375) (476561.J150)+(48586/~1,375) 
Table 8.7 presents the re-estimated EVPI associated with alternative prospective 
samples, and the related EVSI. Each re-analysis of the Markov process was infonned 
bv 10 000 runs, whilst each analysis of the DES model comprised 1,000 runs. The 
. , 
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results show that 650/0 and 690/0 of the EVSI populalion derived from a prospectiYe sample 
of 2,000 patients were provided by a sample of only 500 patients using the Markov 
process and the DES model, respectively. The magnitude of the EVSI J. were popu allan 
slightly higher using the DES model. 
Table 8.7 Calculating the EVSI I I· for both case study models popu a JOn 
Prospective 
sample 
Markov process 
EVP I episode EVSI episode EVSI populalion 
DES model 
EVP I episode EVSI episode 
o (baseline) £214.2 £239.08 
EVSI popula/101l 
100 £158.2 £55.9 £1,664,626 £216.5 £22.6 £686,394 
500 £116.2 £98.0 £2,946,781 £130.4 £108.7 £3,268,146 
1000 £90.4 £123.8 £3,737,909 £110.0 £129.1 £3,913,835 
1500 £72.6 £141.6 £4,282,003 £96.6 £142.5 £4,343,201 
2000 £64.7 £149.4 £4,533,611 £84.6 £154.5 £4,722,612 
2050 £63.6 £150.6 £4,568,562 £79.8 £159.3 £4,874,716 
2100 £63.5 £150.7 £4,575,442 £76.5 £162.6 £4,982.320 
EVSlepisode = BaselineEVPlepisode - Re-estimated EVPlepisode, EVSlpopulation = EVSlepisode.Patient population (29470). 
assumed length of usefulness of research is 5 years. 
Figure 8.6 illustrates the data graphically, plotting the EVSI against prospective sample 
sizes for both modelling techniques. Three curves are displayed to illustrate the effect 
of the assumed duration of applicability of the proposed research. The EVSI populatioll 
rose steeply at lower samples before starting to plateau towards prospective samples of 
around 2,000. The assumed use of the research clearly made a significant impact on the 
EVSI I. which varies by almost £5 million for a sample of 2,000 between an 
popu allan' 
assumed period of research use of 2 and 8 years. The curves reinforce the similarity 
between the results produced by the alternative models. 
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8.4.3 Estimating the expected net benefit of sampling (ENBS) 
The ENBS for each prospective sample size is the EVSI minus the cost of obtaining the 
additional sampling information. The cost of sampling includes the cost of setting up 
the study, and monitoring, analysing and disseminating the data collected. To specify 
increasing costs for larger sample sizes it was necessary to make an assessment of the 
fixed and variable costs associated with the trial. In addition, the cost of chemotherapy 
was subtracted from the EVSI on the assumption that chemotherapy would not be 
administered to this patient group in the absence of the trial. Fortunately, estimates of 
the relevant costs were available from the ABC trial, which is currently ongoing 
[UKCCR, 1993]. The Medical Research Council has funded this trial for a total of 10 
years and the fixed costs have been estimated at around £ 1.125 million. Applying these 
fixed costs, in addition to the marginal costs presented above, to the formula presented 
in section 3.6.3.3 estimates the total costs associated with any prospective samples: 
ENBS population = EVSI population - £ 1,125,000 - £ I50n - £304n 
Table 8.8 presents the previously estimated EVSI population alongside the additional 
sampling costs for alternative prospective samples in order to estimate the 
ENBS I· The DES model reported that net benefits were actually negative for a popu allon • 
prospective sample of 100 patients. Figure 8.7 plots the ENBS population against the 
respective sample sizes, again plotting curves for three assumed lengths of application 
for the proposed research. The assumed use of research had a major impact on the 
value of collecting further information. The baseline assumption of 5 years 
applicability indicated that the ENBS population was maximised at a prospective sample of 
around 2,050 patients using the Markov process and between 2,250 and 2,500 patients 
using the DES model. A similar result was observed for a length of research use of 8 
years. However, if the research influenced policy for only 2 years, the optimal sample 
size would be between 1,500 and 2,000 using the Markov process, and between 1,000 
and 1,500 using the DES model. 
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Table 8.8 Calculating the ENBS population for both ABC models 
Markov process DES model 
Size of EVSI population Sampling ENBS population EVSI population Sampling trial Cost E~VBS /. Cost popu al10n 
100 £1,664,626 £1,170,625 £494,001 100 £686,394 £1,170,625 -£484,231 
500 £2,946,781 £1,353,125 £1,593,656 500 £3,268,146 £1,353,125 £1,915,021 
1000 £3,737,909 £1,581,250 £2,156,659 1000 £3,913,835 £1,581,250 £2,332.585 
1500 £4,282,003 £1,809,375 £2,472,628 1500 £4,343,201 £1,809,375 £2,533,826 
2000 £4,533,611 £2,037,500 £2,496,111 2000 £4,722,612 £2,037,500 £2,685,112 
2050 £4,568,562 £2,060,313 £2,508,249 2250 £4,874,716 £2,151,563 £2,723,153 
2100 £4,575,442 £2,083,125 £2,492,317 2500 £4,982,320 £2,265,625 £2,716,695 
ENBSpopulation EVSlpopulation Sampling Cost 
8.5 Conclusions 
The results derived from experimentation with the two decision models have been 
presented and compared in this Chapter. The analyses compared the administration of 
tamoxifen and chemotherapy versus tamoxifen alone in a subset of breast cancer 
patients - postmenopausal women with node positive early breast cancer. Two broad 
objectives were addressed. Firstly, the question of whether to allocate resources to the 
provision of chemotherapy, given only the identified data, was investigated. Both case 
study models were evaluated three times to inform an immediate resource allocation 
decision, using alternative. methods for pooling and formatting the identified data into 
probability distributions. The second issue covered the analysis of stochastic decision 
models with the objective of valuing the collection of further data, using a Bayesian 
value of information analysis. This section describes the policy implications that could 
be drawn from the various results presented in this Chapter, a discussion of the potential 
causes of differences in the results derived from competing methodologies is presented 
in Chapter 9. 
Comparing the alternative input data analysis techniques the results derived from both 
models showed that the theoretical specification of probability distributions provided 
lower mean estimates of the cost per additional QAL Y from adding chemotherapy to 
tamoxifen. However, the maximum difference between the mean ICERs was only 
around £ 1,400 so the likelihood of alternative decisions being made on the basis of the 
mean results is small. However, if the level of uncertainty around the mean estimates 
was incorporated into the decision making process, the choice of input data analysis 
method could have a significant impact on the resource allocation decision. Comparing 
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the CEAc curves estimated by either model (Figures 8.2 and 8.4), it is clear that the 
results derived using the fitted distributions and the empirical data direct indicate far 
less certainty about the cost-effectiveness of tamoxifen and chemotherapy. These 
analyses showed that over 30 per cent of observations indicated that tamoxifen was the 
dominant strategy, whilst the corresponding percentage using the theoretical 
distributions was less than 10 per cent. Such uncertainty about the cost-effectiveness of 
the more expensive intervention could prevent the allocation of resources to 
chemotherapy, a decision that is more likely using the fitted distributions and the 
empirical data direct. 
Comparison of the results derived from the two models showed that the DES model 
consistently estimated higher values for both costs and effects. but because the 
differences were proportionally similar there was little difference between the estimated 
incremental cost-effectiveness ratios (leERs). Indeed, the largest difference between 
the respective leERs was only £400. It is unlikely, therefore, that decision-makers 
would come to contrary decisions due to the use of alternative modelling techniques 
using the results that are presented in this thesis. 
The second main section in this Chapter covered the results of the analyses of the value 
of information (Vol) within a Bayesian framework. The estimation of the Vol was split 
into three sections. The first stage estimated the expected value of perfect information 
(EVPI), for which all three methods for specifying probability distributions were used. 
The results revealed a huge difference in the potential value of additional research 
depending on the method used to pool and format the identified data. As shown in 
Figure 8.5, at a value of an additional QAL Y of £10,000 the EVPl estimated using the 
theoretically specified distributions was around £3.5 million, whereas the corresponding 
estimates produced using the fitted distributions and the empirical data direct were 
around £43.5 million. The variation in the estimates of the EVPI due to the choice of 
methods over the analysis of the available data has serious implications for the role of 
Vol analyses in informing funding decisions over future research. 
The methodology driving the second stage of Bayesian Vol analyses is under 
development. This stage requires that the baseline probability distributions describing 
uncertainty in the input parameters be updated to reflect the hypothetical collection of 
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further data. At present, simple methods for updating only the theoretically specified 
distributions using the properties of conjugate families of prior distributions are 
available so the full Vol analysis was only undertaken using the theoretical 
distributions. Given the divergent estimates of the EVPL it is likely that the alternative 
methods would value the collection of further infonnation differently. If the difference 
in the valuation of infonnation was of a similar magnitude to the difference in the EVPI 
the choice of input data analysis method could lead to very different research agendas. 
Indeed, such differences would necessitate a finn judgement on the appropriate set of 
probability distributions, a decision that could possibly be avoided if a model were only 
informing the immediate allocation of resources. 
Using the theoretically specified distributions both models estimated a similar optimal 
size for a prospective trial of around 2,050 and between 2,250 and 2,500 for the Markov 
process and the DES model, respectively. However, the predicted Vol differed to a 
larger extent for prospective samples below 1,000. For example, using the baseline 
assumption of the 5-year length of applicability for the proposed research, the Markov 
process predicted continuously positive net benefits of sampling, whilst the DES model 
predicted negative net benefits up to a sample size of around 400. Further discussion of 
the practical and theoretical issues relating to the analysis of the Vol are presented in 
Chapter 10. 
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Chapter 9 Case study: methodological issues arising 
9.1 Introduction 
The main objective of this Chapter is the exploration of the causes of differences in the 
results presented in the previous Chapter and the associated methodological 
implications for the conduct of economic HT A decision models. Three methodological 
issues are discussed in this Chapter, though the primary discussion centres on the main 
objective of this thesis - the comparison of alternative modelling techniques. The 
comparison of the DES model and the Markov process is described in the context of an 
overall economic HT A decision modelling project, relating to the five statements of 
model characteristics defined at the end of Chapter 2. 
One of the secondary objectives concerned the identification of differences between the 
results obtained from alternative methods for pooling and fonnatting data to populate 
decision models. The following sections discuss the results derived from using the 
three identified methods - theoretically-based distributions, fitted distributions, and 
direct empirical data. 
Within the case study evaluation the value of collecting further data on input parameters 
was estimated within a Bayesian value of information (Vol) analysis. Such analyses are 
relatively new to the field of economic evaluation and the methods used were adapted 
from those advocated by the health economists who introduced Vol analysis to 
economic HT A decision modelling. The methodological implications concerning the 
use of the alternative modelling techniques and methods for pooling and formatting the 
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input data in a Vol analysis are presented in this Chapter. However, the main objective 
underlying the application of the Vol analyses was to critique the current methodology 
and to specify particular issues requiring further research, which is presented in Chapter 
10. 
9.2 Comparing the alternative modelling techniques 
At the outset of this thesis the primary objective was to gain a better understanding of 
the relative advantages and disadvantages of discrete event simulation models and 
Markov processes as tools for the economic evaluation of health care technologies. 
Chapter 8 presented the results derived from the alternative techniques and discussed 
the policy implications of the observed differences. To recap, the DES model estimated 
slightly higher costs per additional QAL Y from adding chemotherapy to tamoxifen, but 
the closeness of the results suggested that it was unlikely that the use of one model's 
results over the other would lead to an alternative decision. However, the lack of any 
significant difference in the results produced by the alternative models does not mean 
there are no significant differences between the two modelling techniques. During the 
course of this thesis several potentially important differences have been revealed. 
Chapter 2 set out the, a priori, state of knowledge about the available modelling 
techniques that concluded with five statements regarding potential factors that may 
influence the choice of decision modelling technique. The five statements are discussed 
below in the light of the work completed in this thesis. 
1. If anything other than short-term outcomes are to be modelled decision trees are an 
inappropriate choice of modelling technique. 
This first statement set the scene for the comparison of DES models and Markov 
processes. The case study employed in this thesis covered a long time horizon - 50 
years - and it is inconceivable that a decision trees would be used to model patient 
pathways for any intervention over such an extended time horizon. At present decision 
trees, Markov processes and DES models are the three main modelling techniques that 
have been applied to economic HT A decision models, though it is possible other 
decision modelling techniques may be applied in the future. 
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2. If model parameters are a function of the time spent in particular states DES "will 
more accurately reflect the true relationships between health states. 
This statement relates to the constraining factor in Markov models known as the 
Markovian assumption, whereby the pathway of a patient from their current state is 
dependent only on the current state (and possibly the total length of time spent in the 
model). The Markovian assumption prevents the application of differential probabilities 
to patients within the same health state. In effect, a patient is a patient is a patient in 
every state within the model. DES allows patient pathways to be influenced by any 
factor within the model, including the representation of alternative patient 
characteristics on entry to the model. 
Within the case study evaluation described in this thesis the Markovian assumption 
limited the description of patient pathways after the experience of a locoregional 
relapse. In the ABC models patients experiencing a locoregional relapse progressed to a 
more severe site of relapse (metastases) or straight to death. The identified data 
describing progression from locoregional relapse were mainly presented in the fonn of 
disease-free survival curves representing the probability of progressing in successive 
time periods from the point of diagnosis with a locoregional relapse. To apply data 
directly from a survival curve to patients within a decision model it is necessary to 
know when each patient entered the state of interest in order to apply the differential 
probabilities of experiencing an event over time. In the DES model, patients remaining 
disease free at the end of the available follow-up adopted the survival profile of the 
general population. This assumption was based on qualitative data reported in the 
literature. The DES model noted the time at which patients entered the locoregional 
relapse health state, as well as recording the age of each patient. This enabled the 
application of age-specific mortality rates to each patient that remained in remission to 
the last point of identified follow-up. 
The Markovian assumption requires that the data available in the survival curve must be 
transformed to a constant probability that is applied to every patient within the health 
state. The ideal output from the conversion of the survival data is a mean length of 
disease-free survival (DFS), which would produce, in the absence of discounting, the 
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same mean results as those derived from the use of the survival curye directly. 
However, if a proportion of patients do not experience the event reported by the survi\'al 
curve, the estimation of a constant probability can only be approximate because the 
mean 'survival' cannot be fully estimated. In the case study Markov process it was not 
possible to determine the age of the patient at the end of the period of follow-up because 
the state was within the model and a constant probability of experiencing an event was 
applied to all patients in all time periods. A specific time period spent in the health state 
was required for the whole patient group, which necessarily resulted in some 
inappropriate estimates of the time spent in the state. 
Two options were considered to represent the period of disease-free survival following a 
locoregional relapse in the Markov process. Firstly, in each of the studies presenting 
data on DFS following a locoregional relapse the median patient had experienced a 
relapse, so the median DFS was used as an estimate of the mean DFS. However, when 
the results of the two decision models were compared the DES model produced 
considerably larger estimates of overall survival and QAL Y s associated with both 
interventions. After a thorough inspection of the two models it was discovered that the 
use of the median DFS in the Markov process was the main cause of the observed 
differences in the model outputs. The distribution of DFS was significantly skewed to 
the right and the approximated mean used in the DES model was substantially higher 
than the median estimate. 
An alternative method for estimating the mean DFS for the Markov process was then 
adopted, which assumed a maximum length of survival of 20 years from the point of 
locoregional relapse. For each study a mean survival time within the specified 20 years 
was estimated. The specification of a maximum survival period was necessary because 
the survival curve presented by the majority of the available studies had plateauxed by 
the end of the reported follow-up period so it was difficult to extrapolate the curves. 
Table 9.1 presents the model outputs from the Markov processes analysed using the 
median length of disease-free survival and the approximate mean. The data show that 
the effect on the aggregate costs is negligible, but there is a more substantial effect on 
the total QAL Y s and life years associated with both therapies. The differences give an 
indication of the importance of the assumptions made with respect to this one input 
186 
Ch ... Case study: methodological issues arising 
parameter. The two methods employed to estimate the length of disease-free survival 
required stronger assumptions about the pathways of patients following a loco regional 
relapse than were employed in the DES model. Indeed, these were just two of a 
multitude of alternative approaches that could have been adopted to describe disease-
free survival. 
Table 9.1 Comparison of model outputs from the Markov process using the 
median length of disease-free survival and the approximate mean disease-free 
survival 
Costs QALYs Life years 
Mean (tamoxifen+chemotherapy) £8,862 11.62 15.72 
Median (tamoxifen+chemotherapy) £8,934 11.23 15.13 
Difference 
-£72 0.39 0.58 
Mean (tamoxifen alone) £6,721 11.07 14.90 
Median (tamoxifen alone) £6,741 10.70 14.33 
Difference 
-£20 0.37 0.57 
ICER (mean) £3,896 
ICER (median) £4,159 
Difference £263 
In the case study evaluation, the majority of data identified in the literature described 
survival times for the separate metastatic sites as median survival times. The survival 
times for patients diagnosed with metastases were relatively short - soft tissue 
metastases had the longest median survival of around 31 months. It is likely that a few 
outlying patients with long survival times would increase the mean values, but without 
data to support this assumption the most conservative approach was to use the non-
adjusted medians. If survival curves become available to describe time to events in 
other states, such as survival time from metastases, the assumptions imposed on the data 
employed in Markov processes could considerably undermine confidence in the model's 
outputs. 
The representation of disease-free survival as a constant probability of experiencing an 
event also had another consequence. In the DES model it was possible to make the 
assumption that if patients had not experienced a relapse after 11 years in remission they 
were 'cured' and the next event of interest to the decision model was death. In the 
Markov process it was not possible to split the destination of patients according to time 
spent in the state, so all patients leaving the state were subject to the same probabilities 
of experiencing a more severe relapse, or progressing straight to death. The impact of 
this shortcoming was limited in the case study because only a small proportion of 
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patients remained disease free at the end of the follow-up period. However. modelling 
scenarios in which this issue has a far larger impact can be envisaged and it is more 
difficult to correct for this deficiency than to revise estimates of the median survival 
period. 
There were other areas in the case study evaluation in which the development of patient 
pathways that were influenced by the time spent in a earlier states could have 
demonstrated further advantages of the DES model over the Markov process if more 
detailed data were available for the evaluation. For example, disease-free interval (DFI) 
is known to be a prognostic factor that reflects the intrinsic growth rate of the tumour 
[Bomer et aI, 1994]. It may be plausible to assume that patients with short lengths of 
DFI would be more likely to experience a relapse, rather than dying with no evidence of 
disease, than patients with a longer period of DFI. Moreover, it has been reported that 
the length of DFI affects a patient's prognosis from the time of diagnosis with a 
recurrence [Ingle et aI, 1994; Wong and Henderson, 1994]. Unfortunately the 
secondary data sources used in this thesis did not produce data that described possible 
relationships in enough detail to warrant inclusion in the models. If more detailed 
primary data becomes available it is possible that certain patient characteristics could be 
employed as attributes within the DES model, which may provide an improved 
representation of the treatment area that would enhance the advantages of DES models. 
3. If the specification of similar health states that differ only with respect to the 
experience of previous states compromises the clarity of the model, the use of DES 
should be considered. 
The third statement refers to the possible proliferation of health states in a Markov 
process in order to represent states that have similar characteristics, but where 
subsequent patient pathways are influenced by a patient's treatment history. Only one 
such example occurred in the case study evaluation, which involved the description of 
the experience of toxicity. Three fonns of toxicity were described - major, grade 3 or 4, 
and grade 1 or 2 - that could be experienced simultaneously. The available data 
described the proportion of patients experiencing each fonn of toxicity. 
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In the DES model, no separate health states were defined to represent toxicity, rather the 
experience of toxicity was assigned to each patient within the health state DF!. Each 
patient sampled from three binary distributions representing the probabilities of 
experiencing the three forms of toxicity, so each patient could expenence any 
combination of the toxicity categories. The attributes containing the information on the 
experience of toxicity were incorporated into the estimation of the costs and QAL Y s 
associated with each patient's time in DFI as they left the state. Modelling events such 
as the experience of toxicity as attributes could be viewed as increasing the black box 
nature of the modelling process, because these events are not explicitly presented in any 
structural representation of the model. However, the incorporation of such events can 
be clearly explained in the text and, in any case, the presentation of states in a diagram 
does not guarantee their proper representation in the model itself. 
In the Markov process it would have been possible to create seven states that described 
each possible combination of the different types of toxicity, though this would have 
required probability estimates for each combination of toxicity classifications, which 
were not available in the literature. To avoid further strong assumptions only three 
toxicity states were included in the Markov process representing the experience of each 
type of toxicity independently. Hence, patients could experience only one form of 
toxicity. If, in any run of the Markov process, the sum of the probabilities of 
experiencing the three forms of toxicity exceeded 1 the probability of experiencing the 
least severe form of toxicity (grade 1 or 2) was reduced. 
In the analysis of second-order uncertainty, which concerns differences across 
populations, the aggregate effects of toxicity for a patient group would only differ 
slightly, due to the adjustments to the probability of experiencing grade 1 or 2 toxicity 
when the sum of the toxicity probabilities exceeded 1. Differences may have occurred 
in analyses of first-order uncertainty (if the Markov process had been analysed using 
first-order Monte Carlo simulations) because there would be more variation between the 
individual patients reported by the DES model. However, as described in Chapter 3, for 
the analysis of cost-effectiveness to inform resource allocation first-order uncertainty is 
irrelevant (see section 3.4.3). 
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4. If the data describing the timing of events are not in the form of transition 
probabilities then DES will provide a truer representation of reality. 
Issues around the format of the available data are only applicable to modelling studies 
that employ secondary clinical data. In such circumstances the analyst is normally 
bound by the presentational norms for particular types of data. The case study 
evaluation highlighted clinical data presented as set survival times, rather than as the 
probability of experiencing an event in a particular intervaL as one area in which the 
format of the identified data led to significant differences in the results of the two 
models. The DES model incorporated such data in exactly the format that the data were 
available, whilst the Markov process required the conversion of set survival times to 
constant probabilities of experiencing death at any point following the diagnosis of 
metastases. The impact of these different approaches on the outputs of the models was 
first noted during the verification of the action of discounting within the models (see 
section 7.2.3), where differences between the results of the DES model and the Markov 
process were observed. For example, for a set survival period of 8 months the DES 
model discounted the full survival period for each patient at the same rate (assuming the 
8 months fell within the same year for each patient). However, in the Markov process 
the distribution of outputs associated with the survival time for each patient were spread 
over a longer period because all the patients within the state were subject to a constant 
probability of dying. 
To illustrate the impact on costs, quality adjusted life months (QALMs) and life years, 
which were all subject to alternative discount rates, a macro was set up in an Excel 
spreadsheet to estimate the outputs associated with varying lengths of survival derived 
from the two models. Set survival times of between 1 and 40 months were employed. 
To ascertain the impact on costs, a discount rate of 6% was applied to monthly costs of 
£469 (the mean monthly cost of bone metastases). For QALMs, a utility value of 0.5 
was discounted at a rate of 1.50/0, whilst life years were not discounted. The ABC 
models covered a time horizon of 50 years, which was the maximum period over which 
the constant probabilities were applied to patients remaining in a metastatic state. The 
macro was set up to link the length of follow-up in the assumed metastatic state to the 
start year in the state. For example, if the start year in the state was sampled as year 10 
then the outputs from the state were summed for the follo\\ing 40 years in the state. 
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This set-up provided the most accurate portrayal of the effect of converting set survival 
times to constant probabilities within the ABC models. 
Figures 9.1a, 9.lb and 9.1c represent the difference in outputs as a function of the 
survival time and the start year in the assumed health state. The differential effects of 
discounting, survival, and the time horizon of the model relative to the start year in the 
assumed state can be drawn from the figures. Figure 9.la shows that the cost difference 
between the two modelling techniques, which was subject to the highest discount rate, 
was mainly affected by the length of survival. The maximum difference was almost 
£4,000 for patients with a survival time of 40 months entering the metastatic state in 
year 0 (DES model> Markov process). The cost difference decreased slightly as the 
start year increased, which reflected the increase in the discount factor. F or short 
survival times of under 4 months the Markov process actually over-estimated costs, 
though only by a maximum of £38. Figure 9.lb demonstrates that with a low discount 
rate the start year in a state does not affect the difference in QALMs greatly. For 
example, the difference in QALMs between the two models for a survival time of 40 
months is 0.113 (0.009 QAL Ys) ifpatients enter the state in their first year in the model, 
decreasing to 0.082 (0.007 QAL Ys) if patients enter the state in their 26th year in the 
model. Figure 9.lc appears to show the most significant results, but the magnitude of 
the effects on life years is small, the maximum difference is 0.015 months (roughly half 
a day). The most significant factor causing the differences in the lifeyear estimates was 
the time horizon of the model. This stylised example, following the assumptions 
employed in the case study Markov process, assumed that patients lived for a maximum 
of 100 years. This meant that patients entering the state, for example, in year 25 with a 
survival time of 40 months were not all exiting the model (and hence the state) before 
they reached the age of 100 years. 
The data illustrates that, in the absence of discounting, the conversion of set survival 
times to constant probabilities has little effect, though combinations of longer survival 
times and late entry into the assumed state started to produce some differences. Around 
50 to 60 per cent of patients experienced a metastatic relapse in the ABC models. The 
differential outputs caused by the conversion of set survival times to constant 
probabilities in the Markov process was a significant factor in the observed differences 
between the outputs of the two models. 
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Figure 9.1a Plot showing the difference in cost estimates between a DES model and a Markov 
process for survival from a state described as a set survival time, as a function of the survival 
time and the start year in the state. 
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Figure 9.tb Plot showing the difference in QALY estimates between a DES model and a Markov process 
for survival from a state described as a set survival time, as a function of the survival time and the start year 
in the state. 
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Figure 9.1c Plot showing the difference in life years estimates between a DES model and a Markov 
process for survival from a state described as a set survival time, as a function of the survival time and the 
start year in the state. 
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5. The advantages of DES need to be weighed against the additional resource 
requirements. Realistic assessments of the necessary inputs should inform the 
choice of modelling technique. 
The comparison of modelling techniques undertaken in this thesis was based on the 
premise that the health economist wishes to retain control of the economic HT A 
decision model, which meant that the techniques adopted were accessible to analysts 
with no formal training in operations research. The Markov process was built in Excel 
spreadsheets, using the Crystal Ball add-in to facilitate the stochastic analysis of the 
model. Though specific software were available to build and analyse Markov processes 
[DATA 3.5, 1999], the use of spreadsheets is a common format. The Markov process 
was analysed as a cohort analysis because this is the most common form of analysis in 
the economic evaluation literature, but also because the more complicated first-order 
Monte Carlo simulation approach adds only to one relatively small element of the Vol 
analysis (see section 8.4.2). The DES model was built using software specifically 
designed to create DES models [Simul8, 2000]. DES models are often built using 
independent programming languages that have an even steeper learning curve than DES 
software packages. To facilitate further use of DES, software that provided a 
background to the use of DES and enabled the easiest construction of such models was 
used. 
The overall time to obtain the final results from the DES model far exceeded the time 
employed using the Markov process. The causes of the excess analytic input associated 
with the DES model can be split into two categories - building and analysing. These 
two elements of time and expertise are compared below. 
A Markov process simply multiplies the proportion of patients in each health state in 
each time period by the associated cost and utility value attached to each state, applying 
the relevant discount rates to each time period. To estimate their average value, the 
outputs are then summed across all time periods. In the absence of discounting and the 
use of attributes the building of a DES model would not be significantly more complex 
than a Markov process. The model would monitor when a patient entered a state and 
when they left the state, the length of stay in each state could then be multiplied by the 
associated costs and utility values. To discount the associated costs and utilities it is 
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necessary to distinguish the time spent in a particular state with reference to the time at 
which an individual patient entered the model. The time spent in a state must then be 
separated into the individual years since entry into the model for each patient. 
DES is further complicated if attributes that affect the cost and utility values associated 
with health state are included. In the case study, toxicity was modelled as an attribute 
within the 'DFI' state. This meant that the time spent in the health state 'DFI' had to be 
separated into the different time periods within the state that individual patients spent 
with alternative forms of toxicity, or for which they were disease-free with no toxic 
effects. 
A particularly complicated element of building the DES model was uncovered during 
the validation of the models (see section 7.3). Part of the data employed to validate the 
models described economic outputs for less than the full lifetime of patients. The use of 
these data required collecting data for all patients at exactly 4 and 10 years after they 
entered the model. To collect such data using the Markov process the model was 
simply stopped at the relevant period and the associated costs and effects collected. This 
was possible because all patients start at the same time in the model and the outputs are 
collected at regular time intervals - every month. The collection of model outputs at 
such specific time points was more complicated in the DES model because it is event-
orientated. The collection of data within the model is also event orientated. As a 
patient leaves a particular state the programming code looks back at the history of the 
patient within the state she is leaving and assigns the relevant costs and utility values.' 
The DES model could not simply cut-off the data collection period for patients at a 
specified length. In order to collect data constrained by time it was necessary to run the 
full model, but collect data at the end of each state up to the specified time period. This 
was only possible by inserting programming code that effectively asked if the patient 
had been in the model for the specified period at regular intervals when aggregating the 
costs and effects at the point of exit of each state. In effect, the process of validation 
was necessarily subject to a separate process of verification; to ensure that mechanisms 
put in place for the validation were working properly. 
DES, being event-orientated. was necessarily analysed using first-order Monte Carlo 
simulations. This meant that for each set of input parameter values, data on a large 
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number of individual patients were collected to infonn a mean value for each output. 
After experimentation, 10,000 patients were found to adequately control for first-order 
uncertainty, which was a function of the complexity of the model (see section 7.4). 
Employing cohort analysis, the Markov process estimated the model's outputs for the 
whole cohort simultaneously. The time required to solve the respective models for a 
single set of input parameter values using a 700Mhz PC was a couple of seconds for the 
Markov process, and over a minute for the DES model. In the context of a stochastic 
analysis, which involved solving the models for a large number of sets of input 
parameter values such a difference translated to weeks versus one day in terms of total 
running time for the final experimentation. However, the time to analyse included not 
only the final 'correct' experimentation, but also the whole process of verification and 
validation, which required significantly more analytic time than the final process of 
experimentation. 
9.3 Comparing the alternative methods for assembling input distributions for 
stochastic decision models 
The results presented in the Chapter 8 demonstrated that the most significant differences 
between the input data analysis methods were between the methods based on the 
creation of weighted datasets, which were employed to describe the empirical data 
direct and to inform fitted distributions, and the theoretically specified distributions. 
The following section discusses the causes and methodological implications of the 
observed differences in the mean values of the model outputs, whilst the subsequent 
section covers the substantial difference in the variation observed around the mean 
values estimated using the alternative methods. 
More subtle differences were noted between the use of the empirical data direct and the 
fitted distributions, which are discussed in the third section. 
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9.3.1 Comparing the mean results using weighted datasets and theoretically specified 
probability distributions 
The primary cause of the differences in the mean values of the model outputs between 
the use of weighted datasets and theoretically specified probability distributions relates 
to their respective handling of data presented as proportions. The main causes of the 
differences were the parameters for which measures of variance were available, i.e. the 
clinical parameters represented as proportions. To create weighted datasets for such 
parameters meta-analytic methods for weighting the data were used (see section 
3.4.3.1). Using the fixed effects model (assuming no heterogeneity between the studies) 
the weight for a particular observation was the inverse of the variance. The variance for 
proportions is p(l- p) / n, which decreases as the proportion decreases, but as the 
weight is the inverse of the variance, the weight attached to individual data observations 
increases as the proportion of interest gets smaller. The chosen theoretically specified 
distribution to represent proportions was the beta distribution. The beta distribution 
parameters - a and fJ - are simply the number of events and the number of non-events, 
respectively, thereby applying equal weights to studies of equal sample size, 
irrespective of the number of events recorded. 
Ceteris paribus, the meta-analytic techniques gave greater weight to smaller 
proportions, which led to smaller mean values for proportion parameters. To illustrate, 
the data representing the probability of patients receiving tamoxifen alone experiencing 
grade 3 or 4 toxicity is presented in Table 9.2. 
Table 9.2 Data informing the proportion of patients receiving tamoxifen alone 
who experience grade 3 or 4 toxicity 
(a) study sample 
(b) number of events reported 
( c) proportion of events reported 
(d) meta-analytic weight [aI(b(I-b))] 
(e) proportional meta-analytic weight [d/surn( d)] 
(t) implicit beta distribution weight [alsurn(a)] 
Study 1 
352 
1 
0.003 
117686 
0.59 
0.28 
Study 2 
145 
7 
0.05 
3053 
0.02 
0.11 
Study 3 
771 
8 
0.01 
77879 
0.39 
0.61 
The distribution parameters for a beta distribution representing such data were a = 16 
andfJ = 1252, with a corresponding mean 0.0126 (16/1268). The process for weighting 
the data according to the fixed effects model employed the following fonnula: 
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Wi = _1 = ni , which led to a mean value of 
Vi Pi(1- Pi) 
[ 352 0003] [145 ] [771 ] 0.003(1-0.003) x. + 0.05(1-0.05) xO.05 + 0.01(1-0.01) xO.01 =0.00647 
The beta distribution estimate is double that of the weighted dataset estimate. In 
addition to this general finding of divergence between the meta-analytic weighting 
techniques and the direct incorporation of data into probability distributions using 
method of moments formulae, other differences relating to the different types of input 
parameters were also noted. The following three sections outline such effects in 
parameters describing duration in a state, the type of event to be experienced, and 
parameters for which only a point estimate and a range are available. 
9.3.1.1 Differences in the weighted values of duration parameters 
In the case study evaluation, the mean duration in the DFI was lower in the analyses 
using the theoretical distributions than in the analyses based on meta-analytic 
techniques, which ran contrary to the general fmding presented above. The data 
describing the probability of experiencing an event were presented as survival curves, 
from which the data were recorded as the proportion of patients remaining disease free 
at the end of each time interval. The apparent anomaly in the applied weights was due 
to the fact that weights were attached to the proportion of patients remaining disease-
free at the end of each period. Using the meta-analytic techniques, higher weights were 
attached to data describing lower proportions of patients remaining disease-free, which 
led to higher weights for larger probabilities of experiencing an event. 
Table 9.3 Example of difference in the estimation of the input data due to 
alternative methods of defining probability distributions 
Study A. B. C. D. E. 
1 
2 
Patients Proportion Proportion Proportion Weighting 
disease-free disease-free disease-free experiencing an patients 
at start year at start year x at end year x event remaining 
x [(B-C)/B] disease-free 
148 
148 
0.49 
0.44 
0.46 
0.35 
0.03 
0.09 
[A/(C(l-C))] 
596 
651 
F. 
Weighting 
patients 
expenencmg an 
event 
[A/(D(I-D»] 
5086 
1807 
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Table 9.3 presents an example of the difference in the mean probability of experiencing 
an event derived from weighting the data according to the proportion remaining disease-
free, and to the proportion experiencing an event. At the start of year x, Study 1 reports 
the largest proportion of patients remaining disease-free, but during year x more 
patients' experience an event in Study 2. Applying the alternatively specified weights, 
the following weighted means were estimated: 
Weighting patients remaining disease-free = 
( 596) (651) (596+ 651) .0.03+ (596+ 651) .0.09 = 0.061 
Weighting patients experiencing an event = 
( 5086) ( 1807 ) (5086+ 1807) .0.03+ (5086+ 1807) .0.09 = 0.046 
The observed difference in the weighted mean of 0.015 is a large difference in the 
context of the aggregate proportions (24.5% of 0.061 and 32.8% of 0.046). There were 
two reasons for basing the meta-analytic weighting procedures on the proportion of 
patients remaining disease-free, rather than the proportion of patients experiencing an 
event. Firstly, in time periods in which a study reported zero occurrences of an event 
the meta-analytic weighting procedure attempted to divide the sample by zero, which 
was obviously infeasible. Secondly, weighting data on the basis of the proportion of 
events occurring in each time period applied consistently higher weights to lower 
estimates of the probability of experiencing an event. This approach appeared unwise 
because higher relative weights were applied to whichever study, in a particular time 
period, presented the lowest estimate of the probability of an event in that period. 
Consistently weighting the lowest estimates most highly under-represented the true 
mean survival curve. 
Using the proportion of patients remaining disease-free as the base for the weighting 
procedure did not consistently weight observations reporting fewer events more heavily, 
rather it weighted data according to the variance in the proportion of patients remaining 
disease-free. 
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9.3.1.2 Differences in the weighted values of type of event parameters 
During experimentation with the case study evaluation it was noted that, relatiye to the 
theoretical distributions, the mean values of some events following DFI or remission 
(following locoregional relapse) were increased using the meta-analytic weights. This 
effect was due to the description of the types of event patients experienced as separate 
probability distributions for each event, which were sampled independently and the 
adjusted to equal 1 within the model. Though the meta-analytic weighting procedures 
assigned higher weights to lower probabilities for all such events, those events with the 
lowest probability of occurring - soft tissue metastases and death - were increased 
(relative to the theoretically specified distributions) in order to accommodate larger 
decreases in the mean values of the other events. 
9.3.1.3 Differences in the weighted values for parameters informed by limited 
data 
A third potential area of divergence between the alternative data input analysis 
techniques are parameters that are informed only by a point estimate and a subjectively 
defined range. In the case study evaluation, the utility values associated with each of 
th~ states included in the model were informed by point estimates obtained from the 
literature, but the ranges were subjectively defined after consultations with a range of 
health professionals. The minimum and maximum values that were specified were not 
necessarily symmetric around the derived point estimate. 
The theoretically specified distribution chosen to describe utility values was the beta 
distribution. The distribution parameters for the beta distribution were calculated using 
a formula that required estimates of the mean and standard deviation of the distribution 
of values. The mean was taken as the point estimate derived from the literature, whilst 
the standard deviation was estimated from the specified range for each utility value (see 
Appendix 5). Triangular distributions were fitted to these data, taking the established 
point estimate as the most likely data point (the tip of the triangle). The remaining 
distribution parameters for triangular distributions were the minimum and maximum 
values of the distribution, which were informed by the subjectively specified ranges for 
each utility value. Unless the minimum and maximum values are equidistant from the 
most likely data point in a triangular distribution, the most likely value will not be the 
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mean value for the distribution. The non-symmetry of the ranges within some of the 
triangular distributions specified to describe utility values led to the differences in the 
mean values of some of the theoretical and fitted probability distributions. 
9.3.2 Differences in the variation around the mean results using weighted datasets 
and theoretically specified probability distributions 
The previous section described how differences in the mean values estimated for input 
parameters caused differences in the model outputs derived from the use of weighted 
datasets and theoretically specified distributions. This section illustrates how the 
alternative methods for pooling the identified data caused differences in the variation 
around the mean values for the input parameters, as reflected by the cost-effectiveness 
planes presented in Chapter 8. There was substantially more variation around the mean 
estimate of cost-effectiveness derived from the use of weighted datasets, than from the 
use of the theoretically specified distributions. Differences in the width of probability 
distributions were noted for parameters for which a measure of the variance around each 
estimate was available: the experience of different forms of toxicity, the probability of 
leaving DFI or remission, and the types of events experienced following DFI or 
remission. Figures 9.2a and 9.2b display a theoretically specified beta distribution and a 
normal distribution fitted from the weighted dataset, respectively, to represent the input 
parameter 'probability patient receiving tamoxifen and chemotherapy experiences major 
toxicity'. The fitted (normal) distribution is wider than the theoretically specified (beta) 
distribution because there is increased variation in the weighted dataset due to the larger 
weights placed on the outlier observations, in this case the smaller proportions. 
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Figure 9.2a Beta distribution(109, 1855) 
02 0.4 0.6 0.8 1.0 
Figure 9.2h Norm.al (0.0499, 0.02) 
02 0.4 0.6 0.8 1.0 
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9.3.3 Comparison of direct use of empirical data andfitted distributions based on the 
empirical data 
The mean leERs, the leERs at the chosen credible intervals, and the cost-effecti\-eness 
acceptability curves, were virtually identical using the empirical data directly and the 
fitted distributions based on the empirical data. This closeness was expected as the 
fitted distributions had the same mean value as the empirical data and the variance in 
the empirical data was used to inform the distribution parameters. A difference was 
only noticeable between the two sets of observations when the differences in costs and 
effects were plotted on the cost-effectiveness plane (see Figures 8.1 b and 8.1 c). Though 
the same range of differences were covered by the two sets of observations the spread 
was more even in the results derived from the fitted distributions. Again, this was 
expected because the fitted distributions covered all values within the range specified by 
the empirical data, whilst only the observed values for the input parameters could be 
sampled using the empirical data directly. 
In the case study evaluation the difference in the spread of observations did not cause 
any difference in the interpretation of the two sets of results. It is conceivable that more 
important differences may occur in evaluations where the empirical input data are 
mainly located at the extremes of the ranges. The mean results between the two 
approaches to specifying input distributions will remain equal, but the credible intervals 
may differ more significantly. This is especially likely if the decision-maker 
incorporates a lower credible range into her decision-making process, for example, a 
900/0 limit rather than a 95% limit. 
9.4 Value of information (Vol) analysis 
The application of Vol analyses to economic HTA decision models is a recent 
methodological development - no full Vol analysis was identified in the literature, 
though a number of studies reporting the expected value of perfect information (EVPI) 
were identified [Claxton et al, 1998; Felli and Hazen, 1998; Fenwick et al, 2000]. The 
Vol analysis implemented in this thesis adapted a non-parametric approach to estimate 
the optimal sample size for a prospective study to inform all the input parameters within 
the defined models. The non-parametric approach benefits from requiring weaker 
assumptions than its' parametric equivalent. The examination of the Vol analysis 
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interprets the observed differences in the results of the Vol analysis between the two 
models, and between the alternative methods of specifying probability distributions. A 
further commentary on the methods used to evaluate the Vol and suggestions for further 
research in this area are presented in Chapter 10. 
The first stage in the full estimation of the Vol involves the estimation of the expected 
value of perfect information (EVPI). In this thesis the EVPI was estimated using both 
decision models and for all three alternative methods for specifying probability 
distributions (see section 8.4). The Markov process and the DES model produced 
similar estimates of the EVPI, but the estimation of EVPI was massively different 
according to the choice of data analytic technique (see Figure 8.5). The fitted 
distributions and the empirical data direct resulted in much larger estimates of the EVPI 
than the theoretically specified distributions. 
The EVPI derived from the weighted datasets rose continuously upwards in relation to 
the value of an additional QAL Y, whilst the EVPI associated with the theoretical 
distributions peaked at the value of a QAL Y at which tamoxifen alone had the highest 
probability of being the cost effective therapy option. This result reflected the wider 
dispersion of the net benefit observations using the fitted distributions and the empirical 
data direct. It is likely, therefore, that the use of meta-analytic techniques to analyse the 
identified data will always lead to an increased valuation of the Vol, over the use of 
theoretically specified distributions. 
Unfortunately, the methodological tools for updating the fitted distributions and the 
empirical data, which was required for the next stage of the analysis, were not available 
at the time of undertaking the Vol analysis reported in this thesis. Therefore, the 
remainder of the analysis used only the theoretically specified distributions, which 
could be updated using established formulae (see Appendix 5). Comparing the 
alternative modelling techniques to the remainder of the Vol analysis, it appeared that 
the DES model was more precise in the estimation of the expected value of sampling 
information (EVSI) because it was possible to quantify first-order uncertainties 
(between patient variation), which were arguments in Neyman's formula. However, the 
impact of the increased accuracy was minimal as there was a similar level of variation 
within both therapy groups. 
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The estimation of the Vol necessitated the repeated stochastic analysis of the decision 
model, which required extensive running time for the DES model (weeks), whilst the 
whole process was completed in a day using the Markov process. The comparison of 
the results derived from the Markov process and the DES model showed that the 
expected net benefits of sampling (ENBS) were similar, though the DES model 
estimated a slightly higher optimal prospective sample size. The DES model placed a 
higher value on the collection of further data to inform the decision-maker. This result 
was expected as the increased flexibility of the DES model produced slightly more 
variation in the model's outputs. Indeed, the Vol estimated by DES models should 
always be at least as large as that estimated by a corresponding Markov process, 
because a DES model facilitates a more precise depiction of the true patient pathways, 
which can only lead to more variation in the model's outputs. 
9.5 Conclusions 
This Chapter has described the methodological implications derived from the results 
presented in Chapter 8. The primary objective of this thesis was addressed, using the 
five modelling characteristics statements, which were first defmed in Chapter 2, to 
compare alternative modelling techniques. The first statement set up the choice 
between a Markov model and a DES model for evaluations covering extended time 
horizons. The following four statements were each found to have some impact on the 
results derived from the case study evaluation. The most important factor in terms of 
affecting the results of the evaluation appeared to be statement 4, which noted that 
increased data flexibility enabled more accuracy in the incorporation of data into the 
DES model. The improved accuracy was shown to have a sizeable impact on the 
differential outputs estimated by the Markov process and the DES model, particularly in 
the presence of discounting. 
Another area of difference between the models was due to the enforced Markovian 
assumption, which meant that the Markov process was unable to define transition 
probabilities in terms of how long patients had remained in a particular state. In the 
case study evaluation, the probability of leaving the state 'remission' (following 
locoregional relapse) was a function of the time already spent in the state. The DES 
206 
Case study: methodological issues arising 
model incorporated the exact slope of the disease-free survival curve, whilst the Marko," 
process necessitated the estimation of a constant transition probability. In addition, the 
DES model allowed for a more realistic extrapolation of the available C1ITye using age-
specific mortality rates, whilst the data inputted into the Markov process was based on a 
single cut-off period for all patients. The DES model also enabled a more realistic 
assumption that patients would not experience a further relapse after an extended period 
of remission. Other areas in which the conditional development of patients pathways 
could lead to more significant differences, given appropriate data, were also identified. 
The representation of the relationships between the length of DFI and other parameters 
within the model could have a far larger impact on the models' outputs. 
A less significant factor in the case study evaluation concerned the use of attributes in 
the DES model to represent the experience of treatment side effects, whilst the Markov 
process defined three separate toxicity states. The attributes did allow a more realistic 
representation of toxicity, though the impact on the results of the two models was 
minimal. The final issue related to the analytic input required to build and analyse the 
alternative modelling techniques. The DES required far greater time inputs to build and 
analyse the model. However, there is a steep learning curve in building DES models 
that, once surmounted, will reduce the gap between the analytic input required to build 
the respective models. The time to analyse the models is less open to improvement as 
the use of first-order Monte Carlo simulation to analyse DES models cannot be 
changed. The time to analyse the DES case study model was found to be the most 
restrictive element of DES because a large amount of time was required to verify and 
validate the model, and for the process of experimentation. 
Following the assessment of the two modelling techniques this Chapter reviewed the 
methodological implications of using three alternative methods for pooling and 
formatting data for inputting to a stochastic decision model. Chapter 8 had highlighted 
the main differences as pertaining to the methods based on the creation of weighted 
datasets (fitted distributions and using the empirical data direct) and the specification of 
theoretically defined probability distributions. The major cause of the observed 
differences was the fact that the meta-analytic techniques used to create weighted 
datasets for some of the identified data (those for which a measure of variance was 
available) attached larger weights to smaller proportions than the alternative method. In 
207 
Case study: methodological issues arising 
the case study evaluation, the impact of this effect was tempered due to anomalies 
observed in some data categories, in particular, data describing the probability of 
experiencing an event were weighted on the basis of the proportion of patients 
remaining event-free. The general conclusion arising from these comparisons is that the 
application of meta-analytic weights reduces the transparency of the process of pooling 
and formatting the input data. The use of meta-analytic weighting formulae based upon 
the variance within samples also caused the substantial difference observed in the 
spread of the outputs derived using the alternative methods. 
The examination of the Vol analysis concentrated on a companson of the above 
techniques (models and input data analysis methods) within the application of a Vol 
analysis. A further commentary on the actual process is presented in Chapter 10. The 
two models produced broadly similar estimates of the Vol. The ability of the DES 
model to estimate first-order uncertainty was employed in the allocation to therapy 
formulae used in the estimation of the EVSI to little effect, though the impact could be 
larger in other evaluations. However, the main difference between the models analysis 
of the Vol was the length of time required to obtain the results. The repeated estimation 
of the ENBS for a series of prospective samples took a few weeks using the DES model, 
but only a day using the Markov process. Bearing in mind that the first analysis is 
rarely the final analysis, the time constraints imposed by the use of DES cause more 
concern within a Vol analysis than for analyses to inform immediate resource allocation 
decisions. 
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Chapter 10 Conclusions and recommendations 
10.1 Introduction 
The aim of this final Chapter is to address the objectives raised at the start of this thesis 
by summarising the main fmdings reported in the previous Chapters, and defining 
recommendations regarding the application of decision models, as well as related areas 
for further research. The primary objective of this thesis has been the comparison of 
alternative decision modelling techniques, with respect to the process and outputs of an 
economic evaluation of health care interventions. The investigation was based on the 
application of the two main modelling techniques employed to model patient pathways 
over extended time horizons - Markov processes and DES models - to a case study 
evaluation comparing alternative adjuvant therapies for early breast cancer. The 
comparison of alternative modelling techniques was also presented in the context of a 
stochastic evaluation, which described probability distributions around the outputs of 
the models - the costs and effects associated with each intervention. The distributions 
of outputs were infonned by randomly sampled sets of input parameter values from 
probability distributions representing the uncertainty around the values of the model's 
input parameters. 
Three secondary objectives for this thesis were also defined relating to the application 
of stochastic decision models. The most general objective was the development of a 
complete description of the methodology informing the application of decision 
modelling to the economic evaluation of alternative health care interventions. Secondly, 
alternative methods for pooling and formatting the identified data into probability 
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distributions to populate decision models were compared. Finally, techniques available 
to estimate the value of infonnation (V 01) were adapted and empirically applied. 
The four objectives are addressed in separate sections. Each section presents the 
methodological insight gained from the development of a framework for the modelling 
process, the implications of the empirical evidence derived from the application of the 
defined methodology to the case study evaluation, and areas for future research. 
10.2 Comparison of alternative modelling techniques 
10.2.1 Methodological insight 
Chapter 2 presented a general introduction to the three main modelling techniques -
decision trees, Markov processes and DES models - supported by examples of the use 
of the different modelling techniques, which informed a preliminary assessment of the 
strengths and weaknesses of the alternatives. The characteristics of decision trees and 
Markov processes are very different and the choice between the two techniques in 
alternative treatment settings is relatively straightforward. With the introduction of 
DES to the field of economic evaluation in health care, the issue of choosing the 
appropriate technique could become an important decision in the initial stages of 
modelling projects. The issue of choosing the correct modelling technique has been 
referred to in the health economics literature [Chaussalet et aI, 1999; Sonnenberg et at 
1994], but the consequences of the choice have not been fully explored. 
On the basis of the review reported in Chapter 2 some criteria for the comparison of 
alternative modelling techniques were developed. Five statements were defined that 
related to the characteristics of the treatment area being modelled, or the type of data 
available to populate the model, which were used as the basis for the empirical 
comparison of the alternative modelling techniques (see next section). 
10.2.2 Empirical evidence 
Table 10.1 presents a summary of the differences observed between the DES model and 
the Markov process in the context of the case study evaluation. Despite the relative 
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closeness of the aggregate cost-effectiveness results derived from the two models the , 
structural differences between the models were potentially important. It would appear 
to be a matter of good fortune that the divergences between the models acted in opposite 
directions that almost cancelled each other out. However, the outputs estimated by the 
DES model were uniformly higher than those produced by the Markov process, which 
indicated that the most significant advantage of the DES model was the increased 
flexibility with respect to the handling of time to event data. Another important 
advantage of the DES model concerned the linking of parameter values to the time spent 
in states, which provided a more precise approach to the representation of other forms 
of data. 
The choice of decision model should be judged on the characteristics of alternative 
treatment areas but, on the basis of these results, it is recommended that the use of DES 
should be strongly considered if either of the two issues highlighted in the previous 
paragraph (statements 2 and 4) appear relevant. Statement 3, relating to the use of 
attributes to reduce the number of health states included in a decision model, did not 
appear to have a great impact on the results of the case study evaluation. The additional 
analytic input to the use of DES can be addressed in two stages. Firstly, the increased 
analytic expertise is not as great as may be assumed, because specialist software 
packages are available that provide a framework for the development of DES models. 
Though the initial learning curve is steep relative to the development of a Markov 
process, most health economists who have used Markov processes should be able to 
build a DES model. Secondly, the additional time to analyse a DES model should only 
influence the choice of decision model if the results from an evaluation are required 
quickly and the additional time is simply not available. 
One final recommendation is that the simultaneous application of both modelling 
techniques to a single evaluation provides an excellent basis for checking that both 
models are working correctly. Within the case study evaluation, the process of the 
verification was greatly aided by the ability to compare the respective outputs of the two 
models. 
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Table 10.1 Summary of differences between the case study Markov process and DES model with respect to the five modelling 
characteristics statements 
Statement 
1 if anything other than short-term outcomes 
are to be modelled decision trees are an 
inappropriate choice of modelling technique. 
2 If model parameters are a function of the time 
spent in particular states DES will more 
accurately reflect the true relationships 
between health states. 
3 If the specification of similar health states 
that differ only with respect to the experience 
of previous states compromises the clarity of 
the model, the use of DES should be 
considered. 
4 if the data describing the timing of events are 
not in the form of transition probabilities then 
DES will provide a truer representation of 
reality. 
5 The advantages of DES need to be weighed 
against the additional resource requirements. 
Realistic assessments of the necessary inputs 
should inform the choice of modelling 
technique. 
Model difference 
No difference, both models enabled 
the representation of extended time 
horizons. 
DES: inputted data from survival 
curves in exactly same format to 
describe disease free survival after 
experience of a locoregional relapse. 
Markov process: survival curve data 
was converted to a constant 
probability of experiencing event. 
DES: used attributes to describe 
simultaneous experience of separate 
toxicity categories. 
Markov process: patients could only 
experience toxicities independently. 
DES: survival from metastases was 
specified as set survival times, as 
described in the literature. 
Markov process: set survival times 
were converted to constant probability 
of experiencing death. 
DES: increased analytic input required 
more time and expertise. 
Markov process: low level of 
expertise required, very fast running 
time. 
Impact 
The mean length of DFS was longer in the DES model, but in the Markov process 
all patients leaving remission had a probability of experiencing a further relapse 
(metastases) because it was impossible to distinguish between patients within the 
health state 'remission'. In the DES model patients who remained disease free 
after 11 years were subject to the mortality rate in the general population and went 
straight to death from remission. It is likely that this led to lower costs in the DES 
model, though the effect on life years and QALYs is less clear. 
Small increase in costs estimated by the DES model for patients receiving 
tamoxifen and chemotherapy because combined probability of toxicity can be 
greater than 1. 
The Markov process underestimated costs and QALYs when survival times from 
the metastatic sites over 5 months were converted from set survival times to 
constant probabilities. The magnitude of the effect was influenced by discount 
rates. Assuming discounts rates of6%, 1.5% and 0% for costs, QALYs and life 
years, respectively, the largest impact was on the costs estimated by the model. 
The likely aggregate impact on the ABC models is that the DES model produced 
higher estimates of all three outputs, but the effect will be greatest for costs, then 
QAL Ys and finally life years. 
There was a learning curve associated with the use of DES, though the use of 
specialist software reduced its' steepness. The analysis of DES models was 
substantially longer than for the Markov process. The experimentation time may 
be partly due to the use of specialist software. 
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10.2.3 Future research 
The empirical comparison of the alternative modelling techniques presented in this 
thesis has highlighted three general areas in which DES provided an improved 
representation of the patient pathways associated with alternative adjuvant therapies 
for early breast cancer, given the available information. However, the model structure 
applied within the case study evaluation represented just one option. The findings 
reported in this thesis would be re-enforced if a separate evaluation of the same 
therapies using an alternative model structure arrived at the same conclusions. 
Moreover, the relative importance of each of the three issues is likely to differ 
between treatment areas. Further empirical comparisons of the use of Markov 
processes and DES models in evaluations of different treatment areas will provide 
additional evidence on the extent of the benefits offered by DES, as well as on the 
relative importance of the three identified areas of advantage. 
Another potentially important area is the comparison of the alternative modelling 
techniques using patient-level data to describe some, if not all, of the input parameters 
within a model. This issue was referred to in section 9.2 (statement 2) where it was 
indicated that more detailed data might promote the advantages of DES further 
through the representation of relationships between patients treatment history and 
future prognosis. A comparison of a DES model and a Markov process using patient-
level data to inform input parameters would provide further evidence on which to 
base the choice of appropriate modelling technique. 
10.3 Developing a complete methodology for the modelling process 
10.3.1 Methodological insight 
There is a need for explicit guidelines to inform the use of modelling, especially in the 
context of submissions to official bodies, such as the National Institute for Clinical 
Excellence (NICE) in the UK. At present NICE simply specify that it is important 
that modelling is used appropriately and carried out to the highest standards. The 
development of a complete description of the necessary methods for applying an 
economic HT A model was borne of the realisation that guidance on the different 
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components were available, but that the advice was located in disparate sources. 
Furthermore, different sources of advice relating to the same stage of the modelling 
process recommended alternative procedures. Chapter 3 described the whole 
modelling process, in chronological order moving through five main stages, which 
were applied to the case study in the following Chapters: 
1. Specifying the theoretical model (Chapter 4); 
2. Undertaking a literature review to obtain input data from the model (Chapter 4): 
3. Analysis of the available data to popUlate the model (Chapter 5); 
4. Implementation of the model (Chapters 6 and 7); 
5. Experimentation with the model (Chapter 8). 
Previous work undertaken in the field of health economics was sought. though much 
of the process drew on issues common to the general area of clinical research. 
Insights into individual stages of the modelling process were also obtained from other 
disciplines including the social sciences and operations research. 
10.3.2 Empirical evidence 
This section summarises the experience gained from the application of the modelling 
process to the case study evaluation, incorporating various examples of good practice 
that were established. The review of the modelling proc~ss did not attempt to provide 
a prescriptive methodology for all economic HT A decision modelling projects, but 
rather to bring together the available methods relating to each element of the 
modelling process. The characteristics of the treatment area being evaluated, the 
available data, and the focus of the evaluation will influence the methods adopted for 
different parts of the process. To inform the use of the stated methods the 
accompanying theoretical and pragmatic arguments have been stated explicitly so the 
reader has a clear basis on which to base their own judgement. 
In Chapter 4, the specification of a preliminary model structure was based on 
information obtained from oncology clinicians, a preparatory review of the literature, 
and the Internet, which limited the potential for bias because the structure of the 
model was informed by consensus between the alternative sources. The literature 
review was based on the preliminary model, which informed a series of separate 
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literature reviews relating to different aspects of the patient pathways. The conduct of 
the separate literature reviews was pragmatic. Explicit study inclusion criteria 
relating to year of publication, publication type and language were specified in order 
to limit the scale of the necessary review, though extensions to the criteria were 
enacted if insufficient data were identified to populate particular areas of the model. 
During the extraction of data from the literature any prognostic information reported 
about the identified patient groups were recorded in order to evaluate sub-groups of 
the population. 
Chapter 5 described the procedures for pooling and formatting the identified data to 
populate a decision model. The first task involved the explicit harmonisation of data 
that described similar events, but differed slightly in their definition of the event of 
interest. Harmonisation facilitated the combination of data by making explicit 
alterations to the values reported by one or more of the relevant studies to improve the 
comparability of the underlying parameter definitions. The process of harmonising 
the data cannot be subject to hard and fast rules as the adjustments made to the data 
will depend on the event described and the format of the available data. However, the 
harmonisation of the ABC data illustrated a range of issues with potential relevance to 
other disease areas. For example, during the harmonisation of the DFI data, the 
studies that treated death as a censored event reported the number of deaths observed, 
which were then used to adjust the original disease-free survival data. If the relevant 
data to harmonise a parameter were not presented by a study, data from studies with 
the most similar patient and treatment characteristics were used to adjust the initial 
estimate. 
Chapter 5 also described the implementation of alternative methods for the 
specification of probability distributions to represent the uncertainty around the values 
of the input parameters. The evaluation of this issue developed into a secondary 
objective of the thesis, which is discussed separately in the next section. 
Chapter 6 described the development of a Markov process and a DES model as 
computer-based decision models. The relevant issues relating to building the 
alternative models were presented in the section above comparing the two modelling 
techniques. Chapter 6 also addressed two issues relating to the actual use of the 
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models. Firstly, the DES model was necessarily analysed using flrst-order Monte 
Carlo simulations, which required an adequate number of patients in each (flrst-order) 
run of the model. Testing alternative run sizes, 10,000 patients were found to be 
sufficient to minimise the impact of flrst-order uncertainty on the mean values 
estimated for each set of input parameters. However, it was noted that the necessary 
run size is linked to the complexity of the model and speciflc testing for the minimum 
run size should be undertaken for different models. Secondly, the stochastic sampling 
of monthly versus annual probabilities of experiencing an event was discussed. The 
Chapter concluded that the appropriate method of sampling should follow the 
intervals in the original data. F or example, if the identified data are presented as 
annual probabilities they should also be sampled annually and then converted to 
monthly probabilities within the model. 
Chapter 7 reported the application of methods to verify and validate decision models. 
Three categories of verification were employed. The main form comprised the 
verification of logic, which checked that the internal mechanisms of the models were 
working correctly. The explicit presentation of three classes of logic testing - clinical 
parameters, costs and utility values, and discounting - provided ample evidence of the 
analyst's attention to detail. Secondly, sensitivity testing compared expected and 
observed effects of alternative input parameters on the models' outputs. The 
sensitivity tests backed up the logic checks, but also confirmed that the two decision 
models were producing consistent outputs. Finally, stress testing verified that the 
models recognised nonsensical input data, alerting the analyst to data entry errors. 
The validation of the decision models compared the models' outputs to a range of 
relevant outputs presented in previously published economic studies, as well as 
comparing clinical endpoints such as survival at different cut-off points. Reasons for 
any differences between the compared outputs were sought in the context of 
methodological and data driven differences between the case study evaluation and the 
identified studies. The process of validating economic HT A models is notoriously 
difficult and the methods described in Chapter 7 are not heralded as a definitive 
approach. However. the applied methods did result in the revision of the original 
values for a set of cost parameters within the case study evaluation, which 
demonstrates some success in this approach. 
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The outputs from a stochastic evaluation comprise a series of matched observations of 
the costs and effects associated with the relevant interventions. Chapter 8 presented 
the results of the case study evaluation using the alternative presentational forms 
presented in Chapter 3. Mean incremental cost-effectiveness ratios (lCERs) were 
supplemented by plotting the cost and effects differences on cost-effectiveness planes, 
the presentation of the credible intervals for the ICERs, and the use of cost-
effectiveness acceptability (CEAc) curves. Each method of presentation added to the 
general interpretation of the model outputs, though the relative effectiveness of the 
alternative methods in aiding the comprehension of decision-makers is an empirical 
question beyond the scope of this thesis. The application of the final methodological 
area covered in the modelling process, the analysis of the value of information (Vol), 
developed into a secondary objective of this thesis and is discussed in the final section 
of this Chapter. 
10.3.3 Future research 
The collection of methodologies for the modelling process highlighted certain areas 
that would benefit from further research, either due to a lack of defined methods, or 
due to uncertainty regarding the appropriate methods to employ. The definition of 
economically relevant sub-groups is an important issue because it may be cost-
effective to provide an intervention to a sub-set of a patient population, but not to the 
whole population. Recent recommendations issued by NICE have highlighted the 
importance of sub-group analyses, but research is required on methods for identifying 
which sub-groups should be analysed separately. Indeed, 
Various methods were suggested for the validation of decision models that did 
provide some assistance in identifying parameters values that could be represented 
more realistically, though such modifications did not provide complete assurance of 
the validity of the models. Other authors have suggested that validity can only be 
proved to the point that the modelling process was undertaken to a sufficiently high 
standard [Sculpher et al, 2000; McCabe and Dixon, 2000], which appears to settle for 
a second-best solution. To increase the acceptance of economic HTA models, it is 
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necessary to explore this area further in order to convince potential users of such 
evaluations that the results really do answer the question asked. 
The final area in need of further research follows on from the need to properly 
validate models, to the need to present the outputs of models in the most appropriate 
format for the user to be able to incorporate the information to their requirements. A 
wide range of possible formats for presenting cost-effectiveness information were 
described, but there is no real understanding of the best format, which will persuade 
decision-makers to actually use the available information. Future research IS, 
therefore, required on how best to present cost-effectiveness information. 
10.4 Comparison of alternative data analysis methods 
10.4.1 Methodological insight 
F our alternative methods for pooling and formatting the identified input data into 
probability distributions to populate stochastic decision models were described in 
Chapter 3. The first method, labelled 'theoretically specified distributions', assigned 
the same type of distribution to similar groups of input parameters. The distributions 
were chosen by matching the characteristics of the input parameters to the 
characteristics of different probability distributions. The parameters for each 
distribution were estimated by applying the identified data to established formulae 
that estimated the relevant distribution parameters. 
The second and third methods employed meta-analytic techniques to weight the 
identified data, which were then described in datasets comprising weighted 
representations of the identified data for each input parameter. The weighted datasets 
were either inputted directly into the decision models ('empirical data direct'), or they 
were inputted into statistical fitting software, which fitted the data to the best 
matching probability distribution ('fitted distributions'). The final approach involved 
bootstrapping the identified set of observations to create a bootstrap distribution. 
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10.4.2 Empirical evidence 
The bootstrapping approach was more applicable to the analysis of primary data and 
was not applied to the case study evaluation, but the remaining three methods were 
applied to the case study evaluation. Substantial differences were observed between 
the probability distributions specified using meta-analytic techniques to weight the 
available data (the fitted and empirical distributions) and the theoretically specified 
distributions for parameters for which a measure of variance within each identified 
study was available, i.e. parameters described as proportions that were informed by 
clinical trials or observational studies. The general effect of the meta-analytic 
weighting procedure was to give greater weight to lower proportions. Table 10.2 
shows that the effect on the models' outputs of the different parameter categories was 
mixed, which meant that the respective outputs produced by the three methods did not 
vary greatly. However, the alternative methods did have a substantial effect on the 
variation described in the outputs of the models, which was far greater using the meta-
analytic techniques. 
Table 10.2 Summary of the differences in the mean values of input 
parameters due to the alternative methods of specifying probability distributions 
Parameter 
category 
Experience of 
toxicity 
Time to event 
Type of event 
Infonned only 
by a point 
estimate and a 
non-symmetric 
range 
Impact 
Probability of experiencing toxicity lower using meta-analytic methods, which 
led to higher costs and lower QAL Y s using the theoretical distributions. The 
magnitude of the differences in the mean values was small. 
Probability of experiencing an event was generally lower using theoretical 
distributions, which led to higher life years and QAL Ys, though impact on costs 
was more difficult to determine. 
Lower probability of progressing straight to death with no relapse in the 
theoretically defmed distributions, particularly for patients receiving tamoxifen 
and chemotherapy. Resulted in higher costs, life years and QALYs using the 
theoretical distributions. 
Higher utility values using theoretical probability distributions, because the range 
around the mean was assumed to be symmetric unlike the alternatively specified 
triangular distributions. This led to higher estimates of QAL Y s using the 
theoretical distributions. 
I t is not clear which data input analysis method provides the most reliable data, and 
hence, the results that engender the most confidence in their accuracy. The fact that 
the implications of the cost-effectiveness results arising from the alternative methods 
for specifying input distributions could differ raises the question of which method 
might be preferred. The work presented in this thesis suggests that there are two 
disadvantages to the use of meta-analytic techniques to weight the identified data over 
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the specification of theoretical distributions. Firstly, and most importantly, alternative 
approaches to the application of the meta-analytic weighting techniques were possible 
that increased the scope for differential results between analysts employing seemingly 
similar techniques. The only element that could vary between evaluations using the 
theoretically specified distributions is the choice of the theoretical distributions. which 
should converge to a common set of distributions as their application increases. There 
was no subjectivity apparent in the analysis of the distribution parameters, because 
well-defined fonnulae were employed to estimate the parameter values. Secondly, 
the analysis of the data to create weighted datasets is more complicated, and more 
prone to errors than the simpler process of estimating distribution parameters for the 
theoretically specified probability distributions. 
If only one fonn of analysing the data is to be chosen, on practical grounds the 
general application of theoretically specified distributions is more likely to provide a 
common baseline for the comparison of alternative economic HT A decision models. 
It is also the only method that enables a full analysis of the Vol at present. Ideally, 
however, all three input data analysis methods should be employed in an economic 
HT A decision model, because this provides an excellent basis for the testing the 
sensitivity of the cost-effectiveness results to the alternative methods of populating a 
stochastic decision model. 
10.4.3 Future research 
The empirical evidence suggested that there is potential for far greater discrepancies 
in the estimated mean values between the alternative data analysis methods than was 
found in the case study evaluation. In addition, the observed difference in the 
variation around the cost-effectiveness results is a cause for concern. Though the 
theoretically specified distributions are most likely to provide a common baseline for 
comparisons between evaluations, this choice was based primarily on the ease of use 
and the ability to undertake full Vol analyses. The central question that remains to be 
addressed is which method is the most theoretically correct method? 
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10.5 Analysis of the value of information (Vol) 
1 0.5.1 Methodological insight 
The final element of the research reported in this thesis was the application of 
techniques to estimate the value of conducting further research in a particular 
treatment area. The main objective was to critique the underlying methodology in 
order to highlight areas that could benefit most from further research, though a couple 
of adaptations to the current methodology were developed within the context of the 
case study. The methods for the analysis of the Vol were presented in Chapter 3, 
incorporating a three-stage process: estimating the expected value of perfect 
information (EVPl), estimating the expected value of sampling information (EVSl), 
and estimating the expected net benefits of sampling (ENBS). 
Both methodological alterations related to the estimation of the EVSI. The EVSI is 
based on the premise that hypothetical samples of data can be assumed that are 
analysed within a model to re-estimate the EVPl, which then informs the EVSI. The 
methods adopted in this thesis employed only two types of probability distributions, 
the beta and the gamma, which could incorporate hypothetical data using established 
formulae. The mean values of the new data for each parameter were assumed to be 
the same as the values derived from the identified data, because the mean represented 
the best estimate of the true value of the individual parameters. The hypothetical 
representation of additional data is a key issue in ongoing research. Secondly, 
Claxton stated that every feasible allocation of patients between the relevant therapy 
options, for each prospective sample, should be evaluated in order to estimate the 
optimal prospective trial [Claxton, 1999]. Given the time required to run the DES 
model, in particular, such a detailed level of analysis was not feasible. A simpler, and 
quicker, method of allocating a proposed sample between the treatment options being 
evaluated was adopted in this thesis, Neyman's allocation to strata formula, which 
accounted for the variance within the outputs of each intervention and the costs of 
sampling between the interventions [Cochrane, 1977]. A constant ratio of the sample 
allocation between two treatment options was estimated for all prospective samples. 
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10.5.2 Empirical evidence 
The results of the Vol analysis derived from the alternative modelling techniques 
were relatively close, but the application of the alternative input data analysis methods 
within the first section of the Vol analysis - the estimation of the EVPI - revealed 
huge differences of magnitude. These differences would have persisted if all three 
methods had been able to estimate the full Vol, which reinforces the need to define a 
consistent method for the specification of probability distributions around the input 
parameters across all evaluations. 
The revised methodology for the analysis of the Vol was applied to both decision 
models. The assumption of basing the hypothetical data on the mean values of the 
identified data estimated the minimum possible optimal sample size, as the assumed 
sample led to the maximum reduction in the variation described in the original 
probability distribution. Other options for the specification of hypothetical data to 
inform the estimation of the EVSI are currently being developed, which will 
hopefully provide a more solid base for the analysis, but also enable the use of a wider 
range of probability distributions than those employed in the case study evaluation. It 
was difficult to assess the impact of assuming a constant allocation ratio between the 
interventions, though it is likely that the optimal sample was reduced because the 
estimated net benefits for each sample were underestimated. However, the use of a 
constant allocation ratio reduced the complexity and duration of the Vol analysis 
significantly, which may encourage the application of further Vol analyses. 
A final issue derived from the empirical evidence related to one of the most 
contentious elements of the modelling process - should the final structure of a 
decision model be influenced by the amount of data available to populate the model? 
The omission of qualitatively informed events or relationships in the structure of 
decision models is based on the definition of the practical model as 'the most detailed 
model that can be constructed given the limitations of available data' [Sonnenberg et 
al, 1994]pgJSS4. The objective of most models is to inform a resource allocation 
decision based only on the data identified at the present time. However, Vol analyses 
aim to inform the collection of additional data so to restrict the structure of the model 
on the basis of the currently identified data appears to be nonsensical. It may, 
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therefore, be necessary to adopt different model structures to inform an immediate 
resource decision and to inform a Vol analysis. 
10.5.3 Future research 
The most important output from the application of the Vol analyses was the insight 
that it offered into how the technique could be improved. A number of issues arose 
during the Vol analyses that were beyond the scope of this thesis to explore, but 
which should be addressed during future research on this topic. The most prominent 
issue noted from the results of the Vol analysis concerned the impact of the 
assumptions made with respect to the size of the relevant patient popUlation to whom 
the benefits of further information would apply. Previous estimates of the useful 
lifetime of information included 5 years for interventions to control the symptoms of 
urinary tract infection [Fenwick et aI, 2000] and 3 years for treatments of Alzeimer's 
disease [Claxton et aI, 1998], though no basis for these choices were provided. A 
baseline length of research application of 5 years was employed in this thesis, which 
was chosen on the basis that five years appeared to be a reasonable estimate of the 
time between the availability of new therapy options. Sensitivity analyses undertaken 
to test the impact of the assumed length of usefulness of the prospective research 
demonstrated that the magnitude of the Vol was extremely sensitive to the length of 
applicability. However, in order to persuade decision-makers of the relevance of Vol 
analyses in setting research agendas it will be necessary to develop standardised 
methods for the estimation of the length of research use in alternative treatment areas. 
The length of time required to obtain additional information on specific parameters 
within the model will also affect the length of applicability of the research. The 
implicit assumption in the application of the relevant patient population to the Vol 
was that the prospective sample, n, consisted of the next n patients to require 
treatment for the condition evaluated. The subsequent patients were all assumed to 
benefit from the additional information provided by the n patients until the assumed 
length of research usefulness expired. Ideally, data on all the parameters within the 
decision model could be obtained within the same time horizon within individual 
patients; for example, from the point of entry to a trial the required data from a single 
patient would be available within one year. The estimation of the length of research 
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usefulness could then build in factors relating to the estimated time to recruit the 
required sample of patients, as well as the time to inform all parameters within the 
model. 
Data describing events occurring later in the case study evaluation would only be 
available after time periods of up to 20 to 30 years, such as survival from metastases 
or events experienced following a locoregional relapse. To incorporate such effects 
into the Vol analyses would require the additional estimation of the Vol for different 
lengths of follow-up for prospective trials. The updated probability distributions 
could be estimated to reflect the assumed amount of data that would be available to 
inform alternative input parameters at differing lengths of follow-up. The relevant 
patient population would be re-estimated for every length of follow-up to reflect the 
revised estimates of the length of usefulness for the research. 
The following function provides a foundation for the estimation of the length of 
usefulness of research (U): 
U=t-r-f 
Where t is the anticipated time to the availability of a new intervention, r is the time 
required to recruit prospective sample andfis the length of trial follow-up. 
Other issues raised with respect to the analysis of the Vol encompassed means of 
making the analysis more precise, but also considerably more complicated. For 
example, the above discussion over the estimation of the usefulness of research 
assumed that the choice of intervention for patients who refused to enter a prospective 
trial would not be informed by the additional data obtained to the date at which their 
treatment decision is made. The Vol for non-participating patients could be included 
on the basis that the allocation decision would be updated at regular intervals within 
the follow-up period. 
Additional data on some input parameters may be collected in trials involving other 
patient groups. For example, in the ABC models data relating to the experience of 
treatment side effects were assumed to be specific to the intervention rather than the 
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patient group. Data relating to such parameters as survival from metastases, or the 
cost of treating locoregional relapses could also be incorporated from studies set up to 
investigate treatment in other patient groups. The availability of such data should also 
be included within Vol analyses, which would require the identification of 
prospective trials and an assessment of the likely quantity and timing of the data to be 
obtained. 
At this stage in the development of the analysis of the Vol, this area of research 
appears to be an exciting prospect that will offer useful information to decision-
makers allocating resources to research, but many issues need addressing before such 
analyses are likely to be commonly employed for such tasks. 
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Appendix 1 Literature review details 
A1.l Introduction 
Two broad literature reVlews were undertaken, which are described in the following 
sections. The first review identified work that informed the methodology for the modelling 
process, whilst the second identified data that could be used to populate the decision 
models used in the case study evaluation. 
A1.2 Review of the modelling process 
A large-scale review of the health economics and clinical literature was undertaken to 
identify research describing any methodological issues involving the application of decision 
models to clinical evaluation. Relevant research was also sought from disciplines such as 
operations research and social sciences. The purpose of the literature review was to inform 
the discussion of the characteristics of the alternative modelling techniques (see Chapter 2), 
and to identify research relating to individual aspects of the modelling process (see Chapter 
3). 
The literature review included orthodox searches of the main medical databases (Medline 
and EMBASE). No relevant index terms were identified so the search of the databases 
comprised a range of free-text terms: model*, decision analysis, decision trees, Markov, 
simulation. In addition, manual searches of the most prominent journals were undertken. 
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including Medical Decision Making, Health Economics, Phannacoeconomics, Journal of 
Health Economics, the International Journal of Health Technology Assessment in Health 
Care and the Journal of Health Services Research and Policy. The references lists of the 
identified studies were then searched for further studies, and citation searches for leading 
authors were conducted using the Science Citation Index. Internal publications from 
academic departments and papers presented at relevant conferences and workshops also 
proved to be an important source of additional work. 
OR textbooks were included in the review for general insights into the comparison of the 
modelling techniques. Numerous sources of advice were identified from BruneI University 
library's catalogue and a selection of textbooks was chosen to provide an alternatiYe 
perspective on the modelling process. Social science texts were sought for further advice 
on the conduct of literature reviews. 
A1.3 Review to populate the decision models 
To identify data to populate the case study models Medline was searched initially in May 
1998 using the following search terms: 
• Index terms, Breast neoplasms/, Disease-Free Survival!, Survival/ or survival analysis/ 
or survival rate/, Mortality/, Recurrence/, Neoplasm recurrence, local!, Lymphatic 
metastasis/, Neoplasm metastasis/, Neoplasm metastasis/, Tamoxifenl, Chemotherapy, 
adjuvant!, Drug therapy/, Ovariectomy/, Menopause/, Menopause, premature/, 
Castration!, Postmenopause/, Drug toxicity/, Quality of life/, Costs and cost analysis/ 
• Free text terms, early, site, first recurrence, adjuvant, ovarian, suppression, ablation, 
ovarian suppression, ovarian ablation, estrogen replacement therapy, utility 
Some examples of the searches made using these terms, including the term combinations 
and associated number of hits, are presented below. The identified reference lists and the 
Science Citation Index were also searched to obtain further references. 
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Al.4 Literature search results 
Tamoxifen and survival 
-----------------------------------------------------------------------------
1 Breast neoplasms/ 25074 
2 limit 1 to (human and english language) 18451 
3 Survival! or survival analysis/ or survival rate/ 43428 
4 limit 3 to (human and english language) 34944 
5 Tamoxifenl 3350 
6 limit 5 to (human and english language) 2381 
7 2 and 4 and 6 165 
8 from 7 keep 114 
*************************** 
Tamoxifen and disease-free survival 
Breast neoplasms/ 25074 
2 limit 1 to (human and english language) 22019 
3 Disease-Free Survival! 3147 
4 limit 3 to (human and english language) 2901 
5 early.ti,ab,sh. 160807 
6 limit 5 to (human and english language) 93442 
7 Tamoxifenl 3383 
8 limit 7 to (human and english language) 2399 
9 2 and 4 and 8 47 
10 from 9 keep 32 
*************************** 
Chemotherapy and survival 
-----------------------------------------------------------------------------
Breast neoplasms/ 25074 
2 limit 1 to (human and english language) 22013 
3 Survival! or survival analysis/ or survival rate/ 43428 
4 limit 3 to (human and english language) 34944 
5 Chemotherapy, adjuvant! 5044 
6 limit 6 to (human and english language) 3662 
7 early. ti,ab,sh. 160807 
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8 limit 9 to (human and english language) 
9 2 and 4 and 7 
10 2 and 4 and 7 and 10 
11 from 12 keep 
*************************** 
Chemotherapy and disease-free survival 
Breast neoplasms/ 
2 limit 1 to (human and english language) 
3 DISEASE-FREE SURVIV ALI 
4 limit 3 to (human and english language) 
5 2 and 4 
6 early. ti,ab,sh. 
7 limit 6 to (human and english language) 
8 Chemotherapy, adjuvant! 
9 limit 8 to (human and english language) 
10 2 and 4 and 9 
11 from 10 keep 
*************************** 
Site a/relapse 
93442 
255 
51 
32 
25074 
22019 
3147 
2901 
380 
160807 
93442 
5044 
3662 
86 
65 
-----------------------------------------------------------------------------
Breast neoplasms/ 25074 
2 limit 1 to (human and english language) 21076 
3 Recurrence/ 30651 
4 limit 3 to (human and english language) 23144 
5 site.ti,ab,sh. 122394 
6 limit 5 to (human and english language) 53315 
7 first recurrence.ti,ab,sh. 213 
8 limit 7 to (human and english language) 188 
9 2 and 4 and 6 8 
10 2 and 8 25 
1 1 9 or 10 32 
12 from 11 keep 20 
••• *.* ••••••• * ••••• ******** 
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Survival from relapse 
-----------------------------------------------------------------------------
Breast neoplasms/ 25074 
2 limit 1 to (human and english language) 21076 
3 Recurrence/ 30651 
4 limit 3 to (human and english language) 23144 
5 site.ti,ab,sh. 122394 
6 limit 5 to (human and english language) 53315 
7 first recurrence.ti,ab,sh. 213 
8 limit 7 to (human and english language) 188 
9 2 and 4 and 6 8 
10 2 and 8 25 
11 9 or 10 32 
12 from 11 keep 1-4,6,9,14,16-21,23-25,28-31 20 
13 Survival! or survival analysis/ or survival rate/ 43428 
14 limit 13 to (human and english language) 34944 
15 Neoplasm recurrence, local! 7212 
16 limit 15 to (human and english language) 5395 
17 Neoplasm recurrence, local!mo [Mortality] 942 
18 limit 17 to (human and english language) 649 
19 2 and 14 and 16 198 
20 2 and 17 99 
21 from 1 1 keep 3 1 
22 from 20 keep 68 
24 Lymphatic metastasis/ 10474 
25 limit 24 to (human and english language) 7225 
26 Neoplasm metastasis/ 7728 
27 limit 26 to (human and english language) 5273 
28 2 and 14 and 25 499 
29 Mortality/ 3897 
30 2 and 24 and 29 1 
31 from 20 keep 91,93-96 5 
32 from 30 keep 1 1 
33 or/31-32 6 
34 2 and 26 and 29 0 
35 2 and 14 and 27 212 
36 from 35 keep 137 
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Quality of life 
Breast neoplasms/ 
2 Quality of life 
3 1 and 2 
4 limit 3 to (human and english language) 
5 Adjuvant therapy 
6 1 and 2 and 5 
7 Chemotherapy 
8 1 and 2 and 7 
*************************** 
25074 
671 
210 
35 
67 
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Appendix 2 Data extraction methods 
Using previously published examples as a framework [Dowie, 1996: Murphy et aI, 
1994], an evidential database was set up to collect and manage the relevant data 
obtained from the research identified through the literature review. Three main 
information management criteria were identified as relevant to the case study 
evaluation: 
• an ability to download references from other electronic databases, 
• a facility to search for, and retrieve references stored in the database, and 
• a facility for appending text to references. 
At the time of the current project the software developed by ProCite had been improved 
so that it met each of the three criterion listed above to a high standard. A twin software 
package - Bibliolink 2 - had been developed that enabled the automatic transfer of 
records found by most electronic databases, whilst searching within a database created 
in ProCite was straightforward [procite 5, 1999]. Most importantly workforms could be 
easily adapted for data entry and formatted output. 
Using the flexible workforms, a data extraction form was developed in ProCite that 
categorised the identified data according to the model parameters that they informed. 
Figure 4.1 (section 4.4.4) presents the extraction form. The first section of the forma 
captured the reference details of the papers, as well as the objectives of the paper and 
the characteristics of the patient group included in the study. The aim of a paper 
provided an immediate indication of the type(s) of data (relating to the model 
parameters) that might be found in the paper, as well as allowing a judgement to be 
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made on the authors success in meeting the original objective of the study. Careful 
documentation of the patient characteristics within a study was essential in order to 
ensure that the analyses of the model were as homogeneous as possible. Information on 
the location of the study and the time period were also recorded as potential sub-groups. 
Variable definitions referred to any definition given in a paper that might vary across 
studies, covering such topics as estrogen receptor status [Zambetti et al. 1992]. types of 
toxicity [Alonso et aI, 1995], and types of relapse [Kamby and Sengelov. 1997]. The 
category 'omissions in context' covered all additional information about the study that 
was not described in the previous sections, such as the protocol restrictions on adjuvant 
therapies in trials of treatment for metastases [Falkson et al, 1995], or missing 
information such as the number of cycles of chemotherapy undertaken [Senn et aI, 
1997] or types of costs excluded [Lober et aI, 1988]. The • Comments' category 
incorporated a wide range of information including the conclusions drawn by each 
study. Also captured in this category were comments relating the current results to 
previous studies [Swedish breast cancer cooperative group, 1996] or any general 
statements about breast cancer that were not relevant to any of the other categories, such 
as hypotheses about the spread of cancer cells [Boccardo et al, 1997]. The assessors' 
category simply notes the assessor (all JK) and the date on which the study was 
reviewed. 
The second section of the extraction form covered all the parameters in the model. The 
parameters were split into three types that were identified by their prefix - 'id' covered 
clinical parameters, and 'qu' related to quality of life data. The 'co' category collected 
any available data on the cost of treatments related to breast cancer, but it also contained 
any relevant information on the type and frequency of resource use associated with the 
different stages of breast cancer. The category titles are mostly self-explanatory relating 
to the parameters included in the preliminary model. 'Disease free interval' and 'rates 
of relapse' both cover the probability and timing of experiencing a relapse or death with 
no evidence of disease, reflecting the two main formats of these data. The category 
'overall survival' captured data describing survival from the point of diagnosis with 
early breast cancer. 
Data extraction 
Within the established categories data entry was left unstructured. This flexible fonn of 
data entry was used because of the need to capture both quantitative and qualitative 
data. As there was only one reviewer, who was involved with the mechanics of the 
model, the style of extraction remained similar and was geared towards the t).-pe of data 
required for the model. The data extraction form created in ProCite was adequately 
tractable with respect to the format of data that was entered. There was no limit to the 
size of each category. Tables of data had to be tab-created in Wordpad and pasted into 
ProCite, which sometimes led to messy tables due to the width restriction in ProCite. 
The final category listed - Parameter Keywords - collected the categories that contained 
data for each paper included in the database. For example, a paper presenting disease-
free interval curves and the proportion of patients experiencing different types of 
toxicity would be marked 'idDFII idTox'. Identifying each paper according to the data 
categories they contained made searching the database for particular parameter 
information extremely simple. 
Though the review was ongoing in the sense that new studies were reviewed and added 
to the database as they were identified, the analysis of the data extracted began in May 
1999. Firstly, qualitative data contained in the three categories 'variable definition', 
'omissions in context' and 'comments' were assessed to provide background 
information on the disease area prior to commencing the quantitative analysis of the 
individual parameters. Next the database was searched separately for each parameter by 
entering the necessary keyword in the 'Parameter Keyword' category. These searches 
picked out the papers in the database that held data on the parameters of interest. 
Quantitative data was exported to an excel spreadsheet for analysis. 
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Appendix 3 Meta-analytic formulae for weighting data 
The methods available for weighting data depend on the fonnat of the identified data. If 
good primary data that incorporates measures of the within sample variance are 
available then methods for weighting data based on meta-analytic methods may be 
employed. The fixed effects model should be used if there is limited heterogeneity 
between the data, whilst the random effects model attempts to control for assumed 
heterogeneity. If it is unclear whether heterogeneity is present between the identified 
studies, then a formal test can be applied that tests the hypothesis that the underlying 
effects are equal: 
Q = ± Wj (OJ - e y 
;=1 
Where k is the number of studies, OJ is the treatment effect of the individual study and 
o is the mean value of all the studies. The null hypothesis is rejected if the observed 
variance is higher than would be expected due to chance alone - if value of Q exceeds 
the critical value of the chi squared distribution associated with k -I degrees of 
freedom. It is recognised that this test lacks power and the chance of falsely defining 
studies as homogeneous is quite large [Sutton et al, 1 998]pg77 . 
In heterogeneity is not identified, the fixed effects model involves a simple method of 
weighting the constituent data using the inverse of the variance [Sutton et al, 
1998]pg55. The formulae for calculating weights are: 
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W 
__ 1 _ nj 
j - - , for input parameters defined as proportions, and 
Vi pj(1-pj) 
Wj = ~ = n i2 ' for input parameters measured on a continuous scale. 
Vj O"j 
The random effects model also weights the different data according to their variance, 
but as well as the variance within the studies, the random effects model incorporates 
variance between studies to control for the assumed heterogeneity. There are various 
procedures for combining data assuming random effects [Hasselblad and McCrory, 
1995], though the most commonly used method appears to be the weighted non-iterative 
approach, probably due to its relative simplicity [Sutton et aI, 1998]pg72. This 
approach consists of the following formulas: 
• 1 
Wi - [Crw,)+r2] 
Where f2 = (Q - (k -l))/U 
{- S2 J 
and U = (k-1\W- ~ 
- W kY; 
and w= I i k 
j=1 
1 (k -2) and s~ =-- IW;2 -kw 
k -1 j=1 
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Appendix 4 Analysing survival curves 
A4.1 Introduction 
Data on 'time to event' parameters in the literature are often presented as survival 
curves, including disease-free or event-free survival curves. The process of collecting, 
analysing and inputting such data into decision models comprises three separate stages 
- collating the data from the literature, combining the data, and transforming the data to 
an appropriate format for inputting into a decision model. The following sections 
describe the process of incorporating data described in the form of survival curves into 
decision models. 
A4.2 Coliating the data 
Firstly, the survival estimates and the respective sample sizes must be collated. In cases 
where only graphical data are available the data represented by the curves can either be 
read directly off the presented curves or digitised images of the survival curves can be 
imported into a graphics package enabling a more exact measurement of the proportions 
[Earle and Wells, 2000]. The proportions experiencing an event during each time 
interval must be revised to reflect the proportion of patients remaining event free. To 
explain: the proportion of patients leaving health state A in any given period is read 
from survival curves as the proportion of the original patient cohort (in year 0) who 
experience an event. In a decision model, however, only the patients remaining in state 
A at the start of each time period sample from the assigned probability distribution 
describing the proportion of patients experiencing an event in the ensuing period. 
Applying the probabilities that relate to the original cohort to the cohort of patients 
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remaining in state A will systematically underestimate the number of patients leaving 
the state. 
Detailed information on censored data is rarely published in journals. To obtain a proxy 
for the numbers at risk for each time interval the following formula transforms the 
estimates from describing the proportion of the original cohort that leave a state to 
reflect the probability of the remaining cohort leaving a state. This approach has been 
shown to be the most reasonable assumption in the absence of information on censored 
data [Earle and Wells, 2000]: 
P[ t / .. h t] P[ event / originalcohort]. even remaznzngco or i = I 
P[remaining /originalcohortt 
where P[ event / remainingcohortt is the probability that a patient remaining in a state 
in year i will experience an event in year i; 
P[ event /originalcohortl is the probability that a patient in the original patient 
cohort will experience an event in year i; 
P[remaining /originalcohortl is the probability that a patient in the original 
patient cohort remains event free at the beginning of year i; 
A4.3 Combining the data 
Earle and Wells [2000] presented and compared five possible methods for combining. 
published survival curves. It was noted that the five methods produced similar results 
up to the point at which the trial with the shortest length of follow-up finished. The 
combination of trials with variable lengths of duration is common and a 
recommendation to restrict the combined curve to the duration of the shortest trial is 
unrealistic, especially for their incorporation into decision models. The preferred 
method when it is important to estimate survival beyond the shortest duration was 
termed the 'meta-analysis of failure time data' method (MFD). MFD involves pooling 
the number of patients at risk and the number of events in each time inter;aL from 
which the hazard and survival functions in each interval can be calculated. The process 
of pooling the data incorporates a weighting procedure based on the sample sizes of the 
respective studies. MFD was least affected by the need to extend the period of analysis 
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because it recalculates the number of subjects at risk at every time interval [Earle and 
Wells, 2000]. 
A4.4 Formatting the data 
Undertaking a MFD of alternative survival curves weights the data appropriately but it 
produces only a single aggregate survival curve. No measure of variation is produced 
that can be used to represent the uncertainty in the survival estimates. However. the 
MFD method can be adapted to either create datasets that comprise weighted 
probabilities of experiencing an event within specified time intervals, or to estimate the 
relevant parameters to fit beta distributions that infonn the probability of experiencing 
an event in each time period. To establish weighted datasets, the number of patients at 
risk and the number of events in each time interval reported by each identified study are 
documented separately to produce a range of estimates of the proportion of patients 
experiencing an event in each time interval. The individual estimates are weighted 
using the meta-analytic formulae presented in Appendix 3. More simply, the alpha and 
beta parameters for beta distributions are estimated as the number of patients 
experiencing an event and the number not experiencing an event within a period, 
respecti vel y . 
Bayesian distribution theory 
Appendix 5 Bayesian distribution theory 
AS.1 Introduction 
This appendix describes the process of specifying probability distributions for different 
types of parameters on the basis of theoretical considerations and presents the formulae 
employed to estimate the distribution's parameters using the available data, employing 
method of moments formulae. The process of updating the probability distributions 
derived from the available data to reflect the assumed impact of additional samples (as 
employed in the value of information (V 01) analysis) is also described. 
Both processes are grounded in Bayesian methodology, whereby the estimation of the 
input distributions combines a prior distribution with the additional information to 
produce a posterior distribution for the input parameters. To estimate the baseline 
probability distributions a non-informative prior distribution is usually assumed, which 
is updated with the data obtained from the literature review. For the Vol analysis the 
original probability distributions are treated as the prior distributions and are updated 
under the assumption that new data will not alter the mean value of the distribution, 
only the level of variation described by the distribution. 
The probability distributions that best represent different groups of input parameters are 
presented in the following sections. The first describes the specification of the beta 
distribution as a suitable representation of all input parameters that take the form of a 
proportion bounded by 0 and 1. The following sections link other clinical parameters 
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and cost parameters to the gamma distribution, whilst utility values are suitably 
described by a beta distribution. 
AS.2 Proportion parameters 
The following description is adapted from a text on Bayesian statistical inference 
[Iverson, 1984]. For the analysis of a population proportion (n) it is particularly 
convenient to look at functions that are polynomials in 1L Polynomials in 1t can be 
written as a product of three parts: a numerical constant (C), n to some exponent, and I-
n to some exponent. The general fonnula is: 
Which is the general expression for the beta distribution. The mean and standard 
deviation of the assumed distribution of n can be used to estimate the distribution 
parameters, a and b, using the fonnulae: 
which are calculated from the fact that: 
p = _a_ and b = p(l- p) 
a+b a+b+l 
These calculations may not estimate integer values for a and b but it is usual to round 
off the values to the nearest integer. If the relevant data represents a series of patients 
who have either experienced an event, or not, then a simpler method of estimating the 
parameters for the beta distribution invokes the Bayesian use of a non-infonnative prior 
distribution. If no prior infonnation is available a unifonn prior can be assumed with 
beta distribution parameters a = 1 and b = 1. The beta distribution parameters are 'x+a' 
and 'n-x+b', where x is the number of observations with the event of interest and n-x the 
number without the event. 
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A5.2.1 Updating the beta distribution 
To update the beta distribution to reflect additional data in a Vol analysis the mean 
value from the relevant sample is added to the original a and b proportionately. For 
example, the parameters for a prior beta distribution informed by a meta-analysis of a 
series of trials that reported 100 events in 300 patients would be a = 100, b = 200. If the 
mean value from a prospective sample of 100 is 0.25, the updated distribution 
parameters can be updated proportionately, i.e. a = 125, b = 275. 
AS.3 Non-proportions clinical parameters 
All clinical parameters within a Markov process are described as proportions, but in a 
DES model some clinical parameters may be described as event times. For example, in 
the case study DES model survival from metastases was described as the median length 
of survival, rather than the probability of dying in successive time periods. Discussing 
the specification of a posterior distribution for the mean value of a variable between any 
two extremes Iverson assumed that the variable has a normal distribution [Iverson, 
1984]. Assuming a non-informative prior distribution, the posterior distribution is 
informed solely by the mean and standard deviation of the observed data. However, the 
normal distribution is not bounded by zero and specifying a normal distribution for 
survival parameters may result in negative values being sampled. Alternatively, the 
gamma distribution is bounded by zero and provides a more flexible range of shapes for 
describing non-negative random variables [Rice, 1995]. The gamma distribution has 
appealing properties in that the distribution parameters a and f3 are linked to mean 
and variance [Berry and Stangl, 1996]: 
The distribution parameters can be back solved after specifying a mean and a variance 
for the specified distribution. 
A5.3.1 Updating the gamma distribution 
The easiest model for the likelihood function for event times is the Poisson distribution 
because it resembles a gamma density. The gamma distribution is a conjugate prior 
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when the observations are Poisson distributed. This means that the posterior is also a 
gamma distribution with updated parameters a + I t; and [n + 1/ pr!, where n is the 
increased sample and I t; is the sum of the survival times for the increased sample 
[Berger, 1980]. The original mean value can simply be used to fit the updated a 
parameter as It; = nt . 
Within the case study evaluation, the updated parameters of the gamma distribution 
[a + It;,[n + 1/ pr l ] were estimated assuming that the hypothetical data was Poisson 
distributed, which assumed that the mean of the data was equal to the variance. The 
hypothetical data may be over-dispersed compared to the Poisson distribution that 
explicitly acknowledged the similarity of the two means, which led to a much tighter 
posterior distribution. An alternative approach was to employ the negative binomial to 
update the Gamma distribution, which incorporated a dispersion factor specified as the 
ratio of the mean to the variance. Employing a dispersion factor would reduce the 
narrowness of the updated distribution, but the level of dispersion could only be 
subjectively specified. Despite the assumed narrowness of the resulting updated 
distributions, the Poisson distribution was employed to update Gamma distributions 
because the use of the negative binomial approach would have added further 
subjectivity to the Vol process. 
AS.4 Cost parameters 
Health care costs generally follow a skewed distribution for individual patients [Barber 
and Thompson, 1998; Delong and Simons, 1999], though Briggs and Gray [1998] found 
that a normal distribution was an adequate assumption for the sampling distribution of 
mean per patient costs. A number of authors have assumed that the logarithm of a cost 
is normally distributed, and the log-nonnal distribution has often been used to describe 
uncertainty in the mean value of cost parameters [pasta et al, 1999; Fenwick et a1. 
2000]. However, as cost parameters display similar properties to the event times 
described in the previous section the gamma distribution can also be chosen to describe 
cost parameters. 
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To estimate the distribution parameters for the baseline distribution in the case study 
evaluation, the mean and the standard deviation from the corresponding weighted 
dataset for each cost parameter were inserted into the formulae presented in the previous 
section. Updating the gamma distribution for cost parameters on the basis of additional 
(hypothetical) data also follows the procedure developed above for the non-proportions 
clinical parameters. In the case of cost parameters I ti becomes I C
i 
, where the Ci 
are the individual estimates of the cost parameter. Again, LC
i 
= nc. 
A5.5 Utility value parameters 
In the majority of cases, utility values are subject to the same constraints as proportions 
parameters - they are bounded between 0 and 1. The sample mean and standard 
deviation can be calculated and used to estimate the parameters of the beta distribution 
(a and b). If the assumption of zero as the minimum possible value of a utility value is 
not justified, it is unlikely that the upper bound of the utility value will approach 1. An 
adjustment solution may be possible, whereby the lowest possible utility value is 
specified, which is then added to each possible utility value in order to specify a beta 
distribution. The value added to fit the distribution is subtracted when applied to the 
relevant health state. For example, a range of -0.2 to +0.5 becomes a range of 0 to 0.7 
in order to fit the distribution. Alternatively, a scale parameter can be applied to the 
value sampled from the beta distribution to expand the range outside 0 to 1. To update 
the probability distributions describing utility values the same procedure is employed as 
for the proportions clinical data. 
A5.6 Estimating the standard deviation 
The discussion in the previous sections has assumed that a selection of data is available 
to estimate the standard deviation, which can be employed to estimate the chosen 
distributions' parameters. If, for example, one utility value estimate with no measure of 
variance is available, the required standard deviation can be estimated directly. 
Alternatively, it may be more intuitive to specify a range around the observed value. A 
standard deviation can be estimated as one quarter of the full range, which, together 
with assumed mean value, can be employed to estimate the parameters of the 
appropriate probability distribution. 
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Table A6.1 Details of studies reporting length of DFI following tamoxifen alone 
Percentages 
Study Ther- Regimen details DFI details* IBTR% IBTR% Lgth of f-up Age <50 50-9 60+ <66 65+ Pre Post 
apy reported assumed DFI m m 
[Fisher et ai, 1996] Tam 20mglday,5yrs DND and 2ndP 4 10 10.42 100 
[Fisher et ai, 1996] Tam 20mglday, 5yrs DND and 2ndP 4 10 10.42 50 50 
[Fisher et ai, 1997] Tam 20mglday, 5yrs DND and 2ndP 11 5 4.00 45 28 27 
[Pritchard et ai, 1997] Tam 30mglday,2yrs Neither DND or 2ndP 8 9 0 100 
[Stewart, 1992] Tam 20mglday, 5 yrs DND and likely not 2ndP 0 9 6.75 58 29 71 
[Ribeiro and Swindell, Tam 20mglday, 1 yr DNDonly 0 15 10.00 0 100 
1992] 
[Ribeiro and Swindell, Tam 20mglday, 1 yr DNDonly 0 15 10.00 100 0 
1992] 
[Cummings et ai, 1993] Tam 20mg/day, 2 yrs DND and likely 2ndP 0 12 10.00 70 0 100 
[Baum et aI, 1992] Tam+/- 20mg/day,2yrs, DND and contra' and likely ? 5 8 7.80 54.8 37 63 
peri-CT not2ndP 
[Gerard et ai, 1993] Tam 30mg/day, 3 yrs DND and likely not 2ndP ? 5 5 3.08 0 100 
[Rivkin et ai, 1994] Tam 20mg/day, 1 yr DNDonly 0 12 6.50 61 0 100 
[Castiglione-Gertsch et Tam + 20mglday, I yr, DND and 2ndP 0 14 10.00 lOa a 100 
aI, 1994] P 
[Castiglione-Gertsch et Tam + 20mg/day, I yr DND and 2ndP a 14 10.00 100 a 100 
ai, 1994] P 
[Mustacchi et ai, 1994] Tam 20mg/day die DND and 2ndP ? 5 6 3.08 76 0 100 
[Gundersen et ai, 1995] Tam 20mglday, 2 yrs Neither DND or 2ndP a 10 6.33 32 34 34 
[Martelli et aI, 1995] Tam 20mg/day, DND and 2ndP 9 6 5.58 77 0 100 
indefinitely 
IBTR% reported, % of events named as ipsilateral breast relapse ending OFI; IBTR% assumed, % of ipsilateral breast relapse assumcd to end OFI; f-up, foil 0 w-llP;PrclTl. prcmcllopausal; 
postm, postmenopausal . 
• DFI details describes whether studies included death with no evidence of disease (dnd) and 2nd primary tumours (2ndP) as ending DF/' 
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Table A6.1 Details of studies reporting length of D FI following tamoxifen alone (continued) 
Percentages 
Study Node + 1 to 3 4+ Node - T size SD pTl pT2 pT3+ pT2/3 ER+ PgR+ Mast Lump Lump RT 
positive positive +RT 
[Fisher et ai, 1996] 0 0 0 100 2 1 na 100 78 62 38 38 38 
[Fisher et ai, 1996] 0 0 0 100 2 1 na 100 78 62 38 38 38 
[Fisher et ai, 1997] 0 0 0 100 70 70 27 3 30 100 82 45 55 55 55 
[Pritchard et ai, 100 59 41 0 27 70 3 73 100 100 64 36 27 27 
1997] 
[Stewart, 1992] 0 0 0 100 36 59 5 64 63 100 0 0 0 
[Ribeiro and Swindell, 0 0 0 100 na 100 0 0 0 
1992] 
[Ribeiro and Swindell, 0 0 0 100 na 100 0 0 0 
1992] 
[Cummings et aI, 100 55 45 0 67 33 98 70 100 0 0 0 
1993] 
[Baum et ai, 1992] 42 58 28 72 
[Gerard et ai, 1993] 100 0 0 0 na 
[Rivkin et aI, 1994] 100 49 51 0 6 na 100 96 4 4 4 
[Castiglione-Gertsch 100 54 46 0 39 61 6 100 0 0 0 
et ai, 1994] 
[Castiglione-Gertsch 100 54 46 0 39 61 6 100 0 0 0 
et aI, 1994] 
[Mustacchi et aI, 42 30 - la 12 - Ib 58 41 54 5 59 
1994] 
[Gundersen et ai, 100 67 33 0 27 73 0 73 100 97 3 0 0 
1995] 
[Martelli et ai, 1995] 0 0 0 100 68 24 8 32 90 71 7 93 0 0 
ER+, estrogen receptor positive; PgR+, progesterone receptor positive; Mast., mastectomy; Lump., lumpectomy; RT, radiotherapy. 
• T refers to different tumour grades. 
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Table A6.2 Details of studies reporting length of DFI following tamoxifen and chemotherapy 
Study Therapy Regimen details DFS detailst IBTR% IBTR% Lgth of f-up age 
reported assumed D FI 
[Fisher et ai, 1997] Tam+MF 100-600, 6 cycles DND and2ndP 
DNDand2ndP 
Neither DND or 2ndP 
9 5 4.00 
[Fisher et ai, 1997] Tam+CMF 100-40-600, 6 cycles 4 5 4.00 
[Pritchard et ai, Tam + CMF 600-40-600, 8 cycles 3 9 
1997] 
[Tormey et ai, 1992] Tam + CMFP 10mglday, 1-5 yrs, DND only o 
100-40-600-40 
[Tormey et ai, 1992] Tam + 4.5-45-12 DND only o 
CMFPWVAT 
[Baum et ai, 1992] Tam/Tam+ peri- 20mglday,2yrs, DND and contra' and 
likely not 2ndP 
? 
CT 
[Gerard et ai, 1993] Tam + FEC 
[Gelber et ai, 1993] Tam + CMF 
[Hupperets et ai, CAF + MP A 
1993] 
[Rivkin et ai, 1994] 
[Schumacher et ai, 
1994] 
[Castigl ione-Gertsch 
et ai, 1994] 
Tam+CMFVP 
CMF(w/wo 
Tam) 
Tam+CMFP 
5mg/kg 6 days 
6 cycles (inc. Tam) 
500-40-500,6 cycles, 
MPA 6 months 
? 
DND and likely not 2ndP ? 
DND and unclear 2ndP 
DND and likely not 2ndP ? 
DND only 
500-40-600, 3 cycles DND and 2ndP 
o 
o 
(30mglday, 1 yr) 
100-40-600, 12 cycles DND and 2ndP o 
[Fukutomi et ai, Tam + ACMF 30mglday, 2 yrs, 26- DND and unclear 2ndP 0 
1995] 130-26-600, 6 cycles 
[Fukutomi et ai, Tam + ACMF 30mglday, 2 yrs, 13- DND and unclear 2ndP 0 
1995] 65-13-300, 12 cycles 
5 
5 
5 
5 
8 
8 
8 
5 
7 
8 
12 
6 
14 
7 
7 
5.10 42 
5.10 44 
7.80 54.8 
3.08 
7.00 
3.50 
6.50 60 
4.67 
10.00 
5.40 45 
5.40 45 
Percentages 
<50 50-9 60+ 65+ pre post 
45 29 26 
46 27 27 
42 30 28 
m m 
0 100 
100 0 
100 0 
37 
o 
o 
62 
o 
42 
o 
63 
100 
100 
38 
100 
58 
100 
100 0 
100 0 
lBTR% reported, % of events named as ipsilateral breast relapse ending DFI; lBTR% assumed, % of ipsilateral breast relapse assumed to end DFI; f-up, follow~up; prern, prcrncllopausil!: 
postm, postmenopausal. 
• DFI details describes whether studies included death with no evidence of disease (dnd) and 2nd primary tumours (2ndI') as ending DFI. 
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Table A6.2 Details of studies reporting length of DFI following tamoxifen and chemotherapy (continued) 
Percentages 
Study Node + 1 to 3 4+ Node - T size SD pTl pT2 pT3+ pT2/3 ER+ PgR+ Mast Lump Lump RT 
positive positive +RT 
[Fisher et ai, 1997] 0 0 0 100 68 68 29 3 32 100 83 45 55 55 55 
[Fisher et ai, 1997] 0 0 0 100 70 70 26 4 30 100 82 44 56 56 56 
[Pritchard et ai, 100 61 39 0 29 65 7 71 100 100 66 34 25 25 
1997] 
[Tormey et ai, 1992] 100 54 46 0 52 48 63 61 100 0 0 
[Tormey et ai, 1992] 100 53 47 0 52 48 63 65 100 0 0 
[Baum et aI, 1992] 42 58 28 72 
[Gerard et ai, 1993] 100 0 0 0 na 
[Gelber et aI, 1993] 100 0 0 0 na 
[Hupperets et aI, 100 68 32 0 32 58 10 68 66 
1993] 
[Rivkin et ai, 1994] 100 51 49 0 9 na 100 95 5 5 5 
[Schumacher et aI, 100 58 42 0 12 66 22 88 40 41 100 0 0 0 
1994] 
[Castiglione-Gertsch 100 58 42 0 36 64 75 100 0 0 0 
et aI, 1994] 
[Fukutomi et aI, 100 54 46 0 25 58 17 75 62 60 100 0 0 0 
1995] 
[Fukutomi et aI, 100 56 44 0 32 56 12 68 63 61 100 0 0 0 
1995] 
ER+, estrogen receptor positive; PgR+, progesterone receptor positive; Mast., mastectomy; Lump., lumpectomy; RT, radiotherapy. 
• T refers to different tumour grades. 
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Table A6.3 Details of studies reporting type of event experienced following tamoxifen alone 
Percentages 
Study Therapy Regimen Relapse details* f-up Age SD <40 40-65 <50 50-9 60+ <66 65+ Prem Postm 
details 
[Fisher et ai, 1996] Tam 20mglday, 5yrs L, r, con, dsep, pr, dnd 10.42 55 10 29 71 
[Fisher et ai, 1997] Tam 20mglday, 5yrs Lr, dagg, con, pr, dnd 4.00 45 28 27 
[Pritchard et ai, Tam 30mglday,2yrs L, Ir, dagg, con, pr 0 100 
1997] 
[Stewart, 1992] Tam 20mglday,5 Lr,con,dagg,dnd 6.75 100 0 
yrs 
[Stewart, 1992] Tam 20mglday,5 Lr, con, dagg, dnd 6.75 0 100 
yrs 
[Cummings et ai, Tam 20mglday,2 Lr,dsep,con,pr,dnd 10.00 70 0 100 
1993) yrs 
[Rivkin et ai, 1994] Tam 20mglday, I yr L, r, con, dsep, pr, dnd 6.50 61 0 100 
[Castiglione-Gertsch Tam+ P 20mglday, 1 yr, Lr, con, dsep, pr, dnd 10.00 100 0 100 
et ai, 1994) 
[Castiglione-Gertsch Tam+ P 20mglday, 1 yr, Lr, con, dsep, pr, dnd 10.00 100 0 100 
et ai, 1994] 
[Mustacchi et ai, Tam 20mglday die L,dagg,dnd 3.08 76 0 100 
1994] 
[Gundersen et ai, Tam+ 20mglday,2 L, r, con,'dagg, dnd 6.33 32 
1995) peri-op yrs 
CT 
[Martelli et ai, 1995) Tam 20mg/day, L, r, dagg, pr, dnd 5.58 77 0 100 
indefinitely 
[Kamby et ai, 1988] Tam 30mglday L, r, con, dsep 26 25 49 37 63 
1 year 
P, prednisolone; f-up, follow-up (years); SO, standard deviation; prem, premenopausal; postm, postmenopausal. 
Relapse details describe the types of relapse reported by each study: L, local; r, regional; Lr, locoregional; con, contralateral; dsep, separate sites of metastases; dagg, aggregate metastases; 
pr, primary tumours; dnd, death with no evidence of disease. 
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Table A6.3 Details of studies reporting type of event experienced following tamoxifen alone (continued) 
Percentages 
Study Node + 1 to 3 4+ Node- Tumour pTl* pT2* pT3+* pT2/3* ER+ PgR+ Mast. Lump. lump+R RT 
nodes nodes size T 
[Fisher et aI, 1996] 0 0 0 100 2 na 100 78 62 38 38 38 
[Fisher et ai, 1997] 0 0 0 100 70 27 3 30 100 82 45 55 55 55 
[Pritchard et ai, 100 59 41 0 27 70 3 73 100 100 64 36 27 27 
1997] 
[Stewart, 1992] 0 0 0 100 36 59 5 64 63 100 0 0 0 
[Stewart, 1992] 0 0 0 100 36 59 5 64 63 100 0 0 0 
[Cummings et ai, 100 55 45 0 67 33 98 70 100 0 0 0 
1993] 
[Rivkin et aI, 100 49 51 0 6 na 100 96 4 4 4 
1994] 
[ Castiglione- 100 54 46 0 39 61 6 
Gertsch et ai, 1994] 
[Castigl ione- 100 54 46 0 39 61 6 
Gertsch et ai, 1994] 
[Mustacchi et ai, 42 30 - la 12 - 1 b 58 41 54 5 59 
1994] 
[Gundersen et ai, 100 67 33 0 27 73 0 73 100 97 3 0 0 
1995] 
[Martelli et ai, 0 0 0 100 68 24 8 32 90 71 7 93 0 0 
1995] 
[Kamby et ai, 83 56 27 17 5 71 24 95 100 0 0 100 
1988] 
ER+, estrogen receptor positive; PgR+, progesterone recep-tor positive; Mast., mastectomy; Lump., lumpectomy; RT, radiotherapy. 
• T refers to different tumour grades. 
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Table A6.4 Details of studies reporting type of event experienced following tanioxifen and chemotherapy 
Study Therapy 
[Fisher et ai, 1997] Tam + MF 
[Fisher et ai, 1997] Tam + CMF 
[Pritchard et ai, Tam + CMF 
1997] 
[Tormey et ai, 
1992] 
Tam+CMFP 
Tam + 
CMFPHNAT 
Regimen details 
100-600, 6 cycles 
100-40-600, 6 cycles 
600-40-600,8 cycles 
10mg/day, 1-5 yrs, 100-40-
600-40 
4.5-45-12 [Tormey et ai, 
1992] 
[Lindeman et ai, 
1992] 
CMF (+tam in ER+) 100-40-600,60-40-600,6 or 
12 cycles 
Relapse details* f-up 
Lr,dagg, con, pr, dnd 4.00 
Lr, dagg, con, pr,dnd 4.00 
L, Ir, dagg, con, pr 
L, r, dsep, pr, dnd 5.10 
L, r, dsep, pr, dnd 5.10 
Lr, dsep 5.17 
[Rivkin et ai, 
1994] 
Tam +CMFVP 20mg/day, 1 yr,60/day 15-
400/week, 1 yr 
500-40-600,3 or 6 cycles 
(30mglday, 1 yr) 
100-40-600, 12 cycles 
L, r, con, dsep, pr, dnd 6.50 
[Schumacher et ai, CMF (w/wo Tam) 
1994] 
[Castiglione- Tam + CMFP 
Gertsch et ai, 1994] 
[Gundersen et ai, Tam (with peri-op 
1995] CT) 
[Fukutomi et ai, Tam + ACMF 
1995] 
[Fukutomi et ai, Tam + ACMF 
L, r, dagg, pr, dnd 
Lr,con,dsep,pr,dnd 
20mg/day, 2 yrs L,r,con,dagg,dnd 
3 Omg/ day, 2 yrs, 26-130-26- L, r, dsep 
600,6 cycles 
30mg/day, 2 yrs, 13-65-13- L, r, dsep 
300, 12 cycles 1995] 
[Powles et ai, 
1995] 
3M/2M + tamoxifen Mitom 7 every 6w, mitox 7 e L,r, dagg 
3w, meth 35 e 3w, 8 cycles, 
20mglday 5 years 
4.67 
10.00 
6.33 
5.40 
5.40 
2.33 
Proportions 
Age <50 50-9 60+ 65+ 
45 29 26 
46 27 27 
42 
44 
44 76 
60 
42 30 28 
32 
45 
45 
56 
Prem Postm 
0 100 
100 0 
100 0 
0 100 
42 58 
0 100 
100 o 
100 o 
40 60 
P, prednisolone; f-up, follow-up (years); SD, standard deviation; prem, premenopausal; postm, postmenopausal. --~ ~---
Relapse details describe the types of relapse reported by each study: L, local; r, regional; Lr, locoregional; con, contralateral; dsep, separate sites of metastases; dagg, aggregate metastases; 
pr, primary tumours; dnd, death with no evidence of disease. 
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Table A6.4 Details of studies reporting type of event experienced following tamoxifen and chemotherapy (continued) 
Percentages 
Study Node + 1 to 3 4+ Node - T size pTl pT2 pT3+ pT2/3 ER+ PgR+ Mast Lump Lump RT 
positive positive +RT 
[Fisher et ai, 1997] 0 0 0 100 68 68 29 3 32 100 83 45 55 55 55 
[Fisher et ai, 1997] 0 0 0 100 70 70 26 4 30 100 82 44 56 56 56 
[Pritchard et ai, 100 61 39 0 29 65 7 71 100 100 66 34 25 25 
1997] 
[Tonney et ai, 100 54 46 0 52 48 63 61 100 
1992] 
[Tonney et ai, 100 53 47 0 52 48 63 65 100 
1992] 
[Lindeman et ai, 100 73 27 0 3 53 na 56 100 0 0 0 
1992] 
[Rivkin et ai, 100 51 49 0 9 na 100 95 5 5 5 
1994] 
[Schumacher et ai, 100 58 42 0 12 66 22 88 40 41 100 0 0 0 
1994] 
[Castigl ione- 100 58 42 0 36 64 75 
Gertsch et ai, 1994] 
[Gundersen et ai, 100 67 33 0 27 73 0 73 100 97 3 0 0 
1995] 
[Fukutomi et ai, 100 54 46 0 25 58 17 75 62 60 100 0 0 0 
1995] 
[Fukutomi et ai, 100 56 44 0 32 56 12 68 63 61 100 0 0 0 
1995] 
[Powles et ai, 14 8 - la 6 - Ib 86 10 82 8 90 28 72 72 72 
1995] 
ER+, estrogen receptor positive; PgR+, progesterone receptor positive; Mast., mastectomy; Lump., lumpectomy; RI, radiotherapy. 
• T refers to different tumour grades. 
2')2 
Appendix 7 The input data 
Appendix 7 The in put data 
A 7.1 Introduction 
From the literature reVIew, data were collected for a wide range of patient groups 
experiencing early breast cancer, reflecting many patient characteristics (as described in 
Appendix 6). The process of examining the data to defined relevant sub-groups to evaluate 
was described in Chapter 4. From that process, the patient group chosen for the case study 
evaluation was postmenopausal women with node positive early breast cancer. The 
relevant therapy comparison for this patient group was defined as tamoxifen and 
chemotherapy versus tamoxifen alone. This Appendix describes the probability 
distributions used to populate the case study models, which were derived from the data 
analysis described in Chapter 5. 
The data are presented in the same order as the methods of data analysis were discussed, 
namely, the clinical parameter values are followed by the cost parameters, and then the 
utility values. 
A 7.2 Clinical parameters 
The clinical parameters consist of the different forms of toxicity, disease-free interval (DFI) 
and the clinical events ending DFI, and progress from relapse. Each are de sci bed in the 
following sections. 
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A 7.2.1 Toxicity parameters 
The data identified describing the probability of experiencing different categories of 
toxicity (major toxicity, grade 3 or 4 toxicity, and grade 1 or 2 toxicity), and the types of 
conditions included in each of the categories are described in the following sections. A 
final section describes the representation of treatment compliance, which was linked to the 
experience of toxicity. 
A7.2.1.1 Major toxic events 
Four studies were identified that presented data on major toxic events associated with 
tamoxifen and chemotherapy, including a total of 1964 patients [Tormey et aI, 1992; Rivkin 
et aI, 1994; Pritchard et aI, 1996; Fisher et aI, 1997]. The same number of studies was 
included in the analysis of major toxicity and tamoxifen, but the total number of patients 
was almost double (3733 patients) [Fisher et al, 1996a; Rivkin et al, 1994; Fisher et aI, 
1997; Pritchard et al, 1996]. Table A 7.1 presents the point estimates for the incidence of 
major toxicity for both therapy options alongside the number of patients included in each 
study, and the resulting weight attached to each estimate. A relatively wide range of 
estimates were identified for tamoxifen and chemotherapy that might reflect differences in 
the age and the burden of disease of the patients included in the respective trials, as these 
factors are known to have an impact on the incidence of thromboembolism [Pritchard et al, 
1996]. The tamoxifen figures are very small and there is not much scope for variation 
between the estimates. 
Table A 7.1 Point estimates, and corresponding sample size and weights, for data 
describing the experience of major toxicity 
Tamoxifen+chemotherapy Tamoxifen alone 
Data Sample Weight Data Sample Weight 
0.096 353 10 0.012 1422 29 
0.070 263 10 0.006 1188 49 
0.036 300 21 0.012 771 16 
0.045 778 43 0.014 352 6 
0.040 270 17 
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Table A7.2 shows the types of major toxic events that were experienced. Deep vem 
thrombosis (DVT) is clearly the prominent major toxic event. In patients receiving 
tamoxifen and chemotherapy all major events were thromboembolic, whilst a significant 
proportion of patients receiving tamoxifen alone experienced cardiac events. 
Table A 7.2 Proportion of specific major toxic events experienced by patients 
receiving alkylating drugs-based regimens 
Condition 
Pulmonary Embolism t 
Deep Vein Thrombosis 
Arterial Thrombosis 
Mesenteric Vein Thrombosis 
Unspecified cardiac event 
Total 
Tamoxifen+chemotherapy 
0.196 
0.741 
0.047 
0.016 
1.000 
t pulmonary infarction and embolism are included in this category 
A7.2.1.2 Grade 3 or 4 toxicity 
Tamoxifen alone 
0.l44 
0.462 
0.076 
0.318 
1.000 
The same four studies reporting major toxicity also presented grade 3 or 4 toxicity in 
patients receiving tamoxifen and chemotherapy, involving 1964 patients [Tormey et aI, 
1992; Rivkin et al, 1994; Pritchard et al, 1996; Fisher et al, 1997]. The largest study 
reporting on tamoxifen alone did not report grade 3 or 4 toxicity so only 1268 patients 
informed this analysis [Rivkin et al, 1994; Fisher et aI, 1997; Pritchard et al, 1997]. Table 
A 7.3 presents the separate point estimates for the incidence of grade 3 or 4 toxicity. The 
estimates for tamoxifen and chemotherapy appear stable apart from one low estimate, 
which came from the largest trial [Fisher et al, 1997]. The highest estimate for tamoxifen 
alone is 0.05, but the trial reporting this estimate was small relative to the remaining trials 
and the associated weight reduces it's impact [Rivkin et al, 1994]. 
Table A 7.3 Point estimates, and corresponding sample size and weights, for data 
describing the experience of grade 3/4 toxicity 
Tamoxifen+chemotherapy Tamoxifen alone 
Data Sample Weight Data Sample Weight 
0.482 353 16 0.003 352 59 
0.510 263 12 0.050 145 2 
0.500 270 12 0.010 771 39 
0.610 300 14 
0.250 768 46 
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The grade 3 or 4 toxicity conditions experienced are presented in table A 7.4. The total 
indicates the average number of conditions experienced by a single patient. The 
composition analysis was complicated by the studies that did not present an aggregate 
proportion experiencing grade 3 or 4 toxicity (see section 5.3.1). Using the maximum 
proportion as a proxy for the aggregate proportion overestimated the proportion of patients 
experiencing such conditions, though few resources were associated with two of the main 
events, leukopenia and thrombocytopenia, so the impact of the overestimation was reduced. 
Apart from these two conditions, the main toxicity for patients receiving tamoxifen and 
chemotherapy was nausea and vomiting. The dominance of infection in tamoxifen alone 
was initially surprising, but understandable given the very small incidence of grade 3 or 4 
toxicity. 
Table A 7.4 Proportions of patients experiencing toxicity conditions in the grade 3 
or 4 toxicity category. 
Condition 
N ausealvomiting 
Stomatitis/mucositis 
Diarrhea 
Leukopenia* 
Thrombocytopenia t 
Neurotoxicity~ 
Infection 
Neutropenia: 
Total 
Tamoxifen+chemotherapy 
0.280 
0.037 
0.108 
0.541 
0.259 
0.131 
0.09 
1.447 
* leucocyte is included in this toxicity condition. 
t includes platelet count < 50 x 109/L 
::: includes parestbesias/neuropatby 
A7.2.1.3 Grade 1 or 2 toxicity 
Tamoxifen alone 
0.266 
0.061 
0.278 
0.521 
0.061 
1.186 
Only three studies including tamoxifen and chemotherapy reported grade 1 or 2 toxicity, 
totalling 1421 patients [Rivkin et al, 1994; Pritchard et aI, 1996; Fisher et al, 1997]. Five 
trials with tamoxifen alone presented data on grade 1 or 2 toxicity with 2775 patients 
[Fisher et al, 1996a; Rivkin et aI, 1994; Fisher et aI, 1997; Pritchard et al, 1997; Bergman et 
al,1995]. Table A7.5 presents the separate point estimates for the incidence of grade 1 or 2 
toxicity. There was a large amount of variation in the tamoxifen and chemotherapy data 
but the low estimate of 0.34 was actually a maximum estimate used as a proxy for the 
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aggregate proportion (the proportion of patients experiencing mucositis) [Rivkin et at 
1994] and was almost certainly an underestimate. 
Table A 7.5 Point estimates, and corresponding sample size and weights for data 
describing the experience of grade 112 toxicity , 
Tamoxifen+chemotherapy Tamoxifen alone 
Data Sample Weight Data Sample Weight 
0.620 353 23 0.305 85 .., 
-' 
0.340 300 20 0.640 1422 41 
0.720 768 57 0.085 352 30 
0.300 145 5 
0.430 771 21 
The interpretation of the proportions presented for patients receiving tamoxifen alone is 
difficult. In disaggregating the data the lower proportions were reported in studies 
comparing tamoxifen with a chemotherapy-based treatment arm, which may be due to the 
choice of side effects reported. Comparing tamoxifen with a placebo the occurrence of hot 
flashes, vaginal discharge, fluid retention, and skin changes - all effects that may be 
described as hormonal - were described [Fisher et aI, 1996a]. Two other trials compared 
tamoxifen with a chemotherapy treatment arm, and of the hormonal conditions only 'hot 
flashes' was recorded [Pritchard et aI, 1997; Rivkin et al, 1994]. Fisher et al [1996] 
labelled side effects as 'undesirable sequelae' which gave no indication of their intensity 
and it is likely that only a small proportion would be classified as equivalent to a grade 1 or 
2 toxicity. 
Table A7.6 presents the conditions experienced within grade 1 or 2 toxicity. The data 
reported by one study was excluded from this analysis because the use of the maximum 
proportion led to impossibly high estimates of four conditions [Rivkin et al, 1994]. For 
patients receiving tamoxifen and chemotherapy leukopenia was common, though 
nausea/vomiting was by far the most common form of toxicity with real impact. Hot 
flushes and nausea/vomiting dominated the grade 1 or 2 conditions experienced for 
tamoxifen alone. 
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Table A 7.6 Proportions of patients experiencing toxicity conditions in the orade 1 
or 2 toxicity category. ~ '=' 
Condition 
Nausea/vomiting 
Stomatitis/mucositis 
Diarrhea 
Leukopenia* 
Anemia 
Constipation 
Thrombocytopenia t 
N eurotoxicityt 
Gran ulocytopenia 
Fatigue 
Hot flashes 
Vaginal discharge 
Superficial phlebitis 
Total 
Tamoxifen+chemotherapy 
0.619 
0.077 
0.024 
0.563 
0.210 
0.023 
0.233 
0.046 
1.794 
* leucocyte was included in this toxicity condition. 
t includes platelet count < 50 x 109/L 
t includes paresthesias/neuropathy 
A7.2.1.4 Treatment compliance 
Tamoxifen alone 
0.356 
0.003 
0.093 
0.004 
0.565 
0.246 
0.026 
1.294 
Aggregate proportions of patients completing specific cycles of chemotherapy were 
reported [Schumacher et al, 1994; Coombes et aI, 1996], but the length of treatment was not 
linked to the type of toxicity experienced. In order to model the relationship between non-
compliers and the severity of their toxicity experiences, it was assumed that those patients 
experiencing the worst toxicity would receive the fewest cycles of chemotherapy. Table 
A 7.7 describes the proportion of each class of toxicity receiving specific cycles of 
chemotherapy. 
Table A7.7 Assignment of compliance rates across types of toxicity experienced 
Chemotherapy Aggregate Grade 112 Grade 3/4 Major 
cycles proportions toxicities toxicities toxicities 
receiving specific (0.57) (0.38) (0.05) 
cycles 
1 0.0055 0.00 0.00 0.11 
2 0.0055 0.00 0.00 0.11 
3 0.045 0.00 0.07 0.39 
4 0.0375 0.00 0.05 0.39 
5 0.0375 0.00 0.10 0.00 
6 0.869 1.00 0.79 0.00 
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Only four studies referred to treatment compliance for tamoxifen alone. Three of these 
studies were review papers [Bryson and Plosker, 1993; EBCTCG, 1998; J aiy esimi et al. 
1995], whilst one reported findings from a trial containing 352 patients receiving tamoxifen 
only [Pritchard et aI, 1997]. The latter reports a discontinuation proportion of 0.04. whilst 
the figures in the reviews range from 0.03 to 0.05, with only seldom exceptions. One 
review paper cited a large trial in which about 20% of women either failed to start 
tamoxifen or discontinued it prematurely [EBCTCG, 1998], whilst another study found that 
100/0 of patients did not complete 1 year due to side effects [Jaiyesimi et al, 1995]. 
A7.2.2 Diseasefree interval and clinical events ending DFI 
Input distributions were specified for each year following primary surgery for the analysis 
of DFI, and for each type of event for the clinical events ending DF!. Table A 7.8 presents 
the separate estimates of the proportions leaving DFI in each year following diagnosis, 
whilst Figure A 7.1 shows the aggregate survival curves for each therapy option. Table 
A 7.9 presents the separate estimates for the proportions of patients experiencing the 
alternative events that follow DFI. 
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Table A7.8 Point estimates and corresponding sample sizes, for data describing the annual probability of the 
remaining cohort leaving the health state' disease free interval' 
Tamoxifen+ chemotherapy 
Year 1* 2* 3* 4* 5* 6* 7* 
[Pritchard et aI, 1997] 0.930 352 0.076 327 0.113 303 0.057 268 0.135 253 0.191 219 0.107 177 
[Gerard et aI, 1993] 0.970 182 0.074 176 0.057 163 0.036 154 0.007 148 
[Gelber et ai, 1993] 0.924 341 0.103 315 0.149 283 0.081 241 0.095 221 0.057 200 0.086 189 
[Jansen et ai, 1998] 0.960 303 0.073 291 0.135 270 0.117 233 0.118 206 0.067 182 0.071 170 
[Castiglione-Gertsch et ai, 0.887 97 0.137 86 0.123 74 0.042 65 0.087 62 0.064 57 0.034 53 
1994] 
Year 8 9 10 11 12 13 14 
[Pritchard et aI, 1997] 0.168 158 0.029 132 
[Gerard et aI, 1993] 
[Gelber et aI, 1993] 
[J an sen et aI, 1998] 0.058 158 0.061 148 0.130 139 0.025 121 0.000 118 
[Castiglione-Gertsch et aI, 0.124 52 0.081 45 0.033 41 0.011 40 0.023 40 0.023 39 0.000 38 
1994] 
Tamoxifen alone 
Year 1* 2* 3* 4* 5* 6* 7* 
[Pritchard et aI, 1997] 0.896 353 0.093 316 0.090 287 0.070 261 0.136 243 0.052 210 0.111 199 
[Gerard et aI, 1993] 0.947 192 0.088 182 0.066 166 0.057 155 0.010 146 
[Jansen et aI, 1998] 0.940 295 0.106 277 0.119 248 0.149 218 0.111 186 0.089 165 0.078 150 
[Castiglione-Gertsch et aI, 0.763 116 0.174 89 0.135 73 0.087 63 0.114 58 0.075 51 0.046 47 
1994] 
Year 8 9 10 11 12 13 14 
[Pritchard et aI, 1997] 0.062 177 0.044 166 
[Gerard et aI, 1993] 
[Jansen et ai, 1998] 0.085 139 0.186 127 0.029 103 0.118 100 0.100 89 
[Castiglione-Gertsch et aI, 0.085 45 0.053 41 0.056 39 0.030 37 0.015 36 0.016 35 0.032 35 
1994] 
• The two columns represents the reported value and the sample. The corresponding weights are not displayed, but they can be estimated using the following formula 
p;(I- p;) 
11, 
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Figure A 7.1 Disease-free survival curves for tamoxifen and chemotherapy, and for tamoxifen alone, as 
adjuvant therapies for node-positive, postmenopausal women with early breast cancer 
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Table A 7.9 Point estimates and corresponding sample sizes and weights, for data describing the destination state of 
patients leaving the health state' disease free interval' 
Tamoxifen+chemotherapy Locoregional * Soft tissue* Bone* Visceral* DNED* 
[Pritchard et aI, 1997] 0.332 160 721 0.080 160 2171 
[Rivkin et aI, 1994] 0.223 141 814 0.344 141 625 0.297 141 675 0.006 141 23140 
[Castiglione-Gertsch et ai, 0.254 91 479 0.034 91 2774 0.271 91 460 0.305 91 429 0.136 91 775 
1994] 
Tamoxifen alone Locoregional * Soft tissue* Bone* Visceral* DNED* 
[Pritchard et aI, 1997] 0.355 160 700 0.040 160 4178 
[Rivkin et aI, 1994] 0.320 150 689 0.330 150 678 0.310 150 701 0.113 150 1490 
[Castiglione-Gertsch et aI, 0.306 110 519 0.014 110 8043 0.306 110 519 0.306 Ito 519 0.056 110 2100 
1994] 
• The three columns represents the reported value, the sample, and the corresponding weight applied to the value 
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A 7.2.3 Progress from relapse 
The data describing progression from relapse is presented separately for progression from 
locoregional relapse and from metastases. 
A7.2.3.l LocoregionaI relapse 
Nine studies presented data on the time to metastatic dissemination of locoregional relapse 
[Kamby and Sengelov, 1997; Bomer et aI, 1996; Crowe et ai, 1991; Beck et al, 1983; 
Janjan et aI, 1986; Bedwinek et aI, 1981; Schwaibold et ai, 1991; Toonkel et al, 1983; Toi 
et aI, 1997]. The representation of the time spent in remission (disease-free survival (DFS)) 
following a 10coregionaI relapse was the major difference between the two modelling 
techniques - the Markov process and the DES model. In the DES modeL DFS was 
represented in an identical manner to the representation of DFI, but in the Markov process 
it was only possible to describe DFS as a constant probability of experiencing a further 
relapse (see section 5.4.3). The raw data employed to represent DFS is presented in Table 
A 7.10, whilst the mean survival curve is presented in Figure A 7.1. 
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Table A7.10 Point estimates and corresponding sample sizes, for data describing the annual probability of the 
remaining cohort leaving the health state 'remission' 
Year 1* 2* 3* 4* 5* 
[Bomer et ai, 1996) 0.740 61 317 0.470 45 181 0.390 29 121 0.320 24 109 0.290 20 95 
[Bomer et ai, 1996) 0.850 71 557 0.760 60 331 0.700 54 257 0.650 50 218 0.600 46 192 
[Crowe et ai, 1991] 0.570 81 330 0.325 46 210 0.260 26 137 0.200 21 132 0.150 16 127 
[Beck et ai, 1983) 0.670 121 547 0.400 81 338 0.315 48 224 0.250 38 203 0.200 30 189 
[Janjan et ai, 1986) 0.650 57 251 0.480 37 148 0.325 27 125 0.300 19 88 0.225 17 98 
[Janjan et ai, 1986) 0.850 50 392 0.570 43 173 0.460 29 115 0.370 23 99 0.370 19 79 
[Janjan et aI, 1986] 0.850 57 447 0.550 48 196 0.400 31 131 0.350 23 100 0.325 20 91 
[Bedwinek et aI, 1981] 0.760 32 175 0.630 24 104 0.510 20 81 0.400 16 68 0.360 13 56 
[Schwaibold et aI, 1991] 0.652 128 564 0.460 83 336 0.343 59 261 0.297 44 210 0.235 38 211 
[Toonkel et aI, 1983] 0.835 124 900 0.505 104 414 0.355 63 273 0.335 44 198 0.250 42 222 
Year 6* 7* 8* 9* 10* 
[Bomer et ai, 1996] 0.290 18 86 0.290 18 86 0.290 18 86 0.290 18 86 0.290 18 86 
[Bomer et ai, 1996] 0.540 43 171 0.540 38 154 0.480 38 154 0.400 34 142 0.400 28 118 
[Crowe et aI, 1991] 0.125 12 111 0.100 10 113 0.100 8 90 0.100 8 90 0.090 8 99 
[Beck et ai, 1983] 0.170 24 172 0.150 21 161 0.105 18 193 0.105 13 135 0.105 13 135 
[Janjan et ai, 1986] 0.190 13 83 0.190 11 70 0.190 11 70 0.190 I I 70 
[Janjan et aI, 1986] 0.325 19 84 0.325 16 74 0.325 16 74 0.325 16 74 0.325 16 74 
[Janjan et ai, 1986] 0.300 19 88 0.300 17 81 0.300 17 81 
[Bedwinek et ai, 1981] 0.230 12 65 0.200 7 46 0.200 6 40 0.150 6 50 0.150 5 38 
[Schwaibold et ai, 1991] 
[Toonkel et aI, 1983] 
• The three columns represents the reported value, the sample, and the corresponding weight applied to the value. 
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A7.2.3.2 Metastases 
Substantial amounts of data describing the median length of survival from the point of 
diagnosis with metastases were identified. From clinical trials comparing alternative 
therapies for metastatic cancer, 113 separate treatment arms containing patients diagnosed 
with metastases were identified. 68 reported the component proportions of the different 
metastatic sites, whilst the remaining treatment arms reported data on individual sites - 11 
soft tissue, 15 bone and 19 visceral. Given the reasonable number of studies reporting 
separate survival times for the three metastatic sites, survival data on specific metastatic 
sites were used to estimate median survival times. No information other than median 
survival times were presented in the vast majority of studies reporting such data, no attempt 
was made to estimate mean survival. 
A number of studies presented data on survival from metastases differentiating with respect 
to nodal status [Koenders et aI, 1992; Venturini et aI, 1996]ER status receptor [Koenders et 
aI, 1992; Vogel et aI, 1992; Alonso et ai, 1995 ; Venturini et aI, 19961 PgR receptor status 
[Koenders et aI, 1992], menopausal status [Venturini et al, 1996], and the administration of 
prior adjuvant therapies [de Takats et ai, 1993; Venturini et aI, 1996]. These data were 
used to estimate survival multipliers for different patients groups. For example, node 
negative patients with visceral metastases were estimated to live 33 per cent longer than the 
average survival length for visceral metastases, conversely node positive patients lived 33 
per cent less than the average. Table A 7.11 presents the patient categories and their 
associated multipliers for node positive patients. 
Table A 7.11 Survival from metastases multipliers for node positive patients 
Patient group 
Node positive 
Soft tissue 
0.82 
Bone 
0.82 
Visceral 
0.67 
The respective multipliers were applied to the individual estimates of survival derived from 
the identified studies. The identified data for the three metastatic sites are presented in 
Table A7.I2. 
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Table A 7.12 Point estimates and corresponding sample sizes, for data describing 
median survival from the metastatic health states 
Soft tissue Data Sample Visceral Data Sample 
[Koenders et aI, 1992] 33.62 52 [Koenders et aI, 1992] 10.72 137 [Vogel et aI, 1992] 38.54 70 [Vogel et aI, 1992] 10.72 75 [Alonso et aI, 1995] 16.40 32 [Goldhirsch et aI, 1988] 8.78 24 
[Alonso et aI, 1995] 16.40 30 [Goldhirsch et aI, 1988] 8.31 14 
[Goldhirsch et aI, 1988] 11.56 26 [Kamby et aI, 1988] 7.73 361 
[Leonard et aI, 1994] 12.30 42 [Clark et aI, 1987] 9.38 386 
[Kamby et aI, 1988] 34.06 277 [Paridaens et aI, 1993] 14.22 42 
[Clark et aI, 1987] 32.64 284 [paridaens et aI, 1993] 14.22 41 
[Paridaens et aI, 1993] 27.06 13 [Castiglione-Gertsch et aI, 1997] 8.04 34 
[Paridaens et aI, 1993] 27.06 15 [Alonso et aI, 1995] 8.04 71 
[Castiglione-Gertsch et aI, 1997] 26.08 52 [Alonso et aI, 1995] 8.04 55 
Bone Data Sample [Leonard et aI, 1994] 6.70 55 
[Koenders et aI, 1992] 27.88 70 [Arai et aI, 1994] 8.38 56 
[Vogel et aI, 1992] 19.68 48 [Goldhirsch et aI, 1988] 3.62 18 
[Rasmusson et aI, 1995] 9.84 100 [Goldhirsch et aI, 1988] 5.09 16 
[Rasmusson et aI, 1995] 9.02 100 [Coleman and Rubens, 1987] 1.01 75 
[Alonso et aI, 1995] 16.40 23 [Leonard et aI, 1994] 5.36 55 
[Alonso et aI, 1995] 16.40 39 [Kocher et aI, 1995] 2.14 190 
[Goldhirsch et aI, 1988] 17.88 90 [Kocher et aI, 1995] 8.04 45 
[Goldhirsch et aI, 1988] 12.87 22 
[Coleman and Rubens, 1987] 19.68 150 
[Kamby et aI, 1988] 17.03 225 
[Clark et aI, 1987] 17.55 274 
[Paridaens et aI, 1993] 25.17 27 
[Paridaens et aI, 1993] 25.17 19 
[Castiglione-Gertsch et aI, 1997] 20.66 10 
Estimates of the time to progression (TTP) were required indirectly for the model, in order 
to calculate the monthly costs of the metastases states (see section 5.4.4.4). Three 
categories of patients were specified for whom data describing TTP were required: Patients 
receiving hormonal therapy for bone and soft tissue metastases; chemotherapy for visceral 
metastases; and chemotherapy for bone and soft tissue metastases. Fewer trials presented 
data on the TTP or TTF. For example, TTP estimates were available for only 2 of the 19 
treatment arms presenting specific data on survival from visceral metastases. TTP was 
estimated, therefore, using all studies in which a single metastatic site was dominant in over 
50% of patients. Table A 7.13 presents the separate point estimates of the median TIP for 
the three identified patient groups. 
266 
Appendix 7 The input data 
Tab~e A 7:13 Point esti~ates and corresponding sample sizes, for data describing 
median time to progressIOn from the metastatic health states 
Bone/Soft tissue (honnonal) Visceral (chemotherapy) 
[Pyrhonen et ai, 1997] 7.30 214 [Swain et aI, 1997] 8.55 168 
[Pyrhonen et aI, 1997] 10.20 201 [Swain et aI, 1997] 8.55 181 
[Pyrhonen et aI, 1997] 6.00 91 [Swain et aI, 1997] 7.73 81 
[Muss et aI, 1994] 6.50 91 [Swain et aI, 1997] 7.73 104 
[Jonat et aI, 1995] 5.31 159 [Gabra et aI, 1996] 10.00 56 
[Jonat et aI, 1995] 6.46 159 [Stewart et aI, 1997] 5.30 128 
[Thurlimann et aI, 1996] 19.80 107 [Stewart et aI, 1997] 3.20 121 
[Thurlimann et aI, 1996] 15.00 105 [Richards et aI, 1992] 4.00 28 
[Hayes et aI, 1995] 5.75 215 [Richards et aI, 1992] 5.00 31 
[Hayes et aI, 1995] 5.52 221 [BIomqvist et aI, 1993] 9.20 86 
[Hayes et aI, 1995] 5.49 212 [BIomqvist et aI, 1993] 5.40 84 
Bone/Soft tissue (chemotherapy) [Ingle et aI, 1994] 4.10 80 
[Jones et aI, 1995] 2.77 115 [Ingle et aI, 1994] 4.30 83 
[Jones et aI, 1995] 1.85 64 [Venturini et aI, 1996] 9.80 326 
[Pavesi et aI, 1995] 8.50 71 [Paridaens et aI, 1993] 13.85 82 
[Pavesi et aI, 1995] 7.50 70 [Ibrahim et aI, 1996] 12.00 767 
[Cobau et aI, 1996] 7.00 135 [Ibrahim et aI, 1996] 10.50 244 
[Cobau et aI, 1996] 4.00 131 
[Bastholt et aI, 1996] 4.40 75 
[Bastholt et aI, 1996] 4.70 66 
[Bastholt et aI, 1996] 8.40 64 
[Bastholt et aI, 1996] 8.40 58 
[Aisner et aI, 1995] 8.24 165 
[Aisner et aI, 1995] 8.48 164 
[Aisner et aI, 1995] 8.90 162 
[Chu et aI, 1996] 2.77 21 
[Paridaens et aI, 1993] 8.28 73 
A 7.3 Cost parameters 
Four categories of cost parameters are presented In the following sections: adjuvant 
therapies, surveillance, toxicity, and relapse. 
A 7.3.1 Adjuvant therapies 
To represent the cost of chemotherapy pnmary cost estimates for the individual 
components of chemotherapy were identified, as well as aggregate estimates derived 
directly from the literature. For the former, three resource elements were identified -
drugs, anti-emetics and administration. Drug costs were based on protocols presented in 
the literature, unit costs from various sources were then applied to the protocol to estimate 
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total drug costs. Tamoxifen is self-administered so no costs other than the cost of the 
treatment itself were considered. Table A7.l4 presents the baseline estimates for the 
alternative adjuvant therapies. 
Table A 7.14 Adjuvant therapy costs 
Therapy and source Constituents * Unit cost (£'s) Cost (£'s) 
Milan regimen 
20/30mg 0.12/0.22 3.60/6.54 per month 
Cyclophosphamide 100mg/m2 days 1-14 0.11 - 50mg 4.93 per cycle 
Methotrexate 40 mg/m2 days 1&8 iv. 2.62 - 50mg 10.48 per cycle 
5-Fluorouracil 600 mg/m2 days 1&8 iv. 3.20 - 250mg 19.20 per cycle 
Tamoxifen 
CMF) - standard 
Cyclophosphamide 400 mg/m2 day 1 iv. 1.65 - 200mg 3.30 per cycle 
Adriamycin 40 mg/m2 day 1 iv. 20.60-10mg 82.40 per cycle 
5-Fluorouracil400 mg/m2 days 1&8 iv. 3.20 - 250mg 12.80 per cycle 
* All costs taken from British National Formulary, apart from cost of fraction of radiotherapy [Warde and Murphy. 1996], 
outpatient visit (see text) and surgical oophorectomy (national schedule of reference costs), which are from an NHS 
Trust. The average female body surface was assumed to be 1.6m2. 
t Second year costs have been discounted at 6% 
1 [Fisher et aI, 1996b] 
2 [Alonso et aI, 1995] 
The use of standard anti-emetics alongside the chemotherapy regimens was not reported in 
any study, but a handbook published by the Royal Marsden NHS Trust provided details of 
appropriate schedules [Price et ai, 1995]. Estimates of the necessary inputs from health 
professionals to the administration of chemotherapy were sought from clinicians. Two 
studies were identified that presented the cost of disposable items employed in the 
administration of chemotherapy, and associated laboratory tests, such as blood tests for 
monitoring tumours [Lober et ai, 1988; Lokich et aI, 1996]. Disposable items included 
syringes, drug reservoirs, intravenous tubings, and solutions. 
The cost of an outpatient visit was a key unit cost in calculating the cost of the adjuvant 
therapies. Using data collected by the Institute of Public Finance estimates of net 
expenditure on outpatient attendances within Medical Oncology specialities were divided 
by the number of outpatient visits to estimate a mean cost per outpatient attendance 
[CIPFA, 1999]. Data were available from 100 Trusts, leading to an average cost of £86.35, 
though the standard deviation of £89.84 highlights a wide range of variation. 
268 
Appendix 7 
The input data 
Table A7.14 presents the resource use estimated for standard anti-emetics administered 
alongside the chemotherapy, the assumed health service contact per cycle of chemotherapy. 
and the disposable items employed per cycle. 
Table A7.14 Estimates for anti-emetic schedules for CMF and eAF regimens per 
cycle, disposable items, and clinicians for health professional's time 
CMF Unit cost (£'s) Cost (£'s) CAF Unit cost (£'5) Cost (£'5) 
Dexamethasone 8mg 1.27 - 8mg 2.54 Granisetron Img iv 12.00 - Img 12.00 
iv days 1+8 
Dexamethasone 2mg 
po tds for 3 days 
following days 1 +8 
Domperidone 20mg po 
qds for 3 days 
following days 1 +8 
Folonic acid 15mg 
q.d.s. 3 days 
Disposab les! 
Tests! 
2 breast clinic visit 
Total 
0.085 -2mg 
0.17-20mg 
3.71 -15mg 
1.53 
4.08 
44.52 
14.47 
10.49 
172.70 
250.33 
Dexamethasone 
8mg iv 
Dexamethasone 
4mg po tds for 3 
days 
Domperidone 20mg 
po qds for 3 days 
Disposables2 
Tests! 
1 breast clinic visit 
1.27 - Smg 
0.17 -4mg 
0.17 -20mg 
1.27 
1.53 
2.04 
11.31 
10.49 
86.35 
124.99 
'" Drug costs taken from the British National Formulary 
1 [Lober et aI, 1988] Costs are converted using 1987 Danish crowns:£ exchange rate, and uprated to 1999 levels. 
Laboratory test costs are taken as the difference between the total lab test costs for CMF and the total lab test costs for 
the control group. 
2 [Lokich et aI, 1996], Charges are converted using 1995 $:£ exchange rate, and uprated to 1999 levels. Clinic visits 
incorporate the administration of the drugs. 
The baseline cost for a cycle of chemotherapy was calculated separately for an alkylating 
drugs-based regimen (CMF) and a cytotoxic antibiotics-based regimen (CAF), which are 
presented in Table A7.1S. 
Table A7.15 Total costs per cycle for CMF and CAF chemotherapy regimens 
Components CMF (£'s) CAF (£'s) 
Chemotherapeutic drugs 34.61 98.50 
Anti-emetic drugs 52.67 16.84 
Disposables 14.47 11.31 
Tests 10.49 10.49 
Clinic visits 172.70 86.35 
Total 284.94 223.49 
The cost of chemotherapy is an integral parameter in the model and a wide search for 
alternative estimates of the cost of a cycle was undertaken. Aggregate estimates combining 
the individual components, as well as the identified aggregated estimates are presented in 
Table A7.16. 
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Table A7.16 Cost estimates of cycle of chemotherapy 
Method Source Rank Weight Cost 
Separate CMF, baseline 1 10 28.+.9'+ 
CAF, baseline 2 9 226.65 
CMF, baseline (1 clinic visit) " 8 198.59 ,j 
CMF, health professionals time costs 1 6 5 141.86 
CMF, health professionals time costs2 7 4 700.46 
CAF, health professionals time costs2 8 " 467.60 ;) 
Aggregate NHS reference cost (HRG v.3) 4 7 269 
E Anglia Trust cost 5 6 67 
cosf CMF 9 2 596 
cosf CAF 10 648 
[Lober et aI, 1988], 2 [Lokich et ai, 1996], 3 [Silva and Zurrida, 1999] 
Tamoxifen, 30mg/day, costs less than £7.00 per month, so no distribution was specified for 
such a small total cost, which is incurred by the majority of patients. 
A7.3.2 Surveillance 
Table A 7.17 describes a selection of the follow-up schedules employed to survey patients 
in the absence of symptoms following primary surgery, and their associated costs. 
Table A 7.17 Components of follow-up reported in the literature for patients with no 
symptoms of disease 
Treatment anns Physical exam Biochemical Chest & bone Mammograms Electrocar Total 
tests x-rays -diograms 
Unit costs 89.55* 7.081 122.911 11.292 16.94~ 
12 cycles CMF I 3 weekly for 9 6 monthly for 6 monthly Annually 
controe months, then 6 3 years, then 
monthly annually 
First yeart 97.28 1.17 20.49 0.94 0.00 119.88 
Subsequent years t 14.93 0.59 20.49 0.94 0.00 36.95 
Radiotherapy I 3 monthly for 2 Only in case Only in case of Annually 
Chemotherapy I years, 6 of symptoms symptoms 
Tamoxifen4 monthly to 5 
years, then 
annually 
First yeart 29.85 0.00 0.00 0.94 0.00 30.79 
Subsequent years t 14.93 0.00 0.00 0.94 0.00 15.87 
12 cycles A/CMF5 3 weekly for 1 6 monthly for 6 monthly for Annually Annually 
year, 6 monthly five years, five years, then from end of 
to 5 years, then then annually annually 1 year 
annually 
119.88 First yeart 97.28 1.17 20.49 0.94 0.00 
Subsequent years t 14.93 1.17 20.49 0.94 1.41 38.94 
• Physical exam is assumed to incorporate a visit to a breast clinic or a medical oncology outpatient visit. 
t cost per month. 
t Hospital Trust finance department. 
I [Robertson et ai, 1995], 2 [Johnston et al, 1998], 3 [Zambetti et al, 1992], 4 [Arriagada et ai, 1992], S [Bonadonna et al. 
1995] 
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An UK-based study compared two options for the surveillance of patients \\lth metastatic 
breast cancer [Robertson et aI, 1995]. The reported costs are presented in table A 7.18. The 
surveillance costs following a locoregional or a metastatic relapse were assumed to be the 
same, and the four estimates reported were entered into a discrete uniform distribution. 
Table A 7.18 Annual surveillance costs reported by Robertson et al199S1 
Year VICC assessment 
One 441.57 
Two and beyond 304.62 
UICC - the International Union against Cancer. 
1 [Robertson et aI, 1995] 
A 7. 3. 3 Toxicity parameters 
Serum marker assessment 
252.50 
123.50 
The costs of toxicity were estimated separately for the different categories of toxicity 
severity, for both adjuvant therapies. Within each category, a weighted cost was estimated 
that reflected the proportion of patients experiencing the various conditions defined within 
the group (see section A7.2). Various conditions that required inpatient episodes were 
specified within the major toxicity category. Cost estimates for each event were identified 
through a search of the NBS economic evaluation database [NHS Economic Evaluation 
Database], and the Office of Health Economics' economic evaluation database [OHE 
Health Economic Evaluations Database]. One Italian study provided adequate estimates for 
both life threatening (massive) Pulmonary Embolism (PE) and Deep Vein Thrombosis 
(DVT) [Lloyd et al, 1997]. The presented costs were converted to 1994 pounds, and 
uprated to £4036.80 and £1653.97, respectively. Holloway et al presented inpatient costs 
of four cerebrovascular events, of which 'ischemic cerebral infarction' and 'transient 
ischemic attack' were taken as the closest to the types of events experienced as a 
consequence of chemotherapy [Holloway et al, 1996]. The mean costs of the two events 
were £5981.06 and £2816.22, converted from US dollars and uprated from 1992 values. 
Finally, Quirk et al compared the cost of treating acute upper gastrointestinal bleeding by 
physician speciality [Quirk et al, 1997]. The cost of being treated by a gastroenterologist 
was £1900.42, converted from US dollars and uprated from 1995 values, which was the 
lowest estimate. Table A 7.19 presents the resulting composition for major toxic events. 
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Table A 7.19 Health events included in the major toxicity category, and related cost 
estimates 
Major toxic events Cost 
Pulmonary Embolism 
Thrombosis 
Tamoxifen 
alone 
Chemotherapy 
alone 
Chemotherapy+ 
Tamoxifen Estimate (£'s) 
Myocardial infarction 
Cerebral vascular accident 
Thromboembolic event* 
0.144 
0.538 
Cardiac event* 0.318 
0.235 
0.336 
0.030 
0.180 
0.099 
Gastrointestinal bleeding 0.120 
0.196 
0.794 
Weighted cost (£'s) 2870 3153 2105 
* unspecified, cost taken as the weighted mean of the other thromboembolic/cardiac events 
.f037 
1654 
2816 
5981 
2633 
4398 
1900 
Table A7.20 presents detailed information on the anti-emetics used to control nausea and 
vomiting, arid the anti-biotics associated with infection. Table A7.21 describes the 
assumptions made with respect to the treatment of all conditions included in the graded 
toxicity categories, and their respective costs. 
Table A 7.20 Components and costs of the treatment for nausea/vomiting and 
infection 
Cost component Unit cost Grade 1 or 2 Cost 
(£'s) (£'s) toxicity 
N ausealvom iting 
Ondansetron Smg i.v. 13.50 8mg per cycle 13.50 
Dexamethasone Smg i.v. 1.76 8mg per cycle 1.76 
Metoclopramide 10mg po 0.11 
Lorazepam 2mg 0.02 
Total per cycle 15.26 
Infection 
Gentamicin, 2mL vial (SOmg) 1.54 
Ceftazidime, 2g vial 19.80 
Total 
Grade 3 or 4 toxicity 
16mg per cycle 
16mg per cycle 
180mg per cycle 
2mg per day 
240mglday for 7 days 
4g1day for 7 days 
Cost 
(£'s) 
27.00 
3.52 
2.01 
0.54 
33.07 
32.34 
277.20 
309.54 
Table 21 Health events included in the graded toxicity categories, and related cost and utility estimates 
Graded events Grade 3 or 4 treatment Tamoxifen Tam+Che Grade 1 or 2 treatment Tamoxifen Tam+Che 
Propo- Cost Propo- Cost per Propo Cost Propo Cost 
rtion per rtion cycle -rtion per -11ion per 
cycle cycle cycle 
Nausea/vomiting Anti-emetics, 4 days 0.266 8.80 0.567 18.75 Anti-emetics, 4 days 0.356 5.43 0.850 15.26 
following each cycle following each cycle 
Stomatitis/mucositis Mouth washes, 7 days 0.166 0.19 No treatment 0.003 0.287 
following each cycle 
(Povidone-iodine) 
Diarrhea Self-treatment 0.061 0.041 Self-treatment 0.093 0.266 
Leukopenia Postpone chemotherapy 0.385 Postpone chemotherapy for - 0.920 
until recovery a week 
Thrombocytopenia No treatment 0.278 0.056 No treatment 0.004 0.150 
Neurotoxicity No treatment 0.061 No treatment 0.322 
Anemia Transfusion 0.140 28.00 No treatment 0.112 
In fection * Anti-biotics 7 days 0.521 161.27 0.144 44.57 
(Gentamicin) 
Fatigue No treatment 0.018 No treatment 0.144 
Neutropenia* Inpatient stay' 0.061 99.35 0.048 78.18 
Alopecia Scalp cooling system 0.179 Scalp cooling system 0.464 
Outpatient visits An extra visit every cycle, 1.000 129.55 1.000 129.55 An extra visit every two 1.00 43.18 1.000 43.18 
plus an appointment with a cycles 
dietician every cycle 
Total 398.97 299.24 48.61 58.44 
• It was assumed that patients experienced infection or neutropenia only once. Thus, the cost of treatment was spread over the six cycles. 
I [Leese, 1993] 
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A 7. 3. 4 Costs of relapse 
Differential costs were estimated for each of the four sites of relapse included in the 
structure of the model -locoregional, soft tissue, bone, and visceral. 
A7.3.4.1 Locoregional 
Protocols for the treatment of locoregional relapses were derived from the literature. 
Excisional biopsy is the recommended primary treatment for chest wall relapse, which 
may involve the resection of the chest wall, though in some cases incisional biopsy may 
be the only option [Jardines et aI, 1993]. Radiation therapy should follow, with a 
minimum dose of 45-50Gy to elective sites and 55Gy to unexcised relapses [Willner et 
aI, 1997]. Systemic treatments are commonly implemented in patients following a chest 
wall relapse, though their effect is unproven [Jardines et al, 1993; Willner et al, 1997]. 
Similar treatment patterns were identified for regional relapses, ipsilateral axillary 
relapses requiring repeat axillary dissection, whilst supraclavicular lymph node 
recurrences are excised when possible and radiated [Jardines et aI, 1993; Silva and 
Zurrida, 1999]. 
Surgery for locoregional relapses most closely matched the 'Intermediate Breast 
Surgery' category in the National Schedule of Reference Costs [The new NHS - 1998 
Reference Costs, 1998]. The number and cost of fractions of radiotherapy were 
obtained from the literature, which reported a mean number of 20 fractions [Aberzik et 
al, 1986; Toonkel et ai, 1983], at a cost of a single fraction of radiotherapy of £41.92 
[Read, 1994]. The cost of chemotherapy following locoregional relapse employed the 
same estimates derived for the cost of adjuvant chemotherapy. The baseline cost for the 
treatment of locoregional relapse, and the constituent parts, are presented in table A 7.22 
below. 
Table A7.22 
Treatment 
Surgery 
Baseline cost of treating a loco regional relapse 
Cost (£'s) 
Radiotherapy (20 fractions @ £41.92 each) 
Chemotherapy 
780.00 
838.40 
285.00 
1903.40 Total 
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A7.3.4.2 Metastases 
Protocols were also developed from the literature to estimate separate monthly costs for 
the treatment of the three sites of metastases. The costing of surveillance for patients 
with metastases has been reported above, and the same systemic therapies were 
assumed as described above. Table A7.23 presents details of the assumed local 
treatment of metastases. Data from the literature reported that bone metastases should 
be treated with radiation therapy to palliate pain [Jardines et aI, 1993], though another 
study differentiated between localised and widespread bone pain and offered a range of 
alternative interventions [Leonard et aI, 1994]. Pathological fractures are an infrequent 
problem and should be treated with internal [Jardines et al, 1993] or external [Leonard 
et aI, 1994] fixation and radiation. Bisphosphonates (pamidronate and clodronate) are 
added to systemic therapy and are useful in reducing pain, analgesic use, fractures and 
hypercalcemia [Silva and Zurrida, 1999; Hortobagyi, 1998]. The assumed local 
treatment schedule for bone metastases included radiation therapy and bisphosphonates 
alongside systemic therapy. Following the validation process and the ensuing 
examination of a series of patient notes, the original estimate of patients with bone 
metastases receiving five episodes of radiotherapy per month was thought to be 
excessive. Instead, patients were assigned a 0.5 probability of undergoing one fraction 
of radiotherapy per month. 
Little data was available on the specific interventions for patients with soft tissue 
metastases, only pain through soft tissue infiltration was mentioned, which was treated 
with non-steroidal anti-inflammatory drugs (prednisolone) [Leonard et aI, 1994]. 
Patients with visceral metastases have the least favourable prognosis, local treatment is 
applied only to palliate symptoms, though only around 50 per cent of such patients will 
develop signs, such as coughs and dysponoea (difficulty in breathing) [Jardines et al, 
1993]. Treatment consists of morphine and diazepam (BNF). 
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Table A 7.23 Local treatments used in patients with metastases 
Unit price (£'s) Dose Cost per day 
Bone metastases 
Sodium clodronate 400mg 1.52 1.6g per day 6.08 
Radiotherapy (fraction) 41.92 1 per month 1.40 
Soft tissue 
Prednisolone 5mg 0.016 10mg per day 0.03 
Visceral 
Diazepam 5mg 0.0035 10mg per day 0.01 
Morphine 10mg 0.116 60mgper day 0.69 
Various sources were identified that provided data on the costs associated with inpatient 
episodes for patients experiencing metastases. The three UK-based studies are 
described first. Richards et al presented retrospective data on the aggregate cost of 
treating for 50 patients with advanced breast cancer [Richards et al, 1993]. The costs 
were presented in eight categories, and a total cost of £7620 (1991 costs) from the point 
of diagnosis of advanced breast cancer to death is calculated. Wolstenholme and 
Whynes [1998] presented the mean four-yearly costs of breast cancer treatment by 
stage. Taking stage 4 as the relevant stage, a mean of zero was presented for inpatient 
stay investigations, and £72 ( 1991 costs) for inpatient stay complications, though a 
sample size of 6 restricts the use of such estimates. The other UK study compared two 
options for the surveillance of patients with metastatic breast cancer (see section 
A7.3.2). 
Hurley et al [1992] identified 128 patients and collected resource use information from 
the point of diagnosis until death or the last point of contact (records were treated as 
censored if patients were still alive) in Australia. Patients were classified into five 
groups - visceral, eNS, bone, local, and other. The final category included regional and 
soft tissue relapses. The classes were ordered hierarchically, and separate relapse 
episodes were defined by the occurrence of a more serious site of relapse. Inpatients 
days, daypatient attendance's, outpatient visits and common investigations for each 
category of relapse were presented. These resource estimates were collected and 
equivalent costs from the UK NHS applied. Data from English Trust returns including 
55 Trusts shows that the mean cost per patient day in medical oncology specialities is 
£302.40 (uprated from 1996/7 prices), and a mean cost per outpatient visit as £86.35. 
Patient day includes both inpatients and day case, so the calculated costs were used for 
both types of hospital visit. Table A 7.24 presents the details of the information used. 
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Table A7.24 Median monthly resource use data extracted from Hurley et al 
[1992], and the costs applied from the UK NHS 
Cost category Visceral Bone 
Units * Cost (£'5)* Units * Cost (£'5)* 
Inpatient days 0.63 2.67 190.51 807.41 0.05 1.09 15.12 329.62 
Daypatients 0.33 0.67 99.79 202.61 0 0.33 0.00 99.79 
attendance's 
Outpatient 1.17 1.57 101.03 135.57 l.33 86.35 114.85 
visits 
Total 391.33 1145.59 101.47 544.25 
Cost category Other Local 
Units * Cost (£'s)* Units * Cost (£'s)* 
Inpatient days 0.15 1.06 45.36 320.54 0 0.19 0.00 57.46 
Daypatients 0.07 0.15 21.17 45.36 0 0.1 0.00 30.24 
attendance's 
Outpatient 1.17 1.53 101.03 132.12 1.33 86.35 114.85 
visits 
Total 167.56 498.02 86.35 202.54 
* The left column presents the median number of units/cost, the right column presents the 75th percentile number of 
units/cost (1999£'s), inpatient day/day case = £302.40, outpatient visit = £86.35 
A 7.4 Utility values 
Quality of life in breast cancer patients has been investigated, but the majority of studies 
have used condition- or symptom- specific measures [Macquart-Moulin et al, 1999; 
Fairclough, 1997]. The non-generic QoL data identified included the Rotterdam 
Symptom Checklist [Jonat et aI, 1996; Richards et aI, 1992], the Functional Living 
Index [Chu et al, 1996; The Givio investigators, 1994], the Perceived Adjustment to 
Chronic Illness Scale (P ACIS) [Bernhard et al, 1997; Hurny et aI, 1996], the Symptom 
Checklist-90 Revised [Tross et al, 1996]. In addition, a range of individual dimensions 
such as body image, emotional wellbeing and satisfaction with care, were valued using 
a Visual Analogue Scale (V AS) [The Givio investigators, 1994; Hayes et aI, 1995]. The 
conversion of such measures to utilities was not attempted, though the data provided 
could be used to inform descriptions of health states for the primary collection of health 
state utilities. 
A number of previous modelling studies had assigned utility values using either focus 
groups of oncology professionals [Hillner et al, 1992; Hillner and Smith, 1991; Smith 
and Hillner, 1993; Desch et al, 1993], or direct measurement techniques from oncology 
nurses [Hutton et al, 1996]. Table A7.25 summarises the data available from these 
studies. 
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Table A 7.25 Utility values derived from previous modelling studies 
From start of adjuvant First-line therapy 
therapy! metastases2 
Tamoxifen 0.99 Standard CT 0.7 
Minor 0.9 Induction high dose 0.5 
toxicity(CT) CT 
Major 0.7 Uncomplicated 0.3 
toxicity(CT) ABMT 
1st recurrence 0.7 Complicated ABMT 0.1 
After 1st 0.85 CR 0.85 
recurrence 
2nd recurrence 0.5 PR 0.6 
After 2nd 0.7 Stable 0.5 
recurrence 
3rd recurrence 0.3 PD 0.4 
for Second-line therapy for metastases.) * 
Before second line therapy 0.59 
CR+PR 0.81 
Partial respose and severe 0.75 
peripheral oedema 
Partial response and severe 0.53 
peripheral neuropathy 
Stable disease 0.62 
Progressive disease 0.41 
Sepsis 0.2 
Terminal disease 0.16 
0.56 
0.84 
0.78 
0.62 
0.62 
0.33 
0.16 
0.13 
* Values in left column were derived from UK nurses only, values in the right column were derived from an 
international set of nurses. 
1 [Smith and Hillner, 1993], 2 [Hillner et aI, 1992], 3 [Hutton et aI, 1996] 
Two papers were identified that collected primary estimates of utility values relating to 
some of the health states within the case study models. De Haes et al [1991] used 15 
members of the Department of Public Health and Social Medicine and 12 health 
professionals to value 15 health states on a visual analogue scale (V AS) [de Haes et aI, 
1991]. Citing a function described by Loomes [1988], the median VAS scores were 
converted to time trade-off (TTO) scores that were taken as more accurate valuations of 
utility. Ashby et al [1994] described five health states, one year post-primary surgery 
combining alternative forms of surgery with two scenarios - coping well and coping 
poorly. TTO was used to value the states using 138 subjects, including health 
professionals, breast cancer patients and university staff. The data derived from these 
two studies are presented in table A7.26. A final study used patients with any type of 
metastatic cancer to compare three form of QoL or utility measurement - V AS, TIO 
and the Spitzer Quality of life Index (QLI). The mean scores for the former two 
measures were 0.41 and 0.63 [perez et al, 1997]. 
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[de Haes et aI, 1991] VAS TTO [Ashby et aI, 1994] TTO 
Initial surgery 62 0.867 Lumpectomy, occasional concern 0.784 
2mths-l yr after lump 71 
2mths-lyr after mast 65 
Initial radiotherapy 60 
Initial hormonal therapy 63 
Initial 50 
Chemotherapy 
DF>lyr after 77 
mastectomy 
DF> lyr after BCT 82 
Palliative+ 46 
Surgery 
Palliative+ 36 
Chemotherapy 
Palliative+ 47 
hormonal therapy 
Palliative+ 43 
Radiotherapy 
Terminal illness 19 
0.914 
0.844 
0.803 
0.82 
0.717 
0.947 
0.96 
0.617 
0.531 
0.663 
0.591 
0.288 
V AS=visuai analogue scale, TTO=time trade-off 
over relapse, normal activities, 
well supported 
Mastectomy+plastic surgery, 0.714 
occasional concern over relapse, 
normal activities, well supported 
Mastectomy, occasional concern 0.703 
over relapse, normal activities, 
well supported 
Lumpectomy, swelling of arm, 0.284 
high anxiety and impact on normal 
life, not supported 
Mastectomy, swelling of arm, high 0.257 
anxiety and impact on normal life, 
not supported 
lump=lumpectomy, mast=mastectomy, plas=plastic surgery to make a new breast 
The input data 
The whole range of utility values used in the case study models is presented in Table 
A7.27. 
Table A 7.27 Utility values for all events included in the case study models 
Health state Minimum Likeliest Maximum 
Disease free interval: 
First year 0.7 0.84 0.9 
Subsequent years 0.8 0.95 1 
Toxicity: 
Major 0.3 0.51 0.7 
Grade Y2 0.6 0.78 0.9 
Grade 314 0.55 0.65 0.85 
Menopausal symptoms: 
Moderate 0.61 0.79 0.85 
Severe 0.3 0.64 0.85 
Locoregional relapse 0.3 0.5 0.7 
Remission 0.6 0.84 0.9 
Metastases 0.3 0.55 0.7 
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